{"meta":{"query_hash":"4bfe58bd6a87","filters":{"venue":"Journal of Medical Economics"},"cohort_total":199,"direct_labels_cover":0,"predictions_cover":199,"exported":199,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/4bfe58bd6a87","api":"https://metacan.xera.ac/api/v1/cohort?venue=Journal+of+Medical+Economics"},"results":[{"id":"W1746649267","doi":"10.3111/13696998.2015.1096274","title":"Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarin","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Medicine; Rivaroxaban; Warfarin; Deep vein; Low molecular weight heparin; Vitamin K antagonist; Thrombosis; Retrospective cohort study; Cohort; Emergency medicine; Internal medicine; Surgery; Atrial fibrillation","score_opus":0.009687734678044244,"score_gpt":0.23199207026472532,"score_spread":0.22230433558668108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1746649267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985252,0.000256903,0.00002359036,0.000060195878,0.000004518481,0.0000112745665,0.00080431165,0.0000015579486,0.00031241914],"genre_scores_gemma":[0.9988469,0.00010203049,0.000047999147,0.00002757595,0.0000098778555,0.000011270135,0.0008946716,8.324889e-7,0.000058815956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987275,0.0003424785,0.000271403,0.00021326369,0.0002523554,0.00019289822],"domain_scores_gemma":[0.99685466,0.00045192803,0.0021374652,0.00006789695,0.00016596656,0.0003220188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059829827,0.00023189769,0.0003953782,0.0012923478,0.00036815452,0.0008023037,0.0005010938,0.00040551674,0.0014395178],"category_scores_gemma":[0.0038869884,0.0002430861,0.00082553714,0.0017431139,0.00020525217,0.0005254736,0.00058518146,0.0005690953,0.00010397272],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023875039,0.00004783914,0.99801433,0.000017479724,0.00013875202,0.00009751081,0.000031398427,0.00015526007,0.000048470538,0.000035634803,0.00017286849,0.0010017192],"study_design_scores_gemma":[0.000023338762,0.00011249873,0.9982609,0.00001538264,0.00006536442,0.00040820552,0.00019146025,0.0007020203,0.00004085718,0.000031382384,0.00014270979,0.0000058338724],"about_ca_topic_score_codex":0.012854425,"about_ca_topic_score_gemma":0.015004738,"teacher_disagreement_score":0.012854425,"about_ca_system_score_codex":0.0017672309,"about_ca_system_score_gemma":0.000647154,"threshold_uncertainty_score":0.025559187},"labels":[],"label_agreement":null},{"id":"W1930311159","doi":"10.3111/13696998.2015.1063501","title":"Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer’s type in the US","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVRAZ (Canada)","funders":"","keywords":"Memantine; Medicine; Rivastigmine; Dementia; Galantamine; Deprescribing; Donepezil; Quality of life (healthcare); Clinical trial; Health care; Cohort; Cost–utility analysis; Cost-effectiveness analysis; Disease; Cost effectiveness; Intensive care medicine; Internal medicine; Polypharmacy; Nursing","score_opus":0.10165036613212446,"score_gpt":0.3853281472543629,"score_spread":0.2836777811222384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1930311159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808095,0.004868092,0.0053603896,0.0012179497,0.00009839197,0.00044961396,0.0031416474,0.000060562,0.0039936514],"genre_scores_gemma":[0.9966624,0.00054944307,0.0012971954,0.00013196013,0.000013989042,0.000104949344,0.00081599,0.000008121229,0.00041594697],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9973169,0.0019978776,0.00008861152,0.00016933796,0.0002091633,0.00021813354],"domain_scores_gemma":[0.9934681,0.005027676,0.0006168377,0.00015161166,0.00040419324,0.00033158986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049227863,0.00120835,0.001617761,0.0013173976,0.00024441007,0.001426694,0.0010864079,0.001072765,0.0031759571],"category_scores_gemma":[0.014265616,0.00061389036,0.0040780315,0.001326496,0.00053111615,0.0010602272,0.00079291494,0.0012961173,0.00015774401],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01739937,0.0008596683,0.034205258,0.0006014091,0.0036222253,0.00043503262,0.000063123225,0.91604793,0.00072152715,0.003244956,0.0020180969,0.020781446],"study_design_scores_gemma":[0.0030155035,0.009246125,0.046147753,0.0004014428,0.0062289173,0.000575413,0.00036739837,0.92611897,0.0010862243,0.00404666,0.0026216104,0.00014405932],"about_ca_topic_score_codex":0.017654583,"about_ca_topic_score_gemma":0.008779985,"teacher_disagreement_score":0.017654583,"about_ca_system_score_codex":0.0057105785,"about_ca_system_score_gemma":0.0026003355,"threshold_uncertainty_score":0.041433275},"labels":[],"label_agreement":null},{"id":"W1946341976","doi":"10.3111/13696998.2015.1074583","title":"Daily costs of hospitalization in non-valvular atrial fibrillation patients treated with anticoagulant therapy","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Atrial fibrillation; Cohort; Population; Internal medicine; Cohort study; Pediatrics; Pharmacy; Medical diagnosis; Anticoagulant; Emergency medicine","score_opus":0.03697641372363858,"score_gpt":0.30439554598215685,"score_spread":0.26741913225851827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1946341976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963691,0.00058908673,0.000086018525,0.00021045949,0.000010785482,0.000014930383,0.0018038771,0.0000038499757,0.0009117908],"genre_scores_gemma":[0.9984048,0.0001718009,0.00009471907,0.000028085928,0.000012788014,0.00000933291,0.0012074765,9.490307e-7,0.00007005921],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989039,0.00030188714,0.0002347698,0.00011168823,0.00027134945,0.00017630059],"domain_scores_gemma":[0.9969612,0.00043415264,0.0020098903,0.00006315627,0.00022577736,0.0003057297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006164978,0.00019991395,0.0002943728,0.0011287944,0.00032809,0.0009449576,0.00041250113,0.000293398,0.001668964],"category_scores_gemma":[0.0042641973,0.00014756777,0.0009437581,0.0014907285,0.00016451532,0.0004940856,0.0005651219,0.00051935215,0.00010877487],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001792802,0.00005650719,0.99315864,0.000043253982,0.00023973576,0.00014521406,0.000054313474,0.00077896455,0.000066267916,0.0001378618,0.00051905744,0.004620889],"study_design_scores_gemma":[0.000014810506,0.00012051006,0.9966114,0.00003728108,0.000068525944,0.000511137,0.00017984996,0.0018569506,0.000048513546,0.00012364962,0.0004201159,0.000007245154],"about_ca_topic_score_codex":0.012115785,"about_ca_topic_score_gemma":0.013729485,"teacher_disagreement_score":0.012115785,"about_ca_system_score_codex":0.0019133977,"about_ca_system_score_gemma":0.0008766631,"threshold_uncertainty_score":0.024090528},"labels":[],"label_agreement":null},{"id":"W1952035361","doi":"10.3111/13696998.2015.1116991","title":"Systematic review of models used in economic analyses in moderate-to-severe asthma and COPD","year":2015,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; COPD; Asthma; Intensive care medicine; Bronchodilator Agents; Bronchodilator; Internal medicine","score_opus":0.09494829862117907,"score_gpt":0.39897040001971373,"score_spread":0.3040221013985347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1952035361","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016647137,0.9896827,0.0035228296,0.000730123,0.00024143538,0.0013691818,0.001840244,0.000054015713,0.0008948543],"genre_scores_gemma":[0.05944439,0.925285,0.00895104,0.0007036166,0.00021028027,0.0038001982,0.0013456903,0.00005395872,0.00020593441],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.92825973,0.048796695,0.015106542,0.0017510821,0.005557161,0.000528727],"domain_scores_gemma":[0.7695849,0.2066198,0.014400791,0.0033369863,0.0056832493,0.00037431152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.055192225,0.0033271115,0.012959402,0.016481688,0.0007995619,0.00492779,0.0038469816,0.0027715282,0.005853367],"category_scores_gemma":[0.21114902,0.0020242503,0.020102818,0.014920702,0.00097569154,0.0036876006,0.001991592,0.0021865093,0.0005320571],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044355536,0.00003432003,0.0010422036,0.9039151,0.050648555,0.00017051614,0.00013953002,0.004105291,0.000068341,0.0020176899,0.0023440872,0.03507085],"study_design_scores_gemma":[0.0007886282,0.00037581226,0.0030514493,0.8002331,0.16477297,0.00038341992,0.00018894883,0.00395117,0.00025517694,0.005105851,0.0207757,0.00011770068],"about_ca_topic_score_codex":0.0097328685,"about_ca_topic_score_gemma":0.015551187,"teacher_disagreement_score":0.055192225,"about_ca_system_score_codex":0.008186601,"about_ca_system_score_gemma":0.014029075,"threshold_uncertainty_score":0.29188782},"labels":[],"label_agreement":null},{"id":"W1967232800","doi":"10.3111/13696998.2010.535577","title":"Changing costs and the impact on RSV prophylaxis","year":2010,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Respiratory viral infections research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster Children's Hospital; Sunnybrook Health Science Centre; Health Sciences Centre; University of Toronto","funders":"","keywords":"Medicine; Intensive care medicine; Pre-exposure prophylaxis; Virology; Human immunodeficiency virus (HIV)","score_opus":0.023397017125700272,"score_gpt":0.3641934151618424,"score_spread":0.34079639803614215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967232800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84953606,0.03873868,0.0043785404,0.027272645,0.00035643004,0.00037556168,0.027678836,0.00012192527,0.05154131],"genre_scores_gemma":[0.9862846,0.006261345,0.001420452,0.0007834841,0.000049055932,0.000045889672,0.0031913726,0.000020928514,0.0019429096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966898,0.0008309173,0.00014589111,0.00016881996,0.0014081075,0.000756429],"domain_scores_gemma":[0.99424285,0.0018183006,0.0009736426,0.00010803008,0.0024238112,0.00043328817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020633002,0.00055136235,0.0005098996,0.0014998999,0.0006438473,0.0027194214,0.0008761499,0.0006770003,0.0031280082],"category_scores_gemma":[0.017728368,0.00024306106,0.0016384395,0.0023845274,0.00054171233,0.0008879377,0.0007635964,0.0013021884,0.0001836665],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023679945,0.0002149986,0.6051467,0.0020262566,0.0033694652,0.0010244458,0.00036356892,0.21752435,0.0006977897,0.017266056,0.019940859,0.13005753],"study_design_scores_gemma":[0.00031754884,0.0005344767,0.86671335,0.0019054256,0.0022236302,0.00087314576,0.0015019721,0.08541096,0.0012627854,0.005592784,0.033514906,0.00014900455],"about_ca_topic_score_codex":0.9240474,"about_ca_topic_score_gemma":0.91954005,"teacher_disagreement_score":0.9240474,"about_ca_system_score_codex":0.05325937,"about_ca_system_score_gemma":0.04500928,"threshold_uncertainty_score":0.3864256},"labels":[],"label_agreement":null},{"id":"W1968579243","doi":"10.3111/13696998.2014.909436","title":"Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapy","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Robarts Clinical Trials","funders":"Janssen Scientific Affairs","keywords":"Medicine; Infliximab; Inflammatory bowel disease; Disease; Health care; Internal medicine; Intensive care medicine","score_opus":0.008427640331969043,"score_gpt":0.251802811231127,"score_spread":0.24337517089915797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968579243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99257624,0.002656436,0.00024120692,0.00095891656,0.000019708836,0.000030523308,0.0018032145,0.000006784895,0.0017069529],"genre_scores_gemma":[0.9977197,0.000636736,0.00022683694,0.00016723292,0.000036402515,0.000016667333,0.0009549714,0.0000013595744,0.00024009167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991353,0.0002904236,0.0001350366,0.00009649839,0.00023638693,0.000106340034],"domain_scores_gemma":[0.99721766,0.00033571364,0.0020505488,0.00006545427,0.000112260444,0.00021842448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007144337,0.00020645889,0.00039317057,0.0005379979,0.00030895098,0.0006799463,0.00023905511,0.00042628424,0.0019376111],"category_scores_gemma":[0.0037778337,0.000135512,0.0006452888,0.0011946486,0.00018344913,0.00051377626,0.0006720322,0.00076683547,0.0001510284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023438,0.00012591772,0.98469037,0.00010565685,0.00033234849,0.00010123458,0.00004955972,0.00042193392,0.000094388546,0.00020391836,0.00067075214,0.0129695125],"study_design_scores_gemma":[0.00003060163,0.00014236638,0.9972663,0.00008138191,0.00011716335,0.00040222876,0.00010253493,0.00092440034,0.000036581263,0.00016942403,0.0007221668,0.000004874893],"about_ca_topic_score_codex":0.0046111476,"about_ca_topic_score_gemma":0.007774542,"teacher_disagreement_score":0.0046111476,"about_ca_system_score_codex":0.00044661862,"about_ca_system_score_gemma":0.00045038832,"threshold_uncertainty_score":0.009168565},"labels":[],"label_agreement":null},{"id":"W1971766459","doi":"10.3111/13696998.2014.925462","title":"Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians)","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Spasticity; Botulinum toxin; Stroke (engine); Cross-sectional study; Patient satisfaction; Physical therapy; Surgery","score_opus":0.013724026640931654,"score_gpt":0.2616882392279374,"score_spread":0.24796421258700574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971766459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993856,0.000066296416,0.00007509425,0.000036334925,0.0000021207227,0.000029893597,0.0001971736,0.0000026019295,0.00020488111],"genre_scores_gemma":[0.9993467,0.0000538285,0.00009401143,0.00006007764,0.000004213429,0.000047997433,0.00030167322,9.512015e-7,0.000090709254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969516,0.0017594376,0.00036772457,0.00018386824,0.00045568126,0.0002817766],"domain_scores_gemma":[0.98810554,0.004041661,0.0049298643,0.00027160966,0.0016250216,0.0010261935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043487465,0.00023333801,0.00039175243,0.00075384654,0.0003422742,0.0006069006,0.00022982378,0.0006734957,0.0013423803],"category_scores_gemma":[0.008597451,0.00028609208,0.0007365893,0.0009383444,0.00039736062,0.000596714,0.00064091344,0.0005276861,0.00024908144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015069715,0.000114665774,0.9970036,0.00002260066,0.000069374415,0.000028735501,0.00055994146,0.000048538837,0.00011226482,0.0000055055843,0.000078646386,0.0018054425],"study_design_scores_gemma":[0.000015702599,0.00058013335,0.99836427,0.0000063998327,0.000017293134,0.00008954776,0.00062294543,0.00013265487,0.000058131074,0.000003040838,0.00010468334,0.000005090037],"about_ca_topic_score_codex":0.002684466,"about_ca_topic_score_gemma":0.002967598,"teacher_disagreement_score":0.0043487465,"about_ca_system_score_codex":0.00049423915,"about_ca_system_score_gemma":0.00043103943,"threshold_uncertainty_score":0.022998631},"labels":[],"label_agreement":null},{"id":"W1972283859","doi":"10.3111/13696998.2012.697085","title":"Cost-effectiveness of partially-hydrolyzed formula for prevention of atopic dermatitis in Australia","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Food Allergy and Anaphylaxis Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; PharmIdeas (Canada)","funders":"","keywords":"Medicine; Atopic dermatitis; Dermatology","score_opus":0.0847164040903863,"score_gpt":0.391799723611668,"score_spread":0.30708331952128165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972283859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97054625,0.018495122,0.0019716092,0.0013523748,0.00009184538,0.0020443934,0.00043908882,0.000020215719,0.005039152],"genre_scores_gemma":[0.9948489,0.002715086,0.001463114,0.00015131054,0.000011567139,0.00033786616,0.00011872152,0.0000021686203,0.0003511353],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9925539,0.0059602,0.0002486111,0.00023122085,0.0007282039,0.0002779852],"domain_scores_gemma":[0.99695265,0.0017125427,0.00059835834,0.00006857052,0.00035045133,0.00031733824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006559776,0.00088963186,0.001296718,0.0012293427,0.0002489943,0.0011575607,0.0008289282,0.00096477044,0.0019867604],"category_scores_gemma":[0.018280452,0.00037314979,0.003585711,0.0005851695,0.00051376544,0.0008330445,0.0011357161,0.0009108893,0.000078638455],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12331135,0.007683667,0.08557765,0.017255958,0.01605685,0.0012459299,0.00070430426,0.37591282,0.0047985674,0.0064803194,0.0026276747,0.35834497],"study_design_scores_gemma":[0.04245664,0.14170513,0.28339255,0.009923041,0.027912691,0.002121063,0.0013400416,0.46677324,0.004887134,0.007687203,0.011470256,0.00033110363],"about_ca_topic_score_codex":0.019531963,"about_ca_topic_score_gemma":0.012658721,"teacher_disagreement_score":0.019531963,"about_ca_system_score_codex":0.005907007,"about_ca_system_score_gemma":0.004153888,"threshold_uncertainty_score":0.0428586},"labels":[],"label_agreement":null},{"id":"W1979583846","doi":"10.3111/13696998.2014.950669","title":"Healthcare costs for Crohn’s disease patients treated with infliximab: a propensity weighted comparison of the effects of treatment adherence","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"","keywords":"Medicine; Infliximab; Propensity score matching; Internal medicine; Pharmacy; Rheumatoid arthritis; Crohn's disease; Surgery; Disease; Family medicine","score_opus":0.00986530010196417,"score_gpt":0.2562391222970435,"score_spread":0.2463738221950793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979583846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99854904,0.0004882965,0.00032592833,0.00006523846,0.000012655366,0.00003284691,0.00023261236,0.0000028273778,0.00029051877],"genre_scores_gemma":[0.9991333,0.0001227789,0.00016539019,0.000038326096,0.000012959562,0.000024770121,0.00040994954,0.0000018403824,0.000090699825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99677014,0.0018264065,0.00041248393,0.00039923497,0.00039428935,0.00019758004],"domain_scores_gemma":[0.99532074,0.0016521553,0.0021352104,0.00041470976,0.00019504219,0.0002820851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036384265,0.0003939902,0.00088552263,0.0009199625,0.0002816348,0.00095650763,0.00043163873,0.0006823585,0.0013833545],"category_scores_gemma":[0.011395556,0.00032143286,0.0027708497,0.0011119631,0.00031424107,0.0008157697,0.0007853471,0.00074672676,0.00013387318],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020622732,0.0007762137,0.94841915,0.00014580855,0.008918822,0.00012567361,0.00019716856,0.0018672672,0.00043124877,0.00044143302,0.00039400894,0.017660454],"study_design_scores_gemma":[0.0010159796,0.0040340135,0.98547375,0.000046701167,0.0021448352,0.0002957192,0.00026217964,0.0054483935,0.00017392609,0.00048519528,0.00058484817,0.000034431672],"about_ca_topic_score_codex":0.0016229068,"about_ca_topic_score_gemma":0.0012173333,"teacher_disagreement_score":0.0036384265,"about_ca_system_score_codex":0.00051286956,"about_ca_system_score_gemma":0.00028367504,"threshold_uncertainty_score":0.019242108},"labels":[],"label_agreement":null},{"id":"W1981297777","doi":"10.3111/13696990903442155","title":"The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic","year":2009,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Respiratory viral infections research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Children's Hospital of Eastern Ontario; St. Joseph’s Healthcare Hamilton; McMaster Children's Hospital; St. Michael's Hospital; Sunnybrook Health Science Centre","funders":"Abbott Laboratories","keywords":"Palivizumab; Medicine; Pediatrics; Gestational age; Cost effectiveness; Cost-effectiveness analysis; Emergency medicine; Respiratory system; Pregnancy; Internal medicine","score_opus":0.03774025749135262,"score_gpt":0.36185564054048613,"score_spread":0.3241153830491335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981297777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98527515,0.005083613,0.00057554257,0.0010351711,0.000032934506,0.00013087536,0.0025310025,0.0000174642,0.0053182985],"genre_scores_gemma":[0.99763167,0.0009805474,0.00036048595,0.00008538282,0.0000047732156,0.000031665666,0.00054466206,0.0000041465078,0.00035662475],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99858403,0.00061893027,0.000051429757,0.000101043,0.00029594568,0.0003486108],"domain_scores_gemma":[0.9980108,0.0010053687,0.00023843895,0.00004268469,0.000414594,0.00028817155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027932182,0.00069257966,0.00065202964,0.00058672397,0.0007193506,0.0016249524,0.0014092455,0.00056322233,0.0016290614],"category_scores_gemma":[0.008415022,0.00027561974,0.0014534309,0.00092939334,0.00047326525,0.000358545,0.00080134976,0.00067136897,0.00006565087],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022929592,0.00088916754,0.37766692,0.0038361975,0.00712669,0.0023749415,0.00094734924,0.4892461,0.003383023,0.008192825,0.0089721065,0.074435145],"study_design_scores_gemma":[0.0021713406,0.0042820233,0.5367672,0.0018813048,0.008227905,0.0015872943,0.004224914,0.42496455,0.002988495,0.0043409113,0.00827389,0.00029017215],"about_ca_topic_score_codex":0.9398653,"about_ca_topic_score_gemma":0.917488,"teacher_disagreement_score":0.06013471,"about_ca_system_score_codex":0.041349813,"about_ca_system_score_gemma":0.021873629,"threshold_uncertainty_score":0.30001527},"labels":[],"label_agreement":null},{"id":"W1985042637","doi":"10.3111/13696998.2011.630850","title":"The STARRT trial: a cost comparison of optimal vs sub-optimal initiation of dialysis in Canada","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Dialysis and Renal Disease Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; University of Toronto; Humber River Regional Hospital","funders":"","keywords":"Medicine; Renal replacement therapy; End stage renal disease; Dialysis; Hemodialysis; Emergency medicine; Catheter; Central venous catheter; Confounding; Peritoneal dialysis; Kidney disease; Propensity score matching; Surgery; Internal medicine; Intensive care medicine","score_opus":0.03940392721939861,"score_gpt":0.28253163898858413,"score_spread":0.24312771176918552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985042637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871408,0.0054922323,0.0002959571,0.0012248576,0.000095837764,0.00070846063,0.0026282198,0.000021970216,0.0023918052],"genre_scores_gemma":[0.9954028,0.001607431,0.0004879339,0.00032665615,0.00005150231,0.00022369917,0.0014007932,0.000008155083,0.00049097073],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9972941,0.0013705699,0.00016497225,0.0003076056,0.00047190377,0.0003907713],"domain_scores_gemma":[0.99604803,0.0010000465,0.0011920944,0.0001806867,0.0006079878,0.00097114075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002892227,0.00078314205,0.0018197907,0.00049450446,0.00084971957,0.0012141665,0.0011980194,0.0010368545,0.0026179638],"category_scores_gemma":[0.008663675,0.0003161691,0.0023949814,0.0012118367,0.0010969798,0.0006081866,0.000751126,0.001498754,0.00012987667],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7414293,0.0032360435,0.1402827,0.0032915818,0.010995807,0.00020710417,0.00033712416,0.01283066,0.00072671665,0.002690771,0.008820928,0.075151175],"study_design_scores_gemma":[0.43672204,0.05407722,0.44308951,0.0018709736,0.018334681,0.00041928588,0.00097471586,0.033331692,0.0008250427,0.0025433253,0.007463944,0.00034753288],"about_ca_topic_score_codex":0.6790233,"about_ca_topic_score_gemma":0.74383426,"teacher_disagreement_score":0.6790233,"about_ca_system_score_codex":0.017402893,"about_ca_system_score_gemma":0.02721857,"threshold_uncertainty_score":0.64573395},"labels":[],"label_agreement":null},{"id":"W1992802587","doi":"10.3111/13696998.2014.897626","title":"Economic evaluation of BST-CarGel as an adjunct to microfracture vs microfracture alone in knee cartilage surgery","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Knee replacement; Surgery; Orthopedic surgery; Referral; Cartilage damage; Osteoarthritis; Articular cartilage","score_opus":0.016774454607737667,"score_gpt":0.29043597981595043,"score_spread":0.27366152520821274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992802587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97373104,0.0054729553,0.011889494,0.0013152327,0.000095499185,0.0011684364,0.0010209269,0.000028305338,0.0052781175],"genre_scores_gemma":[0.996911,0.00059014704,0.001788095,0.00006645976,0.000010710514,0.00016195029,0.00018083064,0.0000029125013,0.000287896],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9956161,0.0034386278,0.00011568328,0.00019024409,0.00032182364,0.00031750693],"domain_scores_gemma":[0.98645407,0.011946826,0.0006897765,0.00011020946,0.0003389676,0.00046007798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009681306,0.0011256181,0.0016469377,0.0011921187,0.00026848054,0.0017791324,0.00087546563,0.0015998975,0.0038895574],"category_scores_gemma":[0.015077464,0.0005458739,0.002958423,0.00081775314,0.00065678585,0.0013337274,0.00079939613,0.0014279357,0.00014683284],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019329611,0.0011158447,0.00984908,0.0013577829,0.0015210102,0.0002670366,0.000067797206,0.9369231,0.0008289574,0.004571123,0.0004795572,0.023689087],"study_design_scores_gemma":[0.0022740923,0.016381545,0.010299371,0.00048020578,0.0032838888,0.00020353001,0.0002852428,0.95953107,0.0012150828,0.004590357,0.001367936,0.00008772913],"about_ca_topic_score_codex":0.004691409,"about_ca_topic_score_gemma":0.002629996,"teacher_disagreement_score":0.009681306,"about_ca_system_score_codex":0.005584388,"about_ca_system_score_gemma":0.0034510365,"threshold_uncertainty_score":0.05120021},"labels":[],"label_agreement":null},{"id":"W1997932743","doi":"10.3111/13696998.2011.622323","title":"Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Pneumonia and Respiratory Infections","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"GlaxoSmithKline (Canada); McMaster University","funders":"","keywords":"Medicine; Haemophilus influenzae; Conjugate vaccine; Cohort; Pneumococcal conjugate vaccine; Epidemiology; Disease burden; Pandemic; Pneumonia; Herd immunity; Streptococcus pneumoniae; Intensive care medicine; Disease; Environmental health; Vaccination; Infectious disease (medical specialty); Immunology; Population; Coronavirus disease 2019 (COVID-19); Immunization; Internal medicine; Antibiotics","score_opus":0.02227451260633569,"score_gpt":0.26485415048471544,"score_spread":0.24257963787837974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997932743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9332884,0.0013925721,0.010906065,0.0035684747,0.000082926235,0.0005445331,0.014981722,0.00012508886,0.03511028],"genre_scores_gemma":[0.9812029,0.0009732555,0.0039391634,0.00020098593,0.000015742962,0.00022996085,0.0035360372,0.000024389246,0.009877541],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9989134,0.0003471129,0.00003857542,0.00012507486,0.00012144391,0.00045438716],"domain_scores_gemma":[0.9960925,0.0024188776,0.0002934174,0.00009909965,0.0007527347,0.00034343902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020969503,0.0009969994,0.0012056074,0.0012635274,0.0018446748,0.002446044,0.0021917473,0.0020963836,0.0061262585],"category_scores_gemma":[0.0067346343,0.00083800097,0.0015650778,0.0018087141,0.0012090073,0.00094079954,0.0013491156,0.0017992398,0.00040874816],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004894987,0.00015264521,0.023329858,0.00013769293,0.00013657358,0.0004224897,0.00025358953,0.9548415,0.00015103008,0.011933656,0.003741467,0.0044100434],"study_design_scores_gemma":[0.00031785565,0.00014513436,0.015109112,0.00013390744,0.00018313139,0.000073574854,0.0006510592,0.9758099,0.00020169001,0.0027078593,0.004578523,0.00008839767],"about_ca_topic_score_codex":0.9776863,"about_ca_topic_score_gemma":0.95471966,"teacher_disagreement_score":0.042825907,"about_ca_system_score_codex":0.042825907,"about_ca_system_score_gemma":0.03173797,"threshold_uncertainty_score":0.31072515},"labels":[],"label_agreement":null},{"id":"W1998523970","doi":"10.3111/13696998.2011.627405","title":"The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Population Health Research Institute; McMaster University; Hamilton Health Sciences","funders":"Servier; Sanofi; McMaster University; AstraZeneca","keywords":"Medicine; Telmisartan; Ramipril; Internal medicine; Cardiology; Intensive care medicine","score_opus":0.10158244239599679,"score_gpt":0.3054804258251084,"score_spread":0.20389798342911164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998523970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803388,0.00741068,0.0004980731,0.0024036884,0.00020343349,0.00021791535,0.004941957,0.000009802577,0.0039756307],"genre_scores_gemma":[0.9960967,0.0009472907,0.00025707716,0.0006301623,0.00018877459,0.00012184264,0.0014355435,0.0000049220685,0.00031774445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99569356,0.0027586971,0.00042223325,0.000228929,0.0006696443,0.00022690216],"domain_scores_gemma":[0.98589283,0.007975395,0.004159515,0.00063727057,0.00077139784,0.00056351186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006822943,0.00051097875,0.00065892783,0.0005781419,0.00022089093,0.001193667,0.0005823602,0.00053187204,0.00247097],"category_scores_gemma":[0.012399331,0.00023645078,0.002560698,0.00076439325,0.00024365087,0.0006790827,0.00061076315,0.0012216485,0.00012237129],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2569402,0.0024335992,0.5613426,0.0043588467,0.027723478,0.001623377,0.00037682042,0.009432774,0.0010564679,0.0038590443,0.019930055,0.11092274],"study_design_scores_gemma":[0.039773278,0.012831527,0.8784753,0.0019923032,0.03196414,0.002757812,0.00075377093,0.0134661505,0.0023645395,0.0043695117,0.011022572,0.00022900279],"about_ca_topic_score_codex":0.003525594,"about_ca_topic_score_gemma":0.0051908824,"teacher_disagreement_score":0.006822943,"about_ca_system_score_codex":0.001135694,"about_ca_system_score_gemma":0.0009778901,"threshold_uncertainty_score":0.03608358},"labels":[],"label_agreement":null},{"id":"W2000275242","doi":"10.3111/13696998.2013.823869","title":"Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Novo Nordisk","keywords":"Medicine; Risperidone; Paliperidone; Paliperidone Palmitate; Quality of life (healthcare); Adverse effect; Olanzapine; Schizophrenia (object-oriented programming); Emergency medicine; Pediatrics; Psychiatry; Internal medicine","score_opus":0.04877902442352141,"score_gpt":0.3665994793210382,"score_spread":0.3178204548975168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000275242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802506,0.005327044,0.0049888445,0.00092912256,0.00005852773,0.00034995246,0.0018983703,0.000029769482,0.0061678425],"genre_scores_gemma":[0.99686795,0.00074528705,0.0015369992,0.000066434586,0.000010802188,0.000120483965,0.00035390363,0.0000037136206,0.0002944088],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99849856,0.0010188608,0.00008170876,0.000092759525,0.00012790342,0.00018021459],"domain_scores_gemma":[0.9945511,0.0044878204,0.0004568878,0.000050743965,0.00027995603,0.00017343307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037669472,0.0008417631,0.0010947097,0.0009499028,0.00037791525,0.00091579044,0.0007015514,0.00086277997,0.0030755482],"category_scores_gemma":[0.009589667,0.00042846834,0.0029769454,0.0008755653,0.00031138022,0.0007214607,0.00055587053,0.00067917263,0.000086614375],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012118111,0.00014770766,0.010557429,0.00045205269,0.00092988793,0.00019811196,0.000033578533,0.9782697,0.00020224664,0.0014223004,0.00030275376,0.006272298],"study_design_scores_gemma":[0.0021391802,0.0033756506,0.028596181,0.0006291173,0.0037879364,0.00042010588,0.0003332885,0.9519931,0.0008679935,0.005501965,0.0022676212,0.00008783772],"about_ca_topic_score_codex":0.028379157,"about_ca_topic_score_gemma":0.013011283,"teacher_disagreement_score":0.028379157,"about_ca_system_score_codex":0.0051082107,"about_ca_system_score_gemma":0.0049259197,"threshold_uncertainty_score":0.056427896},"labels":[],"label_agreement":null},{"id":"W2004818337","doi":"10.3111/13696998.2012.703631","title":"A cross-country review of data collected on non-small cell lung cancer (NSCLC) patients in cancer registries, databases, retrospective and non-randomized prospective studies","year":2012,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Database; Retrospective cohort study; Cancer; MEDLINE; Family medicine; Internal medicine","score_opus":0.06342109857381367,"score_gpt":0.4330840846767386,"score_spread":0.3696629861029249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004818337","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.038543608,0.91263443,0.0011505135,0.001205057,0.00024113302,0.0025648472,0.04146952,0.00004144638,0.0021494885],"genre_scores_gemma":[0.21774188,0.73319453,0.0068610352,0.0029219647,0.00018987352,0.007341173,0.03140847,0.000052926778,0.00028807437],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.895714,0.02823097,0.060912445,0.0047445456,0.009330188,0.0010677688],"domain_scores_gemma":[0.68770695,0.17554241,0.08822052,0.011165096,0.03576985,0.0015951927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05317106,0.0010617266,0.0067852163,0.04321819,0.0010877888,0.0043496555,0.0024821656,0.0018106583,0.0037129053],"category_scores_gemma":[0.17456108,0.0015293668,0.0050718975,0.055279724,0.0014712933,0.004430992,0.0028288162,0.0009866453,0.0005690495],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000675485,0.00006617358,0.060598284,0.84067935,0.014633355,0.00059640233,0.0020025284,0.00020872994,0.00039341953,0.000709269,0.0067154933,0.0727214],"study_design_scores_gemma":[0.0005096363,0.00038515785,0.15642488,0.7392578,0.047568068,0.0016052392,0.0035147052,0.00012864819,0.0007719009,0.00035599308,0.0493456,0.00013246786],"about_ca_topic_score_codex":0.008916721,"about_ca_topic_score_gemma":0.021278538,"teacher_disagreement_score":0.05317106,"about_ca_system_score_codex":0.004134239,"about_ca_system_score_gemma":0.019361813,"threshold_uncertainty_score":0.28119874},"labels":[],"label_agreement":null},{"id":"W2007452812","doi":"10.3111/13696998.2014.911184","title":"The cost implications of an early versus delayed invasive strategy in acute coronary syndromes: the TIMACS study","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Acute Myocardial Infarction Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute; University of Alberta","funders":"Canadian Institutes of Health Research; Johnson and Johnson; Medicines Company; Servier; Sanofi; GlaxoSmithKline; Eli Lilly and Company","keywords":"Medicine; Emergency medicine; Stroke (engine); Myocardial infarction; Clinical trial; Randomized controlled trial; Acute coronary syndrome; Intervention (counseling); Indirect costs; Intensive care medicine; Pediatrics; Internal medicine","score_opus":0.054381040330305934,"score_gpt":0.36810470796049427,"score_spread":0.31372366763018833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007452812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898901,0.0049536214,0.0002963433,0.001290378,0.00011988034,0.000106030675,0.0021301615,0.0000040028344,0.0012093678],"genre_scores_gemma":[0.9949469,0.0012092536,0.00036929984,0.00049028365,0.0002538254,0.00016596248,0.0022340247,0.0000067404103,0.00032382322],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99693143,0.0020158482,0.00021072212,0.0002518336,0.0003650903,0.00022502645],"domain_scores_gemma":[0.99517304,0.0019443498,0.0015343998,0.00036556195,0.000342893,0.0006397611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00802913,0.00092379126,0.0010282652,0.00069634314,0.0003112968,0.0017121214,0.00085442176,0.0011500573,0.0020180263],"category_scores_gemma":[0.007945741,0.0003314214,0.0024555742,0.001245972,0.0003926112,0.000999816,0.0010453609,0.0017842539,0.00018597538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19445622,0.0024834892,0.72854275,0.0014341655,0.021182902,0.0004024275,0.00025521635,0.0056714965,0.00053108885,0.0024971915,0.006390963,0.036152016],"study_design_scores_gemma":[0.03605854,0.012822583,0.9077512,0.0008539833,0.020639393,0.00073495094,0.00069896015,0.0116160875,0.00071913254,0.0028519966,0.0050846897,0.00016848659],"about_ca_topic_score_codex":0.0024601736,"about_ca_topic_score_gemma":0.003312944,"teacher_disagreement_score":0.00802913,"about_ca_system_score_codex":0.0013254908,"about_ca_system_score_gemma":0.000995047,"threshold_uncertainty_score":0.042462647},"labels":[],"label_agreement":null},{"id":"W2011880652","doi":"10.3111/13696998.2015.1044457","title":"A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Hepatitis C virus research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Sudbury","funders":"","keywords":"Simeprevir; Medicine; Telaprevir; Ribavirin; Boceprevir; Internal medicine; Hepatitis C; Adverse effect; Sofosbuvir; Hepatitis C virus; Cost-effectiveness analysis; Cost effectiveness; Virology; Virus","score_opus":0.10284127353406106,"score_gpt":0.38346871081932143,"score_spread":0.2806274372852604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011880652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9241873,0.015119754,0.026509548,0.006214968,0.00028337358,0.0011642462,0.0055094548,0.00012236253,0.020888982],"genre_scores_gemma":[0.9935643,0.0009926383,0.002794959,0.00018438911,0.000031981057,0.00020361118,0.00067550724,0.000012197462,0.001540387],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.996309,0.0029492346,0.00008959022,0.00015969295,0.00021372967,0.000278726],"domain_scores_gemma":[0.9890243,0.009380379,0.000574771,0.00011014962,0.00047181317,0.00043866946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065706954,0.0016143118,0.0019636361,0.002242023,0.00042873225,0.0025399257,0.0013821477,0.0019947467,0.005404375],"category_scores_gemma":[0.015939957,0.000991206,0.0029831098,0.0016302933,0.00076595804,0.0021055138,0.0014114287,0.0018502763,0.00029912512],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028939513,0.00021977724,0.0051896726,0.0005215154,0.0005849352,0.00029950053,0.000042809774,0.9765113,0.00014849346,0.004104656,0.001426834,0.008056578],"study_design_scores_gemma":[0.00074545597,0.001129273,0.004589548,0.00022235634,0.0006865377,0.00017984158,0.00014378327,0.9886955,0.0001235075,0.0024685476,0.0009624284,0.000053226096],"about_ca_topic_score_codex":0.045190733,"about_ca_topic_score_gemma":0.02185614,"teacher_disagreement_score":0.045190733,"about_ca_system_score_codex":0.012711332,"about_ca_system_score_gemma":0.0043819724,"threshold_uncertainty_score":0.09222758},"labels":[],"label_agreement":null},{"id":"W2016112560","doi":"10.3111/13696998.2014.1003644","title":"Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Crizotinib; Medicine; Lung cancer; Anaplastic lymphoma kinase; Internal medicine; Medical diagnosis; Oncology; ALK inhibitor; Brain metastasis; Ceritinib; Cancer; Metastasis; Radiology","score_opus":0.018142104251795008,"score_gpt":0.33406712434552266,"score_spread":0.31592502009372764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016112560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99710876,0.00062138285,0.000057134755,0.00012402094,0.0000036064816,0.000013570164,0.0017253114,0.000002335592,0.0003438481],"genre_scores_gemma":[0.99836046,0.00025690446,0.000069653855,0.00003000318,0.0000072560697,0.000011624042,0.0012052451,9.5186e-7,0.00005791565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994289,0.00014688353,0.00011959508,0.00011107978,0.00012280775,0.00007060889],"domain_scores_gemma":[0.9987078,0.00009238738,0.0009860322,0.000029875715,0.00009600035,0.0000879744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044942508,0.00016510827,0.00027871542,0.00089085376,0.00025183975,0.00057265954,0.00027139,0.00024220743,0.0009531756],"category_scores_gemma":[0.0016814452,0.00012547312,0.00035512433,0.0020938732,0.00014245535,0.00036777163,0.00037854534,0.0002481979,0.00017800649],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050096754,0.000015058323,0.9986228,0.000010915523,0.00003817137,0.00003676622,0.00001461981,0.00003366883,0.00004506608,0.000007788231,0.00012708908,0.0009978882],"study_design_scores_gemma":[0.000005816282,0.000031504238,0.9992187,0.000009475827,0.000014823997,0.00023877693,0.00011145036,0.00017138466,0.000033191685,0.000013387499,0.00014933874,0.0000019930305],"about_ca_topic_score_codex":0.012612188,"about_ca_topic_score_gemma":0.018023282,"teacher_disagreement_score":0.012612188,"about_ca_system_score_codex":0.0006553971,"about_ca_system_score_gemma":0.0004324243,"threshold_uncertainty_score":0.025077581},"labels":[],"label_agreement":null},{"id":"W2016463457","doi":"10.3111/13696998.2013.838571","title":"Validation of an economic model of paliperidone palmitate for chronic schizophrenia","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Paliperidone Palmitate; Medicine; Schizophrenia (object-oriented programming); Paliperidone; Psychiatry; Internal medicine; Antipsychotic","score_opus":0.03119009469812346,"score_gpt":0.3072504701223904,"score_spread":0.2760603754242669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016463457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86047965,0.015455004,0.08891507,0.0043653105,0.00034351478,0.0017831912,0.009731772,0.0002823266,0.018644111],"genre_scores_gemma":[0.98588055,0.0016501959,0.009224207,0.00020365922,0.00002716666,0.00059296057,0.0016406466,0.000020904543,0.00075980206],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99453664,0.0043352307,0.00027966138,0.00033186263,0.00029874715,0.00021780361],"domain_scores_gemma":[0.9576032,0.038805928,0.0015419758,0.0003114902,0.0014913549,0.00024605304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015665377,0.0014585957,0.0021116794,0.0026726157,0.0005141152,0.0023129564,0.0017539947,0.0022013476,0.0031354483],"category_scores_gemma":[0.039536532,0.00085136766,0.003937935,0.001462761,0.0006834323,0.0011732504,0.0010875486,0.0014062049,0.0002293162],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086966564,0.00010803895,0.005991981,0.00091069017,0.0008486097,0.00021226233,0.000039597493,0.98403347,0.00017963568,0.001561048,0.00045045026,0.004794506],"study_design_scores_gemma":[0.0007194203,0.0007809156,0.004439185,0.0008302602,0.0014481514,0.00013401305,0.00009232374,0.9851141,0.00042776708,0.004457429,0.0015075859,0.000048821723],"about_ca_topic_score_codex":0.023113715,"about_ca_topic_score_gemma":0.0089444285,"teacher_disagreement_score":0.023113715,"about_ca_system_score_codex":0.005344647,"about_ca_system_score_gemma":0.0052026906,"threshold_uncertainty_score":0.082847476},"labels":[],"label_agreement":null},{"id":"W2020081435","doi":"10.3111/13696998.2010.509244","title":"Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder","year":2010,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Thornhill Medical (Canada); Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Astellas Foundation for Research on Metabolic Disorders","keywords":"Solifenacin; Oxybutynin; Overactive bladder; Medicine; Tolterodine; Urology; Urinary incontinence; Cost–utility analysis; Quality-adjusted life year; Cost effectiveness","score_opus":0.014841219189673594,"score_gpt":0.30791645415538066,"score_spread":0.2930752349657071,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020081435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8692894,0.033139277,0.016986974,0.009234389,0.00041730737,0.0032918877,0.032915685,0.00034211678,0.03438295],"genre_scores_gemma":[0.9872892,0.002773769,0.0037548246,0.000562334,0.000038678943,0.00030171682,0.0035824976,0.000022195187,0.0016747745],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9972555,0.0013814386,0.00010530021,0.00023799983,0.0005848737,0.00043490372],"domain_scores_gemma":[0.99572396,0.0022255431,0.000567273,0.00013964793,0.00087650056,0.000467061],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004331099,0.0014436123,0.00213012,0.0015235875,0.0007738077,0.0015735413,0.0025099637,0.001240191,0.005244035],"category_scores_gemma":[0.01644823,0.00091724005,0.005491636,0.002090577,0.00069413445,0.0006502108,0.00096982316,0.0017140711,0.0002011821],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017486626,0.00043357452,0.021556463,0.00313801,0.008439757,0.0004136629,0.00013799293,0.8998112,0.0006938267,0.012841777,0.00857488,0.026472228],"study_design_scores_gemma":[0.013068627,0.0036159733,0.05787722,0.0013364219,0.011167341,0.00044041488,0.00027152273,0.8936333,0.0007583935,0.007094642,0.010389079,0.0003470356],"about_ca_topic_score_codex":0.88272804,"about_ca_topic_score_gemma":0.83162415,"teacher_disagreement_score":0.11727196,"about_ca_system_score_codex":0.06650741,"about_ca_system_score_gemma":0.045073275,"threshold_uncertainty_score":0.48254728},"labels":[],"label_agreement":null},{"id":"W2025655213","doi":"10.3111/13696998.2014.897628","title":"Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Purdue Pharma (Canada)","funders":"","keywords":"Medicine; Oxycodone; Medicaid; Medical prescription; Pharmacy; Opioid; Propensity score matching; Substance abuse; Medicare Part D; Opioid abuse; Emergency medicine; Observational study; Prescription drug; Psychiatry; Family medicine; Internal medicine; Health care; Pharmacology","score_opus":0.00829051050439042,"score_gpt":0.258836376412609,"score_spread":0.2505458659082186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025655213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99678934,0.0010756041,0.00034781406,0.0004173088,0.000017222912,0.000035956553,0.0005586353,0.000008305859,0.00074987183],"genre_scores_gemma":[0.99836177,0.00052377995,0.00045974477,0.00014351722,0.000012150881,0.00001643163,0.00031506454,0.0000013278767,0.00016620557],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915075,0.0003259733,0.000085546606,0.000087471024,0.0002460397,0.00010414163],"domain_scores_gemma":[0.9986552,0.00028080717,0.00078167167,0.000041238385,0.00013696338,0.00010413823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008217765,0.00025276712,0.00016243689,0.0007026895,0.00018608697,0.0006230432,0.00029356644,0.00036192045,0.0008377922],"category_scores_gemma":[0.0038849155,0.00014609755,0.00085715426,0.00079657696,0.0002547617,0.0005091951,0.0006144037,0.00041508244,0.000045123143],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002102559,0.0007381169,0.88117266,0.00026595505,0.001051258,0.00039003862,0.00013794303,0.018567229,0.001325166,0.0012719046,0.001507612,0.09146957],"study_design_scores_gemma":[0.00011459789,0.0016723718,0.9788963,0.00010091763,0.0005540326,0.00053186726,0.0003275049,0.013514417,0.0012923833,0.00045462744,0.0025158587,0.000024955862],"about_ca_topic_score_codex":0.01810691,"about_ca_topic_score_gemma":0.029406952,"teacher_disagreement_score":0.01810691,"about_ca_system_score_codex":0.003563755,"about_ca_system_score_gemma":0.0013464835,"threshold_uncertainty_score":0.036003053},"labels":[],"label_agreement":null},{"id":"W2029977303","doi":"10.3111/13696990903438617","title":"Impact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysis","year":2009,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; WOMAC; Osteoarthritis; Placebo; Quality of life (healthcare); Chondroitin sulphate; Physical therapy; Internal medicine; Alternative medicine","score_opus":0.009613533774219517,"score_gpt":0.28202257187560875,"score_spread":0.2724090381013892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029977303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7735627,0.12269179,0.061535753,0.011898023,0.00034811895,0.002373194,0.0015922209,0.000056667526,0.025941538],"genre_scores_gemma":[0.98532283,0.0060643703,0.0071840337,0.00032892043,0.00007158387,0.0004337529,0.00026214676,0.000009416169,0.0003228546],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98007315,0.01823666,0.00035355432,0.000150951,0.00092424883,0.00026143304],"domain_scores_gemma":[0.981423,0.016790342,0.00088114146,0.0001716783,0.00048658627,0.00024732001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016129997,0.0008437531,0.0015888384,0.0022938463,0.00021683454,0.0023188484,0.00058874313,0.0010626991,0.0014707028],"category_scores_gemma":[0.0459178,0.0003755061,0.001811153,0.0019168613,0.0006878935,0.0014905361,0.0014980399,0.0016248287,0.0000943886],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0335902,0.0022709144,0.10971037,0.010849562,0.011773479,0.001104289,0.00088388444,0.34109274,0.0013259689,0.07515898,0.00659218,0.4056475],"study_design_scores_gemma":[0.004597682,0.008862679,0.07959424,0.005543777,0.008829203,0.0011102563,0.0013725371,0.80569965,0.0013082816,0.07391641,0.008933539,0.00023173372],"about_ca_topic_score_codex":0.0021954693,"about_ca_topic_score_gemma":0.0012232461,"teacher_disagreement_score":0.016129997,"about_ca_system_score_codex":0.0029071898,"about_ca_system_score_gemma":0.0016523391,"threshold_uncertainty_score":0.08530462},"labels":[],"label_agreement":null},{"id":"W2030020820","doi":"10.3111/13696990802320908","title":"Seretide: a pharmacoeconomic analysis","year":2008,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University Health Network","funders":"U.S. National Library of Medicine","keywords":"Medicine; Pharmacoeconomics; Intensive care medicine","score_opus":0.05159584318216997,"score_gpt":0.3966179577317265,"score_spread":0.3450221145495565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030020820","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16623966,0.7204729,0.012660867,0.009573639,0.0007067232,0.007520598,0.06444633,0.00034154602,0.018037798],"genre_scores_gemma":[0.84979916,0.11800734,0.008514482,0.003066386,0.0005619156,0.002819851,0.014917545,0.00014981409,0.002163581],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.98200005,0.0118112825,0.0013137197,0.0008535136,0.003439527,0.00058187643],"domain_scores_gemma":[0.96029127,0.033726815,0.003202048,0.0005955107,0.0018003252,0.00038400252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014712789,0.0017272901,0.0054577547,0.0072923386,0.0003605593,0.0030143645,0.0012685366,0.0013806557,0.009871957],"category_scores_gemma":[0.03419299,0.00079582474,0.032133523,0.007860172,0.00039297368,0.001544366,0.0012481576,0.0024176466,0.00066212454],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052790884,0.0012393205,0.06283066,0.13910556,0.40418378,0.0012794568,0.00016763032,0.07874338,0.0012773123,0.008633719,0.024161017,0.22558732],"study_design_scores_gemma":[0.020254383,0.011194363,0.16864458,0.024482612,0.6148739,0.002476747,0.0005104578,0.08364009,0.0012737352,0.016254194,0.055982217,0.00041267188],"about_ca_topic_score_codex":0.00788624,"about_ca_topic_score_gemma":0.0068497863,"teacher_disagreement_score":0.014712789,"about_ca_system_score_codex":0.005925567,"about_ca_system_score_gemma":0.0038796526,"threshold_uncertainty_score":0.07780963},"labels":[],"label_agreement":null},{"id":"W2035214881","doi":"10.3111/13696998.2014.979938","title":"Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Ottawa Hospital; Roche (Canada)","funders":"","keywords":"Pertuzumab; Medicine; Trastuzumab; Oncology; Internal medicine; Breast cancer; Neoadjuvant therapy; Inflammatory breast cancer; Cancer","score_opus":0.024272920471406934,"score_gpt":0.34425611307015447,"score_spread":0.3199831925987475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035214881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96745837,0.003519513,0.0044832635,0.0023388544,0.000050976116,0.0012387055,0.008675855,0.00008711115,0.012147399],"genre_scores_gemma":[0.9949675,0.0006137897,0.0014714743,0.00015487174,0.000007687862,0.000150048,0.0015146639,0.000009458181,0.0011105804],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99728286,0.0011689025,0.00008040766,0.00018960869,0.00049784256,0.0007803213],"domain_scores_gemma":[0.9941981,0.00342251,0.00052437605,0.00013205883,0.0011902793,0.0005327296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004155928,0.0010928712,0.0011786154,0.0017012124,0.0010123816,0.0019613851,0.0020287673,0.0009746068,0.0028254515],"category_scores_gemma":[0.013237638,0.0007270274,0.0024773874,0.0022348494,0.00094407244,0.0006309836,0.0010343194,0.0013156001,0.00010820959],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004366669,0.00054664543,0.04233965,0.0006261228,0.0014041173,0.0004556935,0.00014750683,0.9215412,0.0005983169,0.008359242,0.0032233114,0.016391462],"study_design_scores_gemma":[0.0011975266,0.0011364567,0.065061495,0.00017580522,0.001314576,0.00020916527,0.0005165678,0.92328334,0.00059370685,0.0031032267,0.003275704,0.000132353],"about_ca_topic_score_codex":0.9509151,"about_ca_topic_score_gemma":0.9095958,"teacher_disagreement_score":0.10062197,"about_ca_system_score_codex":0.10062197,"about_ca_system_score_gemma":0.049493205,"threshold_uncertainty_score":0.7300669},"labels":[],"label_agreement":null},{"id":"W2041738951","doi":"10.3111/13696998.2011.649326","title":"Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Darbepoetin alfa; Epoetin alfa; Dialysis; Erythropoietin; Kidney disease; Dosing; Emergency medicine; Statistical significance; Intensive care medicine; Internal medicine","score_opus":0.08573305352781532,"score_gpt":0.34126154978902756,"score_spread":0.2555284962612122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041738951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984388,0.00037349667,0.000058546077,0.00005677739,0.0000039061647,0.000009131478,0.0007078818,0.0000025482384,0.00034893362],"genre_scores_gemma":[0.9983808,0.00016724161,0.0001005457,0.000030151718,0.000013020921,0.000009942811,0.0012326591,0.0000017753929,0.000063906526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99889576,0.00036211967,0.00017713202,0.00014369919,0.000254105,0.00016705842],"domain_scores_gemma":[0.9965096,0.0007264571,0.0020296809,0.00007206395,0.00033799265,0.00032415127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054618483,0.00022842432,0.00036511422,0.0011929777,0.00018571226,0.00076296984,0.00038250606,0.00033250632,0.0014976726],"category_scores_gemma":[0.0045159687,0.00016035931,0.0006316662,0.0014509347,0.00016348326,0.00035621985,0.00041319893,0.00035562232,0.00010793515],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005304252,0.00012352112,0.9924333,0.00006570933,0.00034058213,0.00016183677,0.00004881781,0.0005818325,0.00021969952,0.00007619909,0.00039419983,0.005023872],"study_design_scores_gemma":[0.000048625825,0.00041867341,0.996256,0.000034786095,0.00013271211,0.0005891294,0.00023324262,0.0016976672,0.00020722211,0.000031820695,0.00034269705,0.000007345225],"about_ca_topic_score_codex":0.008102517,"about_ca_topic_score_gemma":0.008703033,"teacher_disagreement_score":0.008102517,"about_ca_system_score_codex":0.0013474996,"about_ca_system_score_gemma":0.0006935083,"threshold_uncertainty_score":0.016110718},"labels":[],"label_agreement":null},{"id":"W2045243711","doi":"10.3111/13696998.2015.1036760","title":"Budgetary impact of the utilization of buprenorphine/naloxone sublingual film and tablet for Medicaid in the United States","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Canada","funders":"Reckitt Benckiser Pharmaceuticals","keywords":"Medicine; Medicaid; (+)-Naloxone; Buprenorphine; Opioid; Anesthesia; Medical emergency; Health care; Internal medicine","score_opus":0.04988832863885652,"score_gpt":0.3365930792004357,"score_spread":0.2867047505615792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045243711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96702987,0.0010959298,0.0021883745,0.0033868586,0.00004921012,0.0002722317,0.007959684,0.00011395165,0.017903922],"genre_scores_gemma":[0.9956269,0.0003502743,0.000858376,0.0002083325,0.000009795998,0.00006555429,0.001705572,0.00000849032,0.0011667201],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9984452,0.00066490954,0.00008171873,0.00011377779,0.00027211924,0.0004223135],"domain_scores_gemma":[0.9968225,0.0014694704,0.0008795525,0.000108495944,0.00029559244,0.0004243836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024117678,0.00053429167,0.000361369,0.0010496676,0.0005785655,0.0016556329,0.0008063617,0.00087886065,0.0047733644],"category_scores_gemma":[0.007676161,0.00068238255,0.0011375216,0.0011686422,0.00041947336,0.0011726689,0.0010044756,0.0009334485,0.00026497248],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002002266,0.00072831,0.21338053,0.00026383714,0.0006482262,0.0008981094,0.0002988763,0.7135588,0.0011791355,0.017574808,0.012748151,0.0367189],"study_design_scores_gemma":[0.00032875405,0.0011182963,0.16901106,0.0003043938,0.00062559155,0.00057919155,0.0012142801,0.81032777,0.0011584123,0.00459606,0.010620852,0.00011526901],"about_ca_topic_score_codex":0.17493467,"about_ca_topic_score_gemma":0.1534782,"teacher_disagreement_score":0.17493467,"about_ca_system_score_codex":0.013358718,"about_ca_system_score_gemma":0.007855944,"threshold_uncertainty_score":0.34783292},"labels":[],"label_agreement":null},{"id":"W2048064344","doi":"10.3111/200609083099","title":"Prediction of acute and chronic complications by a new computer simulation model for type 1 and type 2 diabetes: the Diabetes Mel l it us Model (DMM)","year":2006,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"","keywords":"Medicine; Microalbuminuria; Diabetes mellitus; Type 2 diabetes; Myocardial infarction; Type 1 diabetes; Stroke (engine); Retinopathy; Type 2 Diabetes Mellitus; Diabetic retinopathy; Heart failure; Internal medicine; Disease; Surgery; Cardiology","score_opus":0.052407701612765235,"score_gpt":0.31573156604983793,"score_spread":0.2633238644370727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048064344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.51815075,0.00065550214,0.45913896,0.0033747205,0.00029208665,0.0002972413,0.0034738937,0.00080398173,0.013812819],"genre_scores_gemma":[0.94686455,0.0003941124,0.043996975,0.0002476002,0.00009621735,0.00054350594,0.0012789632,0.000056758654,0.0065213963],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99954766,0.00023070844,0.000024328274,0.000063465224,0.000064159394,0.000069737085],"domain_scores_gemma":[0.99805486,0.0013388993,0.00014046238,0.00008405649,0.00022844347,0.00015327874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011861715,0.00059890415,0.0007133557,0.00064132805,0.0004212782,0.0013074029,0.0009266015,0.0010240029,0.0033160425],"category_scores_gemma":[0.00420074,0.00039703687,0.0009438121,0.0005095369,0.00042209463,0.0007020416,0.00082918967,0.0010463842,0.00029369132],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008874594,0.00006049864,0.003966605,0.000013736362,0.00003288376,0.000042981825,0.000025525092,0.9886835,0.00012323375,0.0037079996,0.000670218,0.0025840267],"study_design_scores_gemma":[0.000028217755,0.000013721882,0.00022408564,0.000003436843,0.00000780134,0.000008193789,0.0000040689624,0.9983841,0.000037885708,0.0009679991,0.00031663073,0.0000039033994],"about_ca_topic_score_codex":0.02849237,"about_ca_topic_score_gemma":0.012502009,"teacher_disagreement_score":0.02849237,"about_ca_system_score_codex":0.0013277408,"about_ca_system_score_gemma":0.0018554659,"threshold_uncertainty_score":0.056653023},"labels":[],"label_agreement":null},{"id":"W2049204477","doi":"10.3111/13696998.2014.925905","title":"Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Takeda Pharmaceuticals International; U.S. Department of Labor","keywords":"Medicine; Diabetes mellitus; Emergency medicine; Total cost; Type 2 diabetes; Multivariate analysis; Type 2 Diabetes Mellitus; Logistic regression; Retrospective cohort study; Cost driver; Internal medicine; Endocrinology","score_opus":0.014911014080041403,"score_gpt":0.25825043689007543,"score_spread":0.24333942281003404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049204477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99533725,0.00027971974,0.00020387884,0.00006627846,0.0000040001487,0.000025356283,0.0037593355,0.000005497379,0.0003185264],"genre_scores_gemma":[0.99565315,0.00020566348,0.00017755105,0.000026182188,0.000012025735,0.000024515635,0.0038135168,0.000003999751,0.00008327882],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99812466,0.00044590977,0.00044378772,0.0003220265,0.0004743402,0.00018921214],"domain_scores_gemma":[0.9923949,0.0014075956,0.004744148,0.00044566227,0.0007316605,0.00027594165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001957044,0.00033239127,0.00047150638,0.0029908589,0.0004116422,0.0012871707,0.0006003507,0.00043875645,0.0012809742],"category_scores_gemma":[0.0075418996,0.00044037827,0.00094688084,0.0044101323,0.00024133839,0.0007570667,0.0008432331,0.00060614763,0.00022489746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048404552,0.000018959401,0.99895656,0.00000869404,0.00007023329,0.000029334467,0.000025341269,0.000077703364,0.000017388933,0.000022813267,0.00013162152,0.0005929986],"study_design_scores_gemma":[0.000006425138,0.00003712035,0.997776,0.000020435857,0.00006705607,0.0002638074,0.00018202857,0.0012974576,0.000042875672,0.00004068045,0.0002588369,0.000007346827],"about_ca_topic_score_codex":0.012168966,"about_ca_topic_score_gemma":0.008198123,"teacher_disagreement_score":0.012168966,"about_ca_system_score_codex":0.0009136708,"about_ca_system_score_gemma":0.0007383666,"threshold_uncertainty_score":0.024196267},"labels":[],"label_agreement":null},{"id":"W2050417509","doi":"10.3111/13696998.2013.841705","title":"Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Schizophrenia (object-oriented programming); Medicaid; Pediatrics; Internal medicine; Psychiatry; Health care","score_opus":0.01667223273340371,"score_gpt":0.2778757055518343,"score_spread":0.26120347281843054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050417509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99893385,0.0002665698,0.00011673751,0.000098665754,0.0000015511662,0.000010455948,0.00040776475,0.000005384797,0.00015894223],"genre_scores_gemma":[0.99917847,0.00010345396,0.00019731931,0.000014085411,0.000002919819,0.000006885039,0.00045880565,0.0000020117905,0.000036020705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991291,0.00026338658,0.00015919055,0.000121883706,0.00020209808,0.00012431515],"domain_scores_gemma":[0.997378,0.0003525018,0.0017507038,0.00008011573,0.0002594772,0.00017926983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010670775,0.00031691664,0.00046063532,0.001632217,0.00026573578,0.0007492543,0.0003936347,0.00033701112,0.0010895717],"category_scores_gemma":[0.005933794,0.00021925864,0.001039066,0.0018182297,0.00019326531,0.0005774598,0.0008352689,0.0005058668,0.00013416697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017298659,0.00002528371,0.99518687,0.000016436412,0.00010899426,0.000041674222,0.000049866005,0.00058083783,0.00009604291,0.000044515822,0.00013497891,0.003541603],"study_design_scores_gemma":[0.00000983606,0.000075205,0.99445736,0.000024636242,0.000035505494,0.00022066827,0.00021326248,0.0047087413,0.00004663363,0.00009033607,0.000110685236,0.0000070216292],"about_ca_topic_score_codex":0.013477091,"about_ca_topic_score_gemma":0.016465595,"teacher_disagreement_score":0.013477091,"about_ca_system_score_codex":0.0012519743,"about_ca_system_score_gemma":0.0007061182,"threshold_uncertainty_score":0.026797295},"labels":[],"label_agreement":null},{"id":"W2050660689","doi":"10.3111/13696998.2014.903256","title":"Is transcatheter aortic valve implantation (TAVI) a cost-effective treatment in patients who are ineligible for surgical aortic valve replacement? A systematic review of economic evaluations","year":2014,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Cardiac Valve Diseases and Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Reimbursement; Economic evaluation; Purchasing power parity; MEDLINE; Health technology; Meta-analysis; Aortic valve replacement; Health care; Checklist; Cost effectiveness; Actuarial science; Finance; Stenosis; Internal medicine; Economics; Exchange rate","score_opus":0.034962450793082404,"score_gpt":0.4217727569544759,"score_spread":0.3868103061613935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050660689","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028654945,0.99487394,0.0003414303,0.00063945877,0.00015530708,0.0003707734,0.00041423357,0.000007818283,0.00033156958],"genre_scores_gemma":[0.06682316,0.9284146,0.0019180351,0.00092359754,0.000186005,0.0012500541,0.000367174,0.00001098474,0.00010647054],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9651932,0.016487565,0.012062883,0.0013613318,0.0044849766,0.00041011686],"domain_scores_gemma":[0.8479795,0.12415383,0.019568436,0.0013497521,0.006297304,0.0006512248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02916646,0.0013180037,0.011542705,0.013932423,0.0006322517,0.0045584347,0.0014122602,0.002564275,0.0024708102],"category_scores_gemma":[0.14875965,0.001217473,0.012447003,0.010859793,0.0012715771,0.0031360013,0.0012179584,0.0017850915,0.00015854095],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008210405,0.00003334404,0.001931871,0.91198117,0.03775461,0.00011726808,0.00014122829,0.00035852508,0.00013465011,0.00048651907,0.0010534861,0.045186274],"study_design_scores_gemma":[0.0010276363,0.0006422718,0.008060297,0.7792233,0.19850966,0.00044187065,0.0003452197,0.0006412091,0.00028735885,0.0010211825,0.009726918,0.00007300882],"about_ca_topic_score_codex":0.0057412544,"about_ca_topic_score_gemma":0.013289379,"teacher_disagreement_score":0.02916646,"about_ca_system_score_codex":0.006703603,"about_ca_system_score_gemma":0.011671676,"threshold_uncertainty_score":0.15424883},"labels":[],"label_agreement":null},{"id":"W2055583871","doi":"10.3111/13696998.2010.534670","title":"Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors","year":2010,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Sunitinib; Medicine; GiST; Imatinib; Imatinib mesylate; Oncology; Internal medicine; Tyrosine-kinase inhibitor; Cancer; Stromal cell","score_opus":0.09181737849537273,"score_gpt":0.39409466349560496,"score_spread":0.3022772850002322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055583871","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0373065,0.951216,0.0017776755,0.0029817217,0.00025638484,0.00034779863,0.0015952534,0.000011684114,0.0045071025],"genre_scores_gemma":[0.5509547,0.4434166,0.0026571036,0.00086705724,0.00033698214,0.00063913583,0.0008320079,0.00001507088,0.00028130214],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98806596,0.008403911,0.001394028,0.00029162483,0.001632816,0.00021177568],"domain_scores_gemma":[0.9497431,0.043619346,0.0046839598,0.00023373222,0.0015431198,0.00017673582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011541568,0.0007999967,0.0021845086,0.0055437335,0.00023714887,0.002155654,0.0006932985,0.0009532061,0.002806525],"category_scores_gemma":[0.056644958,0.00039185234,0.005316266,0.005474948,0.0005119079,0.0013208041,0.00065047917,0.0011829743,0.000088101646],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009360956,0.00040231514,0.027411567,0.28013328,0.059138995,0.001090867,0.00028503206,0.054145526,0.000720788,0.015320777,0.005988304,0.5460016],"study_design_scores_gemma":[0.00810341,0.008742386,0.1552389,0.3732449,0.22948231,0.005739597,0.0020994563,0.058324646,0.005121778,0.0691833,0.08431441,0.00040489907],"about_ca_topic_score_codex":0.004122488,"about_ca_topic_score_gemma":0.0043402654,"teacher_disagreement_score":0.011541568,"about_ca_system_score_codex":0.006322328,"about_ca_system_score_gemma":0.0036482674,"threshold_uncertainty_score":0.061038315},"labels":[],"label_agreement":null},{"id":"W2056855548","doi":"10.3111/13696998.2014.897627","title":"Cost-effectiveness of asenapine in the treatment of schizophrenia in Canada","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal","funders":"","keywords":"Asenapine; Medicine; Olanzapine; Ziprasidone; Schizophrenia (object-oriented programming); Antipsychotic; Quetiapine; Pharmacoeconomics; Psychiatry; Lurasidone; Intensive care medicine","score_opus":0.035539038075372634,"score_gpt":0.31342471114943127,"score_spread":0.27788567307405865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056855548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94045895,0.011901127,0.0037382068,0.0070762546,0.00013266921,0.0010095069,0.012275497,0.000083869236,0.023324009],"genre_scores_gemma":[0.9935173,0.0023339638,0.0015380866,0.00020094801,0.000011687322,0.00006255274,0.001429155,0.0000074362856,0.0008989227],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9980957,0.00055757654,0.00008325779,0.00010392635,0.00063537055,0.000524137],"domain_scores_gemma":[0.9974274,0.0006517404,0.00037432517,0.000029467505,0.0009511351,0.00056598656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015096104,0.0005362261,0.00055019034,0.0012320528,0.0009983092,0.001334828,0.001011565,0.0005661403,0.0033638987],"category_scores_gemma":[0.006324737,0.0002890305,0.0019652029,0.0016754256,0.0005668238,0.0005002412,0.0008292806,0.00090244703,0.000087278495],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009471108,0.0007985024,0.18738772,0.0026772667,0.003395443,0.0011535432,0.0003689865,0.62499464,0.0014646528,0.015826603,0.014653557,0.137808],"study_design_scores_gemma":[0.0022869818,0.0025670987,0.29397228,0.0015607161,0.0031377045,0.00081904064,0.0019660408,0.6690981,0.001404086,0.0077313096,0.015224849,0.00023170834],"about_ca_topic_score_codex":0.96603006,"about_ca_topic_score_gemma":0.9692286,"teacher_disagreement_score":0.07731619,"about_ca_system_score_codex":0.07731619,"about_ca_system_score_gemma":0.076006435,"threshold_uncertainty_score":0.5609708},"labels":[],"label_agreement":null},{"id":"W2059760712","doi":"10.3111/13696998.2015.1033423","title":"Costing bias in economic evaluations","year":2015,"lang":"en","type":"editorial","venue":"Journal of Medical Economics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Université du Québec à Montréal","funders":"","keywords":"Activity-based costing; Health care; Risk analysis (engineering); Health economics; Process (computing); Key (lock); Psychological intervention; Target costing; Medicine; Operations management; Actuarial science; Computer science; Business; Economics; Nursing; Accounting; Computer security","score_opus":0.47134491339926743,"score_gpt":0.5149067998982277,"score_spread":0.04356188649896031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059760712","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025878337,0.14788324,0.007070926,0.18602261,0.65250206,0.00018265485,0.00015278743,0.00014323679,0.0057837367],"genre_scores_gemma":[0.0065361536,0.07291145,0.0071108737,0.08765443,0.82123464,0.00033267675,0.0000836956,0.00022693397,0.003909148],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.8321748,0.09658062,0.027283952,0.004879708,0.038062226,0.001018744],"domain_scores_gemma":[0.3722949,0.5503001,0.016304906,0.008633215,0.050733257,0.0017335811],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.12410376,0.0025940582,0.004863806,0.005457331,0.002617345,0.011973531,0.0053216014,0.018242637,0.007167134],"category_scores_gemma":[0.5291955,0.0012889311,0.0047169253,0.00437756,0.00965721,0.008361502,0.0032128433,0.022728771,0.002587599],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015234135,0.000023899682,0.00023103706,0.006201542,0.0006026933,0.00020527275,0.00026875144,0.000325961,0.00006455062,0.026243862,0.8744927,0.091187395],"study_design_scores_gemma":[0.00036737975,0.000083418345,0.0007905,0.020829316,0.0009144862,0.00064172636,0.0002040006,0.001610734,0.0003579704,0.110200204,0.8638491,0.00015123503],"about_ca_topic_score_codex":0.0011492568,"about_ca_topic_score_gemma":0.0018767088,"teacher_disagreement_score":0.8758962,"about_ca_system_score_codex":0.006039084,"about_ca_system_score_gemma":0.0068619745,"threshold_uncertainty_score":0.6563313},"labels":[],"label_agreement":null},{"id":"W2060564338","doi":"10.3111/13696998.2012.757552","title":"Impact of adoption of a decision algorithm including PCA3 for repeat biopsy on the costs for prostate cancer diagnosis in France","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; PCA3; Sample (material); Biopsy; Prostate biopsy; Gynecology; Cancer; Internal medicine","score_opus":0.04159686773515178,"score_gpt":0.3686790785733814,"score_spread":0.32708221083822964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060564338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98599213,0.001577138,0.0053070323,0.0022529615,0.000046478675,0.00013496229,0.0006158496,0.00012056685,0.0039527942],"genre_scores_gemma":[0.9955319,0.00029761475,0.0030329663,0.00032844575,0.000023639073,0.000047323596,0.00046023965,0.000013791666,0.00026401877],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.98634607,0.010926963,0.00028729398,0.00076796114,0.00096586155,0.0007058968],"domain_scores_gemma":[0.973885,0.020604325,0.0023407522,0.0006239035,0.0018925264,0.0006535267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016505273,0.0009890001,0.00083165977,0.001010156,0.0004193046,0.0023554282,0.00094359054,0.0013738628,0.0024092612],"category_scores_gemma":[0.02578436,0.00033975788,0.0021617345,0.0007308487,0.00050723465,0.00085073424,0.0009474904,0.00087650353,0.00030065907],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005289542,0.00078250264,0.37838924,0.00036671344,0.0015031917,0.00046677951,0.0002616072,0.52221924,0.00058176497,0.002999533,0.003912321,0.083227545],"study_design_scores_gemma":[0.00083702034,0.0036971928,0.25060493,0.0003488546,0.0010066171,0.0007875957,0.00045527276,0.73165417,0.0010193436,0.0031156442,0.006327658,0.00014577512],"about_ca_topic_score_codex":0.06831847,"about_ca_topic_score_gemma":0.028661067,"teacher_disagreement_score":0.06831847,"about_ca_system_score_codex":0.0075770724,"about_ca_system_score_gemma":0.0040806374,"threshold_uncertainty_score":0.13584167},"labels":[],"label_agreement":null},{"id":"W2065318007","doi":"10.3111/13696998.2011.653511","title":"Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"Medical Research Council","keywords":"Medicine; Zoledronic acid; Multiple myeloma; Incidence (geometry); Internal medicine; Cost effectiveness; Adverse effect; Oncology","score_opus":0.09017863653723394,"score_gpt":0.3739058121697349,"score_spread":0.28372717563250094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065318007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7992597,0.1469746,0.0073623834,0.01138301,0.00081140833,0.0010032818,0.009542723,0.00015686755,0.023506084],"genre_scores_gemma":[0.9929477,0.0044991537,0.00086692406,0.00042670296,0.000032153323,0.00010363384,0.0006527836,0.000009080661,0.0004618033],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9963025,0.0028506154,0.00016540971,0.00016284092,0.00027825436,0.00024031513],"domain_scores_gemma":[0.99692994,0.0022474346,0.00040599392,0.00004508289,0.00017388986,0.00019772576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030925293,0.00066255213,0.0016871955,0.0009675527,0.00018798231,0.0023103259,0.0006298216,0.001482474,0.0056559457],"category_scores_gemma":[0.012497871,0.00043692815,0.0031205318,0.0010480913,0.00036856695,0.001140714,0.00080445956,0.0012301632,0.00022904284],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057006862,0.0006604138,0.03261417,0.011456262,0.016312355,0.0012298741,0.000295358,0.71352464,0.0018866261,0.016631344,0.010927482,0.1374547],"study_design_scores_gemma":[0.027764611,0.02262367,0.09373594,0.011002385,0.03707869,0.0035056807,0.0015821654,0.74677825,0.003199511,0.02972825,0.02254307,0.00045781382],"about_ca_topic_score_codex":0.022149097,"about_ca_topic_score_gemma":0.015430645,"teacher_disagreement_score":0.022149097,"about_ca_system_score_codex":0.00696432,"about_ca_system_score_gemma":0.0030016862,"threshold_uncertainty_score":0.050529957},"labels":[],"label_agreement":null},{"id":"W2067254496","doi":"10.3111/13696998.2013.858634","title":"Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Rivaroxaban; Vitamin K antagonist; Pulmonary embolism; Low molecular weight heparin; Enoxaparin sodium; Deep vein; Cost effectiveness; Venous thrombosis; Thrombosis; Cost-effectiveness analysis; Anticoagulant; Anesthesia; Internal medicine; Warfarin; Atrial fibrillation","score_opus":0.04347617111276509,"score_gpt":0.3114251669344934,"score_spread":0.2679489958217283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067254496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9660412,0.00441131,0.014729383,0.0019687614,0.00013011311,0.0006895558,0.0035143893,0.00009309793,0.008422208],"genre_scores_gemma":[0.9962656,0.000636631,0.001541434,0.000117982694,0.000013320466,0.000177038,0.00064271915,0.000006546045,0.00059867173],"study_design_codex":"simulation_or_modeling","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9985056,0.000954043,0.00007344158,0.00015583758,0.00012871267,0.00018243567],"domain_scores_gemma":[0.9955445,0.0033518411,0.0006236344,0.00006570652,0.00013796425,0.000276258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003307378,0.0008340974,0.0018855714,0.0011838796,0.00039379415,0.0014645597,0.0011814957,0.0011363134,0.00583021],"category_scores_gemma":[0.010185928,0.0007385038,0.003390465,0.0007678838,0.00055840675,0.0011282853,0.0007265245,0.001160198,0.0001998221],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007918819,0.00035998368,0.011923825,0.00042536735,0.001643355,0.00019714693,0.000040446037,0.9642618,0.0003515808,0.0046367105,0.0007230789,0.0075178137],"study_design_scores_gemma":[0.003105108,0.0033280049,0.011007378,0.00041306077,0.003948839,0.00035552873,0.00008366072,0.9689002,0.00065832003,0.0069143036,0.0012069609,0.00007863666],"about_ca_topic_score_codex":0.013357938,"about_ca_topic_score_gemma":0.007633355,"teacher_disagreement_score":0.013357938,"about_ca_system_score_codex":0.005194203,"about_ca_system_score_gemma":0.0044628493,"threshold_uncertainty_score":0.037686765},"labels":[],"label_agreement":null},{"id":"W2069848730","doi":"10.3111/13696998.2014.914032","title":"A cost-analysis model for anticoagulant treatment in the hospital setting","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Rivaroxaban; Medicine; Deep vein; Pulmonary embolism; Anticoagulant; Atrial fibrillation; Thrombosis; Stroke (engine); Emergency medicine; Cost effectiveness; Intensive care medicine; Surgery; Internal medicine; Warfarin","score_opus":0.0905700533176745,"score_gpt":0.3698003849969684,"score_spread":0.2792303316792939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069848730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4717409,0.0045045516,0.4022465,0.012146098,0.0007886163,0.0026450127,0.02478324,0.0009633241,0.08018174],"genre_scores_gemma":[0.9160019,0.001469125,0.0473393,0.00071208837,0.00016760526,0.0028712219,0.0049588624,0.0001197541,0.026360078],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99853754,0.00075938937,0.000057582183,0.00020904696,0.00014490413,0.00029151147],"domain_scores_gemma":[0.9954354,0.0033935893,0.00029182783,0.00007625296,0.00054204016,0.00026092058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00229078,0.0020527286,0.0020422195,0.002114387,0.0009660375,0.002867896,0.0031938264,0.0042464314,0.015951524],"category_scores_gemma":[0.00820953,0.0015079115,0.0024696516,0.0023537837,0.0008629251,0.0017113449,0.0012438281,0.0030257485,0.0010423026],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014272654,0.000057446297,0.00090191973,0.000045166205,0.000056478868,0.00010321693,0.000014621833,0.9912627,0.00004769324,0.004765887,0.0009127254,0.00168937],"study_design_scores_gemma":[0.00014971271,0.0000589862,0.00040339978,0.000020908943,0.000050923336,0.000039224244,0.000028177494,0.995503,0.000027988546,0.0028968505,0.00080661377,0.000014224326],"about_ca_topic_score_codex":0.06868392,"about_ca_topic_score_gemma":0.029191593,"teacher_disagreement_score":0.06868392,"about_ca_system_score_codex":0.005783116,"about_ca_system_score_gemma":0.0058889217,"threshold_uncertainty_score":0.13656825},"labels":[],"label_agreement":null},{"id":"W2071344217","doi":"10.3111/13696998.2011.653726","title":"Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Merz Pharmaceuticals","keywords":"Medicine; Cervical dystonia; Botulinum toxin; Patient satisfaction; Cross-sectional study; Quality of life (healthcare); Adverse effect; Physical therapy; Visual analogue scale; Internal medicine; Anesthesia; Surgery","score_opus":0.03516939767736518,"score_gpt":0.2643901803924858,"score_spread":0.2292207827151206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071344217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989994,0.00017383204,0.000038931114,0.0001042093,0.0000034272139,0.00001489421,0.00027346864,0.000002633667,0.0003891591],"genre_scores_gemma":[0.99951243,0.00008012211,0.00004389208,0.000077676195,0.0000033525075,0.000010776639,0.00017873272,8.036807e-7,0.00009223108],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991635,0.0002892099,0.00011473132,0.000077411,0.00024044761,0.000114703966],"domain_scores_gemma":[0.99758077,0.00058167585,0.0011248108,0.00005056196,0.0002941572,0.00036796206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012225687,0.00014146004,0.00034017905,0.00058751105,0.0003297177,0.00049119926,0.00021994249,0.0006252352,0.0017242464],"category_scores_gemma":[0.0032503402,0.00019613476,0.00042466394,0.0007965288,0.00029047308,0.0004917186,0.0003841813,0.000544178,0.00022947039],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004538714,0.000048290272,0.9981913,0.000014471367,0.000033746623,0.00003710256,0.00017085418,0.000033980657,0.00009108765,0.0000052745013,0.00011889045,0.0012095202],"study_design_scores_gemma":[0.000007257646,0.00026979097,0.99868876,0.000007448713,0.000012906666,0.0002401038,0.0004533588,0.0001289705,0.000024121957,0.000003188725,0.00016031669,0.0000037794746],"about_ca_topic_score_codex":0.005561303,"about_ca_topic_score_gemma":0.0056323158,"teacher_disagreement_score":0.005561303,"about_ca_system_score_codex":0.00041225072,"about_ca_system_score_gemma":0.00032295918,"threshold_uncertainty_score":0.011057854},"labels":[],"label_agreement":null},{"id":"W2072574820","doi":"10.3111/13696998.2013.772058","title":"Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured population","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"GlaxoSmithKline","keywords":"Medicine; Lupus nephritis; Systemic lupus erythematosus; Population; Internal medicine; Health care; Lupus erythematosus; Disease; Immunology","score_opus":0.014061235590230087,"score_gpt":0.27046570220216126,"score_spread":0.25640446661193117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072574820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99947995,0.00010259254,0.0000128597,0.000041900646,0.00000210694,0.000004111614,0.00020492039,0.0000011741266,0.00015037689],"genre_scores_gemma":[0.9995573,0.000051674422,0.000025817493,0.000027976343,0.000009033755,0.000005134111,0.00027603656,4.2056703e-7,0.000046616282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994956,0.00014418547,0.00006624684,0.00008538431,0.00012519563,0.00008329955],"domain_scores_gemma":[0.9990006,0.00014276025,0.0005634545,0.00003423248,0.00005602613,0.00020302788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045847916,0.0002434333,0.00033418142,0.00085620047,0.00049610593,0.00070054113,0.00032974788,0.00046294014,0.0012752885],"category_scores_gemma":[0.0021427842,0.00023558058,0.0005032188,0.0012419766,0.0002533655,0.0005237924,0.00046424693,0.00058274117,0.00014989528],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006470178,0.0000623404,0.9991092,0.0000035181918,0.000060292583,0.00009134755,0.000032079588,0.000050429644,0.000045453187,0.000010161496,0.00006574293,0.0004047914],"study_design_scores_gemma":[0.000008639161,0.00006935187,0.9992435,0.000003036193,0.000018973204,0.00022492153,0.00009283094,0.00027297728,0.000010735462,0.000011338994,0.000041476356,0.0000022609554],"about_ca_topic_score_codex":0.013580157,"about_ca_topic_score_gemma":0.010961536,"teacher_disagreement_score":0.013580157,"about_ca_system_score_codex":0.00068130286,"about_ca_system_score_gemma":0.00036216516,"threshold_uncertainty_score":0.027002215},"labels":[],"label_agreement":null},{"id":"W2083738707","doi":"10.3111/13696998.2011.578698","title":"Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Pulmonary embolism; Major bleeding; Deep vein; Knee replacement; Thrombosis; Population; Venous thromboembolism; Diagnosis code; Surgery; Arthroplasty; Internal medicine","score_opus":0.04853567880147308,"score_gpt":0.2993872589950098,"score_spread":0.2508515801935367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083738707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985311,0.00028950738,0.00004427786,0.00040750045,0.000005577038,0.000008087379,0.00038288298,0.0000025512315,0.00032839662],"genre_scores_gemma":[0.99913174,0.00017618363,0.000085349966,0.000062803796,0.00002484124,0.000008271617,0.00046739477,6.4389354e-7,0.000042752607],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999413,0.00022390322,0.000058872698,0.000066531444,0.00014457974,0.00009311848],"domain_scores_gemma":[0.99836046,0.00024709228,0.0010694446,0.00003476366,0.0000903773,0.00019784301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000537176,0.00018931463,0.00022243525,0.00074529316,0.00030702536,0.0006855328,0.00032909654,0.00041145863,0.0012961901],"category_scores_gemma":[0.003663992,0.00015708778,0.0005572474,0.0011430396,0.00020996797,0.00049619604,0.0004253044,0.000505551,0.00008766587],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000071138726,0.000068163754,0.99680257,0.00001030641,0.00013070284,0.00013946896,0.000041210747,0.00023984215,0.000048761984,0.00008669756,0.00036210628,0.0019989905],"study_design_scores_gemma":[0.00003181941,0.000112614725,0.9970085,0.000016956761,0.00007800727,0.00040302356,0.00017554166,0.0017655835,0.000020515141,0.0001401533,0.00024230941,0.0000049127048],"about_ca_topic_score_codex":0.009946322,"about_ca_topic_score_gemma":0.010908968,"teacher_disagreement_score":0.009946322,"about_ca_system_score_codex":0.0011402436,"about_ca_system_score_gemma":0.00066976715,"threshold_uncertainty_score":0.019776821},"labels":[],"label_agreement":null},{"id":"W2087722862","doi":"10.3111/13696998.2013.820193","title":"Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University; University of Toronto","funders":"","keywords":"Medicine; Risperidone; Czech; Paliperidone; Paliperidone Palmitate; Atypical antipsychotic; Antipsychotic; Schizophrenia (object-oriented programming); Psychiatry","score_opus":0.05098097676767101,"score_gpt":0.3923835462629965,"score_spread":0.3414025694953255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087722862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97584575,0.012540159,0.0020074034,0.00073612825,0.00007431945,0.0011026014,0.0018844103,0.00001842731,0.005790829],"genre_scores_gemma":[0.9976726,0.0008200507,0.0006184303,0.000063941334,0.000008910468,0.00018004714,0.00042314225,0.000004957805,0.00020786458],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9944681,0.0035237,0.00046400924,0.0002637606,0.0008444098,0.00043603918],"domain_scores_gemma":[0.9953265,0.0024549582,0.0009853299,0.00016361431,0.00058066094,0.00048894685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009455265,0.0006135558,0.001216851,0.0019680685,0.00033271938,0.002099661,0.0009614748,0.0006652181,0.0026662888],"category_scores_gemma":[0.018736009,0.0003621912,0.0038175627,0.0014392965,0.0006174527,0.00072132936,0.0017117792,0.00092443795,0.000113179536],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.098909095,0.0028443714,0.10278338,0.007986401,0.017306102,0.0008181601,0.0003910287,0.6581149,0.0039701457,0.013074664,0.0032857556,0.09051601],"study_design_scores_gemma":[0.030415474,0.03236748,0.5179234,0.0048833275,0.01623891,0.0011707357,0.0020604986,0.3686289,0.003090509,0.010194597,0.012499667,0.00052646763],"about_ca_topic_score_codex":0.02073738,"about_ca_topic_score_gemma":0.016057149,"teacher_disagreement_score":0.02073738,"about_ca_system_score_codex":0.0088351825,"about_ca_system_score_gemma":0.006115398,"threshold_uncertainty_score":0.06410402},"labels":[],"label_agreement":null},{"id":"W2088026712","doi":"10.3111/13696998.2012.693896","title":"The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Lethbridge","keywords":"Medicine; Internal medicine; Confounding; Medical prescription; Myeloid leukemia; Pleural effusion","score_opus":0.007333948391764676,"score_gpt":0.23089702428171546,"score_spread":0.22356307588995078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088026712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997761,0.001020317,0.00005417075,0.0001961709,0.0000065598047,0.00000928511,0.00065626396,0.0000014352321,0.00029474843],"genre_scores_gemma":[0.99907243,0.00036884347,0.000050540737,0.000033926528,0.000017611848,0.00000572336,0.00041458287,4.633069e-7,0.000035808174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892503,0.00040772866,0.00017725347,0.000091574664,0.00026062626,0.00013771892],"domain_scores_gemma":[0.9972963,0.0004019245,0.0019074543,0.00005110613,0.00012725902,0.00021610917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072642136,0.00019413614,0.00030883733,0.00087935897,0.000312544,0.0008020255,0.00026022515,0.00034231483,0.0012746127],"category_scores_gemma":[0.0043069967,0.00015531716,0.0006014982,0.0014543142,0.00021879503,0.0004908943,0.00075463974,0.00039131404,0.000101880665],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010449318,0.000028523398,0.9968586,0.000022567157,0.000117581,0.00011973589,0.000023688619,0.00014656698,0.00006102268,0.000034742297,0.00016320942,0.0023194202],"study_design_scores_gemma":[0.000014330722,0.00005841235,0.9981686,0.000025799334,0.00005218736,0.0005313466,0.00013473288,0.00069696846,0.00003349068,0.000039195707,0.00024193566,0.0000031628656],"about_ca_topic_score_codex":0.004224757,"about_ca_topic_score_gemma":0.004321431,"teacher_disagreement_score":0.004224757,"about_ca_system_score_codex":0.0006272589,"about_ca_system_score_gemma":0.00043997145,"threshold_uncertainty_score":0.008400321},"labels":[],"label_agreement":null},{"id":"W2089796211","doi":"10.3111/13696998.2013.802239","title":"Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Fingolimod; Multiple sclerosis; Randomized controlled trial; Natalizumab; Physical therapy; Disease; Internal medicine","score_opus":0.17371279418505037,"score_gpt":0.369475554435499,"score_spread":0.19576276025044864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089796211","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8831321,0.0023355116,0.0024884,0.0013976801,0.0014076352,0.09961335,0.0052148784,0.00028590398,0.004124451],"genre_scores_gemma":[0.8431445,0.001710774,0.008837585,0.0035389333,0.002319545,0.12999943,0.003443958,0.00007293341,0.0069324053],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99562776,0.0023394038,0.00024109325,0.00065538625,0.00056473643,0.00057169807],"domain_scores_gemma":[0.99453884,0.0014211906,0.0009780013,0.0005786025,0.00069233845,0.0017909517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0077861454,0.0029259557,0.0059257583,0.00096886815,0.0015230146,0.0016512595,0.0018172251,0.004171128,0.010098248],"category_scores_gemma":[0.005407918,0.0012722022,0.0017877436,0.0010465428,0.0037802337,0.0022231012,0.00091666257,0.0053298236,0.001965603],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96799254,0.023561388,0.00086103356,0.00022061648,0.00032667673,0.000038863654,0.000033706772,0.00016922303,0.0013807617,0.00011587948,0.00064167095,0.004657572],"study_design_scores_gemma":[0.9398732,0.058314905,0.00079899945,0.000009403854,0.00010718885,0.000011980386,0.000007606255,0.0001402826,0.00017817243,0.00008859697,0.0004603255,0.000009311516],"about_ca_topic_score_codex":0.0015309134,"about_ca_topic_score_gemma":0.0030868025,"teacher_disagreement_score":0.010098248,"about_ca_system_score_codex":0.0015685756,"about_ca_system_score_gemma":0.0060995333,"threshold_uncertainty_score":0.04117751},"labels":[],"label_agreement":null},{"id":"W2090977676","doi":"10.3111/13696998.2015.1025793","title":"Utilities for asthma and COPD according to category of severity: a comprehensive literature review","year":2015,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; COPD; Asthma; Pulmonary disease; Quality of life (healthcare); MEDLINE; Internal medicine; Severity of illness; Physical therapy; Disease; Intensive care medicine","score_opus":0.07019135828087612,"score_gpt":0.39095609226121186,"score_spread":0.3207647339803357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090977676","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002028879,0.99688476,0.000116421856,0.0002694213,0.000041846808,0.00006310014,0.0003372034,0.0000041186695,0.00025416748],"genre_scores_gemma":[0.024964385,0.97342366,0.00071125716,0.00026552458,0.0000749877,0.00016986961,0.00033413488,0.0000034169643,0.000052695766],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9948631,0.0015730537,0.0019713761,0.0003891203,0.0010216096,0.00018179008],"domain_scores_gemma":[0.97473335,0.020065982,0.0034687368,0.00017039722,0.0013799393,0.0001816081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006526122,0.0013796503,0.0054632085,0.023505962,0.0005066866,0.002478526,0.0013617884,0.0013781938,0.0029688242],"category_scores_gemma":[0.032593157,0.00081130565,0.008042708,0.021317858,0.0006149535,0.002557599,0.001163178,0.00097618246,0.0002005866],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045948933,0.000072040435,0.010393678,0.69927824,0.010919049,0.00028590113,0.00048596744,0.0006838906,0.0001247321,0.0011099898,0.0051266556,0.27106047],"study_design_scores_gemma":[0.00029876188,0.000462029,0.05647365,0.8412522,0.059517294,0.0027537937,0.001432274,0.00082549977,0.00020874233,0.0024409236,0.03418843,0.00014636255],"about_ca_topic_score_codex":0.005958416,"about_ca_topic_score_gemma":0.009558139,"teacher_disagreement_score":0.023505962,"about_ca_system_score_codex":0.004020914,"about_ca_system_score_gemma":0.004606488,"threshold_uncertainty_score":0.03451389},"labels":[],"label_agreement":null},{"id":"W2091519380","doi":"10.3111/13696998.2014.925464","title":"Consequences of patient access restrictions to branded oxycodone hydrochloride extended-release tablets on healthcare utilization and costs in US health plans","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Purdue Pharma (Canada)","funders":"","keywords":"Medicine; Prior authorization; Pharmacy; Oxycodone; Medical prescription; Health care; Health plan; Emergency medicine; Retrospective cohort study; Medicare Advantage; Medical costs; Cohort; Family medicine; Internal medicine; Opioid; Pharmacology","score_opus":0.03254786490543145,"score_gpt":0.3375770262442395,"score_spread":0.3050291613388081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091519380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989706,0.00012712402,0.000034573375,0.00011310645,0.000003333104,0.000007402251,0.00051370217,0.0000015160031,0.00022866442],"genre_scores_gemma":[0.999368,0.00006114975,0.000052977513,0.000046591187,0.000008880592,0.0000068060513,0.00041127932,7.393703e-7,0.000043486983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984547,0.00042982755,0.00019340009,0.00018518485,0.00043789178,0.000298962],"domain_scores_gemma":[0.99358845,0.0009499208,0.004514792,0.00017777509,0.00029958392,0.0004694849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012378619,0.00020823404,0.00025459102,0.00058324734,0.00037801018,0.00080209353,0.0003165075,0.00039059663,0.0013854456],"category_scores_gemma":[0.0067634536,0.00020048105,0.0009154106,0.001039413,0.00026361656,0.0005520257,0.000741159,0.00071350933,0.00007073526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013298752,0.00006421235,0.998235,0.0000061948213,0.0000644346,0.000045253586,0.000030718646,0.0001629175,0.000054336837,0.000018281677,0.00008881262,0.0010968813],"study_design_scores_gemma":[0.000003260137,0.00005024169,0.99953675,0.000003767146,0.000014454173,0.00006214893,0.00005078111,0.00018734054,0.00002403064,0.000006989721,0.000058525726,0.0000018718606],"about_ca_topic_score_codex":0.022441247,"about_ca_topic_score_gemma":0.028431058,"teacher_disagreement_score":0.022441247,"about_ca_system_score_codex":0.0014031456,"about_ca_system_score_gemma":0.0009510996,"threshold_uncertainty_score":0.04462123},"labels":[],"label_agreement":null},{"id":"W2091908067","doi":"10.3111/200407067083","title":"Impact on health outcome and costs of influenza treatment with oseltamivir in elderly and high-risk patients","year":2004,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Toronto General Hospital","funders":"","keywords":"Medicine; Oseltamivir; Health care; Univariate; Population; Quality-adjusted life year; Intensive care medicine; Emergency medicine; Public health; Cost effectiveness; Internal medicine; Environmental health; Multivariate statistics; Risk analysis (engineering); Disease; Statistics","score_opus":0.042468196841185774,"score_gpt":0.3852910886054576,"score_spread":0.34282289176427183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091908067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954217,0.0018538443,0.00066625996,0.0004336939,0.000013946919,0.000030980682,0.00057858427,0.0000043230352,0.0009965874],"genre_scores_gemma":[0.999295,0.00016171117,0.00017142146,0.00004098689,0.0000077038085,0.00001270926,0.00023488548,7.030065e-7,0.000074807605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980574,0.0014175564,0.0001079952,0.0000811873,0.00017992979,0.00015586542],"domain_scores_gemma":[0.99508935,0.0032086156,0.0010012366,0.00011825702,0.00027698255,0.00030564037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030661353,0.0003362534,0.0007178146,0.0005116623,0.00017317025,0.0008516346,0.0002855917,0.0005778347,0.0018152948],"category_scores_gemma":[0.009837275,0.00016045735,0.0017042316,0.00039507865,0.0002579956,0.0005686423,0.0005189652,0.0005938457,0.00011303167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013819661,0.0012498377,0.805587,0.0006277619,0.004823057,0.0012842536,0.00014205363,0.11986329,0.0008310001,0.002676991,0.0010132949,0.048081797],"study_design_scores_gemma":[0.0017421407,0.009233304,0.76554525,0.0003758109,0.0048989933,0.0016929226,0.00049704756,0.20488423,0.0013224878,0.0077172895,0.001982961,0.00010760557],"about_ca_topic_score_codex":0.0038110998,"about_ca_topic_score_gemma":0.0032457244,"teacher_disagreement_score":0.0038110998,"about_ca_system_score_codex":0.0016700823,"about_ca_system_score_gemma":0.000676205,"threshold_uncertainty_score":0.016215503},"labels":[],"label_agreement":null},{"id":"W2095016204","doi":"10.3111/13696990903288970","title":"Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective","year":2009,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Pfizer (Canada); Université Laval; Sunnybrook Health Science Centre; Centre hospitalier de l'Université Laval","funders":"","keywords":"Celecoxib; Medicine; Rheumatoid arthritis; Osteoarthritis; Internal medicine; Physical therapy; Alternative medicine","score_opus":0.027049251592629796,"score_gpt":0.28250903364859586,"score_spread":0.2554597820559661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095016204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90012133,0.029312663,0.008205794,0.006379827,0.00010986168,0.0012113731,0.023213197,0.00008499936,0.031360812],"genre_scores_gemma":[0.99356127,0.0020960688,0.0012729771,0.00020312687,0.000013066348,0.00010812954,0.001633927,0.0000050306176,0.0011064579],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9981694,0.0010025066,0.00008931112,0.00013144384,0.0002926411,0.00031466308],"domain_scores_gemma":[0.9968033,0.0016306494,0.00054025644,0.00004679498,0.0006911363,0.00028785167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022107426,0.00077420933,0.0007687097,0.0017919189,0.00058962335,0.0022930806,0.0011255506,0.0008607567,0.0045393063],"category_scores_gemma":[0.009594705,0.0003367707,0.001814164,0.002489789,0.000522179,0.0007413575,0.0005936909,0.0006101229,0.00016764652],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031263384,0.00028697867,0.12464264,0.0016882558,0.004008951,0.0007019311,0.00019292283,0.8089421,0.00083635066,0.007281408,0.0044715023,0.0438206],"study_design_scores_gemma":[0.0024823972,0.0018007902,0.17220607,0.0014393962,0.004623222,0.00054131495,0.0009083631,0.8000518,0.00075494486,0.0042417045,0.010725,0.00022494503],"about_ca_topic_score_codex":0.898901,"about_ca_topic_score_gemma":0.85810673,"teacher_disagreement_score":0.898901,"about_ca_system_score_codex":0.04094444,"about_ca_system_score_gemma":0.021095755,"threshold_uncertainty_score":0.29707414},"labels":[],"label_agreement":null},{"id":"W2097511134","doi":"10.3111/13696998.2013.857676","title":"Understanding the economic, daily functioning, and diabetes management burden of non-severe nocturnal hypoglycemic events in Canada: differences between type 1 and type 2","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Type 2 diabetes; Nocturnal; Diabetes mellitus; Diabetes management; Type 1 diabetes; Pediatrics; Gerontology; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.039867397513276434,"score_gpt":0.25278472761986875,"score_spread":0.2129173301065923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097511134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99125564,0.0016685025,0.00008210417,0.0012195511,0.000016305137,0.00003156174,0.0024560038,0.000004208641,0.0032661415],"genre_scores_gemma":[0.9970913,0.0012633095,0.000116963856,0.0001864708,0.0000066430116,0.000010176441,0.0008527722,0.0000018803474,0.00047050987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991879,0.000048676135,0.000043884942,0.000065926615,0.00033366313,0.00032005398],"domain_scores_gemma":[0.9984067,0.00011270847,0.00038331826,0.000022043005,0.0006073255,0.000467813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075943314,0.0002656256,0.00030893274,0.0013532927,0.0019484116,0.0014937482,0.00077388214,0.00036086843,0.0021760676],"category_scores_gemma":[0.0029747526,0.00021087662,0.0006225286,0.0033927278,0.0004881686,0.0006126317,0.0008148926,0.0006545993,0.00012464932],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046031157,0.00004060771,0.9891122,0.00006167038,0.00004520338,0.000070067406,0.0010161004,0.00015068096,0.000057977064,0.00009345738,0.0009471545,0.008358904],"study_design_scores_gemma":[0.000003492824,0.000012799048,0.99752,0.000042442043,0.000013889804,0.0000240647,0.0016997625,0.0001671977,0.0000158962,0.000021012236,0.0004738567,0.0000054973416],"about_ca_topic_score_codex":0.9939733,"about_ca_topic_score_gemma":0.995611,"teacher_disagreement_score":0.022241095,"about_ca_system_score_codex":0.022241095,"about_ca_system_score_gemma":0.024020396,"threshold_uncertainty_score":0.16137117},"labels":[],"label_agreement":null},{"id":"W2100428999","doi":"10.3111/13696998.2011.564699","title":"An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Rivaroxaban; Dabigatran; Venous thromboembolism; Knee replacement; Hip replacement; Surgery; Internal medicine; Atrial fibrillation; Warfarin; Arthroplasty; Thrombosis","score_opus":0.03965693725439577,"score_gpt":0.29923342596447877,"score_spread":0.259576488710083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100428999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93122596,0.05608033,0.0018757338,0.0006635822,0.0015231506,0.0017081023,0.0013722187,0.00004859809,0.005502386],"genre_scores_gemma":[0.98535764,0.008809183,0.0019210231,0.00030543312,0.00055545074,0.00094262237,0.00051342,0.000010149885,0.0015850014],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98618907,0.010633566,0.0010920197,0.00082245405,0.0010243789,0.00023854838],"domain_scores_gemma":[0.98334527,0.011910716,0.003014394,0.0006642744,0.000660471,0.00040481542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072865416,0.0016603234,0.0032485207,0.0008497539,0.00030191086,0.001653902,0.00071182166,0.0015692769,0.0068958267],"category_scores_gemma":[0.01878474,0.0006096201,0.005665611,0.0007488343,0.00089980377,0.0011297301,0.0008035363,0.0023253793,0.00053203455],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9295211,0.001963325,0.0039828094,0.006708584,0.031019177,0.00006138112,0.000115757895,0.00091252214,0.001345636,0.0004915923,0.0003064137,0.0235718],"study_design_scores_gemma":[0.64927685,0.23923704,0.019617444,0.0012258351,0.078974165,0.00030076757,0.00013141066,0.0019660497,0.0040472024,0.0010467543,0.0040803966,0.000096100564],"about_ca_topic_score_codex":0.0006832113,"about_ca_topic_score_gemma":0.0009022214,"teacher_disagreement_score":0.0072865416,"about_ca_system_score_codex":0.000819365,"about_ca_system_score_gemma":0.0007894657,"threshold_uncertainty_score":0.038535416},"labels":[],"label_agreement":null},{"id":"W2103138885","doi":"10.3111/13696990801954780","title":"Cost comparison of four revascularisation procedures for the treatment of multivessel coronary artery disease: a commentary","year":2008,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Coronary Interventions and Diagnostics","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University","funders":"","keywords":"Medicine; Coronary artery disease; Cardiology; Internal medicine; Coronary disease; Surgery; Coronary heart disease","score_opus":0.08246746776260393,"score_gpt":0.35269854481115326,"score_spread":0.2702310770485493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103138885","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009392094,0.08461688,0.00070347724,0.8258654,0.06715608,0.0002674135,0.0029982426,0.00006488946,0.008935513],"genre_scores_gemma":[0.09351929,0.03330759,0.002509463,0.7881131,0.07457754,0.0006233907,0.0009770191,0.00012561814,0.006247006],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.987035,0.006540903,0.0015059996,0.0011913097,0.0030088627,0.00071793207],"domain_scores_gemma":[0.90586454,0.07916454,0.0028892374,0.00080177106,0.008726946,0.002553086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014395253,0.0013303896,0.0037207308,0.0019150149,0.0014990111,0.0030235813,0.0053331233,0.020695081,0.012682025],"category_scores_gemma":[0.08719022,0.00080693327,0.0049500596,0.0026712536,0.0022935888,0.0026527124,0.0013667998,0.017902818,0.0017923855],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017988034,0.00035984025,0.0014864102,0.010448781,0.0050086244,0.0007154685,0.00042357002,0.001516238,0.0007412408,0.020114377,0.8642553,0.07694215],"study_design_scores_gemma":[0.046960436,0.0033457193,0.015139485,0.041097045,0.02859695,0.0013971708,0.0025316416,0.003974946,0.0016654498,0.05878052,0.79592353,0.0005872208],"about_ca_topic_score_codex":0.027649708,"about_ca_topic_score_gemma":0.04139448,"teacher_disagreement_score":0.027649708,"about_ca_system_score_codex":0.008918141,"about_ca_system_score_gemma":0.00857252,"threshold_uncertainty_score":0.07613027},"labels":[],"label_agreement":null},{"id":"W2104230558","doi":"10.3111/13696998.2012.669438","title":"In-hospital risk of venous thromboembolism and bleeding and associated costs for patients undergoing total hip or knee arthroplasty","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Venous thromboembolism; Total knee arthroplasty; Arthroplasty; Major bleeding; Surgery; Total hip replacement; Total hip arthroplasty; Thrombosis; Internal medicine","score_opus":0.010209279603239595,"score_gpt":0.25533348836190894,"score_spread":0.24512420875866936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104230558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99551755,0.001162118,0.00011810387,0.0004154989,0.000015728736,0.000021483056,0.0018789981,0.000005450915,0.0008650183],"genre_scores_gemma":[0.99839956,0.00033018,0.00014813109,0.000053870444,0.000025760062,0.000009957059,0.0009416836,0.0000013020575,0.0000896208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993668,0.00018945846,0.00011642092,0.0000663759,0.00015143427,0.000109562854],"domain_scores_gemma":[0.9980292,0.00029516724,0.0013003555,0.000026965432,0.00013088952,0.0002174039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041319206,0.00026387986,0.0002856004,0.0007436596,0.00024390769,0.00060848,0.0002851708,0.0003622192,0.0024203737],"category_scores_gemma":[0.00386125,0.00018284246,0.0007182874,0.0010013898,0.0001216598,0.00040054828,0.00038097615,0.00054858223,0.0001507904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018899386,0.000052883683,0.9956923,0.000060116876,0.00019413907,0.0001366073,0.000023609602,0.0002915073,0.000059484526,0.00005966042,0.0005003717,0.0027403245],"study_design_scores_gemma":[0.000030163685,0.0001226724,0.9971486,0.000036088808,0.00010457372,0.00073448545,0.00012003109,0.0012622344,0.00005547421,0.00007895077,0.00029944093,0.000007272311],"about_ca_topic_score_codex":0.0059915655,"about_ca_topic_score_gemma":0.009838395,"teacher_disagreement_score":0.0059915655,"about_ca_system_score_codex":0.001044686,"about_ca_system_score_gemma":0.000671657,"threshold_uncertainty_score":0.011913419},"labels":[],"label_agreement":null},{"id":"W2105831881","doi":"10.3111/13696998.2012.718019","title":"A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Parathyroid Disorders and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Humber River Regional Hospital","funders":"","keywords":"Sevelamer; Medicine; Hyperphosphatemia; Dialysis; Kidney disease; Intensive care medicine; Internal medicine; Cost effectiveness; Quality-adjusted life year; Emergency medicine","score_opus":0.04638274081642033,"score_gpt":0.3175203668618774,"score_spread":0.27113762604545705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105831881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9647651,0.004362393,0.01073666,0.001339312,0.00009395964,0.0010374193,0.003464455,0.00006828262,0.014132508],"genre_scores_gemma":[0.9951696,0.0005181365,0.0022834933,0.00009775166,0.000007955211,0.00029084095,0.0005423948,0.000007716133,0.0010822291],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9976419,0.0017797443,0.00007988726,0.00012748086,0.00013671459,0.00023423183],"domain_scores_gemma":[0.99175113,0.0068230075,0.00051676715,0.00012192406,0.00047680194,0.0003103725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00402789,0.001202363,0.001585445,0.00093201955,0.0004538982,0.0019973647,0.001132925,0.0017041236,0.0050803116],"category_scores_gemma":[0.013610654,0.00080632296,0.0021819284,0.00081979885,0.0006336805,0.0009990442,0.0011528784,0.0011739089,0.00020723279],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035687278,0.0003081245,0.005204609,0.0006752488,0.00047125987,0.00035730813,0.00007829106,0.9794574,0.00032445265,0.0033451496,0.0008130443,0.0053963987],"study_design_scores_gemma":[0.0027297158,0.0037485836,0.0072938516,0.000392371,0.0008134517,0.0002494774,0.00024049116,0.9799454,0.0003717993,0.0021398072,0.0020038267,0.00007118934],"about_ca_topic_score_codex":0.04913307,"about_ca_topic_score_gemma":0.026514502,"teacher_disagreement_score":0.04913307,"about_ca_system_score_codex":0.008338049,"about_ca_system_score_gemma":0.0039430857,"threshold_uncertainty_score":0.09769416},"labels":[],"label_agreement":null},{"id":"W2106512674","doi":"10.3111/13696990701438629","title":"Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model","year":2007,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Johns Hopkins University; Sanofi","keywords":"Medicine; Rimonabant; Overweight; Quality-adjusted life year; Cost effectiveness; Obesity; Internal medicine; Risk analysis (engineering)","score_opus":0.01895269973768576,"score_gpt":0.2711988113097658,"score_spread":0.25224611157208005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106512674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8949742,0.0033647348,0.07936264,0.0027898757,0.00006676441,0.0006259051,0.0047363136,0.00012417404,0.013955393],"genre_scores_gemma":[0.9912646,0.0007829423,0.0050160442,0.00011462309,0.000021565509,0.00025917793,0.0008424642,0.000013434355,0.001685192],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99785125,0.0015554985,0.00008079319,0.00013844096,0.00013490074,0.00023921045],"domain_scores_gemma":[0.97534025,0.022458065,0.0011038763,0.0003157487,0.00046274404,0.00031929248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072697084,0.0011999918,0.0019039469,0.0014744954,0.00047461284,0.0017293766,0.0013156414,0.0013935327,0.0047149644],"category_scores_gemma":[0.018268807,0.0009335704,0.0030327719,0.0010446402,0.00077180495,0.001284392,0.0013250798,0.0017863137,0.00029927035],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063211436,0.000072540926,0.0036619334,0.00009851829,0.0002433974,0.00010602624,0.000038570826,0.9865558,0.00010389264,0.005861387,0.00039475775,0.0022311304],"study_design_scores_gemma":[0.00014899205,0.00022237636,0.00193952,0.00009131105,0.0002565881,0.00006188959,0.000044572807,0.98960155,0.00009586497,0.007184962,0.00032373043,0.000028619952],"about_ca_topic_score_codex":0.018444417,"about_ca_topic_score_gemma":0.01004845,"teacher_disagreement_score":0.018444417,"about_ca_system_score_codex":0.0037867723,"about_ca_system_score_gemma":0.0025147588,"threshold_uncertainty_score":0.038446367},"labels":[],"label_agreement":null},{"id":"W2107285363","doi":"10.3111/13696998.2014.923892","title":"A Canadian cost-effectiveness analysis of transcatheter mitral valve repair with the MitraClip system in high surgical risk patients with significant mitral regurgitation","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cardiac Valve Diseases and Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal Heart Institute","funders":"","keywords":"MitraClip; Medicine; Mitral regurgitation; Quality-adjusted life year; Mitral valve; Mitral valve repair; Quality of life (healthcare); Heart failure; Cost–utility analysis; Cardiology; Surgery; Cost effectiveness; Intensive care medicine; Internal medicine; Risk analysis (engineering)","score_opus":0.005844515260005902,"score_gpt":0.253686271921591,"score_spread":0.2478417566615851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107285363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8988603,0.022816684,0.009364971,0.0062441803,0.00025433392,0.0028271591,0.02913457,0.00015399528,0.030343771],"genre_scores_gemma":[0.987899,0.002544737,0.0038251681,0.00035096006,0.00002621881,0.00026791764,0.003711973,0.000013703215,0.001360251],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.997267,0.001250257,0.000096977514,0.00021305133,0.0007158278,0.00045695467],"domain_scores_gemma":[0.9964372,0.0017407638,0.00036559586,0.00009961386,0.0010326232,0.00032417563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004306099,0.0016182084,0.0016776938,0.0020284574,0.0009407076,0.0017411404,0.002011545,0.0012199682,0.0032605072],"category_scores_gemma":[0.01356153,0.00074214354,0.0046972306,0.0028233577,0.00062862906,0.0006082504,0.00085623795,0.0014139977,0.000141312],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011387159,0.0008399536,0.038323265,0.0035369454,0.007908685,0.0007338334,0.00015035595,0.8787249,0.0012490852,0.010690097,0.009464861,0.03699089],"study_design_scores_gemma":[0.009739458,0.0034945412,0.1114056,0.0011798419,0.010642676,0.0005798522,0.00039395932,0.845037,0.00088051154,0.0037790153,0.012448911,0.00041859935],"about_ca_topic_score_codex":0.9192695,"about_ca_topic_score_gemma":0.86702543,"teacher_disagreement_score":0.0807305,"about_ca_system_score_codex":0.059381116,"about_ca_system_score_gemma":0.04418763,"threshold_uncertainty_score":0.43084216},"labels":[],"label_agreement":null},{"id":"W2108384961","doi":"10.3111/13696998.2011.629015","title":"Savings from the use of a probiotic formula in the prophylaxis of antibiotic-associated diarrhea","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Clostridium difficile and Clostridium perfringens research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Microsoft","keywords":"Medicine; Probiotic; Lactobacillus casei; Placebo; Diarrhea; Lactobacillus acidophilus; Context (archaeology); Antibiotic-associated diarrhea; Incidence (geometry); Antibiotics; Internal medicine; Clostridium difficile; Microbiology; Food science; Biology; Fermentation; Alternative medicine","score_opus":0.09765356787881542,"score_gpt":0.28696049757163605,"score_spread":0.18930692969282065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108384961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96315676,0.022326218,0.004807943,0.00265095,0.00024368963,0.0010314302,0.001245083,0.00006833008,0.004469647],"genre_scores_gemma":[0.9943178,0.002681601,0.0021777293,0.00017882277,0.000021750426,0.00015654556,0.00019398537,0.0000034584202,0.00026837926],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9959092,0.003048849,0.00018492849,0.00016597351,0.0005184336,0.00017259172],"domain_scores_gemma":[0.99631774,0.0025610635,0.00072973943,0.000095925185,0.00014922247,0.00014630081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038906569,0.000828168,0.0011039007,0.0009596957,0.00017774379,0.0010900244,0.0005843028,0.001023408,0.0022775799],"category_scores_gemma":[0.013108687,0.0003771887,0.002986666,0.00095904304,0.00041518515,0.0010724753,0.0008581276,0.0013536479,0.000102092476],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20918818,0.005652223,0.075225934,0.010345385,0.020954851,0.00086276885,0.00025977023,0.22015221,0.006570063,0.010941436,0.0033232868,0.43652388],"study_design_scores_gemma":[0.074654706,0.17369206,0.2556739,0.008606891,0.065247186,0.0025574295,0.0012097689,0.34881195,0.017470552,0.021717088,0.029773498,0.000585061],"about_ca_topic_score_codex":0.0026841431,"about_ca_topic_score_gemma":0.0028559868,"teacher_disagreement_score":0.0038906569,"about_ca_system_score_codex":0.0024249235,"about_ca_system_score_gemma":0.0023978336,"threshold_uncertainty_score":0.02057606},"labels":[],"label_agreement":null},{"id":"W2109736015","doi":"10.3111/13696990701679230","title":"Contingent valuation of inhaled insulin: a Canadian perspective","year":2007,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Healthcare cost, quality, practices","field":"Health Professions","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Medtronic (Canada)","funders":"","keywords":"Medicine; Insulin; Contingent valuation; Willingness to pay; Diabetes mellitus; Confidence interval; Valuation (finance); Internal medicine; Environmental health; Endocrinology; Economics; Finance","score_opus":0.5709903698322264,"score_gpt":0.555987075065585,"score_spread":0.015003294766641417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109736015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9149791,0.0051315953,0.0032805442,0.009268732,0.00003988386,0.000086897795,0.0012929355,0.000007516014,0.06591282],"genre_scores_gemma":[0.9966959,0.0014556297,0.0005676908,0.00016949869,0.000012952702,0.0000052882615,0.00012814825,0.0000012180099,0.00096368097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992423,0.00021064773,0.00002093365,0.000038228827,0.00033907112,0.0001488354],"domain_scores_gemma":[0.9982638,0.00067969726,0.00018837962,0.00004950461,0.000623049,0.0001956161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010225524,0.00021623334,0.0002759863,0.00078090193,0.001430252,0.0014938768,0.00039064483,0.0003294726,0.004426558],"category_scores_gemma":[0.0043499814,0.00011802832,0.00032155824,0.0014131867,0.0009301016,0.00044438205,0.0002825872,0.00046763773,0.00008512031],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008390219,0.00034863173,0.7152208,0.00049614726,0.0002854353,0.002702817,0.00974428,0.023119213,0.0033328864,0.07892882,0.015616606,0.14936534],"study_design_scores_gemma":[0.00011536791,0.00023686228,0.8875327,0.00041435478,0.00020075498,0.00092175446,0.0160568,0.03868956,0.00065227645,0.017667277,0.037363034,0.00014909895],"about_ca_topic_score_codex":0.952638,"about_ca_topic_score_gemma":0.95780146,"teacher_disagreement_score":0.04736203,"about_ca_system_score_codex":0.01948169,"about_ca_system_score_gemma":0.010661751,"threshold_uncertainty_score":0.14135021},"labels":[],"label_agreement":null},{"id":"W2116314191","doi":"10.3111/13696998.2014.964720","title":"Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Hepatitis C virus research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Internal medicine; Cohort; Hepatitis C; Health care; Pegylated interferon; Cohort study; Retrospective cohort study; Chronic hepatitis; Ribavirin; Immunology; Virus","score_opus":0.0645373882287213,"score_gpt":0.40240155889075957,"score_spread":0.3378641706620383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116314191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99338806,0.002450885,0.00013247944,0.0006735526,0.000030830353,0.00003753312,0.001637167,0.0000056706267,0.0016438286],"genre_scores_gemma":[0.9984542,0.0004174306,0.00009629752,0.00008017411,0.000031528627,0.000016316793,0.0007587201,0.0000018810764,0.00014326053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997364,0.0012983072,0.00024729923,0.00018320445,0.0004167303,0.0004904461],"domain_scores_gemma":[0.9911499,0.0032204352,0.003880499,0.0002473208,0.00057268265,0.0009291551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002145689,0.00030557287,0.0004227925,0.0005011674,0.0003256475,0.001045727,0.00046068887,0.000442774,0.0031239544],"category_scores_gemma":[0.01105789,0.00013363277,0.0017482477,0.0008128498,0.00019902157,0.00064738624,0.0009208745,0.0008901885,0.00016982268],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001281253,0.00024548505,0.9795241,0.000082448,0.00056241895,0.000108156855,0.000045640714,0.001153989,0.00006791437,0.000112892056,0.0005723084,0.016243361],"study_design_scores_gemma":[0.00003145477,0.00038230978,0.9978818,0.00003635555,0.00020606075,0.00015351473,0.000091839254,0.0008031226,0.000032536984,0.000066233224,0.00030932674,0.0000054709103],"about_ca_topic_score_codex":0.009940134,"about_ca_topic_score_gemma":0.009790637,"teacher_disagreement_score":0.009940134,"about_ca_system_score_codex":0.0014204166,"about_ca_system_score_gemma":0.0011325085,"threshold_uncertainty_score":0.019764602},"labels":[],"label_agreement":null},{"id":"W2118409839","doi":"10.3111/13696991003723999","title":"Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting","year":2010,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Insulin aspart; Life expectancy; Diabetes mellitus; Insulin; Type 2 diabetes; Cohort; Observational study; Cost effectiveness; Quality of life (healthcare); Internal medicine; Human insulin; Incidence (geometry); Endocrinology; Environmental health; Population; Risk analysis (engineering)","score_opus":0.03662680478415936,"score_gpt":0.3590542527169888,"score_spread":0.32242744793282946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118409839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938706,0.001321996,0.0012234146,0.0006152932,0.000042901844,0.00021514393,0.0006916397,0.000037140064,0.0019817795],"genre_scores_gemma":[0.9987435,0.00022812109,0.0005272809,0.00015957833,0.000006648881,0.000044010234,0.00020242276,0.0000021648882,0.00008630191],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9976184,0.001625401,0.00010181523,0.00020516232,0.00020497476,0.00024424438],"domain_scores_gemma":[0.99474096,0.0035234417,0.00087087584,0.00011059861,0.00019730064,0.00055683294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003252581,0.00075891486,0.00061259634,0.00052690203,0.0002327006,0.0010190493,0.0010165006,0.0011841406,0.00336588],"category_scores_gemma":[0.014902905,0.00027749338,0.0017466381,0.0005613559,0.0005316536,0.00074166345,0.00066671596,0.0009946224,0.00012747236],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06908082,0.007536558,0.15681265,0.0012719367,0.0037882337,0.00078355987,0.00017470667,0.6138968,0.0016180765,0.0033238556,0.004446088,0.13726674],"study_design_scores_gemma":[0.018886933,0.060315073,0.16067831,0.00073639135,0.005429061,0.0017131802,0.00091222813,0.7382432,0.0024623491,0.007013155,0.0033875518,0.00022258701],"about_ca_topic_score_codex":0.02274699,"about_ca_topic_score_gemma":0.013348094,"teacher_disagreement_score":0.02274699,"about_ca_system_score_codex":0.0050178873,"about_ca_system_score_gemma":0.002942985,"threshold_uncertainty_score":0.045229137},"labels":[],"label_agreement":null},{"id":"W2122195110","doi":"10.3111/13696998.2015.1038270","title":"Inhaled nitric oxide in term/late preterm neonates with hypoxic respiratory failure: estimating the financial impact of earlier use","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Neonatal Respiratory Health Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes; St. Paul's Hospital","funders":"","keywords":"Medicine; Respiratory failure; Respiratory system; Term (time); Nitric oxide; Intensive care medicine; Pediatrics; Emergency medicine; Anesthesia; Cardiology; Internal medicine","score_opus":0.06481795895339988,"score_gpt":0.36080283751962877,"score_spread":0.2959848785662289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122195110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97916573,0.0013324945,0.01506864,0.00077626423,0.000027261847,0.00038803532,0.0015131583,0.000024918325,0.0017033465],"genre_scores_gemma":[0.99588,0.0003658569,0.0030310897,0.00006625113,0.0000073683586,0.00012541826,0.0002596413,0.0000036078404,0.00026070027],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99580693,0.0031734954,0.00013643631,0.00029611588,0.00024587574,0.0003412052],"domain_scores_gemma":[0.9733382,0.023070958,0.0022237864,0.00030082822,0.00067003776,0.0003962145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009444762,0.0013313162,0.001105793,0.001164032,0.00034877198,0.0015743003,0.0015173677,0.00171058,0.0016922383],"category_scores_gemma":[0.030654825,0.0011841417,0.0024797053,0.0011984754,0.00062948075,0.0013010745,0.0014275067,0.0015162685,0.00012275919],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010328054,0.00019133651,0.032001853,0.00018186522,0.00058436097,0.00022103179,0.000035160014,0.9596704,0.00017699397,0.0014307938,0.00015532023,0.004318092],"study_design_scores_gemma":[0.00023035747,0.0010669942,0.018389478,0.000111217494,0.000564592,0.0001896543,0.00013349637,0.9759469,0.00044621268,0.0024703888,0.0004056411,0.000045193792],"about_ca_topic_score_codex":0.029142054,"about_ca_topic_score_gemma":0.010715461,"teacher_disagreement_score":0.029142054,"about_ca_system_score_codex":0.0058727893,"about_ca_system_score_gemma":0.0030385759,"threshold_uncertainty_score":0.057944834},"labels":[],"label_agreement":null},{"id":"W2123354253","doi":"10.3111/13696998.2015.1012513","title":"Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Centre for Advancing Health Outcomes; University of British Columbia","funders":"","keywords":"Golimumab; Adalimumab; Infliximab; Medicine; Ulcerative colitis; Internal medicine; Gastroenterology; Surgery; Tumor necrosis factor alpha; Disease","score_opus":0.02776260451921954,"score_gpt":0.2931311973706892,"score_spread":0.2653685928514697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123354253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95099694,0.0073660854,0.018683158,0.0028535943,0.00008559195,0.00073820946,0.006765859,0.00012723096,0.01238335],"genre_scores_gemma":[0.99284136,0.0013498744,0.0029105197,0.00009234355,0.000011578815,0.00012529759,0.0014815421,0.000011012762,0.0011764436],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9990268,0.00040541805,0.000036022728,0.00006163846,0.0002990717,0.00017112769],"domain_scores_gemma":[0.9985459,0.0008477979,0.0002780367,0.000042005257,0.00014837549,0.0001379546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013757377,0.00048439592,0.0005599481,0.0006113671,0.00042867442,0.0010317164,0.0011402593,0.00080625765,0.0038391682],"category_scores_gemma":[0.005742409,0.00051816565,0.0021969122,0.00088930567,0.00040098035,0.00080803165,0.00044380483,0.00087866466,0.00021381312],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008174834,0.0003871871,0.042921066,0.0008567425,0.0015703511,0.00053715095,0.0001383244,0.8650592,0.0019026817,0.009669367,0.0038332182,0.06494977],"study_design_scores_gemma":[0.001896393,0.0021502324,0.099185,0.00060053443,0.0024690982,0.0013299496,0.00039895653,0.87651885,0.0016714244,0.0066900826,0.0069240765,0.00016537234],"about_ca_topic_score_codex":0.24523842,"about_ca_topic_score_gemma":0.22182773,"teacher_disagreement_score":0.24523842,"about_ca_system_score_codex":0.015420351,"about_ca_system_score_gemma":0.014022989,"threshold_uncertainty_score":0.48762196},"labels":[],"label_agreement":null},{"id":"W2124326496","doi":"10.3111/13696998.2012.734886","title":"The cost effectiveness of palivizumab in congenital heart disease: a review of the current evidence","year":2012,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Congenital Heart Disease Studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto; Sunnybrook Hospital","funders":"","keywords":"Palivizumab; Medicine; Heart disease; Cost effectiveness; Pediatrics; Quality of life (healthcare); Quality-adjusted life year; MEDLINE; Cost–utility analysis; Intensive care medicine; Internal medicine","score_opus":0.09559665054788327,"score_gpt":0.41252653627758495,"score_spread":0.3169298857297017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124326496","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032356317,0.99918073,0.000029605602,0.00023612076,0.000054985205,0.000015951113,0.000047014477,0.0000013150536,0.000110701876],"genre_scores_gemma":[0.0053312173,0.9940474,0.00018811747,0.00021217747,0.00011646342,0.000036782483,0.000037021477,0.000001619036,0.000029255105],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99488294,0.0016316192,0.0016597185,0.00036191253,0.0012949775,0.00016889344],"domain_scores_gemma":[0.96879995,0.025043417,0.004045273,0.00015988886,0.0017311495,0.00022031399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006285573,0.0015957436,0.006327024,0.010422056,0.00040896953,0.0029526171,0.0019353182,0.0028484194,0.004350847],"category_scores_gemma":[0.036381703,0.0010704125,0.0056267693,0.009617751,0.0008054022,0.0023409864,0.00089588016,0.0014454941,0.00030297195],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007465324,0.00008802283,0.0023822046,0.7580226,0.008730175,0.0002531901,0.00011120774,0.0006860841,0.00019665356,0.0011010397,0.005151309,0.2225309],"study_design_scores_gemma":[0.0005489674,0.0007506586,0.0124630695,0.8820044,0.047385853,0.0018838362,0.00040661768,0.00062304654,0.00027705933,0.0014648222,0.052126516,0.00006508696],"about_ca_topic_score_codex":0.0069405767,"about_ca_topic_score_gemma":0.010551081,"teacher_disagreement_score":0.010422056,"about_ca_system_score_codex":0.0046996167,"about_ca_system_score_gemma":0.0072984686,"threshold_uncertainty_score":0.034098268},"labels":[],"label_agreement":null},{"id":"W2124828164","doi":"10.3111/13696990802125760","title":"Cost comparison of prostaglandin analogues: a Canadian population-based analysis","year":2008,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Glaucoma and retinal disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Brock University; PharmIdeas (Canada)","funders":"","keywords":"Travoprost; Bimatoprost; Latanoprost; Medicine; Pharmacoeconomics; Indirect costs; Internal medicine; Glaucoma; Ophthalmology; Intensive care medicine","score_opus":0.035128986850056866,"score_gpt":0.30721743348013675,"score_spread":0.27208844663007986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124828164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95414627,0.013963928,0.00047292904,0.0007311957,0.0000505306,0.00038395968,0.02527069,0.000025199115,0.0049552973],"genre_scores_gemma":[0.98115975,0.005588064,0.0006479001,0.00028713842,0.000034526525,0.00012234974,0.011356664,0.00001839782,0.00078534696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969342,0.00053157314,0.00028800842,0.00043146047,0.0013420992,0.00047266245],"domain_scores_gemma":[0.99482006,0.00088846433,0.0011722385,0.0002045326,0.0022680876,0.00064659107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021748804,0.0010676765,0.0015178019,0.005061542,0.0017586213,0.0022196781,0.0016993006,0.0011692112,0.0060715047],"category_scores_gemma":[0.0082194675,0.00058756204,0.0048550623,0.012252494,0.00066270656,0.000673815,0.0010009778,0.0014584437,0.00032754868],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006109243,0.0003019873,0.94599575,0.0011267735,0.0069387704,0.00049474934,0.00030323866,0.0039024535,0.00025183713,0.0010724498,0.0070756115,0.026427165],"study_design_scores_gemma":[0.0011408478,0.00052573223,0.9839346,0.00035558696,0.003096871,0.0004960873,0.0006705429,0.0053671882,0.00008077977,0.00018948331,0.0040171943,0.0001250618],"about_ca_topic_score_codex":0.97257024,"about_ca_topic_score_gemma":0.963839,"teacher_disagreement_score":0.04744813,"about_ca_system_score_codex":0.04744813,"about_ca_system_score_gemma":0.025724396,"threshold_uncertainty_score":0.34426188},"labels":[],"label_agreement":null},{"id":"W2124964258","doi":"10.3111/13696998.2011.646045","title":"Elicitation of utility scores in Canada for immune thrombocytopenia treated with romiplostim or watch and rescue","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Blood Services; McMaster University; Ottawa Hospital; University of Ottawa; PharmIdeas (Canada)","funders":"","keywords":"Romiplostim; Medicine; Public health; Respondent; Quality of life (healthcare); Time-trade-off; Family medicine; Quality-adjusted life year; Pediatrics; Cost effectiveness; Thrombopoietin; Nursing","score_opus":0.0371163062270349,"score_gpt":0.26398500437051975,"score_spread":0.22686869814348484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124964258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950595,0.00009128357,0.00029131983,0.00012211782,0.0000043973673,0.00020709644,0.0018367766,0.0000086618575,0.002378951],"genre_scores_gemma":[0.9969869,0.0000933092,0.00087983225,0.00007432606,0.0000026565629,0.00011053248,0.0013597413,0.0000019792062,0.0004907732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983772,0.0004149274,0.00015399927,0.0001053016,0.0006810226,0.00026756458],"domain_scores_gemma":[0.99548495,0.0010328916,0.0011263997,0.00011357403,0.0017862379,0.0004559222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023930192,0.00020185384,0.00025856987,0.0011612285,0.0007298649,0.0006684478,0.00038429193,0.00026469928,0.0018972831],"category_scores_gemma":[0.0105359685,0.00013126139,0.00060097873,0.001976232,0.0005009932,0.00021444584,0.0005569495,0.0003702235,0.00016575374],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006332686,0.0001467304,0.97018224,0.00007165992,0.000079402496,0.00009339702,0.0013148092,0.00060198456,0.00038188143,0.00015885974,0.0016446532,0.024691166],"study_design_scores_gemma":[0.000055577926,0.00022852518,0.99446625,0.000026276246,0.000025195071,0.000054685228,0.0014638986,0.0016250911,0.00030054912,0.00007388997,0.0016602871,0.000019743311],"about_ca_topic_score_codex":0.7656682,"about_ca_topic_score_gemma":0.8218094,"teacher_disagreement_score":0.23433179,"about_ca_system_score_codex":0.008933699,"about_ca_system_score_gemma":0.007846429,"threshold_uncertainty_score":0.47142363},"labels":[],"label_agreement":null},{"id":"W2125903849","doi":"10.3111/13696990701646825","title":"Impact of risperidone long-acting injectable on hospitalisation and medication use in Canadian patients with schizophrenia","year":2007,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; McGill University","funders":"Janssen Canada","keywords":"Risperidone; Medicine; Tolerability; Confidence interval; Schizophrenia (object-oriented programming); Pediatrics; Psychosis; Internal medicine; Psychiatry; Adverse effect","score_opus":0.014956056495635849,"score_gpt":0.2908552119073994,"score_spread":0.2758991554117635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125903849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99514127,0.0010379666,0.00004408922,0.00013744188,0.000007575823,0.00003226427,0.0024828375,0.0000065874965,0.0011099568],"genre_scores_gemma":[0.99813867,0.00050798326,0.00009231377,0.000041805408,0.0000047100343,0.000012940081,0.0010430631,0.0000016575501,0.00015677692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998456,0.00016332774,0.00014760146,0.0001304162,0.0008148914,0.00028776884],"domain_scores_gemma":[0.99468684,0.00043459056,0.00262766,0.00009433018,0.001582012,0.00057457364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006377894,0.0001792066,0.00032483853,0.001538525,0.0012449239,0.0007394912,0.00058326847,0.0002441811,0.0011203827],"category_scores_gemma":[0.0036406904,0.00025524164,0.00053216564,0.0027671051,0.00039677956,0.00022254384,0.00046813616,0.0004120411,0.000075265576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008071632,0.000017582137,0.99623674,0.000038538114,0.000040302682,0.00008512628,0.00021851619,0.00005496947,0.0000990082,0.00001827528,0.00032314932,0.0027870343],"study_design_scores_gemma":[0.0000030088684,0.000024274721,0.99931633,0.000016549282,0.000012707847,0.00007515617,0.00018010262,0.00007727775,0.000045393863,0.0000029604917,0.00024058302,0.000005585497],"about_ca_topic_score_codex":0.93166995,"about_ca_topic_score_gemma":0.95501715,"teacher_disagreement_score":0.06833005,"about_ca_system_score_codex":0.015273014,"about_ca_system_score_gemma":0.011631195,"threshold_uncertainty_score":0.13746488},"labels":[],"label_agreement":null},{"id":"W2128124805","doi":"10.3111/13696998.2013.770747","title":"Cost effectiveness of transcatheter aortic valve replacement compared to medical management in inoperable patients with severe aortic stenosis: Canadian analysis based on the PARTNER Trial Cohort B findings","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cardiac Valve Diseases and Treatments","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; University of British Columbia; Université Laval; Toronto General Hospital; University of Toronto","funders":"Edwards Lifesciences","keywords":"Medicine; Valve replacement; Stenosis; Emergency medicine; Cost effectiveness; Quality-adjusted life year; Cost-effectiveness analysis; Aortic valve replacement; Economic evaluation; Randomized controlled trial; Incremental cost-effectiveness ratio; Cohort; Cost–benefit analysis; Surgery; Internal medicine","score_opus":0.01543467519830726,"score_gpt":0.29550042294699397,"score_spread":0.2800657477486867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128124805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8755065,0.021313928,0.002645673,0.002582026,0.00019218544,0.0016798207,0.082223505,0.00012492859,0.013731488],"genre_scores_gemma":[0.9736326,0.0035306914,0.0017501158,0.00051445654,0.000067534354,0.00036216376,0.018633336,0.000039409122,0.0014697078],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99624217,0.0015892392,0.0002862602,0.0005312897,0.00075816736,0.0005929086],"domain_scores_gemma":[0.9916453,0.0038723748,0.001781328,0.00062816247,0.0013647121,0.000708187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007132837,0.0012435741,0.0025202623,0.0013161177,0.0006019079,0.0019665165,0.0021216574,0.0010508638,0.005661063],"category_scores_gemma":[0.017420426,0.000563883,0.01018313,0.002714185,0.00063003897,0.00052670273,0.0009380807,0.0017771104,0.00018479902],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22440179,0.0013145811,0.37590492,0.011073544,0.08866031,0.00078144233,0.00044611996,0.17138417,0.0013368705,0.01174658,0.049130972,0.06381864],"study_design_scores_gemma":[0.115043685,0.007413875,0.57681507,0.0023413543,0.08271377,0.000977006,0.0005889126,0.19244154,0.0011479493,0.0044761365,0.015255258,0.0007854583],"about_ca_topic_score_codex":0.86073816,"about_ca_topic_score_gemma":0.8310335,"teacher_disagreement_score":0.98525655,"about_ca_system_score_codex":0.014743471,"about_ca_system_score_gemma":0.020407334,"threshold_uncertainty_score":0.28016394},"labels":[],"label_agreement":null},{"id":"W2128721688","doi":"10.3111/13696998.2012.756400","title":"Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Hôpital Maisonneuve-Rosemont","funders":"Amgen Canada; Forskningsrådet om Hälsa, Arbetsliv och Välfärd","keywords":"Romiplostim; Medicine; Thrombopoietin; Immune thrombocytopenia; Pediatrics; Emergency medicine; Internal medicine; Platelet","score_opus":0.02503802264846425,"score_gpt":0.28753250658038776,"score_spread":0.2624944839319235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128721688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9632205,0.0039864467,0.0017242732,0.0024859079,0.00008773868,0.000315807,0.014974774,0.00007688203,0.013127672],"genre_scores_gemma":[0.9934769,0.0006836047,0.00081444695,0.00020286416,0.000007782098,0.00005577855,0.0030907583,0.000011656248,0.0016562865],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99826777,0.00052635244,0.000080963764,0.00015591447,0.00038655574,0.0005825451],"domain_scores_gemma":[0.99604356,0.0010073127,0.00051066163,0.00007678021,0.001714784,0.0006469215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001617047,0.000784525,0.0007234039,0.0011646198,0.0010969532,0.0023440085,0.001756406,0.000826788,0.0038706227],"category_scores_gemma":[0.0053283577,0.00047433426,0.0018393699,0.002165863,0.0004638426,0.00061476073,0.0007389301,0.0009113729,0.0002158039],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025130266,0.0005290547,0.35137603,0.00047639493,0.0017257561,0.00074828643,0.00019640446,0.5960083,0.0005406573,0.0047142105,0.01120817,0.029963719],"study_design_scores_gemma":[0.0010337186,0.0008661217,0.37739816,0.0004719894,0.0010367258,0.00034096712,0.0011137314,0.60961175,0.0005911244,0.0007777572,0.006588105,0.00016983518],"about_ca_topic_score_codex":0.99208635,"about_ca_topic_score_gemma":0.9899115,"teacher_disagreement_score":0.13690226,"about_ca_system_score_codex":0.13690226,"about_ca_system_score_gemma":0.05226715,"threshold_uncertainty_score":0.9933001},"labels":[],"label_agreement":null},{"id":"W2130922075","doi":"10.3111/13696998.2012.737393","title":"Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Programs for Assessment of Technology in Health Research Institute; McMaster University; St. Joseph’s Healthcare Hamilton; Amgen (Canada)","funders":"","keywords":"Medicine; Denosumab; Discontinuation; Osteoporosis; Femoral neck; Cost effectiveness; Internal medicine; Teriparatide; Cost-effectiveness analysis; Cohort; Adverse effect; Bone mineral","score_opus":0.055857514077070944,"score_gpt":0.35734132471385055,"score_spread":0.3014838106367796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130922075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9224259,0.017493892,0.0064634853,0.0077565853,0.00012744573,0.0014724733,0.021959884,0.00013743658,0.022162944],"genre_scores_gemma":[0.9913421,0.0026916736,0.00176446,0.000327801,0.000015968213,0.00011892179,0.0022127342,0.000013064709,0.0015132284],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99789643,0.00085194706,0.00008453236,0.00013842266,0.00049640844,0.00053216843],"domain_scores_gemma":[0.9966,0.0015502623,0.0003829064,0.00007936279,0.0010686562,0.00031891404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00307457,0.000636496,0.0008136809,0.0011421188,0.0009256834,0.0017111892,0.0015020716,0.00076066336,0.0027053042],"category_scores_gemma":[0.009982486,0.00052541075,0.0018721164,0.0021053385,0.0006599479,0.00058727677,0.0009653967,0.0010903925,0.00008993685],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039839456,0.00029920108,0.09750312,0.0014130463,0.0031051654,0.00045496368,0.00021435307,0.8280095,0.00047166357,0.015950857,0.008841597,0.039752685],"study_design_scores_gemma":[0.0037627418,0.0009624781,0.1333217,0.0010996731,0.003922963,0.00029807823,0.00078373635,0.83042175,0.00096199213,0.0074342876,0.016822254,0.00020843535],"about_ca_topic_score_codex":0.98545873,"about_ca_topic_score_gemma":0.9785913,"teacher_disagreement_score":0.07821641,"about_ca_system_score_codex":0.07821641,"about_ca_system_score_gemma":0.07900496,"threshold_uncertainty_score":0.56750244},"labels":[],"label_agreement":null},{"id":"W2132129334","doi":"10.3111/13696990801954756","title":"Cost comparison of four revascularisation procedures for the treatment of multivessel coronary artery disease","year":2008,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Coronary Interventions and Diagnostics","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Hamilton Health Sciences","funders":"","keywords":"Conventional PCI; Medicine; Percutaneous coronary intervention; Coronary artery disease; Cardiology; Internal medicine; Bypass grafting; Artery; Surgery; Myocardial infarction","score_opus":0.09029051761902525,"score_gpt":0.35397319119057075,"score_spread":0.2636826735715455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132129334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772798,0.008256716,0.0062481654,0.00050493807,0.00010146354,0.0012337106,0.0015836355,0.00002633,0.0047652777],"genre_scores_gemma":[0.995135,0.00088974467,0.0027728681,0.00004010655,0.000010878706,0.00049690966,0.00036235966,0.000004537693,0.00028756156],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99247193,0.0058237533,0.00035258045,0.00024419007,0.00077012595,0.00033743796],"domain_scores_gemma":[0.9892062,0.008585086,0.0009492592,0.0002775816,0.0006097109,0.00037215615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009672659,0.0016806673,0.0020953703,0.0024431266,0.00051603664,0.0016949616,0.0015326105,0.0013699777,0.0029988121],"category_scores_gemma":[0.021967603,0.0006480702,0.004464127,0.0023002885,0.00067612214,0.0012306658,0.00096013874,0.00096793904,0.00011999816],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.098482996,0.0037367241,0.0322697,0.005429808,0.0147953825,0.00034476537,0.00030469647,0.75852525,0.001607513,0.011029962,0.0011318267,0.07234147],"study_design_scores_gemma":[0.035025463,0.075016245,0.082965285,0.002028238,0.028293943,0.0011540615,0.0007553979,0.75051624,0.0039474247,0.011916933,0.008000479,0.00038021954],"about_ca_topic_score_codex":0.01453026,"about_ca_topic_score_gemma":0.010377476,"teacher_disagreement_score":0.01453026,"about_ca_system_score_codex":0.009624812,"about_ca_system_score_gemma":0.0037951064,"threshold_uncertainty_score":0.06983322},"labels":[],"label_agreement":null},{"id":"W2132266888","doi":"10.3111/13696998.2013.851082","title":"Prevalence and impact of constipation and bowel dysfunction induced by strong opioids: a cross-sectional survey of 520 patients with cancer pain: DYONISOS study","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Gastrointestinal motility and disorders","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Constipation; Cross-sectional study; Internal medicine; Cancer; Colorectal cancer; Physical therapy; Pathology","score_opus":0.022796946312457416,"score_gpt":0.29946144952046405,"score_spread":0.2766645032080066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132266888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99936885,0.00010187374,0.000022660823,0.000025327103,0.0000022954314,0.000010457557,0.0003286731,0.0000011405607,0.00013878367],"genre_scores_gemma":[0.99912244,0.0001140372,0.000048167265,0.000051310573,0.0000060309335,0.00001691504,0.0004928359,8.6815754e-7,0.00014729965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99950516,0.00017597873,0.00005756948,0.000089820984,0.000088966,0.00008242736],"domain_scores_gemma":[0.9989492,0.00015724551,0.00040868612,0.000043989294,0.00013598628,0.00030484374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059290713,0.0002795716,0.0003553092,0.00065112766,0.00039308454,0.0005547305,0.00023447652,0.00051168277,0.0013861689],"category_scores_gemma":[0.0010898754,0.0003373403,0.00039295887,0.00062314596,0.00023167934,0.00042405393,0.00043772458,0.00042339248,0.00041697916],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003805283,0.000040720905,0.999337,0.00000674572,0.000019831936,0.000035414076,0.000081941005,0.000009989599,0.00010816481,0.0000024450023,0.000048357597,0.00027121353],"study_design_scores_gemma":[0.000009013042,0.00016223297,0.9992436,0.000004027692,0.000009856442,0.00014734772,0.00026041863,0.000037695932,0.00001312929,0.0000013795609,0.000109141096,0.0000021523756],"about_ca_topic_score_codex":0.011027724,"about_ca_topic_score_gemma":0.013585044,"teacher_disagreement_score":0.011027724,"about_ca_system_score_codex":0.00046780045,"about_ca_system_score_gemma":0.00031311545,"threshold_uncertainty_score":0.021927059},"labels":[],"label_agreement":null},{"id":"W2134289044","doi":"10.3111/13696998.2011.561390","title":"Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis","year":2011,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sanofi (Canada)","funders":"Sanofi","keywords":"Insulin detemir; Medicine; Insulin glargine; Type 1 diabetes; Type 2 Diabetes Mellitus; Type 2 diabetes; Insulin; Internal medicine; Cost-minimization analysis; Diabetes mellitus; Hypoglycemia; Endocrinology","score_opus":0.06545180482882385,"score_gpt":0.31225013221462644,"score_spread":0.2467983273858026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134289044","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6930718,0.25303134,0.018254949,0.0072091874,0.00048697082,0.0022155282,0.017087901,0.00023416168,0.008408198],"genre_scores_gemma":[0.9615729,0.025605943,0.007481587,0.000674889,0.000053707532,0.00052541913,0.0028472396,0.000028689727,0.0012095125],"study_design_codex":"simulation_or_modeling","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9963642,0.0026246777,0.000174069,0.0002621272,0.00034409552,0.0002308482],"domain_scores_gemma":[0.9920162,0.0060622306,0.00061386934,0.00019003444,0.000827944,0.00028973306],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.007845412,0.0021219735,0.0044763545,0.0025834094,0.00062668824,0.0020205153,0.002476314,0.0014122986,0.0023377647],"category_scores_gemma":[0.01592729,0.0011684985,0.013340586,0.0037789734,0.0005417815,0.0005447764,0.0007374419,0.001730368,0.00010944104],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013717244,0.00040691358,0.050480574,0.011098723,0.15391286,0.0005718671,0.00017299279,0.7264952,0.0003762275,0.0033415188,0.004949853,0.034476016],"study_design_scores_gemma":[0.011651377,0.0019291781,0.051662,0.0042692963,0.27800807,0.00048370523,0.0004025226,0.6348138,0.0005132606,0.0075540184,0.008450346,0.00026257773],"about_ca_topic_score_codex":0.7616261,"about_ca_topic_score_gemma":0.66747975,"teacher_disagreement_score":0.99552363,"about_ca_system_score_codex":0.027249485,"about_ca_system_score_gemma":0.022036832,"threshold_uncertainty_score":0.47955537},"labels":[],"label_agreement":null},{"id":"W2136970911","doi":"10.3111/13696998.2014.953680","title":"Assessing the burden of illness from cervical dystonia using the Toronto Western Spasmodic Torticollis Rating Scale scores and health utility: a meta-analysis of baseline patient-level clinical trial data","year":2014,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Spasmodic Torticollis; Medicine; Quality of life (healthcare); Cervical dystonia; Physical therapy; Rating scale; Severity of illness; Clinical trial; Disease; Placebo; Botulinum toxin; Internal medicine; Dystonia; Psychiatry; Psychology; Surgery","score_opus":0.49010930002830455,"score_gpt":0.4986480290291424,"score_spread":0.008538729000837852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136970911","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05184594,0.94400525,0.0018048786,0.00039831788,0.00027688994,0.00032790366,0.0007883446,0.00004323359,0.0005091819],"genre_scores_gemma":[0.8244624,0.16903499,0.0028344705,0.00084812,0.00040462313,0.0007605033,0.0012773888,0.000043008386,0.0003344889],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.97948027,0.013028865,0.0034906357,0.0020180896,0.001667111,0.0003150468],"domain_scores_gemma":[0.96335953,0.027342226,0.0061632893,0.0015755014,0.0011758144,0.00038361197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.031019643,0.0026096958,0.013638016,0.003950357,0.00050727255,0.0036272304,0.0016061983,0.0018131557,0.0017971239],"category_scores_gemma":[0.03742849,0.0010599762,0.039548878,0.004600364,0.0009565016,0.0012614568,0.0013229841,0.0020930634,0.00014853026],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064972187,0.000031664702,0.010052854,0.033237163,0.9429673,0.00004700969,0.000030086087,0.0007064993,0.00020066218,0.000062331426,0.00015179574,0.0060154153],"study_design_scores_gemma":[0.0015728632,0.00067627843,0.009209252,0.0023751257,0.98482347,0.00007288022,0.000025558931,0.00043775828,0.00012683558,0.00017884314,0.0004828037,0.000018425304],"about_ca_topic_score_codex":0.002713723,"about_ca_topic_score_gemma":0.0049420167,"teacher_disagreement_score":0.031019643,"about_ca_system_score_codex":0.0018328914,"about_ca_system_score_gemma":0.0015162837,"threshold_uncertainty_score":0.1640495},"labels":[],"label_agreement":null},{"id":"W2137881910","doi":"10.3111/13696990802579966","title":"Principal components analysis of drug expenditure and utilisation trends for major therapeutic classes in US Medicaid programmes","year":2008,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicaid; Medicine; Medical prescription; Principal (computer security); Quarter (Canadian coin); Drug; Demography; Gerontology; Actuarial science; Business; Economic growth; Pharmacology; Geography; Economics; Computer science; Health care","score_opus":0.06650273456870241,"score_gpt":0.33881254415486517,"score_spread":0.27230980958616274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137881910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953447,0.000091248185,0.0026481838,0.00015656489,0.000008878678,0.000097072436,0.0009132876,0.000056483354,0.00068344275],"genre_scores_gemma":[0.99409735,0.00010027571,0.0029199896,0.000010362939,0.000011548429,0.00009794396,0.0022819554,0.000009925108,0.0004706839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989686,0.0004574241,0.00008698221,0.00013120026,0.0002325681,0.00012322608],"domain_scores_gemma":[0.99777955,0.0012346649,0.00044338708,0.00012089768,0.00034043327,0.00008107434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001601838,0.00054827356,0.00034217077,0.0027739173,0.00032923147,0.00079025823,0.0002473682,0.00022787509,0.0023906492],"category_scores_gemma":[0.0055594207,0.00020322263,0.00095803576,0.0030175722,0.00024228918,0.00033264613,0.00057073496,0.0004385501,0.00025490165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029306585,0.0002539403,0.9127026,0.00006896184,0.0005301216,0.00013163938,0.0006643985,0.009308464,0.0014761632,0.0008862255,0.0019005091,0.071784],"study_design_scores_gemma":[0.000011361746,0.00011228688,0.9696256,0.000018258499,0.00006353473,0.00006406498,0.000343351,0.028271724,0.00023690608,0.00045873222,0.0007799809,0.000014256791],"about_ca_topic_score_codex":0.020583646,"about_ca_topic_score_gemma":0.012387365,"teacher_disagreement_score":0.020583646,"about_ca_system_score_codex":0.00072046375,"about_ca_system_score_gemma":0.0011479219,"threshold_uncertainty_score":0.04092771},"labels":[],"label_agreement":null},{"id":"W2141205234","doi":"10.3111/13696998.2013.846262","title":"Flexible insulin dosing improves health-related quality-of-life (HRQoL): a time trade-off survey","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Diabetes mellitus; Dosing; Basal (medicine); Population; Regimen; Type 2 diabetes; Basal insulin; Bolus (digestion); Quality of life (healthcare); Internal medicine; Endocrinology; Environmental health; Nursing","score_opus":0.061067269851679346,"score_gpt":0.34540855673629106,"score_spread":0.2843412868846117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141205234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99907327,0.000112979855,0.0001711355,0.000027727703,0.0000030679844,0.0000127384965,0.00027306692,0.0000025464021,0.00032338806],"genre_scores_gemma":[0.9993437,0.000063249565,0.00019554367,0.000023063792,0.000004020159,0.000009591808,0.00027721553,9.918209e-7,0.000082621875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981516,0.0010922451,0.00016078366,0.00013146919,0.00031511422,0.00014885268],"domain_scores_gemma":[0.99574655,0.0009854962,0.0023695303,0.0002594696,0.00026748225,0.00037157242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026641288,0.0002998475,0.0002505097,0.00054723874,0.00023733822,0.0005988346,0.00021481993,0.00035235076,0.0010349064],"category_scores_gemma":[0.0050740056,0.00017361034,0.0010458963,0.0010023277,0.00025651488,0.00055062945,0.0005207031,0.00044400943,0.000163652],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004010297,0.00013382478,0.9940057,0.000018281731,0.00020084076,0.000017975193,0.00008142096,0.00023276462,0.00013082413,0.000021193671,0.00011077443,0.004645447],"study_design_scores_gemma":[0.000014474958,0.00039934338,0.99852765,0.000008236186,0.000045907713,0.00005668003,0.0001148737,0.00054858683,0.00008168449,0.000027197579,0.00016934736,0.0000058789115],"about_ca_topic_score_codex":0.0040715626,"about_ca_topic_score_gemma":0.0056689726,"teacher_disagreement_score":0.0040715626,"about_ca_system_score_codex":0.0005179523,"about_ca_system_score_gemma":0.00019697643,"threshold_uncertainty_score":0.014089465},"labels":[],"label_agreement":null},{"id":"W2141479869","doi":"10.3111/13696998.2013.852097","title":"Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC)","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Cetuximab; Medicine; Panitumumab; Bevacizumab; KRAS; Colorectal cancer; Internal medicine; Oncology; Chemotherapy; Cancer","score_opus":0.020973881015520494,"score_gpt":0.2953600767874404,"score_spread":0.2743861957719199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141479869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9051465,0.015753863,0.029194813,0.00509757,0.0002471814,0.0025017,0.006067186,0.00012097396,0.035870153],"genre_scores_gemma":[0.9908959,0.0015370619,0.0040108534,0.00023144235,0.000028903805,0.00034579524,0.0009361539,0.000016434673,0.0019973216],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9977996,0.0014645127,0.00005604978,0.00012717483,0.0002226711,0.000330003],"domain_scores_gemma":[0.9915206,0.0066664484,0.00061907177,0.00012162921,0.00045354542,0.0006187657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006629556,0.0012759599,0.0018967323,0.0015766677,0.0005163656,0.002014205,0.0013049608,0.001366075,0.004481004],"category_scores_gemma":[0.016176889,0.00093849556,0.0032313876,0.0012989523,0.0007156061,0.0012271105,0.0011564014,0.0017950217,0.00018150998],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004522868,0.00029504378,0.0047224495,0.000608433,0.00080234796,0.00019318411,0.00003240729,0.97271097,0.00026059555,0.006200224,0.0012372257,0.00841425],"study_design_scores_gemma":[0.0015477764,0.0018342328,0.0064716637,0.00035805255,0.0017798622,0.00018724434,0.000108677435,0.98030615,0.0004208085,0.0044733994,0.0024453532,0.00006668207],"about_ca_topic_score_codex":0.07419808,"about_ca_topic_score_gemma":0.046325173,"teacher_disagreement_score":0.07419808,"about_ca_system_score_codex":0.016104665,"about_ca_system_score_gemma":0.01084982,"threshold_uncertainty_score":0.14753234},"labels":[],"label_agreement":null},{"id":"W2141519001","doi":"10.3111/13696998.2011.650521","title":"Economic evaluation of a 100% whey-based partially hydrolyzed infant formula in the prevention of atopic dermatitis among Swiss children","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Food Allergy and Anaphylaxis Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; PharmIdeas (Canada)","funders":"Bundesamt für Sozialversicherungen","keywords":"Medicine; Atopic dermatitis; Infant formula; Pediatrics; Dermatology","score_opus":0.04012483709666384,"score_gpt":0.3182215672743979,"score_spread":0.27809673017773406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141519001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787123,0.00491498,0.0071495343,0.0011059658,0.00005008717,0.0005647245,0.0022030508,0.000044308974,0.005255024],"genre_scores_gemma":[0.99694973,0.00083422306,0.0011320553,0.000043554082,0.000006815811,0.00015652091,0.0003874462,0.000004017545,0.00048562474],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9983265,0.0012791165,0.00003693691,0.0000836049,0.00012274846,0.00015125239],"domain_scores_gemma":[0.9969421,0.0024479532,0.00025617375,0.00005181644,0.00013410176,0.00016777388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031199905,0.0011784037,0.0013561415,0.001236084,0.0003435842,0.0014135917,0.0010051448,0.0012475877,0.0030072979],"category_scores_gemma":[0.006290629,0.00071211375,0.00251985,0.0009253413,0.000526228,0.00077068567,0.00073970086,0.000922988,0.00010787742],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030942818,0.00029943782,0.0045490395,0.0004602965,0.0005270234,0.00018761495,0.000024808916,0.98435545,0.00031068976,0.0011382994,0.00025273426,0.0048003807],"study_design_scores_gemma":[0.0020418274,0.005913652,0.011655177,0.00036526084,0.0020605458,0.00018292623,0.00018800503,0.9742846,0.0006982633,0.0013108687,0.0012444785,0.000054327924],"about_ca_topic_score_codex":0.04160981,"about_ca_topic_score_gemma":0.020434083,"teacher_disagreement_score":0.04160981,"about_ca_system_score_codex":0.008275241,"about_ca_system_score_gemma":0.004691812,"threshold_uncertainty_score":0.08273524},"labels":[],"label_agreement":null},{"id":"W2160034796","doi":"10.3111/13696998.2014.909435","title":"A United Kingdom-based economic evaluation of ranibizumab for patients with retinal vein occlusion (RVO)","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Ranibizumab; Medicine; Branch retinal vein occlusion; Central retinal vein occlusion; Macular edema; Cost effectiveness; Retinal Vein; Occlusion; Quality of life (healthcare); Quality-adjusted life year; Ophthalmology; Incremental cost-effectiveness ratio; Surgery; Retinal; Bevacizumab","score_opus":0.025160850929691527,"score_gpt":0.3111070444981639,"score_spread":0.2859461935684724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160034796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8132498,0.12522873,0.0070413323,0.0065203956,0.00088042545,0.0031363228,0.02117044,0.00014896225,0.022623563],"genre_scores_gemma":[0.98796415,0.0054728384,0.0016903925,0.0005438966,0.000042347136,0.00067917636,0.0029195612,0.0000124634935,0.00067518523],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9879809,0.010253662,0.00054188503,0.00029533202,0.00066367787,0.00026459483],"domain_scores_gemma":[0.99201924,0.004633109,0.0019522002,0.00026277578,0.00068089727,0.00045175705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058917776,0.0007803072,0.0015897418,0.0013158977,0.00025448084,0.0015373754,0.00068760576,0.0014189923,0.005798897],"category_scores_gemma":[0.02994257,0.0005175331,0.003143459,0.0014126189,0.00034841074,0.0009387275,0.0011469306,0.0008995591,0.00031920755],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18475832,0.0032400684,0.13190193,0.038318515,0.051956322,0.0022029448,0.00058973907,0.3053893,0.002701551,0.011103756,0.046353098,0.22148442],"study_design_scores_gemma":[0.17559211,0.04168673,0.30230963,0.02167525,0.047728237,0.0041955495,0.0010554885,0.34362665,0.0014706191,0.005291387,0.05465965,0.0007087032],"about_ca_topic_score_codex":0.024869308,"about_ca_topic_score_gemma":0.019625863,"teacher_disagreement_score":0.024869308,"about_ca_system_score_codex":0.006289556,"about_ca_system_score_gemma":0.0027145296,"threshold_uncertainty_score":0.049449146},"labels":[],"label_agreement":null},{"id":"W2160861863","doi":"10.3111/13696998.2011.571328","title":"Impact of upper and lower gastrointestinal blood loss on healthcare utilization and costs: a systematic review","year":2011,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Blood donation and transfusion practices","field":"Business, Management and Accounting","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Anemia; Health care; Upper gastrointestinal bleeding; Blood loss; Gastrointestinal bleeding; Retrospective cohort study; Emergency medicine; Intensive care medicine; Medical record; MEDLINE; Disease; Blood transfusion; Systematic review; Surgery; Internal medicine; Endoscopy","score_opus":0.06400063312899791,"score_gpt":0.3410981287151585,"score_spread":0.2770974955861606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160861863","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019666436,0.9967565,0.00008368879,0.00024047235,0.00007162864,0.00012501527,0.00051137764,0.0000052701353,0.00023938091],"genre_scores_gemma":[0.04410665,0.9538268,0.0006091426,0.0004934535,0.00010037734,0.0004092057,0.0003524917,0.0000060678385,0.000095852185],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98927337,0.004018168,0.0036363925,0.0006439678,0.0021189873,0.00030914036],"domain_scores_gemma":[0.94895387,0.036748555,0.009663961,0.00043683848,0.0037832002,0.00041359157],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.00844318,0.0014220983,0.007965348,0.010822573,0.0004882409,0.0027844328,0.0016080675,0.0016939548,0.0035997273],"category_scores_gemma":[0.051958647,0.0011393398,0.009235987,0.0145647805,0.00075488706,0.0018739891,0.0011265025,0.0011217614,0.0002357882],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021942313,0.00001953542,0.003925308,0.9384922,0.030530104,0.00014348706,0.00013987518,0.000157761,0.00007248467,0.00015927956,0.0015107131,0.024629802],"study_design_scores_gemma":[0.00037271556,0.0002448474,0.019775806,0.78648955,0.17969343,0.00078299403,0.00033212916,0.00024357952,0.00018158142,0.00033670888,0.0114878835,0.000058780864],"about_ca_topic_score_codex":0.011959036,"about_ca_topic_score_gemma":0.029014805,"teacher_disagreement_score":0.9920347,"about_ca_system_score_codex":0.00355012,"about_ca_system_score_gemma":0.010005107,"threshold_uncertainty_score":0.044652343},"labels":[],"label_agreement":null},{"id":"W2166937404","doi":"10.3111/13696998.2010.499749","title":"The cost effectiveness of palivizumab: a systematic review of the evidence","year":2010,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Respiratory viral infections research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster Children's Hospital; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Palivizumab; Medicine; Cost effectiveness; Population; Pediatrics; MEDLINE; Cost-effectiveness analysis; Cost–utility analysis; Intensive care medicine; Environmental health; Risk analysis (engineering); Internal medicine; Respiratory system","score_opus":0.1409699726642448,"score_gpt":0.47145864189459175,"score_spread":0.3304886692303469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166937404","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000775399,0.99782515,0.00010293284,0.00040347487,0.00009623088,0.00018483668,0.00036629755,0.0000053560266,0.00024038283],"genre_scores_gemma":[0.015554821,0.9826278,0.00051937666,0.000494235,0.00010861355,0.00041882525,0.00019392803,0.0000073616566,0.00007508259],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9864218,0.005404212,0.0043046726,0.0007041705,0.0027526359,0.00041253289],"domain_scores_gemma":[0.94047564,0.04494779,0.008901543,0.00051517313,0.0047568795,0.00040300738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0143280905,0.002205093,0.01102177,0.013566808,0.0006126054,0.004182512,0.0023716695,0.0026927306,0.005903464],"category_scores_gemma":[0.06948308,0.0016546525,0.012775589,0.013093115,0.0009300435,0.0026429459,0.0015282356,0.0020515185,0.0003738309],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048949145,0.000023627263,0.0008424991,0.93825567,0.01957622,0.000119506076,0.00006647031,0.00029291824,0.00008301249,0.00033484964,0.0016914437,0.038224377],"study_design_scores_gemma":[0.0005706484,0.00026911907,0.004254023,0.8668084,0.113311715,0.00047103973,0.00018445392,0.00026092175,0.00015965074,0.00061763887,0.013052577,0.000039782986],"about_ca_topic_score_codex":0.012085312,"about_ca_topic_score_gemma":0.025026888,"teacher_disagreement_score":0.0143280905,"about_ca_system_score_codex":0.009341356,"about_ca_system_score_gemma":0.014956559,"threshold_uncertainty_score":0.07577509},"labels":[],"label_agreement":null},{"id":"W2166962814","doi":"10.3111/13696998.2013.851083","title":"Further validation of the psychometric properties of the Bowel Function Index for evaluating opioid-induced constipation (OIC)","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Gastrointestinal motility and disorders","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Constipation; Quality of life (healthcare); Physical therapy; Functional constipation; Opioid; Psychometrics; Internal medicine; Clinical psychology; Nursing","score_opus":0.06586046611436944,"score_gpt":0.2959547595350054,"score_spread":0.23009429342063595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166962814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854027,0.0006148584,0.006616424,0.00059247116,0.00013998557,0.0019054138,0.0015107704,0.000039491257,0.0031777876],"genre_scores_gemma":[0.98714405,0.00020768911,0.0072467434,0.00025152924,0.000084421205,0.0017714252,0.0026264593,0.000020778152,0.00064697495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9867498,0.009333093,0.0010714227,0.00057952804,0.001709939,0.00055618834],"domain_scores_gemma":[0.9659126,0.017518125,0.0037320906,0.003359037,0.008293424,0.0011847158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.038833734,0.00056010904,0.00057715527,0.0010025187,0.00034684467,0.0008103155,0.0006604969,0.0006012414,0.0030718632],"category_scores_gemma":[0.048924122,0.00018820309,0.00100171,0.0009548468,0.00055227283,0.0009740462,0.0009420333,0.0008361899,0.0007516641],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011885741,0.0015985734,0.93169445,0.00026180822,0.00025946106,0.00009140449,0.0007601182,0.0005384987,0.0029355027,0.00021540748,0.0014821303,0.058973912],"study_design_scores_gemma":[0.00021437641,0.005582767,0.98752403,0.000117416836,0.00010090794,0.00023265746,0.0002919005,0.0016475425,0.0010499023,0.00012748127,0.0030921942,0.000018706152],"about_ca_topic_score_codex":0.0016264198,"about_ca_topic_score_gemma":0.0013293005,"teacher_disagreement_score":0.038833734,"about_ca_system_score_codex":0.00057274906,"about_ca_system_score_gemma":0.0013329891,"threshold_uncertainty_score":0.2053749},"labels":[],"label_agreement":null},{"id":"W2168221836","doi":"10.3111/13696998.2013.779277","title":"Medical resource use and costs associated with chylomicronemia","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Lipid metabolism and disorders","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Acute pancreatitis; Hypertriglyceridemia; Pancreatitis; Internal medicine; Medical costs; Demographics; Gastroenterology; Pediatrics; Triglyceride; Cholesterol; Demography; Health care","score_opus":0.010336646389222208,"score_gpt":0.22747254911971737,"score_spread":0.21713590273049516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168221836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99565035,0.0009687189,0.00007100664,0.00031871925,0.000010428131,0.000018758987,0.0019847935,0.000003986316,0.000973106],"genre_scores_gemma":[0.998425,0.0002912294,0.00007004646,0.000032581807,0.000014285083,0.00001090117,0.001074413,9.4401474e-7,0.00008063367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894744,0.00032376818,0.00020281524,0.00009884774,0.00022620388,0.00020087491],"domain_scores_gemma":[0.9972357,0.0004409381,0.0017340779,0.00005689847,0.00019609738,0.00033626767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004586671,0.0002194251,0.00023285304,0.0014991994,0.00028158512,0.0007482116,0.00037041766,0.00038064417,0.001982902],"category_scores_gemma":[0.004711589,0.00018542842,0.0006194557,0.002390905,0.00019067294,0.00043641863,0.00068207766,0.00054814684,0.0001392522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010434056,0.00005295681,0.9961367,0.0000312444,0.00012299271,0.00014810266,0.000029671251,0.00045665842,0.00004687992,0.00007595601,0.00033750612,0.0024570175],"study_design_scores_gemma":[0.0000058496944,0.000033325963,0.9979716,0.000029007993,0.00003414836,0.00034202877,0.00009846286,0.0011724934,0.000027688147,0.000055647644,0.00022479382,0.000004878559],"about_ca_topic_score_codex":0.0152038485,"about_ca_topic_score_gemma":0.013796065,"teacher_disagreement_score":0.0152038485,"about_ca_system_score_codex":0.0013575766,"about_ca_system_score_gemma":0.0005903474,"threshold_uncertainty_score":0.030230701},"labels":[],"label_agreement":null},{"id":"W2171819381","doi":"10.3111/13696998.2012.684116","title":"Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa; Bayer (Canada)","funders":"Bayer","keywords":"Rivaroxaban; Medicine; Cost-effectiveness analysis; Cost effectiveness; Time horizon; Pulmonary embolism; Emergency medicine; Intensive care medicine; Surgery; Internal medicine; Atrial fibrillation; Warfarin; Risk analysis (engineering)","score_opus":0.07944289797029809,"score_gpt":0.37235758021225135,"score_spread":0.2929146822419533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171819381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8160942,0.027984202,0.015589527,0.009026663,0.00031228727,0.0018287215,0.054612562,0.00017321948,0.07437859],"genre_scores_gemma":[0.9795355,0.0056516123,0.005017737,0.000415777,0.000036053585,0.00018060487,0.0052188598,0.000039487193,0.003904301],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99730766,0.00092777895,0.00011428626,0.00024247805,0.0007499048,0.00065789226],"domain_scores_gemma":[0.9955147,0.0016023936,0.0004720331,0.00012008048,0.0019018525,0.0003889042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036493803,0.0014732014,0.0015426676,0.0028257163,0.0015238132,0.0025651348,0.0021910842,0.0010533505,0.0045457794],"category_scores_gemma":[0.00966175,0.0009872424,0.0045961277,0.005731977,0.00077902444,0.0008244692,0.00086657907,0.0015008943,0.0001888232],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018639697,0.0002115309,0.043096185,0.0015575275,0.0033639385,0.0005640921,0.00023116956,0.89968663,0.00052895263,0.018199598,0.011864191,0.018832259],"study_design_scores_gemma":[0.0022444099,0.0006004119,0.086129986,0.00085717737,0.00566781,0.00037674306,0.0008179068,0.8767358,0.000552336,0.0053369515,0.02033257,0.00034796447],"about_ca_topic_score_codex":0.9940485,"about_ca_topic_score_gemma":0.9902216,"teacher_disagreement_score":0.11722593,"about_ca_system_score_codex":0.11722593,"about_ca_system_score_gemma":0.09670307,"threshold_uncertainty_score":0.85053766},"labels":[],"label_agreement":null},{"id":"W2171964208","doi":"10.3111/13696998.2012.667028","title":"Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thomson Reuters (Canada)","funders":"","keywords":"Medicine; Etanercept; Adalimumab; Infliximab; Rheumatoid arthritis; Internal medicine; Tumor necrosis factor alpha; Surgery","score_opus":0.020433945557357704,"score_gpt":0.2750843191235194,"score_spread":0.25465037356616166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171964208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999199,0.0002255686,0.000114913884,0.000041500265,0.000001991969,0.000010093291,0.00022804216,0.000004620953,0.0001743049],"genre_scores_gemma":[0.9993623,0.000054017815,0.00014594759,0.000022930219,0.000008155976,0.000007899029,0.00036213538,9.337162e-7,0.000035740934],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971403,0.0011846619,0.0003896459,0.00049409753,0.0005801617,0.00021115495],"domain_scores_gemma":[0.9840259,0.002945536,0.01165685,0.00039467498,0.0005042492,0.00047282447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027768973,0.0002266117,0.0003293479,0.0009840524,0.00025220355,0.00097123085,0.00042412567,0.00050411315,0.0006489695],"category_scores_gemma":[0.011778016,0.00020640378,0.000692289,0.0011732538,0.00021302217,0.0007403807,0.0005090854,0.0005992525,0.00013278706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016376567,0.000029052557,0.9982863,0.0000045788606,0.00004795812,0.000034251087,0.000044110027,0.0001417536,0.000049884824,0.0000099580775,0.000041147665,0.0011472229],"study_design_scores_gemma":[0.000028201017,0.00024658322,0.99681973,0.000009842497,0.000054409968,0.00030745575,0.000110613895,0.0020678726,0.0001426068,0.000020800946,0.00018652172,0.0000053745225],"about_ca_topic_score_codex":0.0066308123,"about_ca_topic_score_gemma":0.0065213772,"teacher_disagreement_score":0.0066308123,"about_ca_system_score_codex":0.0011420393,"about_ca_system_score_gemma":0.00055841554,"threshold_uncertainty_score":0.01468575},"labels":[],"label_agreement":null},{"id":"W2207823877","doi":"10.3111/13696998.2015.1131705","title":"Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Comprehensive Cancer Network; Canadian Centre for Applied Research in Cancer Control","keywords":"Axitinib; Everolimus; Medicine; Sunitinib; Hazard ratio; Internal medicine; Renal cell carcinoma; Pazopanib; Oncology; Sorafenib; Retrospective cohort study; Dosing; Discontinuation; Confidence interval; Hepatocellular carcinoma","score_opus":0.023934877566439083,"score_gpt":0.2883542912529376,"score_spread":0.2644194136864985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2207823877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98094165,0.0054826387,0.00056304224,0.0002369024,0.000014972964,0.00017076089,0.011132222,0.000028870363,0.0014290169],"genre_scores_gemma":[0.9920879,0.002126075,0.00072787626,0.00013662428,0.000022598919,0.00008303888,0.0046403194,0.000009759065,0.00016584803],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99699605,0.0006560097,0.0009480163,0.000416659,0.00081656367,0.00016677156],"domain_scores_gemma":[0.9818463,0.002564498,0.0129978685,0.00042780413,0.0018666098,0.00029689108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016849067,0.00021648005,0.00039994923,0.0032470159,0.00034101467,0.0008343795,0.0004613267,0.0003572447,0.000814544],"category_scores_gemma":[0.007156921,0.00031708862,0.0004952102,0.0060673803,0.00030969916,0.00061502506,0.0004178072,0.00031961073,0.00016759185],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006846726,0.000020295398,0.9950004,0.00012581964,0.000086254084,0.00038402385,0.0001571519,0.00011611937,0.00009115487,0.00003441903,0.00060016435,0.003315654],"study_design_scores_gemma":[0.000012968927,0.00008459432,0.9944178,0.00010690583,0.0000745254,0.001674304,0.000494136,0.00042779872,0.0002941749,0.000018412498,0.002382308,0.000012111794],"about_ca_topic_score_codex":0.023325691,"about_ca_topic_score_gemma":0.022088468,"teacher_disagreement_score":0.023325691,"about_ca_system_score_codex":0.0017092616,"about_ca_system_score_gemma":0.0019260588,"threshold_uncertainty_score":0.046379805},"labels":[],"label_agreement":null},{"id":"W2252889185","doi":"10.3111/13696998.2015.1100115","title":"Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Risperidone; Aripiprazole; Tolerability; Paliperidone; Olanzapine; Internal medicine; Schizophrenia (object-oriented programming); Adverse effect; Psychiatry","score_opus":0.059788747396948526,"score_gpt":0.37644823819064643,"score_spread":0.31665949079369793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2252889185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98875636,0.0055589695,0.0007161368,0.0010513582,0.000015380185,0.00008126844,0.0029530125,0.000009012808,0.00085850287],"genre_scores_gemma":[0.9978217,0.0008259157,0.00027747548,0.00011187696,0.000010330909,0.000035310975,0.00082549365,0.0000026000462,0.000089204936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973832,0.0017653125,0.00016620854,0.00018140557,0.0003073249,0.00019658233],"domain_scores_gemma":[0.9894723,0.00824395,0.0017124735,0.000117736716,0.00024988884,0.00020353985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054212403,0.0004106099,0.0007862029,0.0008877728,0.00030315024,0.0011115978,0.00043722268,0.00074911834,0.0015581257],"category_scores_gemma":[0.014567868,0.0002741108,0.0027090826,0.00088753726,0.00023438754,0.0005014237,0.00062205706,0.00057604595,0.000054848148],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008211907,0.0005777425,0.55479246,0.0016988154,0.010264333,0.0024509097,0.00036661475,0.3874968,0.0013112093,0.0028244802,0.0019507926,0.028053995],"study_design_scores_gemma":[0.001542792,0.0022800043,0.74759114,0.0012560089,0.0066173957,0.00159884,0.0008416465,0.22549307,0.0011603872,0.008348619,0.0030931798,0.00017691268],"about_ca_topic_score_codex":0.023571258,"about_ca_topic_score_gemma":0.013028489,"teacher_disagreement_score":0.023571258,"about_ca_system_score_codex":0.0047365553,"about_ca_system_score_gemma":0.0031110663,"threshold_uncertainty_score":0.046868086},"labels":[],"label_agreement":null},{"id":"W2262803926","doi":"10.3111/13696998.2016.1141780","title":"Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada","year":2016,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bristol-Myers Squibb (Canada); Pfizer (Canada)","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Apixaban; Venous thromboembolism; Intensive care medicine; Internal medicine; Warfarin; Atrial fibrillation; Rivaroxaban; Thrombosis","score_opus":0.03019685173148177,"score_gpt":0.30518240421543796,"score_spread":0.2749855524839562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2262803926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8699794,0.057896573,0.0042160703,0.013969484,0.00024872523,0.00073447806,0.033207927,0.00012790415,0.019619508],"genre_scores_gemma":[0.9881989,0.0062034847,0.0013765526,0.00054344605,0.000029212824,0.000066766224,0.0024526895,0.000011115612,0.0011178002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980021,0.00069874746,0.00012846878,0.00022893999,0.00051589817,0.00042579116],"domain_scores_gemma":[0.9942002,0.0020687825,0.00090243365,0.00017875133,0.0017731276,0.0008767407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00269557,0.00046611103,0.0009762648,0.001030299,0.001112664,0.0013308674,0.0012119965,0.00055233174,0.0033217082],"category_scores_gemma":[0.011212638,0.0003107536,0.0021155523,0.0020586916,0.0006195427,0.0003891037,0.000957522,0.0011112638,0.00006704997],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017654264,0.00077566016,0.499858,0.0057260673,0.014389492,0.0010264535,0.00061138446,0.25466552,0.0011440503,0.02372822,0.032707646,0.14771324],"study_design_scores_gemma":[0.009268976,0.0022622326,0.59766906,0.0029478762,0.02357229,0.00071867683,0.0012507219,0.3179095,0.0018817558,0.0117665,0.03034566,0.00040666843],"about_ca_topic_score_codex":0.9878884,"about_ca_topic_score_gemma":0.98889333,"teacher_disagreement_score":0.06525097,"about_ca_system_score_codex":0.06525097,"about_ca_system_score_gemma":0.08725726,"threshold_uncertainty_score":0.47343117},"labels":[],"label_agreement":null},{"id":"W2264465777","doi":"10.3111/13696998.2016.1151432","title":"Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes","year":2016,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bristol-Myers Squibb (Canada); McMaster University; McGill University; Golder Associates (Canada)","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Erlotinib; Nivolumab; Docetaxel; Quality-adjusted life year; Oncology; Lung cancer; Quality of life (healthcare); Cost effectiveness; Survival analysis; Internal medicine; Cancer; Immunotherapy; Epidermal growth factor receptor; Risk analysis (engineering)","score_opus":0.13854774319199728,"score_gpt":0.36274728020138175,"score_spread":0.22419953700938447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264465777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9496212,0.009273515,0.014157242,0.0036468105,0.00011972733,0.0021395786,0.0041955765,0.00015063399,0.01669572],"genre_scores_gemma":[0.98983663,0.0021182676,0.005638544,0.00019904778,0.00001479263,0.00036464105,0.0009445027,0.000022292645,0.00086123275],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9962263,0.0024075198,0.00015400801,0.00018226501,0.00062673894,0.0004032087],"domain_scores_gemma":[0.98957866,0.0066913613,0.0007252249,0.00018926254,0.0022643288,0.0005510311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008419349,0.0016346409,0.0012461012,0.0021294693,0.0014126651,0.0024401092,0.002028522,0.0012552986,0.0019781394],"category_scores_gemma":[0.022987863,0.0006125555,0.0020570525,0.0025646286,0.00082289544,0.0009090287,0.0013592973,0.0012742499,0.00009608243],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049996935,0.00077205966,0.025819592,0.0013125264,0.0011846824,0.00021100474,0.0002672743,0.9152192,0.0003495405,0.008841014,0.0021705711,0.038852993],"study_design_scores_gemma":[0.0009874158,0.0011235668,0.018577127,0.0003639433,0.0007701238,0.00007986882,0.0004820534,0.97333527,0.00032587053,0.0019414363,0.0019199502,0.00009332296],"about_ca_topic_score_codex":0.91588336,"about_ca_topic_score_gemma":0.85262257,"teacher_disagreement_score":0.08521019,"about_ca_system_score_codex":0.08521019,"about_ca_system_score_gemma":0.049015068,"threshold_uncertainty_score":0.6182461},"labels":[],"label_agreement":null},{"id":"W2280216291","doi":"10.3111/13696998.2016.1154566","title":"Cost-effectiveness of ranibizumab in the treatment of visual impairment due to diabetic macular edema","year":2016,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada)","funders":"Novartis Pharmaceuticals Canada; Public Health Agency of Canada","keywords":"Medicine; Ranibizumab; Diabetic macular edema; Ophthalmology; Edema; Visual impairment; Macular edema; Diabetic retinopathy; Diabetes mellitus; Visual acuity; Surgery; Bevacizumab; Chemotherapy","score_opus":0.02298697161475093,"score_gpt":0.33643614135231387,"score_spread":0.3134491697375629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2280216291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93297106,0.039625674,0.005835947,0.0032982037,0.00010925607,0.00056223135,0.003953496,0.00008449534,0.013559599],"genre_scores_gemma":[0.9968278,0.001695711,0.0006887812,0.000109646644,0.000010331254,0.00003676326,0.00031689508,0.0000029344474,0.00031115368],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9986644,0.00091219984,0.000051574174,0.00006756706,0.00016598696,0.00013835372],"domain_scores_gemma":[0.9980714,0.0013783119,0.00028380414,0.00003301566,0.00011020187,0.0001233406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022914524,0.00041407152,0.0007945956,0.00060361275,0.00018577157,0.0009874644,0.0005554177,0.00044372003,0.001778637],"category_scores_gemma":[0.006470632,0.00024655586,0.0017359465,0.00057529396,0.0002786429,0.0004502965,0.0004406777,0.0006042689,0.00006671773],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021303909,0.0006769729,0.08240129,0.0019330863,0.0061158384,0.0006601283,0.00008975552,0.77044094,0.0015669152,0.0061282124,0.0038208885,0.10486207],"study_design_scores_gemma":[0.004264652,0.005459246,0.12294636,0.001164593,0.009197502,0.00085318135,0.00030426384,0.8413989,0.001634332,0.0062994063,0.0063367244,0.0001408257],"about_ca_topic_score_codex":0.2009755,"about_ca_topic_score_gemma":0.21370111,"teacher_disagreement_score":0.2009755,"about_ca_system_score_codex":0.009981755,"about_ca_system_score_gemma":0.0058336104,"threshold_uncertainty_score":0.39961135},"labels":[],"label_agreement":null},{"id":"W2288006965","doi":"10.3111/13696998.2015.1116992","title":"Cost-effectiveness analysis of oxycodone with naloxone versus oxycodone alone for the management of moderate-to-severe pain in patients with opioid-induced constipation in Canada","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Gastrointestinal motility and disorders","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"Purdue Pharma","keywords":"Oxycodone; Medicine; Opioid; Chronic pain; (+)-Naloxone; Analgesic; Constipation; Anesthesia; Cost effectiveness; Physical therapy; Internal medicine","score_opus":0.042985781415556146,"score_gpt":0.2773973107426432,"score_spread":0.23441152932708703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2288006965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96708083,0.007856277,0.005923192,0.002582996,0.0000959919,0.0020120537,0.005598291,0.0000838243,0.008766512],"genre_scores_gemma":[0.99402183,0.0011832075,0.0027682097,0.00020607845,0.000011714632,0.00022215322,0.0008660079,0.0000059121376,0.00071491685],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9981382,0.00095888297,0.000056154848,0.00013141916,0.00025390333,0.00046146853],"domain_scores_gemma":[0.99630475,0.0021679336,0.0003538864,0.00005382703,0.0005737516,0.00054581615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033131265,0.0014483347,0.0019758127,0.0016559031,0.00084615004,0.0018054036,0.0017874415,0.001033303,0.0032563878],"category_scores_gemma":[0.008036125,0.0006698134,0.0037220782,0.0015912857,0.00079508947,0.00059382245,0.0010010111,0.0013314044,0.00011160923],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012576047,0.0009877795,0.026029589,0.0016818462,0.004229768,0.0002985643,0.00009191523,0.9237854,0.00069136504,0.0037403635,0.0025925336,0.02329475],"study_design_scores_gemma":[0.00463683,0.003967659,0.030580513,0.00050766126,0.004938078,0.00019641177,0.00034273116,0.9500989,0.0004785616,0.0021780739,0.001957878,0.00011671155],"about_ca_topic_score_codex":0.791211,"about_ca_topic_score_gemma":0.71271807,"teacher_disagreement_score":0.20878899,"about_ca_system_score_codex":0.049782246,"about_ca_system_score_gemma":0.0389003,"threshold_uncertainty_score":0.42003715},"labels":[],"label_agreement":null},{"id":"W2290821530","doi":"10.3111/13696998.2016.1151431","title":"A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada","year":2016,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Notre-Dame; Université de Montréal","funders":"","keywords":"Medicine; Lapatinib; Letrozole; Anastrozole; Breast cancer; Quality-adjusted life year; Context (archaeology); Cost effectiveness; Metastatic breast cancer; Oncology; Internal medicine; Pharmacoeconomics; Economic evaluation; Quality of life (healthcare); Tamoxifen; Cancer; Trastuzumab; Intensive care medicine","score_opus":0.05054085207464628,"score_gpt":0.31177162081062276,"score_spread":0.2612307687359765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2290821530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46604565,0.0058301385,0.2618045,0.0126075605,0.0005187965,0.0024095338,0.03838994,0.00078121223,0.2116127],"genre_scores_gemma":[0.9338687,0.002011815,0.033399176,0.00051457196,0.000059079266,0.0007489824,0.004842634,0.000088887384,0.024466202],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.999276,0.0003066682,0.000022407363,0.00009922911,0.00011050673,0.00018518294],"domain_scores_gemma":[0.9983359,0.00095167785,0.000094022274,0.00003584578,0.00045101863,0.00013159344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001659308,0.0014725183,0.0010264071,0.0016244388,0.0008892314,0.0021312484,0.0021666186,0.001734427,0.008262313],"category_scores_gemma":[0.0060635423,0.0006879324,0.0012618323,0.002534876,0.0009874997,0.0010423283,0.00106099,0.0015240373,0.000415456],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006842272,0.000013209751,0.0010219822,0.000032972912,0.000031254764,0.00006356471,0.000015710113,0.9849059,0.00003385032,0.010144601,0.0014774115,0.0021911405],"study_design_scores_gemma":[0.00009043939,0.00003117494,0.0008543086,0.000022970566,0.00004134544,0.000035431265,0.000045832538,0.9906791,0.00003289766,0.0053414586,0.0028100102,0.000015062856],"about_ca_topic_score_codex":0.7329158,"about_ca_topic_score_gemma":0.5827721,"teacher_disagreement_score":0.9782342,"about_ca_system_score_codex":0.02176585,"about_ca_system_score_gemma":0.018820213,"threshold_uncertainty_score":0.5373142},"labels":[],"label_agreement":null},{"id":"W2292517844","doi":"10.3111/13696998.2015.1106546","title":"Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Hepatitis C virus research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Sofosbuvir; Medicine; Daclatasvir; Internal medicine; Regimen; Ribavirin; Quality-adjusted life year; Cost effectiveness; Hepatitis C; Hepatitis C virus; Gastroenterology; Virology; Virus","score_opus":0.10394248166757698,"score_gpt":0.36719780092797444,"score_spread":0.26325531926039747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2292517844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98279405,0.0034744518,0.0022570675,0.0018350205,0.000038196653,0.0005129278,0.0029740266,0.000048759306,0.006065463],"genre_scores_gemma":[0.9968663,0.0007317274,0.0011467059,0.000097251985,0.0000052445876,0.00004717249,0.00052877964,0.000004401472,0.0005723797],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9988342,0.00044259525,0.000042727155,0.000088812296,0.00025797475,0.0003336751],"domain_scores_gemma":[0.99818665,0.0007355236,0.00023059806,0.00003347663,0.00046090092,0.00035285458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017844196,0.0006316403,0.0007451189,0.0008324598,0.0011063236,0.0011281446,0.0011755532,0.0005790013,0.0022567583],"category_scores_gemma":[0.005504631,0.00040399554,0.0013297702,0.0010716211,0.0005755723,0.00039450565,0.00076577417,0.00073608785,0.000061356644],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009609959,0.0009955546,0.1047305,0.00091385946,0.0015843593,0.0006367461,0.00026895426,0.8078677,0.0015152784,0.0078002824,0.0050878907,0.058988936],"study_design_scores_gemma":[0.0027122297,0.0016892387,0.09448418,0.00024718966,0.0012489477,0.00024555667,0.0004991761,0.89286244,0.0008343033,0.0020114572,0.0030400136,0.00012522137],"about_ca_topic_score_codex":0.97369856,"about_ca_topic_score_gemma":0.9691852,"teacher_disagreement_score":0.072786756,"about_ca_system_score_codex":0.072786756,"about_ca_system_score_gemma":0.058414623,"threshold_uncertainty_score":0.52810735},"labels":[],"label_agreement":null},{"id":"W2292965968","doi":"10.3111/13696998.2016.1148043","title":"Estimating healthcare resource use associated with the treatment of metastatic melanoma in eight countries","year":2016,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"European Society for Medical Oncology; Amgen","keywords":"Medicine; Palliative care; Health care; Radiation oncologist; Delphi method; Disease; Family medicine; Intensive care medicine; Internal medicine; Oncology; Radiation therapy; Nursing","score_opus":0.02535785315555483,"score_gpt":0.2717050905676122,"score_spread":0.24634723741205738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2292965968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846591,0.0027196275,0.0031877568,0.00025070633,0.000008563398,0.00015129833,0.0076968013,0.000021289443,0.0013049382],"genre_scores_gemma":[0.99132335,0.0010269171,0.0044075283,0.000050655108,0.000008512792,0.00024004291,0.0028538061,0.000005389301,0.00008382944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936511,0.003864308,0.0011432086,0.0005815916,0.00045834834,0.0003015437],"domain_scores_gemma":[0.9812448,0.009583615,0.007032896,0.00041656446,0.0014916908,0.00023046312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006540802,0.0006210388,0.0005770926,0.0062911357,0.00027778666,0.0016566908,0.00067894417,0.0007640342,0.00079328637],"category_scores_gemma":[0.023731304,0.00053410785,0.0022634098,0.0072573847,0.00054553396,0.0010386775,0.0016261031,0.00048786803,0.00011697833],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010818314,0.000052606923,0.96366847,0.000649896,0.0012132206,0.0001498446,0.000552536,0.021474263,0.000075283395,0.00042270185,0.0003675262,0.011265489],"study_design_scores_gemma":[0.000053735417,0.00043146854,0.9639264,0.0012785314,0.0007855704,0.00039330006,0.004124,0.025544688,0.0004517131,0.00063019386,0.0023245325,0.00005593096],"about_ca_topic_score_codex":0.028355252,"about_ca_topic_score_gemma":0.011856924,"teacher_disagreement_score":0.028355252,"about_ca_system_score_codex":0.0018682843,"about_ca_system_score_gemma":0.0012465394,"threshold_uncertainty_score":0.05638039},"labels":[],"label_agreement":null},{"id":"W2325992311","doi":"10.3111/13696998.2012.726674","title":"Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Casa","funders":"European Commission","keywords":"Rosuvastatin; Medicine; Atorvastatin; Statin; Rosuvastatin Calcium; Cost effectiveness; Internal medicine; Risk analysis (engineering)","score_opus":0.040634616720675476,"score_gpt":0.3254239922523687,"score_spread":0.2847893755316932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325992311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.959173,0.025432585,0.005109584,0.0018339878,0.00015408293,0.0005983632,0.0036790266,0.00010643779,0.003912852],"genre_scores_gemma":[0.99486804,0.0017930401,0.0011574556,0.00023032729,0.00003421333,0.00014498785,0.0013758149,0.000013700564,0.00038252174],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99335515,0.005220031,0.00025492068,0.00035110814,0.0004277954,0.00039098333],"domain_scores_gemma":[0.99409604,0.0038171115,0.0010652015,0.00020945218,0.0004748318,0.0003373025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008824738,0.0009937846,0.002174868,0.0012118783,0.00012795912,0.0014212845,0.0010643987,0.0010302166,0.0023918527],"category_scores_gemma":[0.015532138,0.00033656255,0.0037675411,0.0010673068,0.00036362073,0.0007013421,0.0008438709,0.0007914388,0.00016159756],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09937925,0.0028790173,0.08155069,0.0048786127,0.01543526,0.00076353067,0.00011264172,0.69767314,0.0013131936,0.0040607774,0.004541339,0.087412596],"study_design_scores_gemma":[0.057922907,0.02553332,0.14765333,0.0028082505,0.02273805,0.0011860947,0.0009457021,0.71747047,0.00236138,0.010340227,0.010758305,0.0002819695],"about_ca_topic_score_codex":0.013328095,"about_ca_topic_score_gemma":0.004956506,"teacher_disagreement_score":0.013328095,"about_ca_system_score_codex":0.0057972693,"about_ca_system_score_gemma":0.003137373,"threshold_uncertainty_score":0.0466702},"labels":[],"label_agreement":null},{"id":"W2337280501","doi":"10.3111/13696998.2016.1164174","title":"The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada","year":2016,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Biogen","keywords":"Dimethyl fumarate; Relapsing remitting; Medicine; Multiple sclerosis; Cost effectiveness; Internal medicine; Oncology; Immunology","score_opus":0.08091913144112999,"score_gpt":0.3192051370431769,"score_spread":0.23828600560204688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337280501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92088836,0.01386231,0.008023104,0.008282104,0.00017852649,0.0013332149,0.019242065,0.00023063441,0.027959678],"genre_scores_gemma":[0.9923746,0.0020253889,0.001948823,0.00021612101,0.000009156434,0.000098847915,0.0016545119,0.00001396541,0.0016587445],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9990939,0.00031203506,0.000034472938,0.00008757271,0.00019782131,0.00027426032],"domain_scores_gemma":[0.99794906,0.0009037863,0.00017323345,0.000041341176,0.00057124835,0.0003613699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019114282,0.0008661441,0.0009901442,0.0010728218,0.0011380023,0.0018843219,0.0018186086,0.00096574903,0.0043851],"category_scores_gemma":[0.006560541,0.00052844686,0.0017980405,0.0011785245,0.00069081265,0.0006390894,0.0010020436,0.0012787434,0.00015225788],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058878423,0.00036965247,0.030164786,0.0009526219,0.0010130554,0.0004370064,0.00013338546,0.9028155,0.0006290303,0.009841871,0.007477019,0.040278252],"study_design_scores_gemma":[0.0034088886,0.0009781567,0.027153922,0.0004963973,0.0014947553,0.00020626304,0.00042760812,0.95408964,0.0007942239,0.0040336982,0.00678918,0.0001272541],"about_ca_topic_score_codex":0.97788334,"about_ca_topic_score_gemma":0.9649132,"teacher_disagreement_score":0.081088334,"about_ca_system_score_codex":0.081088334,"about_ca_system_score_gemma":0.08000493,"threshold_uncertainty_score":0.5883398},"labels":[],"label_agreement":null},{"id":"W2546071416","doi":"10.1080/13696998.2016.1254090","title":"Ulipristal acetate for pre-operative treatment of moderate-to-severe uterine fibroids in women of reproductive age in The Netherlands: cost minimization analysis and budget impact analysis","year":2016,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Uterine Myomas and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Toronto","keywords":"Ulipristal acetate; Medicine; Uterine fibroids; Reimbursement; Gynecology; Population; Obstetrics; Health care; Family planning; Research methodology; Environmental health","score_opus":0.014795165088812998,"score_gpt":0.33683622796714313,"score_spread":0.3220410628783301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2546071416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8559462,0.020360328,0.07457742,0.004396972,0.0001941263,0.0035998751,0.01057993,0.00011949524,0.03022564],"genre_scores_gemma":[0.97516894,0.0036515961,0.014503696,0.00028986335,0.000031231877,0.0013827604,0.0017318297,0.000029847633,0.0032102712],"study_design_codex":"simulation_or_modeling","study_design_gemma":"not_applicable","domain_scores_codex":[0.99720037,0.0020253228,0.000088565015,0.00018968017,0.00018528553,0.00031077908],"domain_scores_gemma":[0.9947221,0.004409394,0.00039215552,0.000061315666,0.00022238438,0.0001926659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004978108,0.0010917136,0.0022507752,0.0016598246,0.00031415388,0.0024076148,0.0011858073,0.0014854105,0.004829291],"category_scores_gemma":[0.010001566,0.001180313,0.0038657757,0.0018451369,0.0004245101,0.0011957523,0.0010013841,0.0014225373,0.00023742375],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009854507,0.00015852762,0.003011628,0.00066219276,0.0006635532,0.0002868326,0.00003726472,0.98229873,0.00020778092,0.0026241606,0.000784286,0.008279601],"study_design_scores_gemma":[0.0009214713,0.0010200297,0.005759712,0.00051034667,0.0014654484,0.00021741507,0.00022618222,0.98296285,0.0003808751,0.0037497447,0.00272748,0.00005838648],"about_ca_topic_score_codex":0.031297043,"about_ca_topic_score_gemma":0.016531572,"teacher_disagreement_score":0.031297043,"about_ca_system_score_codex":0.006460829,"about_ca_system_score_gemma":0.0060624275,"threshold_uncertainty_score":0.062229693},"labels":[],"label_agreement":null},{"id":"W2564573601","doi":"10.1080/13696998.2016.1273229","title":"Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study","year":2016,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Thrombosis and Atherosclerosis Research Institute","funders":"Medicines Company; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Idarucizumab; Dabigatran; Anticoagulant; Surgery; Interim analysis; Psychological intervention; Intensive care unit; Emergency medicine; Anesthesia; Randomized controlled trial; Intensive care medicine; Warfarin; Internal medicine","score_opus":0.17826688296940718,"score_gpt":0.3904857417989905,"score_spread":0.2122188588295833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564573601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993383,0.00068918406,0.00014133325,0.00010874711,0.000017701963,0.000113381684,0.0049199397,0.000010347012,0.0006163324],"genre_scores_gemma":[0.98740107,0.00035631825,0.00040293732,0.00015278776,0.00006970759,0.00020134218,0.010928614,0.000008909214,0.00047832087],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985746,0.00056296354,0.00017972745,0.0002753497,0.00021820857,0.0001891437],"domain_scores_gemma":[0.9968749,0.00067176233,0.001440655,0.00026063144,0.0002697431,0.0004822123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003037109,0.00050880795,0.0008666748,0.000586386,0.00018201048,0.0013365314,0.00061485067,0.00048979855,0.0016536335],"category_scores_gemma":[0.0025614593,0.00037850437,0.002441039,0.00091106293,0.00021740675,0.0009524041,0.00075193204,0.000875607,0.00032558417],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029482452,0.0011143216,0.9520471,0.00027797095,0.0027866797,0.00007617036,0.00016179797,0.00055648905,0.00045212955,0.000093788854,0.0019875593,0.010963502],"study_design_scores_gemma":[0.0034304794,0.0055728685,0.98604244,0.00007758608,0.0019730534,0.000118913646,0.00022827729,0.00087783457,0.0003821664,0.00005655904,0.0012011749,0.00003862741],"about_ca_topic_score_codex":0.0026488851,"about_ca_topic_score_gemma":0.003579945,"teacher_disagreement_score":0.003037109,"about_ca_system_score_codex":0.0005578394,"about_ca_system_score_gemma":0.0009411034,"threshold_uncertainty_score":0.016061962},"labels":[],"label_agreement":null},{"id":"W2704483287","doi":"10.1080/13696998.2017.1347792","title":"Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer’s perspective","year":2017,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Institute for Clinical Evaluative Sciences; University of Ottawa","funders":"","keywords":"Medicine; Insulin detemir; Insulin glargine; Type 2 diabetes; Context (archaeology); Type 2 Diabetes Mellitus; Cost effectiveness; Diabetes mellitus; Cohort; Intensive care medicine; Internal medicine; Endocrinology; Risk analysis (engineering)","score_opus":0.08740198163052294,"score_gpt":0.3885485808099122,"score_spread":0.3011465991793893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2704483287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.580936,0.36557212,0.019131018,0.008827821,0.0009988517,0.0017294018,0.005587387,0.00011856891,0.017098863],"genre_scores_gemma":[0.976105,0.0189573,0.002904177,0.00059249805,0.000119666394,0.0003211072,0.00060830003,0.000013551556,0.00037849462],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99135256,0.0068134945,0.0005529325,0.0003161352,0.0007471942,0.00021765442],"domain_scores_gemma":[0.9882095,0.009780503,0.001322526,0.00014886563,0.00034859602,0.0001899403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010897895,0.0009957673,0.0022013967,0.0017597718,0.00020946786,0.0024444342,0.00063578575,0.0011066378,0.0038245872],"category_scores_gemma":[0.025462791,0.0004642571,0.0074171866,0.0014823059,0.0005813786,0.0018979766,0.00094280904,0.0019179098,0.0001052826],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11054066,0.0016240334,0.059333988,0.06808646,0.12821822,0.0015480312,0.0005243841,0.3115074,0.0027506647,0.018293818,0.0058348123,0.2917376],"study_design_scores_gemma":[0.03226792,0.038794775,0.09786412,0.044453412,0.33372003,0.004820159,0.0025170862,0.34639993,0.007859096,0.06534863,0.025147459,0.00080730557],"about_ca_topic_score_codex":0.0031312064,"about_ca_topic_score_gemma":0.002431173,"teacher_disagreement_score":0.010897895,"about_ca_system_score_codex":0.0028234478,"about_ca_system_score_gemma":0.0021334237,"threshold_uncertainty_score":0.057634234},"labels":[],"label_agreement":null},{"id":"W2740431138","doi":"10.1080/13696998.2017.1363050","title":"Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands","year":2017,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Paliperidone Palmitate; Paliperidone; Risperidone; Cost effectiveness; Olanzapine; Quality-adjusted life year; Emergency medicine; Schizophrenia (object-oriented programming); Psychiatry","score_opus":0.0715635955191591,"score_gpt":0.38269670465807637,"score_spread":0.3111331091389173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740431138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95833135,0.00797273,0.0071150223,0.002432725,0.00015341175,0.0009445652,0.010465411,0.000055767283,0.012528926],"genre_scores_gemma":[0.9937692,0.0011615573,0.001847499,0.00015547068,0.000014486865,0.00035357082,0.0015177828,0.00002001675,0.0011603555],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99702966,0.0022095744,0.00012767059,0.00018239042,0.00021833397,0.00023238714],"domain_scores_gemma":[0.99523526,0.0036702203,0.0005725822,0.00006743519,0.00024212262,0.00021236925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004031438,0.0007220914,0.001029363,0.00072040025,0.00018914665,0.0015815203,0.0010723895,0.0008286629,0.003743469],"category_scores_gemma":[0.016421607,0.0005731469,0.0027197863,0.0009816576,0.00029918275,0.0012367659,0.00075717276,0.0008860734,0.00018424427],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041253464,0.00033679215,0.013214408,0.0009569022,0.0016326264,0.0004478209,0.00009588475,0.94920087,0.00026368574,0.0038632548,0.0023048592,0.02355757],"study_design_scores_gemma":[0.0036200774,0.0021452555,0.030173223,0.0007186357,0.0021851982,0.00038566074,0.0004985745,0.9468915,0.0005754768,0.007804352,0.004880026,0.000122063306],"about_ca_topic_score_codex":0.0884488,"about_ca_topic_score_gemma":0.04051896,"teacher_disagreement_score":0.0884488,"about_ca_system_score_codex":0.008753928,"about_ca_system_score_gemma":0.0046061254,"threshold_uncertainty_score":0.17586792},"labels":[],"label_agreement":null},{"id":"W2765403114","doi":"10.1080/13696998.2018.1539400","title":"Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective","year":2018,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada); McMaster University","funders":"","keywords":"Medicine; Secukinumab; BASDAI; Golimumab; Adalimumab; BASFI; Ankylosing spondylitis; Certolizumab pegol; Etanercept; Infliximab; Population; Cost effectiveness; Discontinuation; Internal medicine; Tumor necrosis factor alpha; Disease","score_opus":0.03604495381201373,"score_gpt":0.3326350826472689,"score_spread":0.29659012883525515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765403114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83971065,0.06002752,0.015670538,0.012904948,0.00035042837,0.0013009977,0.022191932,0.00018695714,0.047656067],"genre_scores_gemma":[0.9858267,0.006207144,0.003962974,0.00036397486,0.000035160683,0.00012516887,0.00191464,0.000020594009,0.0015437208],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99804497,0.0007515148,0.00007134187,0.00014669875,0.0005942705,0.0003911157],"domain_scores_gemma":[0.99755245,0.0010366079,0.00024270672,0.000044541364,0.000837139,0.00028646566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00249129,0.0012860935,0.0012751276,0.0022970242,0.00091668835,0.0022468967,0.0015093625,0.000987903,0.0042942734],"category_scores_gemma":[0.008426696,0.0005466539,0.0026641656,0.0032042312,0.0007150944,0.00064110017,0.0007558351,0.0011248582,0.00015203984],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005607827,0.00033997084,0.027574183,0.0026853455,0.004796674,0.0004623956,0.0001761683,0.86302775,0.001082299,0.025226638,0.008624915,0.06039588],"study_design_scores_gemma":[0.002499671,0.001270057,0.053268597,0.0011157088,0.0066272914,0.00045824042,0.0005107278,0.90733963,0.0010536052,0.010362784,0.015219028,0.000274733],"about_ca_topic_score_codex":0.9262653,"about_ca_topic_score_gemma":0.888352,"teacher_disagreement_score":0.0737347,"about_ca_system_score_codex":0.067680895,"about_ca_system_score_gemma":0.057093132,"threshold_uncertainty_score":0.49106157},"labels":[],"label_agreement":null},{"id":"W2806175845","doi":"10.1080/13696998.2018.1486846","title":"The impact of different scenarios for intermittent bladder catheterization on health state utilities: results from an internet-based time trade-off survey","year":2018,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Urinary Tract Infections Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"International Collaboration On Repair Discoveries; GF Strong Rehabilitation Centre; University of British Columbia","funders":"","keywords":"Medicine; Catheter; The Internet; Time-trade-off; Quality of life (healthcare); Population; Gold standard (test); Intensive care medicine; Emergency medicine; Environmental health; Surgery; Nursing; Internal medicine","score_opus":0.03653573159351569,"score_gpt":0.3403987896737409,"score_spread":0.3038630580802252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806175845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987909,0.000046781584,0.00012362884,0.00003327586,0.0000020926996,0.000021823449,0.00062710745,0.0000037823852,0.00035069964],"genre_scores_gemma":[0.99878794,0.00004233871,0.00024540612,0.000024930907,0.0000026196092,0.000033282813,0.00076071534,0.0000021808767,0.00010059515],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973839,0.0015740411,0.00024029166,0.00021399597,0.00038608792,0.0002016862],"domain_scores_gemma":[0.9811405,0.011753008,0.0046575484,0.00051746954,0.00096716196,0.00096441456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047542998,0.00028129667,0.00032999727,0.0007272991,0.0001918717,0.00080335943,0.0003380919,0.0006802742,0.0018504928],"category_scores_gemma":[0.018834434,0.00013342866,0.00133345,0.00087428483,0.0003239982,0.00075255457,0.0006729064,0.00062145706,0.00031167007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011711459,0.0005959078,0.98434526,0.00008012382,0.00027127858,0.000077414654,0.00037900495,0.003130737,0.00020468493,0.00009862375,0.00039206984,0.009253771],"study_design_scores_gemma":[0.000038653812,0.0012298118,0.99241453,0.000029234974,0.00007469927,0.00015489123,0.00067918946,0.004605375,0.0001581005,0.0000993133,0.00049085857,0.000025298275],"about_ca_topic_score_codex":0.003782984,"about_ca_topic_score_gemma":0.0042404816,"teacher_disagreement_score":0.0047542998,"about_ca_system_score_codex":0.0007205204,"about_ca_system_score_gemma":0.00029953007,"threshold_uncertainty_score":0.025143445},"labels":[],"label_agreement":null},{"id":"W2887537762","doi":"10.1080/13696998.2018.1511566","title":"Cost consequence analysis of use of a balloon expandable vascular access system and standard vascular sheath for transcatheter aortic valve implantation","year":2018,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cardiac Valve Diseases and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Columbian Hospital; Université de Montréal; Montreal Heart Institute","funders":"","keywords":"Medicine; Stenosis; Surgery; Balloon; Retrospective cohort study; Vascular access; Cardiology","score_opus":0.03803053530142948,"score_gpt":0.35875473697368737,"score_spread":0.3207242016722579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887537762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778479,0.0006752105,0.012963634,0.0007228379,0.000038646216,0.0004166959,0.0016023437,0.000036122172,0.005696535],"genre_scores_gemma":[0.9964659,0.000121891986,0.0023413405,0.000058720037,0.000008824893,0.00010410713,0.0003994855,0.000004526302,0.000495268],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9975816,0.0017131768,0.00008051141,0.00015571906,0.00022442886,0.00024458315],"domain_scores_gemma":[0.9834948,0.0142863095,0.0010245278,0.00019685007,0.000613965,0.0003834099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005780718,0.00075837114,0.00086999807,0.0013502294,0.00033575544,0.0016980771,0.0010186024,0.00089784013,0.0040952843],"category_scores_gemma":[0.014632793,0.0005369387,0.0021396757,0.00092128926,0.00044885694,0.0011179497,0.0006624903,0.0010343214,0.00012319577],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027277449,0.0004078441,0.030260418,0.00025341107,0.00065449293,0.00029246125,0.000045958794,0.9507278,0.00038704198,0.0059554027,0.00078902964,0.007498408],"study_design_scores_gemma":[0.00038199863,0.0016786796,0.015239773,0.000074745425,0.0007769461,0.00026377695,0.000106955624,0.97681683,0.00046468576,0.0035469204,0.0006047827,0.000043875163],"about_ca_topic_score_codex":0.009013185,"about_ca_topic_score_gemma":0.006931476,"teacher_disagreement_score":0.009013185,"about_ca_system_score_codex":0.00505571,"about_ca_system_score_gemma":0.0026842298,"threshold_uncertainty_score":0.03668189},"labels":[],"label_agreement":null},{"id":"W2904389052","doi":"10.1080/13696998.2018.1558866","title":"Decrease in American birth rates makes it imperative for the United States to implement state mandated fertility coverage","year":2018,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Assisted Reproductive Technology and Twin Pregnancy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Infertility; Medicine; Fertility; Live birth; Obstetrics; Assisted reproductive technology; Embryo transfer; Single Embryo Transfer; Multiple birth; Pregnancy; Demography; Environmental health; Population","score_opus":0.0235166893265398,"score_gpt":0.3442517936237993,"score_spread":0.32073510429725954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904389052","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14603576,0.022393204,0.006852913,0.4936708,0.0078048026,0.00015265292,0.0066810367,0.0010083289,0.3154005],"genre_scores_gemma":[0.6760226,0.037032556,0.018580897,0.15676336,0.0046047387,0.00027719178,0.007863983,0.00021058047,0.09864423],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9992937,0.00013063308,0.00003944681,0.00004592655,0.0003727542,0.00011754707],"domain_scores_gemma":[0.9967272,0.0006482392,0.00054298947,0.00014408067,0.0013203714,0.00061716523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012884475,0.00017485234,0.00021831969,0.00057285966,0.000777062,0.00091866835,0.0005114899,0.0011535814,0.017429437],"category_scores_gemma":[0.0041519417,0.000102658014,0.0003089457,0.0008625342,0.0003654968,0.0006027682,0.000804246,0.0021936984,0.00279534],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010845778,0.00046784797,0.08248375,0.00032304376,0.00005189435,0.0003875435,0.00045661122,0.00048723063,0.002363395,0.04689212,0.45920378,0.40677434],"study_design_scores_gemma":[0.000022816914,0.00022394497,0.22007088,0.0003749109,0.000046334928,0.0008948928,0.00069520465,0.0008249707,0.0007895338,0.004462432,0.7715648,0.000029333703],"about_ca_topic_score_codex":0.03247518,"about_ca_topic_score_gemma":0.056599595,"teacher_disagreement_score":0.03247518,"about_ca_system_score_codex":0.0013883897,"about_ca_system_score_gemma":0.0032579433,"threshold_uncertainty_score":0.064572275},"labels":[],"label_agreement":null},{"id":"W2906443950","doi":"10.1080/13696998.2019.1590843","title":"The burden of osteoporosis in four Latin American countries: Brazil, Mexico, Colombia, and Argentina","year":2019,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada)","funders":"","keywords":"Medicine; Latin Americans; Osteoporosis; Environmental health; Medical prescription; Indirect costs; Business","score_opus":0.049133716734967206,"score_gpt":0.3803805302742925,"score_spread":0.33124681353932534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906443950","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85330623,0.069760546,0.003909959,0.01461673,0.00019490987,0.00043826518,0.02539585,0.00013659506,0.0322409],"genre_scores_gemma":[0.9703545,0.021305874,0.0028081788,0.00032768265,0.000043978882,0.00018222551,0.0041455496,0.0000144175965,0.00081759924],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996178,0.00015929453,0.000033730194,0.000049930786,0.00008400415,0.000055232667],"domain_scores_gemma":[0.999252,0.00019135338,0.0002584812,0.000022065435,0.00020677807,0.00006930353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010933987,0.0004964129,0.00039739604,0.0015013195,0.00042095367,0.001212153,0.0003625436,0.0003458104,0.0017490442],"category_scores_gemma":[0.002485152,0.00024064128,0.0008439067,0.0018069631,0.00031174615,0.00054261636,0.00066272676,0.00036979915,0.00010052575],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048504144,0.00012575518,0.8740832,0.002642163,0.0013927404,0.0015208782,0.0012493073,0.013047612,0.00060312933,0.008266131,0.015089643,0.081494346],"study_design_scores_gemma":[0.0003782855,0.00017479122,0.9098638,0.004322831,0.0021006523,0.0017148886,0.004605159,0.020256264,0.0003906241,0.0039517116,0.052137543,0.00010342013],"about_ca_topic_score_codex":0.27244836,"about_ca_topic_score_gemma":0.21450269,"teacher_disagreement_score":0.27244836,"about_ca_system_score_codex":0.0032466485,"about_ca_system_score_gemma":0.0029103276,"threshold_uncertainty_score":0.54172504},"labels":[],"label_agreement":null},{"id":"W2910482049","doi":"10.1080/13696998.2019.1569446","title":"Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma","year":2019,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Medicine; Metastatic melanoma; Cohort; Oncology; Internal medicine; Melanoma; Overall survival; Cancer","score_opus":0.14165245733668508,"score_gpt":0.4049893729289035,"score_spread":0.26333691559221845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910482049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5239168,0.0020873363,0.44827902,0.00443601,0.00025772792,0.0011229032,0.0024406973,0.00036544408,0.017094022],"genre_scores_gemma":[0.9595191,0.0005892847,0.03663727,0.00028910153,0.000045530334,0.00066040165,0.0005142649,0.000039106162,0.001705887],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9963731,0.003093024,0.00007450144,0.00016313195,0.0001617413,0.00013441667],"domain_scores_gemma":[0.9614375,0.03568821,0.0011948433,0.0004001369,0.0008311002,0.0004482218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012382502,0.00081690704,0.0009932185,0.0008743111,0.00041940634,0.0013242548,0.0012097665,0.0013906348,0.0047169565],"category_scores_gemma":[0.029370314,0.0006620829,0.0017667448,0.00082451745,0.00064291706,0.0012661766,0.0012552405,0.0020718577,0.00021186151],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029589038,0.00003585722,0.001472827,0.000044419234,0.00007134169,0.000026454692,0.000024971336,0.9886346,0.000050431747,0.0070091146,0.00020762597,0.0021265966],"study_design_scores_gemma":[0.000056133766,0.000105111285,0.0002808833,0.000026809574,0.000027224469,0.000007033171,0.000012970001,0.99438643,0.00005709294,0.0047426056,0.0002900699,0.000007689237],"about_ca_topic_score_codex":0.018585972,"about_ca_topic_score_gemma":0.013925252,"teacher_disagreement_score":0.018585972,"about_ca_system_score_codex":0.003267266,"about_ca_system_score_gemma":0.002839268,"threshold_uncertainty_score":0.065485716},"labels":[],"label_agreement":null},{"id":"W2911474691","doi":"10.1080/13696998.2019.1582059","title":"CAR T-cells: costs, comparisons, and commentary","year":2019,"lang":"en","type":"letter","venue":"Journal of Medical Economics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Intensive care medicine; Actuarial science; Economics","score_opus":0.033320510649939156,"score_gpt":0.3124527859559872,"score_spread":0.279132275306048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911474691","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001296392,0.001105024,0.000030020225,0.9919293,0.0057115313,0.0000027658234,0.000040934367,0.0000035006324,0.0010473373],"genre_scores_gemma":[0.0056092353,0.0017397775,0.00014029394,0.94848746,0.04199433,0.00002198469,0.00003239739,0.000013640896,0.0019608405],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9839749,0.006541175,0.0017297735,0.0015574116,0.005107652,0.0010890678],"domain_scores_gemma":[0.8875842,0.08945348,0.0033614645,0.0014016946,0.014112191,0.0040870104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018262636,0.00077512546,0.0017779607,0.0018424428,0.0035786526,0.0057788054,0.003850755,0.05288355,0.012395768],"category_scores_gemma":[0.138107,0.0006858955,0.0014603741,0.0026306505,0.0057354625,0.0070078922,0.001990219,0.04121503,0.0064538205],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012930868,0.000019413355,0.00023877119,0.000099322424,0.000018687757,0.00049905246,0.00010468212,0.0001089524,0.00005571616,0.012935099,0.9763257,0.009465295],"study_design_scores_gemma":[0.0002851999,0.0000853397,0.0009515508,0.0013591057,0.00007532308,0.0015687955,0.00080348074,0.0007478536,0.00031831735,0.063156575,0.9305331,0.000115370814],"about_ca_topic_score_codex":0.009271184,"about_ca_topic_score_gemma":0.008660207,"teacher_disagreement_score":0.05288355,"about_ca_system_score_codex":0.012724534,"about_ca_system_score_gemma":0.010795393,"threshold_uncertainty_score":0.09658325},"labels":[],"label_agreement":null},{"id":"W2919228285","doi":"10.1080/13696998.2019.1590842","title":"Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)","year":2019,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Western University; University of Alberta; William Osler Health System; Roche (Canada)","funders":"","keywords":"Atezolizumab; Docetaxel; Medicine; Nivolumab; Oncology; Lung cancer; Cost effectiveness; Clinical trial; Internal medicine; Chemotherapy; Cancer; Immunotherapy; Risk analysis (engineering)","score_opus":0.016275617865555925,"score_gpt":0.29182496836964344,"score_spread":0.2755493505040875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2919228285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89947796,0.04172386,0.0076317927,0.01061679,0.00034991797,0.001487835,0.020507162,0.0001788578,0.018025896],"genre_scores_gemma":[0.99084234,0.0034187087,0.0018453203,0.00036386773,0.000020324973,0.000113738606,0.0020823253,0.000015724565,0.0012976808],"study_design_codex":"simulation_or_modeling","study_design_gemma":"not_applicable","domain_scores_codex":[0.99871397,0.00046695324,0.00005652142,0.00014244027,0.0003085466,0.00031145927],"domain_scores_gemma":[0.99736446,0.0010762776,0.00035606013,0.000055225802,0.0007470879,0.00040079848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021773134,0.0010726358,0.0011488107,0.0010629466,0.00085625215,0.0020676553,0.0015318912,0.001094838,0.0034298028],"category_scores_gemma":[0.010935466,0.0005029028,0.0025656924,0.0013282291,0.00068363367,0.0008252933,0.0008997036,0.0015950562,0.00012459372],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015654093,0.0008751741,0.06323203,0.0035474282,0.005406884,0.0006344479,0.00020582862,0.7645606,0.0010962622,0.013793026,0.01471277,0.1162815],"study_design_scores_gemma":[0.008114524,0.003958237,0.1034946,0.0020906725,0.011044186,0.00083936437,0.0008832753,0.83556885,0.0021896348,0.009417695,0.022076087,0.0003229605],"about_ca_topic_score_codex":0.95175946,"about_ca_topic_score_gemma":0.94423336,"teacher_disagreement_score":0.9216784,"about_ca_system_score_codex":0.07832159,"about_ca_system_score_gemma":0.071593784,"threshold_uncertainty_score":0.56826556},"labels":[],"label_agreement":null},{"id":"W2945206773","doi":"10.1080/13696998.2019.1620243","title":"Guidelines-based treatment associated with improved economic outcomes in nontuberculous mycobacterial lung disease","year":2019,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Mycobacterium research and diagnosis","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Mount Sinai Hospital","funders":"Insmed","keywords":"Medicine; Internal medicine; Odds ratio; Nontuberculous mycobacteria; Retrospective cohort study; Cohort; Health care; Emergency medicine; Tuberculosis; Mycobacterium","score_opus":0.01999539016700081,"score_gpt":0.31916590772575676,"score_spread":0.29917051755875596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945206773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99768186,0.00075683795,0.00005925709,0.00035664692,0.000015153973,0.000008594105,0.00058366166,0.0000026870925,0.00053531036],"genre_scores_gemma":[0.9991166,0.00017888441,0.000056916157,0.00007232127,0.000020396586,0.000005552163,0.0004779648,0.0000011064936,0.000070242204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883825,0.00045123353,0.00015470895,0.00014129223,0.00021465964,0.00019983838],"domain_scores_gemma":[0.9921383,0.0011349088,0.0055084946,0.0001580559,0.00039184888,0.0006683569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012047654,0.00015009036,0.00026587973,0.0005175494,0.000263072,0.0008685125,0.0002957453,0.00041700123,0.0015113566],"category_scores_gemma":[0.007887958,0.000119967386,0.00057941064,0.0009014515,0.00020894305,0.00042215057,0.00051380735,0.0008964249,0.000105082094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023674693,0.00012270351,0.99631387,0.000021170705,0.00010977327,0.000034946126,0.000022302003,0.00011841824,0.00004515336,0.000036507,0.00026318425,0.0026751563],"study_design_scores_gemma":[0.00001785504,0.000091043556,0.9991879,0.000013916969,0.000044089233,0.00006448399,0.000042087733,0.00030815855,0.000021668857,0.000042415893,0.00016417107,0.0000022906734],"about_ca_topic_score_codex":0.0058187237,"about_ca_topic_score_gemma":0.0070669437,"teacher_disagreement_score":0.0058187237,"about_ca_system_score_codex":0.0007559695,"about_ca_system_score_gemma":0.0006994988,"threshold_uncertainty_score":0.011569738},"labels":[],"label_agreement":null},{"id":"W2948865799","doi":"10.1080/13696998.2019.1627364","title":"Cost of operating room time for endovascular transcatheter aortic valve replacement","year":2019,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cardiac Valve Diseases and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Valve replacement; Comorbidity; Cohort; Charlson comorbidity index; Emergency medicine; Variable cost; Surgery; Cardiology; Internal medicine; Stenosis","score_opus":0.016025664826337587,"score_gpt":0.3164916511245503,"score_spread":0.3004659862982127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948865799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97864234,0.0021307096,0.0036795894,0.0010467,0.000059343834,0.000053075375,0.009535017,0.000036245696,0.004816972],"genre_scores_gemma":[0.9956436,0.00051544036,0.0009987628,0.000050336068,0.000028910368,0.000019458746,0.0024626881,0.00000668929,0.00027405575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989982,0.00031120965,0.00014508967,0.00010864123,0.00029297237,0.00014392239],"domain_scores_gemma":[0.9961045,0.00091510284,0.002308128,0.00008893769,0.0003242609,0.00025900232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082427316,0.00027821818,0.00015400685,0.000952365,0.00014358973,0.00093162403,0.00047787823,0.00020797053,0.0023895726],"category_scores_gemma":[0.0057503968,0.00013522725,0.00056059024,0.0012177873,0.00023654525,0.0006781556,0.00052899116,0.00044204757,0.00025838971],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005245505,0.00011464586,0.9114462,0.0003651588,0.0005311029,0.00020392121,0.00014965606,0.026129548,0.0005770281,0.0028651012,0.0046165064,0.052476592],"study_design_scores_gemma":[0.00004003667,0.00037759417,0.9641301,0.00019027703,0.00020063555,0.0009981248,0.0004829759,0.02269162,0.0007644616,0.0014531732,0.008630173,0.00004083387],"about_ca_topic_score_codex":0.00758424,"about_ca_topic_score_gemma":0.009603061,"teacher_disagreement_score":0.00758424,"about_ca_system_score_codex":0.0022575937,"about_ca_system_score_gemma":0.0011743925,"threshold_uncertainty_score":0.016380131},"labels":[],"label_agreement":null},{"id":"W2988380919","doi":"10.1080/13696998.2019.1686311","title":"Economic burden associated with inadequate antidepressant medication management among patients with depression and known cardiovascular diseases: insights from a United States–based retrospective claims database analysis","year":2019,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cardiac Health and Mental Health","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Brain and Cognition Discovery Foundation","funders":"","keywords":"Medicine; Major depressive disorder; Retrospective cohort study; Depression (economics); Emergency medicine; Fluoxetine; Antidepressant; Myocardial infarction; Emergency department; Internal medicine; Database; Psychiatry; Anxiety","score_opus":0.005058976549069971,"score_gpt":0.23826029643699242,"score_spread":0.23320131988792245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988380919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947465,0.0007839463,0.00017158735,0.00020255931,0.000009822279,0.000023736968,0.0035946553,0.000005267936,0.0004618341],"genre_scores_gemma":[0.9956707,0.00037726515,0.00021856058,0.00008526571,0.000024981155,0.000017010667,0.0035388113,0.000002570802,0.00006494683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998218,0.0006312072,0.00043471192,0.00025440866,0.0003407643,0.00012080671],"domain_scores_gemma":[0.99034333,0.0015267079,0.0065868106,0.0006121665,0.0006185857,0.00031232284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021235773,0.0002933709,0.00044588224,0.0021098314,0.0003609918,0.0011594826,0.00055395905,0.0004668009,0.0010044752],"category_scores_gemma":[0.008262735,0.00039282028,0.0010778152,0.0035729224,0.00024201536,0.0005781485,0.0010063258,0.0006422244,0.00014749996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056494213,0.000025927617,0.99857414,0.000014613954,0.00021283455,0.000038969614,0.000028037219,0.00008576255,0.000020871747,0.000032405038,0.00020744358,0.00070235314],"study_design_scores_gemma":[0.0000068775034,0.000028934941,0.99853516,0.000021872527,0.00010453156,0.00019770031,0.000095744595,0.0007387126,0.00002054287,0.000033572196,0.00021098946,0.0000052667865],"about_ca_topic_score_codex":0.0100776255,"about_ca_topic_score_gemma":0.011322744,"teacher_disagreement_score":0.0100776255,"about_ca_system_score_codex":0.00059027766,"about_ca_system_score_gemma":0.00054635014,"threshold_uncertainty_score":0.02003795},"labels":[],"label_agreement":null},{"id":"W3000406225","doi":"10.1080/13696998.2020.1717499","title":"Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal","year":2020,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fingolimod; Medicine; Cladribine; Multiple sclerosis; Expanded Disability Status Scale; Quality-adjusted life year; Internal medicine; Cost effectiveness; Immunology","score_opus":0.12037512007868408,"score_gpt":0.31522119481138305,"score_spread":0.194846074732699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000406225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98633736,0.005608022,0.0017519597,0.0010289481,0.000071495866,0.00017644944,0.0016975547,0.000027443717,0.0033008538],"genre_scores_gemma":[0.9987128,0.00044747157,0.0003897458,0.000041909392,0.000009983606,0.00003445026,0.00023235449,0.0000034197146,0.00012782234],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99829215,0.0012314547,0.000072745475,0.00012954364,0.00012447688,0.00014965642],"domain_scores_gemma":[0.9950531,0.0032549999,0.0010218262,0.00015357601,0.00014700755,0.00036963332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003118367,0.00048749565,0.000953891,0.0004391611,0.00019962365,0.00096362404,0.00067481794,0.0005902228,0.0026438197],"category_scores_gemma":[0.010585684,0.00036507353,0.0026097442,0.0004789182,0.0003295587,0.00041811416,0.00068988994,0.000652379,0.00009485708],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10804303,0.0026077698,0.15427703,0.0040740464,0.0071176603,0.0018202008,0.0003767505,0.5810053,0.0018311044,0.004454095,0.0030086925,0.13138433],"study_design_scores_gemma":[0.018329337,0.019362185,0.3195249,0.00362385,0.008841437,0.002253814,0.0010017753,0.61281735,0.0025059364,0.006585501,0.004976352,0.00017745547],"about_ca_topic_score_codex":0.011339385,"about_ca_topic_score_gemma":0.008123475,"teacher_disagreement_score":0.011339385,"about_ca_system_score_codex":0.0035634926,"about_ca_system_score_gemma":0.002068546,"threshold_uncertainty_score":0.025855064},"labels":[],"label_agreement":null},{"id":"W3001381091","doi":"10.1080/13696998.2020.1722138","title":"Cost effectiveness and impact on quality of life of abobotulinumtoxinA and onabotulinumtoxinA in the treatment of children with lower limb spasticity in Canada","year":2020,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver Coastal Health","funders":"","keywords":"Medicine; Spasticity; Quality of life (healthcare); Cost effectiveness; Physical medicine and rehabilitation; Physical therapy; Quality-adjusted life year","score_opus":0.0318918515765523,"score_gpt":0.2930713692873646,"score_spread":0.2611795177108123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001381091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830982,0.0033212025,0.0014568471,0.0023873318,0.000045184377,0.00035108408,0.004764482,0.00003762048,0.0045378837],"genre_scores_gemma":[0.9963791,0.00080758665,0.0008080138,0.00014731452,0.000006311804,0.0000628467,0.0011428396,0.0000064578253,0.00063963607],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9981913,0.00056613644,0.000068065136,0.00018892725,0.00031944094,0.0006660757],"domain_scores_gemma":[0.9961021,0.001662204,0.0005847603,0.00008601828,0.0006425665,0.0009223606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002314341,0.000649333,0.0009864822,0.00092609663,0.00081470975,0.0016788074,0.0015792173,0.0009931405,0.0028759625],"category_scores_gemma":[0.009978566,0.00049079844,0.002652227,0.0010879968,0.0008650042,0.0005693172,0.0012166232,0.0013378342,0.00010608245],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012317364,0.00093864533,0.2086595,0.0008614858,0.0034459285,0.000525536,0.00025674302,0.7232323,0.0007591703,0.00802642,0.0052668573,0.035710078],"study_design_scores_gemma":[0.00290108,0.002424608,0.16573279,0.0005427369,0.0028413294,0.0003555515,0.00074678194,0.8170592,0.000811377,0.0029560877,0.0034637495,0.00016465523],"about_ca_topic_score_codex":0.9605029,"about_ca_topic_score_gemma":0.94676393,"teacher_disagreement_score":0.06833646,"about_ca_system_score_codex":0.06833646,"about_ca_system_score_gemma":0.045922577,"threshold_uncertainty_score":0.49581802},"labels":[],"label_agreement":null},{"id":"W3009349222","doi":"10.1080/13696998.2020.1737536","title":"The burden of osteoporosis in Saudi Arabia: a scorecard and economic model","year":2020,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); Amgen (Canada)","funders":"","keywords":"Medicine; Balanced scorecard; Osteoporosis; Traditional medicine; Environmental health; Internal medicine; Process management","score_opus":0.0604248716602036,"score_gpt":0.3699678145198404,"score_spread":0.3095429428596368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009349222","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8728193,0.0027962392,0.06667886,0.011609721,0.0002323025,0.0013123094,0.00606151,0.0001392872,0.038350414],"genre_scores_gemma":[0.9843381,0.0008695575,0.0109199695,0.000207968,0.00005235253,0.00033475325,0.0011467311,0.0000090349595,0.0021215843],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9971379,0.0019158295,0.00013386205,0.00023559711,0.00023462043,0.000342134],"domain_scores_gemma":[0.9961355,0.0025536045,0.00045618205,0.00008918525,0.0004432614,0.00032230307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004846999,0.0013409589,0.0010985306,0.0028587028,0.00066299655,0.0043239347,0.001184957,0.001862289,0.003946183],"category_scores_gemma":[0.010738692,0.00045228133,0.000982627,0.0032334265,0.0011374007,0.0029046352,0.001833237,0.0011853905,0.00031405987],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041777187,0.00035317655,0.055806402,0.00029347048,0.00045988508,0.0005489143,0.00041814116,0.8201401,0.00018708687,0.08082406,0.007004286,0.033546664],"study_design_scores_gemma":[0.00012155314,0.00018717958,0.010284309,0.00011644833,0.00011010742,0.0001251241,0.0004185788,0.96455795,0.00005781518,0.020554578,0.0034236582,0.00004264252],"about_ca_topic_score_codex":0.027495882,"about_ca_topic_score_gemma":0.01128461,"teacher_disagreement_score":0.027495882,"about_ca_system_score_codex":0.0073480555,"about_ca_system_score_gemma":0.003247258,"threshold_uncertainty_score":0.054671705},"labels":[],"label_agreement":null},{"id":"W3029092466","doi":"10.1080/13696998.2020.1776297","title":"Economic and humanistic burden associated with noncommunicable diseases among adults with depression and anxiety in the United States","year":2020,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cardiac Health and Mental Health","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Medical Expenditure Panel Survey; Depression (economics); Anxiety; Quality of life (healthcare); Obesity; Diabetes mellitus; Cohort; Health care; Internal medicine; Psychiatry","score_opus":0.011528167845995259,"score_gpt":0.27466957368992406,"score_spread":0.2631414058439288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029092466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98762995,0.0021709173,0.00010175918,0.0038360595,0.00007136366,0.000024211013,0.0016594367,0.000005158259,0.0045011374],"genre_scores_gemma":[0.9977568,0.0010310918,0.00008436285,0.00032420334,0.000064642416,0.000008068463,0.0004673629,9.887908e-7,0.0002625336],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99934644,0.00027323328,0.00009470376,0.000033572054,0.0001457183,0.00010638766],"domain_scores_gemma":[0.99833775,0.00017414604,0.0008863581,0.000045165325,0.00017701484,0.00037950397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052372355,0.00010885808,0.00016411878,0.00074362947,0.00038349774,0.00056191,0.0001669674,0.00022985446,0.002195814],"category_scores_gemma":[0.0028677476,0.00011487629,0.00036342893,0.00086741924,0.00024053162,0.0003647884,0.000770679,0.0006050383,0.00010177152],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008546241,0.00008638707,0.98651123,0.000036754507,0.00019473178,0.000160452,0.00009913757,0.0002520641,0.000054579115,0.00032346143,0.002572976,0.009622692],"study_design_scores_gemma":[0.0000084918165,0.000020803573,0.998247,0.000046960286,0.000032017902,0.00012237974,0.00026263128,0.00037313413,0.0000099972485,0.00015654728,0.00071587146,0.000004210097],"about_ca_topic_score_codex":0.026695387,"about_ca_topic_score_gemma":0.06051709,"teacher_disagreement_score":0.026695387,"about_ca_system_score_codex":0.00080082694,"about_ca_system_score_gemma":0.0006471398,"threshold_uncertainty_score":0.053080022},"labels":[],"label_agreement":null},{"id":"W3037379129","doi":"10.1080/13696998.2020.1789152","title":"Costs of in-house genomic profiling and implications for economic evaluation: a case example of non-small cell lung cancer (NSCLC)","year":2020,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Spinal Cord Injury BC; Roche (Canada); William Osler Health System; Vancouver Coastal Health","funders":"","keywords":"Medicine; Profiling (computer programming); Activity-based costing; Lung cancer; Operations management; Oncology; Business; Accounting; Computer science","score_opus":0.04434937502367767,"score_gpt":0.3662375444127789,"score_spread":0.32188816938910125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037379129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8481987,0.0075374832,0.024580637,0.030580662,0.00023236373,0.001957704,0.0017905132,0.0001075911,0.085014366],"genre_scores_gemma":[0.98440754,0.0014458023,0.0123144435,0.00046069457,0.00003936497,0.00023881199,0.00021981663,0.000019380765,0.0008543545],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98826224,0.008126773,0.00039091628,0.0002836138,0.0016988567,0.0012376665],"domain_scores_gemma":[0.9561542,0.035450436,0.0018320536,0.00089673727,0.004241961,0.0014246021],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016203403,0.0011325205,0.00073928543,0.0023671675,0.002970229,0.005161976,0.0017056129,0.0021578623,0.004157766],"category_scores_gemma":[0.043670036,0.00044560203,0.0016062664,0.003820393,0.0019161571,0.002580337,0.0021341853,0.0026708497,0.00018498341],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032617764,0.0029731093,0.17435485,0.0018277211,0.00060736656,0.013789487,0.004030369,0.26428443,0.0018413122,0.17885125,0.029411694,0.32476667],"study_design_scores_gemma":[0.0015965006,0.00417123,0.17332079,0.0043729916,0.0015380691,0.01096645,0.0356266,0.5946537,0.0050555365,0.09839351,0.06939757,0.00090710394],"about_ca_topic_score_codex":0.21602249,"about_ca_topic_score_gemma":0.19454537,"teacher_disagreement_score":0.21602249,"about_ca_system_score_codex":0.042142946,"about_ca_system_score_gemma":0.022400824,"threshold_uncertainty_score":0.4295302},"labels":[],"label_agreement":null},{"id":"W3039853632","doi":"10.1080/13696998.2020.1791889","title":"The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia","year":2020,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal General Hospital","funders":"","keywords":"Medicine; Visual analogue scale; Inflammatory bowel disease; Confidence interval; Quality of life (healthcare); Internal medicine; Ulcerative colitis; Retrospective cohort study; Physical therapy; Adalimumab; Cohort; Infliximab; Disease","score_opus":0.012412975289260783,"score_gpt":0.2572623991760171,"score_spread":0.24484942388675635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039853632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9997043,0.0001551997,0.000007299034,0.000021206557,0.0000011239899,0.0000023483358,0.00006778614,1.8698343e-7,0.00004052767],"genre_scores_gemma":[0.9996673,0.00011051406,0.000019968646,0.000024588899,0.000004100941,0.0000030562107,0.00013458497,1.9789056e-7,0.000035736743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99963176,0.00011824536,0.00006545679,0.000047594316,0.00007620797,0.000060696904],"domain_scores_gemma":[0.9989869,0.0001640376,0.0005855998,0.000036038986,0.0001033721,0.0001241039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041451896,0.00019804499,0.00025275,0.0005509767,0.00030946542,0.00046547834,0.00026308477,0.00029653922,0.0010352368],"category_scores_gemma":[0.0015433258,0.00014106349,0.00040314242,0.00058490713,0.000192354,0.00029859575,0.0003385073,0.00025244197,0.000096535194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000960092,0.000048696224,0.9984951,0.00001564261,0.000050181243,0.000052804284,0.0000832045,0.000023729726,0.00009297832,0.0000080028,0.000041615203,0.0009920065],"study_design_scores_gemma":[0.000011411956,0.00018887181,0.99871814,0.000010784354,0.000027986598,0.0002831427,0.00044346592,0.00016574848,0.000039241342,0.000006929336,0.00010168961,0.0000025371596],"about_ca_topic_score_codex":0.0066950168,"about_ca_topic_score_gemma":0.007832991,"teacher_disagreement_score":0.0066950168,"about_ca_system_score_codex":0.0005867338,"about_ca_system_score_gemma":0.00031246204,"threshold_uncertainty_score":0.013312042},"labels":[],"label_agreement":null},{"id":"W3091869780","doi":"10.1080/13696998.2020.1835333","title":"Economic implications of adding a novel algorithm to optimize cardiac resynchronization therapy: rationale and design of economic analysis for the AdaptResponse trial","year":2020,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cardiac pacing and defibrillation studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Wilfrid Laurier University; University of Ottawa","funders":"Medtronic","keywords":"Medicine; Cardiac resynchronization therapy; Internal medicine; Algorithm; Heart failure; Cardiology; Intensive care medicine; Ejection fraction; Computer science","score_opus":0.08060196100767866,"score_gpt":0.3311108763835697,"score_spread":0.25050891537589104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091869780","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08979927,0.011127928,0.5023906,0.04891984,0.0053388667,0.30194768,0.005912713,0.0004989506,0.03406408],"genre_scores_gemma":[0.37883043,0.0033928968,0.29647237,0.010326502,0.0019579378,0.30463466,0.0010490726,0.00012819638,0.0032079828],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.8389331,0.14670338,0.0038147776,0.003267723,0.0055147638,0.0017662894],"domain_scores_gemma":[0.90228117,0.08369566,0.005477958,0.0031090318,0.0039710384,0.00146525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.11168428,0.0030578908,0.0037600887,0.0017684747,0.0008360417,0.0051720547,0.0024104742,0.0048289862,0.0074345316],"category_scores_gemma":[0.16114056,0.001128811,0.0049469857,0.0014345379,0.0029097593,0.0026565115,0.00314452,0.0068333205,0.0007633876],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.114690356,0.005745959,0.014771325,0.0123825865,0.009868745,0.0015974435,0.000492482,0.23012014,0.0025518958,0.41881517,0.024214497,0.16474938],"study_design_scores_gemma":[0.1289211,0.022507142,0.0041427794,0.005422736,0.007730764,0.00065178727,0.00025417842,0.5296789,0.0040736124,0.24376354,0.05228909,0.00056447525],"about_ca_topic_score_codex":0.0006256692,"about_ca_topic_score_gemma":0.0006187255,"teacher_disagreement_score":0.11168428,"about_ca_system_score_codex":0.0032312893,"about_ca_system_score_gemma":0.007377685,"threshold_uncertainty_score":0.59064996},"labels":[],"label_agreement":null},{"id":"W3092295665","doi":"10.1080/13696998.2020.1835305","title":"Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis. J Med Econ. 2020;23(6):641–649","year":2020,"lang":"en","type":"letter","venue":"Journal of Medical Economics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Betamethasone dipropionate; Medicine; Tazarotene; Lotion; Dermatology; Psoriasis; Pharmacology","score_opus":0.24880238701289326,"score_gpt":0.4378970647347771,"score_spread":0.18909467772188382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092295665","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00055552967,0.0032425432,0.00018174712,0.9615786,0.02493965,0.000053993288,0.00039452448,0.000044876942,0.00900864],"genre_scores_gemma":[0.012101558,0.0032406503,0.0006972704,0.89659774,0.062011223,0.00027584456,0.00023221775,0.00007294063,0.02477065],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99526864,0.0018904312,0.0008542166,0.00039784584,0.0013004184,0.00028830208],"domain_scores_gemma":[0.9488406,0.03442604,0.0019533243,0.0014534262,0.011655343,0.0016712473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075249583,0.00078509416,0.0017677095,0.0014527908,0.0018564765,0.0027323088,0.0017012011,0.024796234,0.034620646],"category_scores_gemma":[0.108500406,0.00067094265,0.0015018437,0.001511066,0.0015606387,0.0028103336,0.00089766097,0.018337157,0.029127412],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019314284,0.000023111443,0.0003362841,0.00007994748,0.000020977166,0.00026731912,0.000019597524,0.000032561973,0.000041179977,0.0013255727,0.9830645,0.014595742],"study_design_scores_gemma":[0.001173342,0.00016047369,0.0031285167,0.0017212004,0.00019335345,0.0025054591,0.00029113036,0.0011325675,0.0006126995,0.015697826,0.97327775,0.00010575513],"about_ca_topic_score_codex":0.0083757,"about_ca_topic_score_gemma":0.011932455,"teacher_disagreement_score":0.034620646,"about_ca_system_score_codex":0.0052452544,"about_ca_system_score_gemma":0.0047108736,"threshold_uncertainty_score":0.11581761},"labels":[],"label_agreement":null},{"id":"W3093960533","doi":"10.1080/13696998.2020.1840138","title":"Cost-effectiveness of fingolimod versus interferon-β1a for the treatment of pediatric-onset multiple sclerosis in Canada","year":2020,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Alberta Children's Hospital; Children's Hospital of Eastern Ontario; University of Calgary; McGill University; Montreal Children's Hospital; Novartis (Canada)","funders":"","keywords":"Fingolimod; Medicine; Quality-adjusted life year; Expanded Disability Status Scale; Cost effectiveness; Multiple sclerosis; Demography; Pediatrics; Immunology","score_opus":0.22889309778335293,"score_gpt":0.3534979604582821,"score_spread":0.12460486267492915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093960533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.968648,0.009077831,0.0021209586,0.0038089068,0.0000906648,0.00055288005,0.0064955824,0.000085265645,0.009120003],"genre_scores_gemma":[0.994991,0.0014993347,0.0012607533,0.00020760977,0.000012046618,0.000063517764,0.0011927827,0.000009028973,0.0007638589],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9986719,0.00048156222,0.00005056072,0.00011617808,0.00029192437,0.0003879236],"domain_scores_gemma":[0.99775046,0.00093866064,0.00033667957,0.00003853389,0.0005163119,0.0004192745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017545277,0.00070280506,0.0010705058,0.00094828964,0.00093921024,0.0016013142,0.001447619,0.0008479814,0.0030498526],"category_scores_gemma":[0.0076116514,0.00046714433,0.0015967193,0.001234859,0.00073865167,0.00056553545,0.00076448283,0.0010542043,0.00009264375],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016125165,0.00075444387,0.082576014,0.0013374629,0.0024694174,0.00054501207,0.00015843559,0.82265586,0.0011822743,0.008614993,0.007626047,0.05595486],"study_design_scores_gemma":[0.0053804824,0.0017785819,0.08693308,0.00051158667,0.002308583,0.0003141808,0.00050073303,0.8942548,0.0010975567,0.002837851,0.0039383415,0.00014426572],"about_ca_topic_score_codex":0.97048616,"about_ca_topic_score_gemma":0.96025336,"teacher_disagreement_score":0.08261872,"about_ca_system_score_codex":0.08261872,"about_ca_system_score_gemma":0.07578347,"threshold_uncertainty_score":0.59944355},"labels":[],"label_agreement":null},{"id":"W3115065302","doi":"10.1080/13696998.2020.1864920","title":"Benefits of fracture liaison services (FLS) in four Latin American countries: Brazil, Mexico, Colombia, and Argentina","year":2020,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Hip and Femur Fractures","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); Amgen (Canada)","funders":"","keywords":"Latin Americans; Medicine; Socioeconomics; Environmental health; Political science","score_opus":0.013916230084183905,"score_gpt":0.27086673988373877,"score_spread":0.25695050979955486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3115065302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84985965,0.11675895,0.0009641303,0.004285234,0.000088194094,0.0005284719,0.017297594,0.000049543174,0.010168117],"genre_scores_gemma":[0.9698877,0.02479401,0.0014558971,0.00028117883,0.000025835847,0.000302793,0.0029394748,0.0000066081025,0.00030654515],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913967,0.0004002418,0.0001157139,0.00009275175,0.00016447234,0.000087080356],"domain_scores_gemma":[0.9979553,0.0007792555,0.0007788748,0.00003359522,0.00033487726,0.00011809199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002002362,0.00045532285,0.0005150948,0.0020179246,0.00033949304,0.00087572506,0.0003852693,0.00035093658,0.0012477546],"category_scores_gemma":[0.004905201,0.00023850964,0.0010164251,0.0030120038,0.00032299155,0.0003983492,0.0006016785,0.0004018178,0.000042612097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012345711,0.00035226066,0.80483663,0.015403702,0.0039068437,0.0009101298,0.0014842444,0.0031005235,0.00045421877,0.0025890323,0.0073691523,0.1583586],"study_design_scores_gemma":[0.0006001054,0.00037428117,0.96119344,0.008522472,0.004795951,0.0008223219,0.003686778,0.0020098106,0.0002817006,0.00058441464,0.017075012,0.000053749045],"about_ca_topic_score_codex":0.19283707,"about_ca_topic_score_gemma":0.21975888,"teacher_disagreement_score":0.19283707,"about_ca_system_score_codex":0.0036491929,"about_ca_system_score_gemma":0.0037832877,"threshold_uncertainty_score":0.38342923},"labels":[],"label_agreement":null},{"id":"W3124381759","doi":"10.1080/13696998.2021.1875743","title":"The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada","year":2021,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Medicine; Azacitidine; Cytarabine; Internal medicine; Oncology; Myeloid leukemia; Induction chemotherapy; Cost effectiveness; Clinical trial; Chemotherapy","score_opus":0.01477245771784256,"score_gpt":0.28539256468498775,"score_spread":0.27062010696714517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124381759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9780676,0.008298988,0.0015063636,0.0019708453,0.000034842218,0.00045621896,0.004256283,0.000038736383,0.00537006],"genre_scores_gemma":[0.9961564,0.0014739148,0.00078068714,0.000118280004,0.0000066926386,0.000036619636,0.0009291131,0.0000038910734,0.0004945038],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99923337,0.00032085704,0.000033499273,0.000075565105,0.00016135875,0.00017539263],"domain_scores_gemma":[0.9989416,0.00049716345,0.00016131194,0.000024125924,0.000162792,0.00021302438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001473484,0.0006218887,0.0006991216,0.00052338245,0.00048074176,0.0011263931,0.0010363484,0.0004933823,0.0019232065],"category_scores_gemma":[0.0042927405,0.00027755054,0.0013893368,0.000838883,0.00047212344,0.00042408198,0.0005835985,0.0008202927,0.0000735043],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027190164,0.00097323244,0.14625934,0.002293881,0.0044402108,0.0005675946,0.0002016442,0.6917621,0.0017458529,0.0053236363,0.00675669,0.11248568],"study_design_scores_gemma":[0.00897353,0.0069534862,0.23251626,0.00088822516,0.0084159775,0.0007157327,0.0008599152,0.7243648,0.0021349275,0.004411371,0.009597102,0.00016863117],"about_ca_topic_score_codex":0.9042155,"about_ca_topic_score_gemma":0.9281379,"teacher_disagreement_score":0.095784485,"about_ca_system_score_codex":0.035574816,"about_ca_system_score_gemma":0.033447515,"threshold_uncertainty_score":0.25811458},"labels":[],"label_agreement":null},{"id":"W3127334177","doi":"10.1080/13696998.2021.1885194","title":"Influence of neurovascular embolic coil primary wind diameter on aneurysm packing density and case costs","year":2021,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Intracranial Aneurysms: Treatment and Complications","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Electromagnetic coil; Sphere packing; Neurovascular bundle; Volume (thermodynamics); Materials science; Medicine; Composite material; Physics; Surgery; Electrical engineering; Engineering","score_opus":0.012286893965751996,"score_gpt":0.24602864924688617,"score_spread":0.23374175528113417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127334177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933814,0.0003866471,0.002574994,0.00010967147,0.000012202663,0.000064839594,0.00017174322,0.00001396311,0.0032845482],"genre_scores_gemma":[0.99872416,0.00014743935,0.00078032305,0.000010673883,0.000004270064,0.000024838972,0.0000911933,0.0000037583368,0.00021334596],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99787545,0.0010990121,0.00009650842,0.00018106411,0.00045424196,0.00029371365],"domain_scores_gemma":[0.9856098,0.011215373,0.0015198854,0.0003242207,0.00090190314,0.0004288362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020938702,0.0004592492,0.00033824987,0.00077776134,0.00022697,0.0009935753,0.0005932257,0.0003688192,0.0026933954],"category_scores_gemma":[0.013105017,0.00024059034,0.0006135289,0.0005710808,0.00041128194,0.0008509143,0.00046106958,0.0003015257,0.00023662962],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077401255,0.0009825635,0.3073973,0.0006403942,0.0005666978,0.004804134,0.0002952106,0.55531794,0.015313955,0.0052379253,0.0020268273,0.09967691],"study_design_scores_gemma":[0.00037934014,0.0093181785,0.56675065,0.00024349487,0.00095909927,0.009157369,0.0015876786,0.36711115,0.031801637,0.0061503,0.0063272696,0.00021377072],"about_ca_topic_score_codex":0.002195745,"about_ca_topic_score_gemma":0.0018293764,"teacher_disagreement_score":0.0026933954,"about_ca_system_score_codex":0.0013836273,"about_ca_system_score_gemma":0.0006739615,"threshold_uncertainty_score":0.01107353},"labels":[],"label_agreement":null},{"id":"W3130545975","doi":"10.3111/13696998.2013.784591","title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement","year":2013,"lang":"en","type":"editorial","venue":"Journal of Medical Economics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Institute of Health Economics; University of Ottawa","funders":"","keywords":"Checklist; Government (linguistics); Medicine; Statement (logic); Delphi method; Psychological intervention; Consolidated Standards of Reporting Trials; Systematic review; Economic evaluation; Delphi; MEDLINE; Public relations; Medical education; Political science; Psychology; Nursing; Law; Computer science","score_opus":0.31607405893797513,"score_gpt":0.5300803307364624,"score_spread":0.2140062717984873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130545975","genre_codex":"methods","genre_gemma":"methods","domain_codex":"methods","domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041702255,0.03182135,0.34441972,0.20224069,0.040741295,0.16218731,0.13951984,0.011074167,0.06382544],"genre_scores_gemma":[0.026617445,0.024695462,0.46802947,0.03316002,0.006548612,0.33648252,0.09132899,0.0029375835,0.010199968],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.3520709,0.39494684,0.16223107,0.0074510896,0.07819878,0.0051012496],"domain_scores_gemma":[0.1388697,0.472687,0.0796115,0.05821542,0.24606548,0.004550943],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.5288697,0.0033630978,0.009426631,0.023629583,0.0033990105,0.016923709,0.010121416,0.012718952,0.024547452],"category_scores_gemma":[0.7891197,0.0040031667,0.013325129,0.028673898,0.006892712,0.011492402,0.008398188,0.028264763,0.015130359],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092788966,0.00021701843,0.0020487695,0.03793144,0.0011779644,0.00015988437,0.0010814327,0.002062751,0.0002743853,0.03659577,0.8145609,0.10296185],"study_design_scores_gemma":[0.0018400502,0.00034369796,0.0077242013,0.07720659,0.0014673966,0.000445248,0.0009780987,0.004694156,0.0013488838,0.067514904,0.83594483,0.00049196836],"about_ca_topic_score_codex":0.0063115167,"about_ca_topic_score_gemma":0.003768984,"teacher_disagreement_score":0.4711303,"about_ca_system_score_codex":0.012479,"about_ca_system_score_gemma":0.05891144,"threshold_uncertainty_score":0.5809876},"labels":[],"label_agreement":null},{"id":"W3153392867","doi":"10.1080/13696998.2021.1915626","title":"A device category economic model of electrosurgery technologies across procedure types: a U.S. hospital budget impact analysis","year":2021,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Thyroid and Parathyroid Surgery","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Electrosurgery; Single use; Operations management; Emergency medicine; Medical emergency; Surgery","score_opus":0.013049471692332388,"score_gpt":0.2999056111815729,"score_spread":0.2868561394892405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3153392867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48693436,0.044301976,0.20805448,0.019471629,0.0013355818,0.010063292,0.08404411,0.0010536498,0.14474098],"genre_scores_gemma":[0.9228356,0.0076289237,0.030770285,0.0021264052,0.00017185842,0.0060569267,0.011375463,0.00009862865,0.018935978],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9925242,0.005624839,0.00019298596,0.00055261276,0.0004947036,0.0006106724],"domain_scores_gemma":[0.987929,0.009622529,0.0008901396,0.00024784377,0.0010133858,0.0002970905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010171478,0.0027694402,0.0033615255,0.0051263133,0.00068686105,0.0038095305,0.002698847,0.0034574925,0.012446259],"category_scores_gemma":[0.021279132,0.0020752095,0.007294293,0.0065546264,0.0009347706,0.0024916194,0.0018755336,0.0033551734,0.0009339801],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094133243,0.00022641502,0.0049663363,0.0007304829,0.0016415189,0.00020595946,0.0000675776,0.9574938,0.000119653276,0.018730246,0.005468266,0.009408367],"study_design_scores_gemma":[0.0014454377,0.0010175095,0.007875818,0.0009509613,0.004586727,0.00024481275,0.0003615907,0.9433775,0.00021236375,0.02442665,0.015347036,0.00015358023],"about_ca_topic_score_codex":0.06945273,"about_ca_topic_score_gemma":0.028959122,"teacher_disagreement_score":0.06945273,"about_ca_system_score_codex":0.010555479,"about_ca_system_score_gemma":0.006895196,"threshold_uncertainty_score":0.13809693},"labels":[],"label_agreement":null},{"id":"W3154244221","doi":"10.1080/13696998.2021.1917139","title":"Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year data","year":2021,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bristol-Myers Squibb (Canada)","funders":"","keywords":"Medicine; Nivolumab; Docetaxel; Population; Clinical trial; Cost effectiveness; Quality-adjusted life year; Internal medicine; Oncology; Randomized controlled trial; Cost–benefit analysis; Demography; Cancer; Environmental health; Immunotherapy","score_opus":0.02007993074301333,"score_gpt":0.2834601182077676,"score_spread":0.2633801874647543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154244221","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2843096,0.5724242,0.0035707771,0.010489093,0.0007045796,0.000409366,0.11317971,0.00020051678,0.014712189],"genre_scores_gemma":[0.74900895,0.18958475,0.0041456013,0.001863827,0.00023195722,0.0003187773,0.052292798,0.0001289604,0.0024244117],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996119,0.00079260295,0.0003972929,0.0002496959,0.002028356,0.0004130921],"domain_scores_gemma":[0.9849488,0.0029723633,0.001590283,0.00024704737,0.009505506,0.00073603715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065022362,0.0010436767,0.002106959,0.0057527083,0.0007588027,0.0036810243,0.0020047228,0.0010304276,0.0021082228],"category_scores_gemma":[0.017938433,0.0005632038,0.005397456,0.01158969,0.0006523426,0.001065995,0.0009002811,0.0019324098,0.0002235764],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006617877,0.00030831655,0.35978818,0.023349907,0.026001794,0.0010222468,0.0012048561,0.1097472,0.0004417534,0.00953371,0.09959779,0.36238623],"study_design_scores_gemma":[0.0016214174,0.0006487534,0.7439255,0.025445146,0.022460526,0.001373669,0.0020098716,0.046504494,0.0016474442,0.004926453,0.14878789,0.0006488425],"about_ca_topic_score_codex":0.9731618,"about_ca_topic_score_gemma":0.9726428,"teacher_disagreement_score":0.07627092,"about_ca_system_score_codex":0.07627092,"about_ca_system_score_gemma":0.08025655,"threshold_uncertainty_score":0.55338687},"labels":[],"label_agreement":null},{"id":"W3155883542","doi":"10.1080/13696998.2021.1917140","title":"Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer","year":2021,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Medicine; Pembrolizumab; Endometrial cancer; Microsatellite instability; Oncology; Internal medicine; Chemotherapy; Cost effectiveness; Cancer; Quality of life (healthcare); Clinical trial; Immunotherapy","score_opus":0.0601413884066394,"score_gpt":0.34328911807943985,"score_spread":0.28314772967280044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155883542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9735771,0.010990975,0.0040826458,0.00247631,0.000109125525,0.000535284,0.003589023,0.0000639258,0.004575627],"genre_scores_gemma":[0.9967244,0.0011968142,0.00069628865,0.00023550885,0.00001388965,0.00015175229,0.0006063971,0.0000065017207,0.00036836654],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9973948,0.0019658043,0.00009713638,0.00020593898,0.00015052268,0.00018575233],"domain_scores_gemma":[0.9945852,0.0041857483,0.00075422187,0.000121646386,0.00016083162,0.00019241592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053338544,0.0007960078,0.0013661648,0.0008064374,0.00023042652,0.0013249745,0.00085818645,0.001174552,0.0038664516],"category_scores_gemma":[0.019919332,0.00053059706,0.003456247,0.0008346197,0.00042418792,0.0011110901,0.00085075333,0.001342101,0.00013156515],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06271152,0.0014978817,0.039319377,0.002045914,0.0091954535,0.00040714839,0.00014187211,0.81122905,0.0010113822,0.008765877,0.003713882,0.059960626],"study_design_scores_gemma":[0.015225837,0.023374394,0.068343826,0.0018004241,0.016459526,0.0008173933,0.0005380907,0.8491526,0.0019134779,0.015061244,0.0071271816,0.00018598969],"about_ca_topic_score_codex":0.01862414,"about_ca_topic_score_gemma":0.012653471,"teacher_disagreement_score":0.01862414,"about_ca_system_score_codex":0.0056419782,"about_ca_system_score_gemma":0.0023840533,"threshold_uncertainty_score":0.040935636},"labels":[],"label_agreement":null},{"id":"W3174480137","doi":"10.1080/13696998.2021.1946326","title":"The most important facilitators and barriers to the use of Health Technology Assessment in Canada: a best–worst scaling approach","year":2021,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"Dalhousie University","keywords":"Medicine; Scaling; Family medicine","score_opus":0.23062563386427604,"score_gpt":0.39846172618442116,"score_spread":0.16783609232014512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174480137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9486313,0.0025932451,0.016409786,0.006844062,0.000060793496,0.002272064,0.0012113309,0.00007142263,0.021905892],"genre_scores_gemma":[0.97294927,0.00078622444,0.024320127,0.00021985042,0.000009863561,0.000637946,0.00029666096,0.000013994288,0.0007660296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9718463,0.010575995,0.0020348616,0.0015020533,0.011255651,0.0027851665],"domain_scores_gemma":[0.95998776,0.01683537,0.0036221729,0.000880489,0.016923325,0.0017510039],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.024396019,0.0016936412,0.0011112981,0.013235875,0.011766515,0.006258445,0.0019214711,0.0010063747,0.0017047444],"category_scores_gemma":[0.06546606,0.00080164464,0.0017469623,0.010884407,0.005471355,0.0025359627,0.0049781795,0.0016064905,0.000085831634],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047884937,0.00021501584,0.6791983,0.004240973,0.0007516436,0.00073009054,0.11712326,0.007699826,0.0024904364,0.016589696,0.004540972,0.16594094],"study_design_scores_gemma":[0.000092103306,0.00031204865,0.7381073,0.0019891926,0.001014475,0.00023985273,0.19771323,0.030924598,0.001967087,0.014217934,0.0131088225,0.00031334496],"about_ca_topic_score_codex":0.9387457,"about_ca_topic_score_gemma":0.9631093,"teacher_disagreement_score":0.975604,"about_ca_system_score_codex":0.09126155,"about_ca_system_score_gemma":0.12515798,"threshold_uncertainty_score":0.662152},"labels":[],"label_agreement":null},{"id":"W3174798083","doi":"10.1080/13696998.2021.1948681","title":"Healthcare costs of patients with cancer stratified by Khorana score risk levels","year":2021,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Medicine; Cancer; Health care; Internal medicine; Intensive care medicine; Emergency medicine","score_opus":0.021541374900351698,"score_gpt":0.28961048883788276,"score_spread":0.2680691139375311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174798083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99790156,0.00021978896,0.000029915864,0.00006842058,0.00000607551,0.0000099658655,0.0014299739,0.0000025436243,0.00033181158],"genre_scores_gemma":[0.99811375,0.00009716581,0.00003592636,0.000022976366,0.000011088722,0.000012556305,0.0016135682,0.0000010051976,0.000091944035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99945706,0.00009889363,0.000091643975,0.000120324796,0.000076694625,0.00015539351],"domain_scores_gemma":[0.9988373,0.00014035241,0.00067420444,0.000049358106,0.00010319736,0.00019557473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036179574,0.000254185,0.00038667704,0.0009946858,0.00039687927,0.0008025373,0.00026029834,0.00032600225,0.0017484581],"category_scores_gemma":[0.0023987931,0.00016662006,0.00071758585,0.0016018815,0.00015626162,0.00058687694,0.00072504306,0.0004946841,0.00017748246],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016137975,0.000019282814,0.99832135,0.000008058574,0.000064108855,0.000027413726,0.000016243688,0.00015931811,0.00002419248,0.000018991757,0.00018473258,0.0009950433],"study_design_scores_gemma":[0.0000121509365,0.000063813335,0.99893874,0.000007532431,0.00003629929,0.00009953411,0.00008750753,0.0005368226,0.00001564647,0.000037081543,0.00016108673,0.0000037124023],"about_ca_topic_score_codex":0.01244749,"about_ca_topic_score_gemma":0.010977491,"teacher_disagreement_score":0.01244749,"about_ca_system_score_codex":0.00077718124,"about_ca_system_score_gemma":0.0004901175,"threshold_uncertainty_score":0.024750054},"labels":[],"label_agreement":null},{"id":"W3183895493","doi":"10.1080/13696998.2021.1962664","title":"The burden of skeletal-related events in four Latin American countries: Argentina, Brazil, Colombia, and Mexico","year":2021,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); Amgen (Canada)","funders":"Amgen","keywords":"Latin Americans; Medicine; Demography; Environmental health; Socioeconomics","score_opus":0.032495212423711964,"score_gpt":0.3590363809811568,"score_spread":0.32654116855744486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183895493","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20280609,0.7473507,0.0019327481,0.009577931,0.00024033629,0.00036994932,0.025440684,0.000057028443,0.012224575],"genre_scores_gemma":[0.6526913,0.33459023,0.003668833,0.0010044983,0.00012991956,0.00053551485,0.0068141376,0.000012546522,0.00055297354],"study_design_codex":"observational","study_design_gemma":"systematic_review","domain_scores_codex":[0.999113,0.00041382623,0.00016112297,0.00010034518,0.0001455114,0.000066076886],"domain_scores_gemma":[0.9981053,0.0007695694,0.000752726,0.000029759218,0.00027958694,0.00006306134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025840718,0.0006463527,0.0007353927,0.0041708485,0.00041934696,0.0011560478,0.00048967905,0.0006131667,0.0018294192],"category_scores_gemma":[0.0051191906,0.0002520288,0.001623453,0.00553459,0.0003531109,0.00070607045,0.0005515726,0.00040093123,0.00008287951],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001306828,0.00021232475,0.57388115,0.094394155,0.011136992,0.001971227,0.0014654726,0.009038599,0.000732402,0.008424058,0.01980901,0.27762777],"study_design_scores_gemma":[0.0007762972,0.0004888095,0.7593467,0.088153444,0.022167591,0.0027381016,0.00601029,0.007008587,0.00057033694,0.004520665,0.10804661,0.00017257736],"about_ca_topic_score_codex":0.09053833,"about_ca_topic_score_gemma":0.091335215,"teacher_disagreement_score":0.09053833,"about_ca_system_score_codex":0.0028263545,"about_ca_system_score_gemma":0.0038007065,"threshold_uncertainty_score":0.18002266},"labels":[],"label_agreement":null},{"id":"W3190179948","doi":"10.1080/13696998.2021.1957582","title":"Comparative efficacy, safety, and cost-effectiveness of abobotulinumtoxinA and onabotulinumtoxinA in children with upper limb spasticity: a systematic literature review, indirect treatment comparison, and economic evaluation","year":2021,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health","funders":"","keywords":"Medicine; Cost effectiveness; Quality of life (healthcare); Spasticity; Physical therapy; Botulinum toxin; Adverse effect; Randomized controlled trial; Quality-adjusted life year; Indirect costs; Economic evaluation; Surgery; Internal medicine; Nursing","score_opus":0.05089289765251078,"score_gpt":0.3719166455498343,"score_spread":0.3210237478973235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190179948","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010281176,0.9872463,0.00025576464,0.0003258765,0.00013971028,0.0006870921,0.0005674449,0.000008981218,0.00048767935],"genre_scores_gemma":[0.21622504,0.7776484,0.0021557969,0.0007463775,0.00022996106,0.0020178221,0.00074457383,0.000016352895,0.00021559375],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9759706,0.012534608,0.005991075,0.00121673,0.00379184,0.00049518014],"domain_scores_gemma":[0.95485365,0.03283197,0.00844281,0.00051281776,0.002899849,0.00045883656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020807007,0.0019637258,0.013987945,0.009721211,0.00046831623,0.0039335275,0.0017173887,0.0023902091,0.003585774],"category_scores_gemma":[0.06122819,0.0012169969,0.01942586,0.0070205424,0.0011000292,0.002210829,0.001470632,0.0019630662,0.0001864484],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006597887,0.00013898783,0.0032915678,0.7411307,0.19773786,0.00014945015,0.00012354196,0.0009082072,0.0002600612,0.0006115774,0.00060772843,0.048442375],"study_design_scores_gemma":[0.00717544,0.0026904927,0.011757086,0.27631187,0.6923428,0.0006073576,0.00031314787,0.0010901021,0.0005092948,0.00091799395,0.0061966013,0.00008771735],"about_ca_topic_score_codex":0.006122859,"about_ca_topic_score_gemma":0.011258942,"teacher_disagreement_score":0.020807007,"about_ca_system_score_codex":0.007983583,"about_ca_system_score_gemma":0.008827661,"threshold_uncertainty_score":0.110039294},"labels":[],"label_agreement":null},{"id":"W3211731066","doi":"10.1080/13696998.2021.2003804","title":"Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial","year":2021,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; McMaster University; Ted Rogers Centre for Heart Research; Impact","funders":"","keywords":"Medicine; Insulin glargine; Insulin degludec; Confidence interval; Pediatrics; Adverse effect; Type 2 diabetes; Randomized controlled trial; Diabetes mellitus; Internal medicine; Emergency medicine; Endocrinology","score_opus":0.005918474577636413,"score_gpt":0.21089628994057324,"score_spread":0.20497781536293683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211731066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9611827,0.01551822,0.0020480289,0.0017726842,0.00025485386,0.0020801653,0.008411937,0.000060437455,0.008671028],"genre_scores_gemma":[0.9892564,0.0028657308,0.003007099,0.00042850402,0.000055611126,0.00038526044,0.0033065586,0.000013304174,0.0006814836],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9957392,0.00245267,0.000315045,0.00029013288,0.00082080817,0.00038215233],"domain_scores_gemma":[0.9963761,0.0016038711,0.00083037146,0.00015544015,0.0006929166,0.00034122166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004981239,0.00094769034,0.0015069039,0.0011661252,0.00065727613,0.0015425722,0.0010463125,0.0005389608,0.0021464578],"category_scores_gemma":[0.013762971,0.00030699492,0.0040526805,0.0025312426,0.00065492536,0.000566252,0.0007997733,0.0014400079,0.00006210875],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40268236,0.0022841187,0.20722064,0.011373208,0.033946097,0.0004334667,0.0006218997,0.05547367,0.0019900799,0.0075022364,0.015435868,0.26103634],"study_design_scores_gemma":[0.16957222,0.021197014,0.6688177,0.0029019534,0.04371157,0.00045894377,0.0013267465,0.070423536,0.002070956,0.0039693452,0.015012664,0.00053730013],"about_ca_topic_score_codex":0.7325789,"about_ca_topic_score_gemma":0.7980889,"teacher_disagreement_score":0.26742113,"about_ca_system_score_codex":0.017270425,"about_ca_system_score_gemma":0.01668299,"threshold_uncertainty_score":0.537992},"labels":[],"label_agreement":null},{"id":"W4200054040","doi":"10.1080/13696998.2021.2007691","title":"The Global South political economy of health financing and spending landscape – history and presence","year":2021,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Global Public Health Policies and Epidemiology","field":"Business, Management and Accounting","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Science Fund of the Republic of Serbia; Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja","keywords":"Politics; Multinational corporation; Economic growth; East Asia; Development economics; Medicine; China; Business; Economics; Political science; Finance","score_opus":0.07373820326831175,"score_gpt":0.3464244995850857,"score_spread":0.27268629631677394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200054040","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10999563,0.2512557,0.004023534,0.46321505,0.0019688117,0.000033506174,0.00053010555,0.00005064065,0.16892694],"genre_scores_gemma":[0.8128793,0.1511392,0.001136858,0.024359327,0.0018660515,0.000041932595,0.00024101404,0.00007733177,0.008259027],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986985,0.00066691765,0.000049865743,0.00010340348,0.00023360184,0.00024773716],"domain_scores_gemma":[0.99857223,0.00060782087,0.00025829946,0.000073385425,0.00024448775,0.00024369765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027439937,0.00014677434,0.00021624281,0.0009854903,0.0010543293,0.005160326,0.00027914837,0.0007173578,0.004267367],"category_scores_gemma":[0.0025659013,0.00017249818,0.00022702495,0.0020708987,0.0037941546,0.003024214,0.0019990688,0.0022675628,0.00031746278],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000689936,0.000026459846,0.00990558,0.0012020397,0.00008579811,0.00058626884,0.011143273,0.0012495742,0.00076609204,0.7307499,0.05343261,0.1907833],"study_design_scores_gemma":[0.000014982317,0.00003984197,0.02773155,0.0018388135,0.00002881947,0.00050526665,0.008467045,0.000519263,0.00038016983,0.10586098,0.85457635,0.000036876096],"about_ca_topic_score_codex":0.0059049358,"about_ca_topic_score_gemma":0.0069130803,"teacher_disagreement_score":0.0059049358,"about_ca_system_score_codex":0.0038749033,"about_ca_system_score_gemma":0.0067401323,"threshold_uncertainty_score":0.028114498},"labels":[],"label_agreement":null},{"id":"W4200209188","doi":"10.1080/13696998.2021.2013676","title":"Epidemiology, healthcare resource utilization and healthcare costs for spinal muscular atrophy in Alberta, Canada","year":2021,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Neurogenetic and Muscular Disorders Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Libin Cardiovascular Institute of Alberta; Roche (Canada); University of Calgary","funders":"","keywords":"Medicine; SMA*; Epidemiology; Health care; Spinal muscular atrophy; Ambulatory; Incidence (geometry); Ambulatory care; Healthcare Cost and Utilization Project; Pediatrics; Emergency medicine; Disease; Surgery; Internal medicine","score_opus":0.07006822663938389,"score_gpt":0.37823941091476004,"score_spread":0.30817118427537615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200209188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8825561,0.01746662,0.00063096377,0.0036522816,0.00013197119,0.00022255119,0.08465878,0.000104033155,0.010576818],"genre_scores_gemma":[0.96915406,0.006690632,0.0009988506,0.0005493003,0.000045195266,0.0000835933,0.020720989,0.00001706687,0.0017403932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975896,0.0002024289,0.00021359783,0.00021042452,0.0012005356,0.00058350613],"domain_scores_gemma":[0.99632794,0.00021552575,0.0008907463,0.00006337189,0.0017766468,0.00072565273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010037845,0.00053074723,0.0004953322,0.004348553,0.0016921777,0.0016229849,0.0016054903,0.00044911396,0.0019891993],"category_scores_gemma":[0.0037584836,0.00036857947,0.000957231,0.009453827,0.00057536253,0.0004077002,0.0009132034,0.0009377894,0.00018114637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042687956,0.00002563341,0.9870482,0.00015144574,0.0001816235,0.00012894248,0.00025217704,0.00063864805,0.000063261745,0.00028140057,0.0060502207,0.005135708],"study_design_scores_gemma":[0.0000101566175,0.00001544067,0.9963541,0.00018002262,0.000057437755,0.00013372368,0.0005978075,0.00079038215,0.000024026489,0.000052819705,0.0017683159,0.00001579606],"about_ca_topic_score_codex":0.9972282,"about_ca_topic_score_gemma":0.9972983,"teacher_disagreement_score":0.055986274,"about_ca_system_score_codex":0.055986274,"about_ca_system_score_gemma":0.056963485,"threshold_uncertainty_score":0.40621072},"labels":[],"label_agreement":null},{"id":"W4205669185","doi":"10.1080/13696998.2021.2014721","title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations","year":2022,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Institute of Health Economics; University of Ottawa","funders":"National Institute for Health and Care Research","keywords":"Checklist; Economic evaluation; Medicine; Context (archaeology); Public health; Health care; Stakeholder; Psychological intervention; Public relations; Population; Political science; Psychology; Nursing; Environmental health; Law","score_opus":0.319495175828176,"score_gpt":0.5390198283255929,"score_spread":0.21952465249741693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205669185","genre_codex":"dataset","genre_gemma":"methods","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026101389,0.06900628,0.23027176,0.11374205,0.040827394,0.1286421,0.3208454,0.011253949,0.082800925],"genre_scores_gemma":[0.019064704,0.072167434,0.3079341,0.029700467,0.007695898,0.3183704,0.22131234,0.0047604316,0.01899415],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.48531243,0.31377336,0.1119766,0.008167418,0.07529483,0.005475287],"domain_scores_gemma":[0.2670116,0.3763275,0.09263197,0.040356193,0.21943974,0.0042330036],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.35525686,0.0049135988,0.01158999,0.021256408,0.002628722,0.01905913,0.010345016,0.012894646,0.050401516],"category_scores_gemma":[0.72282916,0.004589986,0.0146547,0.03951825,0.005036842,0.010683548,0.008238486,0.022889776,0.029076176],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012964626,0.00015623536,0.0011729292,0.04572259,0.0014568481,0.00013970165,0.0006835286,0.002375066,0.00020627986,0.023286175,0.8003899,0.123114355],"study_design_scores_gemma":[0.0020586853,0.00024829182,0.0034484847,0.0876812,0.0016839181,0.00027241788,0.0004582882,0.0036220998,0.0010300562,0.03775299,0.8612835,0.00046006986],"about_ca_topic_score_codex":0.010802657,"about_ca_topic_score_gemma":0.0056097256,"teacher_disagreement_score":0.64474314,"about_ca_system_score_codex":0.013931755,"about_ca_system_score_gemma":0.05262755,"threshold_uncertainty_score":0.7950831},"labels":[],"label_agreement":null},{"id":"W4205746204","doi":"10.1080/13696998.2022.2030148","title":"Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective","year":2022,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"COVID-19 Clinical Research Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Population; Mechanical ventilation; Intensive care unit; Emergency medicine; Pneumonia; Clinical trial; Intensive care medicine; Internal medicine; Environmental health","score_opus":0.03335726888210563,"score_gpt":0.381984455753694,"score_spread":0.3486271868715884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205746204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777573,0.007445935,0.0037747556,0.0012213867,0.000082441,0.00052942656,0.004305436,0.000056362784,0.0048269844],"genre_scores_gemma":[0.99638665,0.00082472875,0.001338319,0.0001406617,0.000014525672,0.00009636195,0.0010252502,0.000004508864,0.00016904857],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9975859,0.0015307462,0.00013962194,0.00020917405,0.0003212942,0.00021319774],"domain_scores_gemma":[0.99755186,0.0012479002,0.00074470916,0.000068416055,0.00021289667,0.00017433501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028605666,0.000867092,0.0007600337,0.0013377795,0.00020924548,0.0014835021,0.0006501108,0.00076057855,0.0017472168],"category_scores_gemma":[0.008037121,0.00038009483,0.0027496389,0.0012489044,0.0003434578,0.0009872274,0.00077961193,0.0007290047,0.00014090445],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015842147,0.0009760317,0.22461398,0.0017157554,0.0091272425,0.0006161182,0.000101330064,0.6649073,0.0014334006,0.00435042,0.0044564297,0.07185985],"study_design_scores_gemma":[0.005197628,0.014254063,0.3446783,0.0015840476,0.009023014,0.0016273909,0.00075347483,0.6031057,0.0036227894,0.0069402005,0.008994792,0.00021856467],"about_ca_topic_score_codex":0.01264468,"about_ca_topic_score_gemma":0.01124224,"teacher_disagreement_score":0.01264468,"about_ca_system_score_codex":0.004773686,"about_ca_system_score_gemma":0.0021536374,"threshold_uncertainty_score":0.034635723},"labels":[],"label_agreement":null},{"id":"W4206083502","doi":"10.1080/13696998.2022.2027706","title":"Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome","year":2022,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health; Dalhousie University","funders":"","keywords":"Eculizumab; Atypical hemolytic uremic syndrome; Productivity; Adverse effect; Hemoglobinuria","score_opus":0.015630096427270628,"score_gpt":0.2520832225586991,"score_spread":0.23645312613142846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206083502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99189043,0.0015279828,0.003867594,0.00046485523,0.00001887993,0.00013716206,0.00053516246,0.000014861045,0.0015429673],"genre_scores_gemma":[0.9982303,0.00017539042,0.0012283289,0.000037173075,0.0000055310734,0.000033110755,0.00015571188,0.0000015423968,0.00013304727],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99724823,0.002003246,0.000121855126,0.00018440206,0.0002020638,0.00024008741],"domain_scores_gemma":[0.9966568,0.002292734,0.0006208616,0.00008665595,0.00017006247,0.00017296031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034673114,0.00070566277,0.00078709493,0.00076968485,0.0002673872,0.0012274273,0.0006474026,0.0006665197,0.0015541353],"category_scores_gemma":[0.009974789,0.00033094024,0.0015967877,0.0008999338,0.0003369454,0.00090347347,0.00093886984,0.0006657258,0.00007617182],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005449164,0.0006467637,0.17636806,0.00037124948,0.0017977038,0.00044978483,0.00015234493,0.7641809,0.0012698452,0.0023297307,0.00073268777,0.046251815],"study_design_scores_gemma":[0.00077539217,0.0049184356,0.1711459,0.00023442945,0.0017933622,0.00044311004,0.00078112865,0.81292194,0.0016300672,0.0030628992,0.0022184195,0.00007486972],"about_ca_topic_score_codex":0.014466059,"about_ca_topic_score_gemma":0.011245812,"teacher_disagreement_score":0.014466059,"about_ca_system_score_codex":0.004268431,"about_ca_system_score_gemma":0.0023727426,"threshold_uncertainty_score":0.030969799},"labels":[],"label_agreement":null},{"id":"W4210251137","doi":"10.1080/13696998.2022.2035131","title":"Evaluation of the cost and medical resource use outcomes associated with nasal glucagon versus injectable glucagon for treatment of severe hypoglycemia in people with diabetes in Canada: a modeling analysis","year":2022,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Eli Lilly (Canada); McMaster University; Impact; McGill University","funders":"Eli Lilly and Company","keywords":"Medicine; Glucagon; Hypoglycemia; Psychological intervention; Emergency medicine; Type 2 diabetes; Diabetes mellitus; Glucagon receptor; Intensive care medicine; Medical emergency; Insulin; Internal medicine; Endocrinology; Nursing","score_opus":0.0448619192863499,"score_gpt":0.29080398657987816,"score_spread":0.24594206729352824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210251137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97327393,0.0010121049,0.0043838904,0.0014728371,0.00004524857,0.0005158713,0.010573874,0.00007977488,0.008642622],"genre_scores_gemma":[0.9874834,0.0008957659,0.0044883094,0.00015191633,0.000017631992,0.00032070337,0.0034276384,0.000019885132,0.0031948765],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9985753,0.000502719,0.000059477024,0.00015552614,0.00018480726,0.0005222035],"domain_scores_gemma":[0.99456465,0.003015295,0.00051896257,0.000095444586,0.0013060811,0.0004995529],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031150305,0.0014934125,0.0015048956,0.0027238955,0.0015579951,0.002502431,0.0027097731,0.0014056856,0.00425092],"category_scores_gemma":[0.0068610706,0.00094150024,0.0036716282,0.00347548,0.0009065584,0.00079631404,0.0011451533,0.0016485826,0.00021456917],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059293886,0.00034377706,0.055547733,0.00026043408,0.00061721535,0.00023102576,0.00014565719,0.93074054,0.00019784269,0.0049617076,0.0019788777,0.004382157],"study_design_scores_gemma":[0.00018347624,0.00021792353,0.017607152,0.00008332884,0.00042246986,0.000049518865,0.00037325543,0.97898906,0.00012837457,0.00085532,0.0010421188,0.00004796915],"about_ca_topic_score_codex":0.9522466,"about_ca_topic_score_gemma":0.9152501,"teacher_disagreement_score":0.05672173,"about_ca_system_score_codex":0.05672173,"about_ca_system_score_gemma":0.037869982,"threshold_uncertainty_score":0.4115469},"labels":[],"label_agreement":null},{"id":"W4210759142","doi":"10.1080/13696998.2022.2033493","title":"Epidemiology and economic burden of Huntington’s disease: a Canadian provincial public health system perspective","year":2022,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Genetic Neurodegenerative Diseases","field":"Neuroscience","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa; Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Epidemiology; Health care; Public health; Proxy (statistics); Incidence (geometry); Cohort; Disease burden; Retrospective cohort study; Disease; Demography; Indirect costs; Gerontology; Environmental health; Emergency medicine; Surgery; Internal medicine","score_opus":0.044430487514849244,"score_gpt":0.2987692817046934,"score_spread":0.2543387941898442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210759142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8185424,0.04084867,0.0012101245,0.04264265,0.0002918236,0.00025417312,0.054066665,0.000106997766,0.04203641],"genre_scores_gemma":[0.9798226,0.011463584,0.0009704651,0.00088884,0.00009595778,0.00003259821,0.005519133,0.000014323059,0.0011924381],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809855,0.00020651455,0.00009664679,0.000119511424,0.00082958164,0.00064929505],"domain_scores_gemma":[0.9965467,0.00019056033,0.0005452415,0.000067111185,0.001887001,0.0007634341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011546677,0.0004607082,0.0005086746,0.00415914,0.0025220574,0.0026319781,0.0013272238,0.0006701618,0.0027537437],"category_scores_gemma":[0.0047021843,0.0003145465,0.00096780766,0.008099015,0.0008955273,0.00065079296,0.0012341876,0.0009595586,0.00015817628],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011800886,0.000060862712,0.9449808,0.00043643528,0.00053697714,0.0003911466,0.0008133589,0.002895374,0.00021662985,0.003282028,0.016364755,0.02990371],"study_design_scores_gemma":[0.000020706206,0.00003249306,0.9865652,0.00037175787,0.00023137154,0.00019728224,0.0014745252,0.0021728487,0.000047042213,0.00049986213,0.00834515,0.000041658812],"about_ca_topic_score_codex":0.9976688,"about_ca_topic_score_gemma":0.99790025,"teacher_disagreement_score":0.92999554,"about_ca_system_score_codex":0.07000445,"about_ca_system_score_gemma":0.09321944,"threshold_uncertainty_score":0.5079202},"labels":[],"label_agreement":null},{"id":"W4220766721","doi":"10.1080/13696998.2022.2049552","title":"Association of factor expression levels with health-related quality of life and direct medical costs for people with haemophilia B","year":2022,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Haemophilia; Quality of life (healthcare); Tobit model; Body mass index; Haemophilia A; Population; Haemophilia B; Medical record; EQ-5D; Factor IX; Internal medicine; Health related quality of life; Pediatrics; Physical therapy; Disease; Environmental health","score_opus":0.0532654150044163,"score_gpt":0.34627892845941805,"score_spread":0.29301351345500176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220766721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937896,0.003536096,0.00018958404,0.00014214254,0.000008539295,0.000019357793,0.00152526,0.000005093573,0.00078430434],"genre_scores_gemma":[0.9986628,0.00046079152,0.00012337153,0.000044615783,0.000014735781,0.000015286765,0.0005288402,9.79427e-7,0.00014855783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993672,0.00018201343,0.00011224971,0.00013498963,0.000130801,0.00007281881],"domain_scores_gemma":[0.9982114,0.00030105302,0.0012405755,0.0000597613,0.00009442729,0.00009279326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007896034,0.00019585501,0.00029500437,0.0007000076,0.00025011878,0.000545736,0.00017533131,0.00028931032,0.0017687752],"category_scores_gemma":[0.002809651,0.0001500008,0.0004995041,0.0010815735,0.00021345423,0.00036549193,0.00023019222,0.0005568131,0.00015336016],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011644545,0.00002260509,0.99731785,0.000031877706,0.00010267596,0.00001871804,0.000025789908,0.000046433302,0.00005436499,0.000026320047,0.00013081917,0.002106118],"study_design_scores_gemma":[0.0000068017675,0.000106974425,0.9990609,0.000017115337,0.00006683617,0.00019340019,0.000052207117,0.00013212577,0.000046848618,0.000031685606,0.000282088,0.0000029613557],"about_ca_topic_score_codex":0.002047395,"about_ca_topic_score_gemma":0.0020221148,"teacher_disagreement_score":0.002047395,"about_ca_system_score_codex":0.00031475647,"about_ca_system_score_gemma":0.00013468831,"threshold_uncertainty_score":0.005917132},"labels":[],"label_agreement":null},{"id":"W4220928355","doi":"10.1080/13696998.2022.2053403","title":"Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Medicine; KRAS; Internal medicine; Oncology; Personalized medicine; Polymerase chain reaction; Genetic testing; Cancer; Bioinformatics; Gene; Genetics; Colorectal cancer","score_opus":0.057040984885594635,"score_gpt":0.2991262615221178,"score_spread":0.24208527663652316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220928355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97938204,0.0008853599,0.007974607,0.0023545886,0.00003620321,0.0002470115,0.0034605095,0.000043010707,0.005616731],"genre_scores_gemma":[0.99626714,0.00030957194,0.001716671,0.00015230074,0.000012428261,0.000054298907,0.0008154229,0.0000060270754,0.0006660971],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99798334,0.0011241796,0.0000974917,0.00019424703,0.0002035604,0.00039726702],"domain_scores_gemma":[0.9952867,0.0032167225,0.0007781663,0.00006527597,0.00021776384,0.00043536344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002455038,0.0005427858,0.00060811074,0.000919704,0.0004388897,0.0015309331,0.00083001103,0.000929985,0.005306967],"category_scores_gemma":[0.008593046,0.0005262155,0.002046201,0.0014668922,0.00039942097,0.0014059412,0.00074047106,0.0008387507,0.00023673952],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019854323,0.0003477778,0.1664063,0.00019782671,0.0006435488,0.0007136624,0.00011591609,0.79944557,0.00043074336,0.004992107,0.002094627,0.022626491],"study_design_scores_gemma":[0.00038190497,0.0017528519,0.090680405,0.00021658283,0.0010565376,0.0014350776,0.00065777317,0.89514595,0.00060548785,0.005757043,0.00224147,0.00006895053],"about_ca_topic_score_codex":0.03302751,"about_ca_topic_score_gemma":0.023904992,"teacher_disagreement_score":0.03302751,"about_ca_system_score_codex":0.0066418145,"about_ca_system_score_gemma":0.0032240883,"threshold_uncertainty_score":0.06567049},"labels":[],"label_agreement":null},{"id":"W4223492032","doi":"10.1080/13696998.2022.2063603","title":"Carbon footprint and associated costs of asthma exacerbation care among UK adults","year":2022,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Climate Change and Health Impacts","field":"Environmental Science","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Carbon footprint; Exacerbation; Greenhouse gas; Asthma; Medicine; Asthma exacerbations; Environmental health; Population; Internal medicine","score_opus":0.016006508914593823,"score_gpt":0.2557213518250877,"score_spread":0.23971484291049389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223492032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90711564,0.019297533,0.0023892897,0.0043791467,0.00013925476,0.00023894978,0.048625216,0.00007051873,0.017744409],"genre_scores_gemma":[0.9859848,0.0056209727,0.0009670804,0.00028095266,0.000059659782,0.00010023945,0.005988732,0.000008232002,0.0009891808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879384,0.000312303,0.00020816448,0.0001234268,0.00038424772,0.00017801007],"domain_scores_gemma":[0.9976968,0.00039731964,0.0011986325,0.000062555715,0.0004937622,0.00015089256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006048757,0.0003396761,0.00027485008,0.0014407509,0.00019154504,0.0010635721,0.00029466508,0.0005778656,0.0040719165],"category_scores_gemma":[0.0044760164,0.00018743373,0.0009547448,0.0025314556,0.000251412,0.0009087087,0.0009256454,0.0004722065,0.0003764907],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002672735,0.000054493146,0.9084987,0.0023558242,0.0006992693,0.0008528887,0.00055834407,0.014513377,0.00062827585,0.003083847,0.012661178,0.05582656],"study_design_scores_gemma":[0.000035086905,0.00016209064,0.970087,0.0013798283,0.00026545787,0.0011048927,0.00079895055,0.0069813086,0.00031422268,0.0012822933,0.017545436,0.00004340102],"about_ca_topic_score_codex":0.07807621,"about_ca_topic_score_gemma":0.06350673,"teacher_disagreement_score":0.07807621,"about_ca_system_score_codex":0.0024090884,"about_ca_system_score_gemma":0.0011207055,"threshold_uncertainty_score":0.15524352},"labels":[],"label_agreement":null},{"id":"W4240567294","doi":"10.3111/13696998.2014.909438","title":"Letter to the Editor","year":2014,"lang":"en","type":"letter","venue":"Journal of Medical Economics","topic":"Veterinary Practice and Education Studies","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Ottawa","funders":"","keywords":"Medicine; Family medicine","score_opus":0.20580695784900213,"score_gpt":0.4714749754306188,"score_spread":0.2656680175816166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240567294","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00051475305,0.0010640308,0.00006288282,0.9341286,0.05168436,0.000018044515,0.00005098811,0.000029521787,0.0124469185],"genre_scores_gemma":[0.005367159,0.0009103675,0.00013195844,0.9203844,0.03607013,0.00004056681,0.000022853153,0.000028546454,0.037044074],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971306,0.00068199943,0.0002472027,0.0004056992,0.00096212374,0.0005723748],"domain_scores_gemma":[0.9942702,0.001985027,0.00040723142,0.0001777358,0.0017147306,0.0014450081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002758408,0.0007435831,0.0014467983,0.0009946267,0.0044599604,0.0045537096,0.0018303981,0.03793092,0.013402089],"category_scores_gemma":[0.030719703,0.00082934933,0.0011555689,0.0006066285,0.0019304537,0.0027072912,0.001541843,0.02509895,0.0077905296],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023984887,0.000018475353,0.00033972174,0.000022214148,0.0000081309645,0.0015648361,0.00007113898,0.00003641093,0.000043365875,0.001118803,0.9942352,0.0025177212],"study_design_scores_gemma":[0.000055984405,0.00003337843,0.0011874079,0.0002399489,0.000023900942,0.0022903902,0.0005055168,0.000283323,0.00015900514,0.004797065,0.9903758,0.000048375485],"about_ca_topic_score_codex":0.008887999,"about_ca_topic_score_gemma":0.011911484,"teacher_disagreement_score":0.03793092,"about_ca_system_score_codex":0.004383964,"about_ca_system_score_gemma":0.008355712,"threshold_uncertainty_score":0.044834435},"labels":[],"label_agreement":null},{"id":"W4242597024","doi":"10.3111/13696998.2011.650528","title":"Economic evaluation of a 100% whey-based partially hydrolyzed infant formula in the prevention of atopic dermatitis among Danish children","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; PharmIdeas (Canada)","funders":"","keywords":"Medicine; Atopic dermatitis; Danish; Infant formula; Dermatology; Pediatrics","score_opus":0.026658612745991222,"score_gpt":0.29242777042454543,"score_spread":0.2657691576785542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242597024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979285,0.00711945,0.0052191056,0.0007665631,0.00007753624,0.0010755503,0.0014739981,0.00002251116,0.004960432],"genre_scores_gemma":[0.99689627,0.0011705372,0.0010917898,0.000041757314,0.000004889405,0.00017269542,0.00022299842,0.0000030694466,0.00039602732],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.995314,0.0036466382,0.00016037184,0.0001891732,0.00031369203,0.0003760404],"domain_scores_gemma":[0.9955147,0.003585449,0.00034457733,0.00008662007,0.00018294116,0.00028561748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007418191,0.0010752779,0.0019407793,0.0012791198,0.00040483486,0.0022536125,0.0010669307,0.0014359,0.0021840618],"category_scores_gemma":[0.010996937,0.00097591797,0.0040920125,0.0010177565,0.0006632503,0.0009584045,0.0009873529,0.0013965128,0.000091119604],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02364611,0.0012546653,0.007037125,0.002701747,0.0026169927,0.0003718092,0.00012403194,0.93987983,0.001582584,0.0050897584,0.00043821716,0.015257077],"study_design_scores_gemma":[0.0086765755,0.02999484,0.036720455,0.0014292197,0.0117185395,0.00045316367,0.0010893034,0.8970071,0.0037297755,0.0037699498,0.005176708,0.00023434899],"about_ca_topic_score_codex":0.033939477,"about_ca_topic_score_gemma":0.016669488,"teacher_disagreement_score":0.033939477,"about_ca_system_score_codex":0.011845784,"about_ca_system_score_gemma":0.0056573353,"threshold_uncertainty_score":0.08594757},"labels":[],"label_agreement":null},{"id":"W4280552376","doi":"10.1080/13696998.2022.2078574","title":"Cost-effectiveness analysis of arthroscopic injection of a bioadhesive hydrogel implant in conjunction with microfracture for the treatment of focal chondral defects of the knee – an Australian perspective","year":2022,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; WOMAC; Surgery; Quality-adjusted life year; Osteoarthritis; Cost effectiveness; Quality of life (healthcare); Arthroplasty; Arthrofibrosis; Physical therapy; Range of motion","score_opus":0.02512278779591039,"score_gpt":0.3073446473954924,"score_spread":0.282221859599582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280552376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9646207,0.010262312,0.010768301,0.0028916902,0.00008273537,0.00093571516,0.002094378,0.00005753029,0.0082867285],"genre_scores_gemma":[0.9953993,0.0015479546,0.0018058149,0.00013445073,0.000016052505,0.00013558682,0.0002810043,0.0000054597986,0.0006744524],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9979475,0.00146926,0.000062487125,0.00013220932,0.00019777344,0.00019083913],"domain_scores_gemma":[0.9953435,0.0034375226,0.0005618991,0.00007908808,0.00031011165,0.00026778254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004803959,0.001027848,0.0012952436,0.0013352609,0.0002746777,0.0012291898,0.0012945135,0.0013185613,0.0039780377],"category_scores_gemma":[0.009765046,0.0007197394,0.0040659667,0.0008446677,0.0005612575,0.0009908043,0.0010039327,0.001319712,0.0001507441],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0105742505,0.0010686476,0.017032271,0.0020713294,0.0030475645,0.0006212554,0.00012090354,0.9265861,0.0017265079,0.0056188894,0.0012276031,0.030304711],"study_design_scores_gemma":[0.0023482277,0.008543738,0.03924739,0.00052577164,0.0046976423,0.00053950236,0.00022644826,0.93710625,0.0010443098,0.003726044,0.0018848943,0.00010975362],"about_ca_topic_score_codex":0.042741615,"about_ca_topic_score_gemma":0.023101455,"teacher_disagreement_score":0.042741615,"about_ca_system_score_codex":0.010168443,"about_ca_system_score_gemma":0.004231031,"threshold_uncertainty_score":0.08498567},"labels":[],"label_agreement":null},{"id":"W4311206227","doi":"10.1080/13696998.2022.2157596","title":"Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries","year":2022,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Socioeconomic status; Schizophrenia (object-oriented programming); Psychiatry; Demography; Environmental health; Gerontology; Population","score_opus":0.020873750268871782,"score_gpt":0.34054225721086384,"score_spread":0.31966850694199206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311206227","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005219036,0.9906121,0.00016394882,0.00093074684,0.00010624107,0.00012743738,0.0016985688,0.000009056511,0.0011329986],"genre_scores_gemma":[0.022481633,0.9758958,0.0004252068,0.00032402878,0.000063359366,0.00009986735,0.0006342415,0.000003822528,0.000072099814],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9958177,0.001136308,0.0016155816,0.00031732695,0.0009038355,0.0002092141],"domain_scores_gemma":[0.9892876,0.0063302564,0.0024903936,0.00011290326,0.0016397496,0.00013906184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004610025,0.0013441407,0.0028515009,0.025880441,0.0006249144,0.0025492944,0.0008142925,0.0009859862,0.002913605],"category_scores_gemma":[0.014007355,0.0006939787,0.005095354,0.025707109,0.0005166873,0.0020430505,0.0014900927,0.0006754449,0.00025557086],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037744857,0.00004964857,0.01494055,0.6248464,0.00935355,0.0008069518,0.0007688156,0.0008736558,0.00029281795,0.0018516064,0.010288518,0.33555],"study_design_scores_gemma":[0.00014950035,0.00036655492,0.089960374,0.77592105,0.043706104,0.0029391393,0.0030855055,0.00055162754,0.00048605836,0.0017594862,0.08094173,0.00013293882],"about_ca_topic_score_codex":0.013103488,"about_ca_topic_score_gemma":0.021949815,"teacher_disagreement_score":0.025880441,"about_ca_system_score_codex":0.0048456695,"about_ca_system_score_gemma":0.007907856,"threshold_uncertainty_score":0.03515792},"labels":[],"label_agreement":null},{"id":"W4311367134","doi":"10.1080/13696998.2022.2156152","title":"The cost-effectiveness of a nursing home-based transitional care unit for increasing the potential for independent living in the community among hospitalized older adults","year":2022,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Geriatric Care and Nursing Homes","field":"Health Professions","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa; Bruyère","funders":"","keywords":"Medicine; Transitional care; Nursing homes; Independent living; Unit (ring theory); Nursing; Skilled Nursing Facility; Gerontology; Intensive care medicine; Health care","score_opus":0.035483687080570106,"score_gpt":0.37385944076368816,"score_spread":0.33837575368311806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311367134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941158,0.004003393,0.00020427596,0.00054879475,0.000045484292,0.000106676125,0.00023412336,0.000007578699,0.00073374755],"genre_scores_gemma":[0.9987802,0.00070357544,0.0002617384,0.000061463725,0.000023957213,0.000027898079,0.000087595414,7.4301425e-7,0.000052851254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788034,0.0010799051,0.00022608749,0.00015653112,0.00042019496,0.00023694872],"domain_scores_gemma":[0.99733126,0.0007762031,0.0011392981,0.000079068624,0.00016348952,0.0005106194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022434134,0.00037923342,0.0002984096,0.0007185281,0.0003243378,0.0010275973,0.0007084379,0.00064735016,0.0011745106],"category_scores_gemma":[0.010123017,0.00013698057,0.0014799068,0.0004885782,0.00043129077,0.0006261098,0.00096322654,0.00050797174,0.00005587491],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011643746,0.0036755335,0.8145031,0.0017192782,0.0031090446,0.00039408167,0.00018237189,0.0043856646,0.0007581901,0.0009146208,0.0018202934,0.1568942],"study_design_scores_gemma":[0.0011433642,0.015615465,0.9646029,0.001221417,0.002093972,0.001022615,0.0008620875,0.010719387,0.0006977051,0.00069323747,0.0012758069,0.000052125117],"about_ca_topic_score_codex":0.01017735,"about_ca_topic_score_gemma":0.016653331,"teacher_disagreement_score":0.01017735,"about_ca_system_score_codex":0.0030518784,"about_ca_system_score_gemma":0.0019867406,"threshold_uncertainty_score":0.022143006},"labels":[],"label_agreement":null},{"id":"W4316927784","doi":"10.1080/13696998.2023.2169496","title":"Adopting a portfolio of ultrasonic and advanced bipolar electrosurgery devices from a single manufacturer compared to currently used ultrasonic and advanced bipolar devices: a probabilistic budget impact analysis from a Spanish hospital perspective","year":2023,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Thyroid and Parathyroid Surgery","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Electrosurgery; Portfolio; Energy budget; Surgery; Operations management; Engineering; Business","score_opus":0.01377082045706182,"score_gpt":0.282899033202611,"score_spread":0.2691282127455492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4316927784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9165223,0.012674799,0.035194304,0.0024225565,0.00016645367,0.0013404981,0.01338531,0.00012213543,0.018171657],"genre_scores_gemma":[0.986471,0.0024395126,0.005382256,0.00020490543,0.000033398504,0.0004843585,0.0037490267,0.000037261536,0.0011983507],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99173474,0.005201347,0.00036134437,0.00065936777,0.0011474097,0.0008958964],"domain_scores_gemma":[0.98282224,0.0118940305,0.002386086,0.00052594004,0.0018355483,0.0005361282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011165883,0.0012987277,0.0012472585,0.0022159985,0.00026535068,0.0029790564,0.0012709384,0.0009338271,0.006506202],"category_scores_gemma":[0.026785586,0.0006702841,0.0040409495,0.002470426,0.0005246371,0.0015748393,0.0018800059,0.0015677917,0.00032510993],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00611247,0.00046200806,0.12911746,0.0013430133,0.004451469,0.00055243785,0.00020411403,0.7800542,0.00089799217,0.014102893,0.004953613,0.057748348],"study_design_scores_gemma":[0.0019320145,0.0049743387,0.24572967,0.0020219763,0.007938009,0.0010978475,0.0023243902,0.68450487,0.0018304702,0.01834419,0.028967086,0.00033507805],"about_ca_topic_score_codex":0.02368822,"about_ca_topic_score_gemma":0.008270761,"teacher_disagreement_score":0.02368822,"about_ca_system_score_codex":0.00714828,"about_ca_system_score_gemma":0.0037482148,"threshold_uncertainty_score":0.059051573},"labels":[],"label_agreement":null},{"id":"W4318263697","doi":"10.1080/13696998.2023.2173466","title":"Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France","year":2023,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Bristol-Myers Squibb","keywords":"Medicine; Refractory (planetary science); Multiple myeloma; Internal medicine; Oncology; Surgery","score_opus":0.030366608140798463,"score_gpt":0.2906257714463823,"score_spread":0.26025916330558385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318263697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98581845,0.006214034,0.00043726797,0.0014299108,0.000045844015,0.00018628959,0.002590338,0.0000376002,0.0032402514],"genre_scores_gemma":[0.99713093,0.00071803544,0.00034003842,0.0001832878,0.000009531938,0.000045234843,0.001082895,0.000006181977,0.00048394257],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99877673,0.00051395426,0.00004117,0.00013951694,0.00016975039,0.00035881947],"domain_scores_gemma":[0.99820626,0.0006151702,0.00027837852,0.00003748338,0.00031568974,0.00054703833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016774222,0.00072879985,0.0010410631,0.0007453532,0.00067427306,0.0018375654,0.0011425638,0.0008943259,0.0032010572],"category_scores_gemma":[0.004168251,0.00021812598,0.0021754971,0.0010696317,0.00059837213,0.00046318027,0.00086958654,0.0008907312,0.0001261792],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08418471,0.0037606556,0.30787605,0.0018842097,0.007695786,0.0013365698,0.0005416273,0.41303712,0.0015817316,0.008863342,0.01671185,0.1525263],"study_design_scores_gemma":[0.015932625,0.015652688,0.5224686,0.0012771179,0.0060680658,0.0010671595,0.0026379297,0.41679752,0.0016078022,0.002759235,0.013353779,0.00037745413],"about_ca_topic_score_codex":0.86777246,"about_ca_topic_score_gemma":0.8426271,"teacher_disagreement_score":0.13222754,"about_ca_system_score_codex":0.05613078,"about_ca_system_score_gemma":0.025321094,"threshold_uncertainty_score":0.40725923},"labels":[],"label_agreement":null},{"id":"W4327684313","doi":"10.1080/13696998.2023.2192588","title":"Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving <i>reldesemtiv</i> or placebo in FORTITUDE-ALS","year":2023,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Amyotrophic Lateral Sclerosis Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"Cytokinetics","keywords":"Medicine; Placebo; Amyotrophic lateral sclerosis; Post-hoc analysis; Quality of life (healthcare); Confidence interval; Quality-adjusted life year; Post hoc; Physical therapy; Randomized controlled trial; Clinical trial; Internal medicine; Cost effectiveness; Disease; Alternative medicine","score_opus":0.101716665152335,"score_gpt":0.34966019826966394,"score_spread":0.24794353311732892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327684313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931212,0.004503248,0.00046945797,0.00010031271,0.00004043121,0.00026460175,0.0008187469,0.000014595559,0.0006673603],"genre_scores_gemma":[0.9973506,0.00071666547,0.00038715568,0.000101758604,0.00003250075,0.00036875127,0.000808736,0.000002753292,0.00023116183],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9986241,0.00087403867,0.00010989054,0.00017372267,0.00011672335,0.000101629616],"domain_scores_gemma":[0.998324,0.0008422642,0.0005748985,0.00006201577,0.000060608014,0.00013623181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038655973,0.0005377982,0.002030133,0.00035681226,0.0001477532,0.0005833221,0.0003091717,0.00051438535,0.001474174],"category_scores_gemma":[0.004073224,0.00022525198,0.0022473885,0.00039607933,0.00032024668,0.0006224787,0.0003110968,0.0009069597,0.00012649206],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8726508,0.0023606045,0.04796017,0.0013442406,0.00837124,0.00009135014,0.00013891664,0.005360658,0.0037574947,0.00026163034,0.0008528655,0.056849986],"study_design_scores_gemma":[0.27234003,0.37979367,0.31402647,0.0003148775,0.014165736,0.000354334,0.00023753133,0.010595407,0.0038662122,0.0013727936,0.0027845104,0.0001483428],"about_ca_topic_score_codex":0.0004706144,"about_ca_topic_score_gemma":0.0004998713,"teacher_disagreement_score":0.0038655973,"about_ca_system_score_codex":0.0003788699,"about_ca_system_score_gemma":0.00035753121,"threshold_uncertainty_score":0.0204435},"labels":[],"label_agreement":null},{"id":"W4328049416","doi":"10.1080/13696998.2023.2193112","title":"A practical guide for clinical and key opinion leader validation of health economic models","year":2023,"lang":"en","type":"editorial","venue":"Journal of Medical Economics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Key (lock); Opinion leadership; Expert opinion; Actuarial science; Family medicine; Management science; Intensive care medicine; Public relations; Computer science","score_opus":0.6558185005833402,"score_gpt":0.5904005839349129,"score_spread":0.06541791664842733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4328049416","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000088867084,0.014759797,0.04919246,0.3200771,0.6007203,0.0016292068,0.00077188126,0.0014967589,0.01126366],"genre_scores_gemma":[0.0027033791,0.017132208,0.1250975,0.22630098,0.57754487,0.005358173,0.00094849395,0.0015822538,0.04333213],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9035357,0.057455275,0.015975652,0.0025001399,0.019481067,0.0010521952],"domain_scores_gemma":[0.44473267,0.36910638,0.012260537,0.018711708,0.14601576,0.009172907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.12082724,0.003845975,0.003574773,0.0095370775,0.003992128,0.011442661,0.006280943,0.0188981,0.037585516],"category_scores_gemma":[0.40612707,0.0021998973,0.0038821355,0.0026179971,0.008356166,0.010571915,0.0057886406,0.036268443,0.027746765],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012865782,0.000015066833,0.000021146787,0.00038862787,0.000014578313,0.00005207274,0.00009730853,0.00008886733,0.00004327373,0.0041252743,0.97343636,0.0217046],"study_design_scores_gemma":[0.000068034,0.000023487853,0.00014770035,0.0024626013,0.000033547236,0.0002007411,0.00016580841,0.0007555911,0.00008107163,0.028627133,0.9673845,0.00004974821],"about_ca_topic_score_codex":0.003265082,"about_ca_topic_score_gemma":0.005511344,"teacher_disagreement_score":0.12082724,"about_ca_system_score_codex":0.004536864,"about_ca_system_score_gemma":0.015312457,"threshold_uncertainty_score":0.63900316},"labels":[],"label_agreement":null},{"id":"W4360989335","doi":"10.1080/13696998.2023.2195753","title":"A systematic review of SF-6D health state valuation studies","year":2023,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Fonds de Recherche du Québec - Santé","keywords":"Checklist; Medicine; Valuation (finance); Preference; Dimension (graph theory); Health economics; Quality-adjusted life year; Population; Quality of life (healthcare); Scopus; EQ-5D; Systematic review; MEDLINE; Actuarial science; Health related quality of life; Statistics; Psychology; Public health; Environmental health; Cost effectiveness; Economics","score_opus":0.7462706308130562,"score_gpt":0.5826734476324421,"score_spread":0.16359718318061411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360989335","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015677599,0.9938445,0.00057652395,0.00041496026,0.00015226255,0.0009306195,0.0017695475,0.000017212875,0.0007265631],"genre_scores_gemma":[0.016943451,0.97733486,0.001777162,0.00061393,0.00009717045,0.0021533694,0.00091626,0.00001056601,0.00015317644],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98155254,0.005953746,0.007830911,0.0011407809,0.003131107,0.00039099777],"domain_scores_gemma":[0.94747895,0.038394455,0.00846404,0.0008224846,0.0044889525,0.00035120983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015592193,0.0022470923,0.008618921,0.027996866,0.0010038199,0.0031598045,0.0023948231,0.002139285,0.006707868],"category_scores_gemma":[0.07658693,0.0010417461,0.009884049,0.023732543,0.0012441789,0.0029267194,0.0022222605,0.0012630179,0.00050835806],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001227924,0.000011732244,0.0006713498,0.95599645,0.004521594,0.00009918326,0.00020234197,0.000112272166,0.0000977447,0.00036552228,0.0013947914,0.036404222],"study_design_scores_gemma":[0.00012668555,0.00012093251,0.002905942,0.9495535,0.02860323,0.00028204423,0.00027467276,0.000070792565,0.00011591742,0.00043819993,0.017473266,0.000034857705],"about_ca_topic_score_codex":0.007907875,"about_ca_topic_score_gemma":0.017289486,"teacher_disagreement_score":0.027996866,"about_ca_system_score_codex":0.0062184925,"about_ca_system_score_gemma":0.017061152,"threshold_uncertainty_score":0.082460344},"labels":[],"label_agreement":null},{"id":"W4383481487","doi":"10.1080/13696998.2023.2234235","title":"Cost-effectiveness of tezepelumab in Canada for severe asthma","year":2023,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"EVERSANA (Canada); University of Alberta; AstraZeneca (Canada)","funders":"AstraZeneca Canada; AstraZeneca","keywords":"Medicine; Asthma; Cost–utility analysis; Exacerbation; Quality-adjusted life year; Cost-effectiveness analysis; Cost effectiveness; Incremental cost-effectiveness ratio; Cohort; Cost–benefit analysis; Emergency medicine; Internal medicine","score_opus":0.03029584279058423,"score_gpt":0.3078310479287403,"score_spread":0.27753520513815605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383481487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90571094,0.03520052,0.0059325616,0.0103706,0.00024506066,0.0021303508,0.017410934,0.00019652268,0.022802385],"genre_scores_gemma":[0.9912565,0.0033725153,0.0020438102,0.0004341411,0.000019161333,0.00013492338,0.0017511144,0.000011147742,0.0009767701],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99826497,0.0006683998,0.00007327229,0.00015510754,0.0005154547,0.00032289966],"domain_scores_gemma":[0.9974371,0.000962375,0.00039972505,0.0000645702,0.000696214,0.0004400021],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023939314,0.0008299122,0.00086831354,0.0010306921,0.00087351917,0.0017333976,0.0012896826,0.0008605206,0.003445603],"category_scores_gemma":[0.011548979,0.0003730701,0.0024349738,0.0013027056,0.00071511586,0.0006308029,0.0007442864,0.0012533572,0.00011112287],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039882652,0.0013874932,0.1554084,0.00523878,0.008024162,0.000904735,0.00035247055,0.50661755,0.0019636077,0.015540288,0.021384584,0.24329527],"study_design_scores_gemma":[0.017860474,0.0075366963,0.29412735,0.0035542941,0.014244546,0.0012367578,0.0011516402,0.61953837,0.0026897595,0.01025389,0.027394408,0.00041183314],"about_ca_topic_score_codex":0.9518209,"about_ca_topic_score_gemma":0.9529323,"teacher_disagreement_score":0.07088895,"about_ca_system_score_codex":0.07088895,"about_ca_system_score_gemma":0.076519325,"threshold_uncertainty_score":0.5143378},"labels":[],"label_agreement":null},{"id":"W4383872109","doi":"10.1080/13696998.2023.2234776","title":"Health care resource utilization in 3L + patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib","year":2023,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Novartis Portugal","keywords":"Medicine; Bosutinib; Myeloid leukemia; Chronic care; Health care; Chronic disease; Internal medicine; Oncology; Intensive care medicine; Imatinib; Dasatinib","score_opus":0.029984387243782135,"score_gpt":0.3263907657694533,"score_spread":0.2964063785256712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383872109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99901927,0.00052866957,0.000030965144,0.000057286663,0.0000075657526,0.000020233221,0.00020803718,0.0000013736211,0.00012653378],"genre_scores_gemma":[0.9994357,0.000113792514,0.000043154127,0.00006125096,0.000012515118,0.000034268032,0.0002470762,5.907425e-7,0.000051554976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985025,0.00091281295,0.00010140079,0.00016590246,0.00012163743,0.00019578458],"domain_scores_gemma":[0.9986957,0.00032694568,0.00068237714,0.000056604207,0.0000436754,0.00019466356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019767624,0.00022598855,0.00059653964,0.00020803936,0.0001981432,0.0005430554,0.00026203663,0.00041253297,0.0011683227],"category_scores_gemma":[0.0022811268,0.0001607445,0.00091064494,0.00044610183,0.0002027535,0.0003201673,0.0003731037,0.00049159484,0.00009185338],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059459172,0.0011928258,0.91071236,0.00021820946,0.0016529915,0.000068295434,0.000085587926,0.0010025828,0.0010133171,0.00007328023,0.0009284074,0.023592955],"study_design_scores_gemma":[0.005209223,0.009160079,0.9821494,0.000050212093,0.0006860075,0.00014292817,0.00012773872,0.0015701378,0.00034421013,0.000080871025,0.00046408534,0.000015039985],"about_ca_topic_score_codex":0.001761453,"about_ca_topic_score_gemma":0.0025497808,"teacher_disagreement_score":0.0019767624,"about_ca_system_score_codex":0.0005529573,"about_ca_system_score_gemma":0.00046467237,"threshold_uncertainty_score":0.010454237},"labels":[],"label_agreement":null},{"id":"W4384664050","doi":"10.1080/13696998.2023.2237336","title":"Early access for innovative oncology medicines: a different story in each nation","year":2023,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"ABB (Canada)","funders":"AbbVie Canada","keywords":"Medicine; Internal medicine; Oncology; Family medicine","score_opus":0.7144830394150865,"score_gpt":0.5836889240515664,"score_spread":0.13079411536352015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384664050","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03662968,0.04333975,0.002614575,0.8702229,0.003346431,0.0000615325,0.0011712556,0.00008032839,0.042533606],"genre_scores_gemma":[0.5883566,0.1224832,0.007852444,0.2664852,0.0036184182,0.00032821178,0.0017920432,0.00036847335,0.008715457],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9804971,0.010013423,0.002309992,0.0013989393,0.0034206603,0.0023598922],"domain_scores_gemma":[0.924028,0.045104634,0.0084481025,0.003910741,0.010125771,0.008382742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020937558,0.00032896321,0.00079517125,0.0033612587,0.005050901,0.015194693,0.001393284,0.007483874,0.0067344494],"category_scores_gemma":[0.070384316,0.00065136445,0.0016397318,0.004990287,0.008292002,0.028477294,0.010065968,0.0134463655,0.00066791923],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005216812,0.00023877269,0.052501835,0.0047613885,0.00034976072,0.004136427,0.061258774,0.0006900817,0.0006088126,0.34461436,0.25569603,0.27462208],"study_design_scores_gemma":[0.000038498496,0.0001635051,0.023048662,0.0072948416,0.00018825247,0.0027494999,0.05644839,0.00029816633,0.00059966,0.05605041,0.85289586,0.00022422557],"about_ca_topic_score_codex":0.0141384825,"about_ca_topic_score_gemma":0.0112310555,"teacher_disagreement_score":0.020937558,"about_ca_system_score_codex":0.008712958,"about_ca_system_score_gemma":0.012513647,"threshold_uncertainty_score":0.110729754},"labels":[],"label_agreement":null},{"id":"W4385341021","doi":"10.1080/13696998.2023.2242197","title":"Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan","year":2023,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVRAZ (Canada)","funders":"Takeda Pharmaceutical Company","keywords":"Axitinib; Cabozantinib; Everolimus; Nivolumab; Medicine; Renal cell carcinoma; Oncology; Internal medicine; Urology; Second line; Tyrosine-kinase inhibitor; Sunitinib; Immunotherapy; First line; Cancer","score_opus":0.04274972990295816,"score_gpt":0.3051754524786486,"score_spread":0.2624257225756904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385341021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97444195,0.0153401755,0.0036878707,0.0012064653,0.00010119438,0.00059240963,0.0023374863,0.000038658174,0.002253774],"genre_scores_gemma":[0.99622935,0.001441132,0.0010144408,0.00013354229,0.000018096334,0.00018416044,0.00075148203,0.00000586321,0.00022199038],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9968631,0.002124639,0.00020366047,0.00029410206,0.00019995496,0.00031441436],"domain_scores_gemma":[0.99567646,0.0029545357,0.0006434338,0.00012789102,0.00029532466,0.00030233013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059997295,0.001347309,0.0030639789,0.0016835621,0.00036287188,0.0017107152,0.0011849711,0.0009894063,0.0025310873],"category_scores_gemma":[0.012938291,0.0008473275,0.007616768,0.0014874218,0.0005108796,0.00109112,0.0010479101,0.0012529197,0.000077202334],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030521316,0.0014757208,0.08381037,0.005035537,0.024398955,0.0011038287,0.00020696729,0.8166944,0.0012428795,0.0032849216,0.0021966505,0.030028472],"study_design_scores_gemma":[0.011243021,0.0076620122,0.101838134,0.001202633,0.052973993,0.0008737168,0.0008141396,0.81455255,0.0013613862,0.0047901697,0.002441521,0.00024669804],"about_ca_topic_score_codex":0.04496674,"about_ca_topic_score_gemma":0.0235059,"teacher_disagreement_score":0.04496674,"about_ca_system_score_codex":0.007498924,"about_ca_system_score_gemma":0.0044313096,"threshold_uncertainty_score":0.08941001},"labels":[],"label_agreement":null},{"id":"W4387542065","doi":"10.1080/13696998.2023.2269748","title":"A cost-effectiveness analysis of national smoking cessation services among chronic obstructive pulmonary disease patients in Thailand","year":2023,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Center for Advancing Translational Sciences","keywords":"Medicine; COPD; Pulmonary disease; Smoking cessation; Prioritization; Value for money; Multidisciplinary approach; Cost-effectiveness analysis; Cost–utility analysis; Disease; Intensive care medicine; Cost effectiveness; Physical therapy; Family medicine; Internal medicine","score_opus":0.025073270264530455,"score_gpt":0.3208668528375725,"score_spread":0.29579358257304206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387542065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9687575,0.0144142965,0.0059756706,0.0012762822,0.00008524764,0.0013071871,0.0027956064,0.000046386234,0.0053417296],"genre_scores_gemma":[0.99607736,0.0017452622,0.0010956719,0.000078345554,0.00001454553,0.0002630977,0.0005213554,0.0000042043052,0.00020025192],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99500895,0.0038868329,0.00025490302,0.00020335456,0.00031105313,0.0003349487],"domain_scores_gemma":[0.99183017,0.006350321,0.00078448013,0.00014501692,0.00047499317,0.00041504932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005970318,0.00127377,0.001505451,0.0015449255,0.00036779442,0.0015747321,0.0008099164,0.00084366545,0.003633716],"category_scores_gemma":[0.014761012,0.00049667584,0.0057472596,0.0013904811,0.00042044814,0.0010565444,0.0009807172,0.0012316069,0.00010566267],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025959274,0.0021008141,0.06331304,0.0063771075,0.017255727,0.0013114801,0.00024454834,0.81769836,0.001083658,0.004215507,0.0016948878,0.05874556],"study_design_scores_gemma":[0.0079193255,0.01787335,0.094947666,0.0028548916,0.027592262,0.00161244,0.0011034497,0.8332073,0.0018818211,0.0071821534,0.0035487623,0.00027655612],"about_ca_topic_score_codex":0.018690713,"about_ca_topic_score_gemma":0.008145778,"teacher_disagreement_score":0.018690713,"about_ca_system_score_codex":0.00678954,"about_ca_system_score_gemma":0.004235232,"threshold_uncertainty_score":0.04926175},"labels":[],"label_agreement":null},{"id":"W4388902364","doi":"10.1080/13696998.2023.2286778","title":"Real-world clinical management of individuals with Rett syndrome: a physician survey","year":2023,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Genetics and Neurodevelopmental Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"ACADIA Pharmaceuticals","keywords":"Medicine; Rett syndrome; Family medicine; Pediatrics; Physical therapy","score_opus":0.028675360006546857,"score_gpt":0.3101046103406345,"score_spread":0.28142925033408767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388902364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99898034,0.00017335972,0.00005442031,0.00029897055,0.000002968086,0.000010797127,0.00016021307,0.0000023058608,0.00031665247],"genre_scores_gemma":[0.9992874,0.0001824605,0.00012814191,0.00019579615,0.0000072452285,0.000012259558,0.00013838461,0.0000011277831,0.00004715705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982205,0.00082869607,0.00024196094,0.00019307114,0.00033900456,0.00017673733],"domain_scores_gemma":[0.9919567,0.0024124645,0.003661756,0.00016215135,0.0008393689,0.0009676264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016963604,0.00011495858,0.00017017557,0.000680979,0.00049494824,0.0005367709,0.00024166258,0.00064891105,0.000851878],"category_scores_gemma":[0.007572559,0.0001969554,0.0001881349,0.0008585897,0.0004098528,0.00080418895,0.0005520739,0.0004518879,0.00017669881],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020030255,0.00004075388,0.9966832,0.000014074872,0.000011987961,0.00012738776,0.0010486299,0.000031564527,0.00007488583,0.000010667521,0.000271371,0.0016654092],"study_design_scores_gemma":[0.000007701283,0.00017307201,0.9936388,0.000024364981,0.000009988884,0.0007010443,0.0045020315,0.00023964795,0.00005781015,0.000012954357,0.00062603643,0.0000065362174],"about_ca_topic_score_codex":0.0075947666,"about_ca_topic_score_gemma":0.010486324,"teacher_disagreement_score":0.0075947666,"about_ca_system_score_codex":0.00071394333,"about_ca_system_score_gemma":0.0006426558,"threshold_uncertainty_score":0.015101135},"labels":[],"label_agreement":null},{"id":"W4389627613","doi":"10.1080/13696998.2023.2293379","title":"Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom","year":2023,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Cegep de Saint Jerome; Université de Montréal","funders":"Canadian Institutes of Health Research; Sanofi Genzyme; Novartis Pharma; Multiple Sclerosis International Federation; Sanofi; World Health Organization; Bayer HealthCare; Università di Catania; Multiple Sclerosis Society of Canada; Biogen; Celgene; Alexion Pharmaceuticals; Teva Pharmaceutical Industries; Atara Biotherapeutics; Eisai; Bristol-Myers Squibb","keywords":"Fingolimod; Medicine; Natalizumab; Relapsing remitting; Multiple sclerosis; Cost effectiveness; Physical therapy; Intensive care medicine; Internal medicine; Immunology","score_opus":0.14205289601937748,"score_gpt":0.3668817237976787,"score_spread":0.2248288277783012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389627613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.928534,0.06509984,0.001159703,0.001202879,0.00013066607,0.00021502367,0.0012293914,0.000014974416,0.0024136254],"genre_scores_gemma":[0.99642795,0.0026598333,0.00033823744,0.00013664516,0.000016690852,0.00005361859,0.00027767118,0.000002493062,0.000086877495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9740025,0.022306237,0.001342541,0.0007588877,0.0011165495,0.0004732622],"domain_scores_gemma":[0.97993946,0.014254817,0.004241428,0.000506419,0.0005863227,0.00047163706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011992465,0.00057295273,0.0017431182,0.0010649601,0.00014302878,0.001427152,0.0005995636,0.0010237133,0.0016239872],"category_scores_gemma":[0.045689847,0.00035766384,0.0031865146,0.00096083427,0.00068395527,0.0009271734,0.0011998077,0.0007595446,0.000088770226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2480433,0.0012668741,0.30266955,0.014171147,0.058815278,0.0015863125,0.00091980153,0.16360779,0.0024972581,0.007825911,0.0036401274,0.19495668],"study_design_scores_gemma":[0.061569743,0.048166037,0.68078905,0.008017807,0.059132714,0.0040241163,0.0015242428,0.11702941,0.0033825047,0.0061324583,0.009726184,0.0005057211],"about_ca_topic_score_codex":0.015580306,"about_ca_topic_score_gemma":0.010434491,"teacher_disagreement_score":0.015580306,"about_ca_system_score_codex":0.0051414305,"about_ca_system_score_gemma":0.001292996,"threshold_uncertainty_score":0.06342298},"labels":[],"label_agreement":null},{"id":"W4391401198","doi":"10.1080/13696998.2024.2311507","title":"Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Pembrolizumab; Medicine; Microsatellite instability; Oncology; Internal medicine; Adverse effect; Cancer; Immunotherapy","score_opus":0.051633340835480455,"score_gpt":0.3702759509359163,"score_spread":0.3186426101004359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391401198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9611723,0.02053496,0.0022643127,0.0027840724,0.00014193056,0.0002706689,0.0067018704,0.000041484596,0.0060883462],"genre_scores_gemma":[0.99640214,0.0016203923,0.0003773782,0.00012847313,0.000012684137,0.00008215892,0.0009661475,0.0000050844246,0.00040547474],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9972144,0.001694637,0.00024092928,0.00024199983,0.00034973843,0.00025831553],"domain_scores_gemma":[0.9964706,0.002185476,0.0008256135,0.000102700906,0.0002461743,0.00016953702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032583866,0.00045758783,0.0009464546,0.0009357347,0.0001652612,0.0014376718,0.0005378523,0.0008404776,0.003673462],"category_scores_gemma":[0.015786117,0.0003577897,0.0020778636,0.00092821947,0.0003258643,0.0010847667,0.0011026926,0.00091482635,0.0001782052],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034269944,0.00067373255,0.17980698,0.007305319,0.0070474874,0.0026516996,0.000705262,0.58827955,0.002512677,0.014951181,0.011507353,0.15028885],"study_design_scores_gemma":[0.008592285,0.012537347,0.47445366,0.0066773286,0.00784325,0.0044988915,0.0014615307,0.45032975,0.0029126958,0.010061367,0.020311853,0.0003200377],"about_ca_topic_score_codex":0.041473646,"about_ca_topic_score_gemma":0.018616518,"teacher_disagreement_score":0.041473646,"about_ca_system_score_codex":0.007717833,"about_ca_system_score_gemma":0.0016205712,"threshold_uncertainty_score":0.082464516},"labels":[],"label_agreement":null},{"id":"W4391749439","doi":"10.1080/13696998.2024.2314429","title":"Economic burden and secondary complications of influenza-related hospitalization among adults in the US: a retrospective cohort study","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Medicine; Retrospective cohort study; Cohort; Health care; Emergency medicine; Cohort study; Environmental health; Medical costs; Economic impact analysis; Intensive care medicine; Pediatrics; Internal medicine","score_opus":0.017877827480009743,"score_gpt":0.3360064667503775,"score_spread":0.3181286392703677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391749439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971238,0.00027752476,0.00009274902,0.00003855595,0.000007453378,0.00002705405,0.0021179996,0.0000031063191,0.00031161404],"genre_scores_gemma":[0.9980281,0.00018582828,0.00010454316,0.000039540566,0.000011994617,0.000026257383,0.0015017779,0.0000015378372,0.00010046879],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994985,0.000094493706,0.00009355452,0.00011387598,0.00011154442,0.00008804304],"domain_scores_gemma":[0.99913293,0.00004510166,0.0005397743,0.00007860507,0.00010999855,0.00009358079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063490134,0.0003219868,0.00028991033,0.0009771283,0.00040395645,0.0005812437,0.0003144038,0.00031873348,0.0008917166],"category_scores_gemma":[0.0013402387,0.00028655832,0.0007189374,0.0013493018,0.00014383353,0.00045653826,0.0004290393,0.00044508473,0.00018772206],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002433083,0.000012737439,0.9995497,0.0000034726806,0.000047380465,0.000027404612,0.000013320298,0.000010129752,0.000025462428,0.000005160461,0.00006375106,0.00021709628],"study_design_scores_gemma":[0.000003852858,0.000049999842,0.9993474,0.000006263624,0.000026197507,0.00020796049,0.000089948495,0.00009487426,0.000018221068,0.0000061905557,0.00014690979,0.0000022582487],"about_ca_topic_score_codex":0.013808592,"about_ca_topic_score_gemma":0.016724616,"teacher_disagreement_score":0.013808592,"about_ca_system_score_codex":0.00034314473,"about_ca_system_score_gemma":0.00042096167,"threshold_uncertainty_score":0.027456403},"labels":[],"label_agreement":null},{"id":"W4393037974","doi":"10.1080/13696998.2024.2333683","title":"Assessing the economics of biologic and small molecule therapies for the treatment of moderate to severe ulcerative colitis in Japan: a cost per responder analysis of upadacitinib","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AbbVie Canada","keywords":"Medicine; Ulcerative colitis; Internal medicine; Intensive care medicine; Disease","score_opus":0.027120433038650665,"score_gpt":0.31007530068372613,"score_spread":0.2829548676450755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393037974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98232067,0.0028452794,0.009047244,0.0010246807,0.000053734395,0.0003182415,0.0015215587,0.000035165584,0.002833399],"genre_scores_gemma":[0.99541605,0.00058093993,0.0021317198,0.00010523257,0.000013629987,0.00013361318,0.0008015542,0.00001272022,0.00080458546],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9989637,0.00060214824,0.00004986971,0.00012886609,0.00008096221,0.00017434401],"domain_scores_gemma":[0.9961784,0.0024784815,0.00056571676,0.00012376255,0.00034535365,0.00030823555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003179568,0.0012639962,0.0018509765,0.0011752807,0.00047215942,0.0018404191,0.0014211831,0.0013577279,0.0028123548],"category_scores_gemma":[0.0059150155,0.00095249974,0.004040934,0.0012093564,0.00064045005,0.0014228061,0.0010741876,0.0014574475,0.0001244276],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002120561,0.0005195565,0.032417394,0.0005060539,0.0010694241,0.0006150831,0.00008511764,0.9495841,0.00062838563,0.0031927335,0.0012675085,0.007994065],"study_design_scores_gemma":[0.00050155283,0.0011753626,0.020638779,0.00013025608,0.001711695,0.00022658992,0.0004398842,0.9716429,0.0003643134,0.0019566747,0.0011331253,0.00007887476],"about_ca_topic_score_codex":0.05579844,"about_ca_topic_score_gemma":0.027230885,"teacher_disagreement_score":0.05579844,"about_ca_system_score_codex":0.008232651,"about_ca_system_score_gemma":0.004128414,"threshold_uncertainty_score":0.11094731},"labels":[],"label_agreement":null},{"id":"W4394612987","doi":"10.1080/13696998.2024.2340932","title":"Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); Vancouver Coastal Health","funders":"","keywords":"Medicine; Triptans; Phonophobia; Migraine; Photophobia; Nausea; Acute migraine; Calcitonin gene-related peptide; Vomiting; Migraine treatment; Anesthesia; Physical therapy; Pediatrics; Intensive care medicine; Internal medicine; Surgery; Alternative medicine; Placebo","score_opus":0.09629634190561051,"score_gpt":0.4055890361913808,"score_spread":0.30929269428577033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394612987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9305269,0.02315058,0.014583336,0.005896658,0.0003475248,0.0017384611,0.011197982,0.0002489696,0.012309602],"genre_scores_gemma":[0.9937784,0.0015848977,0.0016481295,0.00032705654,0.000017791363,0.00033740254,0.0012574226,0.000011634204,0.0010373485],"study_design_codex":"simulation_or_modeling","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977912,0.0016297161,0.00008135302,0.0001524773,0.000115111485,0.00023008152],"domain_scores_gemma":[0.99574786,0.003264537,0.00047330768,0.000061568244,0.00017038493,0.00028244467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037022277,0.0008214935,0.0022015162,0.00089778926,0.00020570651,0.0016946702,0.0011267118,0.0015330752,0.0063677174],"category_scores_gemma":[0.013397891,0.00065277884,0.0033748397,0.0008490276,0.00046893893,0.0012243481,0.0009116039,0.0014056037,0.0003063044],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03051181,0.0005831084,0.011275766,0.0023269048,0.0024196976,0.0004170025,0.00008188025,0.9033756,0.00040920536,0.0037268738,0.0043525593,0.04051963],"study_design_scores_gemma":[0.014177451,0.014474396,0.022766015,0.0022455945,0.0063298363,0.0007407442,0.00026317156,0.92704946,0.0006744334,0.006796158,0.0043324344,0.00015033295],"about_ca_topic_score_codex":0.026350686,"about_ca_topic_score_gemma":0.013116561,"teacher_disagreement_score":0.026350686,"about_ca_system_score_codex":0.006654388,"about_ca_system_score_gemma":0.0028200264,"threshold_uncertainty_score":0.05239457},"labels":[],"label_agreement":null},{"id":"W4394727331","doi":"10.1080/13696998.2024.2342749","title":"Costs associated with adverse events during treatment episodes for adult attention-deficit/hyperactivity disorder","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Attention deficit hyperactivity disorder; Medicine; Adverse effect; Psychiatry; Perspective (graphical); Attention deficit; Pediatrics; Internal medicine","score_opus":0.02027486281548536,"score_gpt":0.30703266958094594,"score_spread":0.2867578067654606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394727331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98234946,0.0047764876,0.0012761502,0.0010850665,0.000062857755,0.00020502854,0.006737694,0.000020684785,0.0034865155],"genre_scores_gemma":[0.996496,0.0008634227,0.000545086,0.00011131354,0.000056435438,0.00006327423,0.0016655086,0.0000031307202,0.00019586578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956318,0.001928341,0.00090003805,0.00037024106,0.0008792559,0.00029036202],"domain_scores_gemma":[0.9871781,0.0033874975,0.008157507,0.00022447,0.00066299597,0.00038944127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00236013,0.00026610238,0.0003874329,0.0013606106,0.00038466943,0.000936932,0.00033540273,0.00029284914,0.0025872162],"category_scores_gemma":[0.017040301,0.00017114394,0.0015085888,0.0017664025,0.00020850163,0.0006716391,0.0008351297,0.0007599081,0.00011368836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000677986,0.00017333604,0.9629112,0.00038497784,0.001272237,0.00018061264,0.0000938274,0.0021390615,0.00012447621,0.0007342797,0.0013995529,0.029908484],"study_design_scores_gemma":[0.000062762934,0.00034228765,0.99215066,0.00023509443,0.0005367404,0.00065044634,0.00017485853,0.0033842446,0.00016424777,0.0005964177,0.0016860374,0.000016388642],"about_ca_topic_score_codex":0.008097394,"about_ca_topic_score_gemma":0.011076259,"teacher_disagreement_score":0.008097394,"about_ca_system_score_codex":0.0022738543,"about_ca_system_score_gemma":0.001216191,"threshold_uncertainty_score":0.016498089},"labels":[],"label_agreement":null},{"id":"W4395043933","doi":"10.1080/13696998.2024.2345507","title":"Economic and healthcare resource utilization assessments of PET imaging in Coronary Artery Disease diagnosis: a systematic review and discussion of opportunities for future economic evaluations","year":2024,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Cardiac Imaging and Diagnostics","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"GE Healthcare","keywords":"Medicine; Coronary artery disease; Health care; Resource (disambiguation); Disease; Economic evaluation; Appropriate Use Criteria; Intensive care medicine; Cardiology; Pathology; Internal medicine; Economic growth","score_opus":0.09200519105737925,"score_gpt":0.4260465318408872,"score_spread":0.33404134078350795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395043933","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011497452,0.9936359,0.0009791787,0.0024488212,0.00022531419,0.00060798234,0.00041869347,0.000010429884,0.000523911],"genre_scores_gemma":[0.046996146,0.93961525,0.0059375395,0.0029491337,0.00039895021,0.0034761666,0.00041486393,0.000017735341,0.00019424265],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.91512454,0.055032652,0.019101555,0.0020634893,0.007683624,0.0009940835],"domain_scores_gemma":[0.6855312,0.28064996,0.020849993,0.00287392,0.009475779,0.0006192017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.10430682,0.0021838748,0.012044141,0.016806483,0.00084930065,0.006076926,0.0026409996,0.0030755803,0.0036388952],"category_scores_gemma":[0.2507692,0.0014189781,0.016247626,0.013952326,0.0016489923,0.0044674063,0.0022058056,0.002732731,0.00021830491],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036896573,0.00004106209,0.0016492069,0.9010873,0.027196731,0.00011459014,0.0002683935,0.0006315012,0.00010173922,0.002970552,0.002065021,0.06350492],"study_design_scores_gemma":[0.0003009264,0.00021648718,0.0033661523,0.90851855,0.06883657,0.00018864746,0.00032608229,0.0005113329,0.00017884646,0.0028710682,0.014630679,0.000054744054],"about_ca_topic_score_codex":0.0072403275,"about_ca_topic_score_gemma":0.01840978,"teacher_disagreement_score":0.10430682,"about_ca_system_score_codex":0.008864348,"about_ca_system_score_gemma":0.019969454,"threshold_uncertainty_score":0.5516338},"labels":[],"label_agreement":null},{"id":"W4400319636","doi":"10.1080/13696998.2024.2367919","title":"The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Insulet Corporation; Gilead Sciences; Novo Nordisk; Sanofi; AstraZeneca; Eli Lilly and Company; Roche Diabetes Care; Amgen","keywords":"Medicine; Observational study; Liraglutide; Type 2 diabetes; Dulaglutide; Exenatide; Health care; Diabetes mellitus; Glucagon-like peptide 1 receptor; Real world evidence; Intensive care medicine; Internal medicine; Family medicine; Agonist; Endocrinology","score_opus":0.03135285047652705,"score_gpt":0.3399828926197037,"score_spread":0.3086300421431767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400319636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969404,0.0005423654,0.000058443944,0.00011510002,0.0000048817283,0.00001593488,0.0019911632,0.0000034880852,0.00032823268],"genre_scores_gemma":[0.997166,0.0002094552,0.00010620242,0.00007445357,0.000014927767,0.000029175071,0.0022966692,0.0000021686315,0.0001008716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976162,0.0012111588,0.00024703596,0.00039115688,0.00026909413,0.00026541157],"domain_scores_gemma":[0.9956514,0.0007583988,0.0027097987,0.00019578752,0.000219086,0.00046545916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022056375,0.00052165467,0.0005565292,0.0014149069,0.00026103025,0.0013637098,0.0006139679,0.0008643908,0.0009963418],"category_scores_gemma":[0.004004481,0.0003167161,0.001180562,0.002354132,0.00040044478,0.0007849045,0.00083837,0.00056508015,0.00015439752],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028478447,0.000047332403,0.99780566,0.000016392543,0.00025752778,0.000059028836,0.000058048372,0.00018482214,0.000029708184,0.000026475798,0.00031908497,0.000911133],"study_design_scores_gemma":[0.00004473252,0.00009428323,0.9989304,0.000013830593,0.000054682696,0.000090566384,0.00012380125,0.00043605166,0.000012515365,0.000010074675,0.00018363012,0.0000053880294],"about_ca_topic_score_codex":0.036290172,"about_ca_topic_score_gemma":0.02931152,"teacher_disagreement_score":0.036290172,"about_ca_system_score_codex":0.002253338,"about_ca_system_score_gemma":0.00070799916,"threshold_uncertainty_score":0.07215786},"labels":[],"label_agreement":null},{"id":"W4400366419","doi":"10.1080/13696998.2024.2374645","title":"The economic impact of suboptimal treatment and treatment switch among patients with Crohn’s disease treated with a first-line biologic – A US retrospective claims database study","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Crohn's disease; Retrospective cohort study; Disease; Pediatrics; Database; Internal medicine","score_opus":0.006707122821189735,"score_gpt":0.248372093474541,"score_spread":0.24166497065335127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400366419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99533385,0.0008344161,0.00011000981,0.00017019668,0.0000089897185,0.000021280946,0.0029452748,0.0000032785313,0.0005726166],"genre_scores_gemma":[0.99721056,0.0002635563,0.00011815047,0.00007913335,0.000017543087,0.000016065436,0.0022396732,0.0000017401246,0.00005351424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972242,0.00093456823,0.0006160161,0.00036853013,0.00056570716,0.00029089133],"domain_scores_gemma":[0.9900412,0.0015778756,0.006844573,0.00049117225,0.00050997094,0.0005351953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019142211,0.00023343101,0.0005355041,0.0015729481,0.0004654071,0.0013618675,0.0004949956,0.00049986824,0.0011632318],"category_scores_gemma":[0.0076018176,0.00031140514,0.0011318615,0.003017711,0.00025921682,0.00067549705,0.00078073266,0.00091123255,0.0001252448],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015838603,0.0000398112,0.99819034,0.00001985923,0.00017784737,0.00003974792,0.000025656433,0.00016277525,0.000018651002,0.00004940933,0.00023054263,0.0008869713],"study_design_scores_gemma":[0.000022940027,0.00006998045,0.9974527,0.000038660844,0.00010574515,0.00025465374,0.00014155988,0.0014719154,0.000032415755,0.00006303122,0.0003379117,0.000008399676],"about_ca_topic_score_codex":0.016254807,"about_ca_topic_score_gemma":0.014032178,"teacher_disagreement_score":0.016254807,"about_ca_system_score_codex":0.0012904567,"about_ca_system_score_gemma":0.0007551555,"threshold_uncertainty_score":0.03232038},"labels":[],"label_agreement":null},{"id":"W4400741621","doi":"10.1080/13696998.2024.2379212","title":"Modelling the opportunity for cost-savings or patient access with biosimilar adalimumab and tocilizumab: a European perspective","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Fresenius Kabi","keywords":"Biosimilar; Medicine; Tocilizumab; Adalimumab; Intensive care medicine; Rheumatoid arthritis; Internal medicine","score_opus":0.08273379655443044,"score_gpt":0.3413688276508669,"score_spread":0.2586350310964365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400741621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.902322,0.005079153,0.04290564,0.0034264608,0.000119375196,0.00032662405,0.004698063,0.000095993055,0.041026622],"genre_scores_gemma":[0.9842317,0.0010381241,0.0068968413,0.0002265552,0.000027393278,0.00015064723,0.00070554,0.000026814812,0.0066964165],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9986701,0.0008300076,0.000039495502,0.00017634759,0.000071771974,0.0002122969],"domain_scores_gemma":[0.9949824,0.0040356815,0.00047068554,0.00012382092,0.0002091054,0.00017837629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002531611,0.0012803199,0.0009833131,0.0010276708,0.0003352047,0.0026780728,0.0014363088,0.0031876946,0.010203418],"category_scores_gemma":[0.0076479185,0.0007626016,0.0027495695,0.001265208,0.0007131059,0.0020252736,0.0010906798,0.00167362,0.0005167471],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005265108,0.0001657013,0.0032774666,0.00015164973,0.00017331447,0.00016932146,0.00006888756,0.9785997,0.00033514015,0.011523939,0.00066770695,0.0043404847],"study_design_scores_gemma":[0.00045981334,0.0004922322,0.0030358841,0.00014097607,0.00038945515,0.0001712995,0.0002308437,0.9754667,0.00045381882,0.014551815,0.004549505,0.000057628207],"about_ca_topic_score_codex":0.024444327,"about_ca_topic_score_gemma":0.010214124,"teacher_disagreement_score":0.024444327,"about_ca_system_score_codex":0.0034512875,"about_ca_system_score_gemma":0.0017006018,"threshold_uncertainty_score":0.04860413},"labels":[],"label_agreement":null},{"id":"W4402221900","doi":"10.1080/13696998.2024.2400856","title":"Societal costs and quality of life associated with arginase 1 deficiency in a European setting – a multinational, cross-sectional survey","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Metabolism and Genetic Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Inversago Pharma (Canada)","funders":"Immedica Pharma; Universitätsklinikum Heidelberg; Queen Mary University of London","keywords":"Medicine; Cross-sectional study; Multinational corporation; Quality of life (healthcare); Disease; Environmental health; Arginase; Cognitive impairment; Health care; Gerontology; Economic growth; Internal medicine; Pathology; Nursing","score_opus":0.026291049317596186,"score_gpt":0.3155181711262586,"score_spread":0.2892271218086624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402221900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99810314,0.00019499722,0.000033758868,0.000104138846,0.0000037312764,0.00000907281,0.0012491765,0.000001620526,0.0003004617],"genre_scores_gemma":[0.9985304,0.000166606,0.00005653356,0.00007128066,0.000005857661,0.000014206619,0.001067345,0.0000011200715,0.0000867055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885416,0.00057717046,0.00018219571,0.00014767413,0.00011990249,0.000118876625],"domain_scores_gemma":[0.99758625,0.00038123238,0.0014326227,0.00010736742,0.0001815261,0.00031102714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015844022,0.00032435916,0.00032860524,0.00093841145,0.00031966987,0.00081415405,0.00036130683,0.000653081,0.00095426786],"category_scores_gemma":[0.0031605333,0.00020481093,0.0008148995,0.0015725744,0.00028759427,0.0006933355,0.0008603746,0.00057665294,0.00018846238],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054625183,0.000053582484,0.9985851,0.000016193499,0.00008575515,0.000073555515,0.000093780196,0.000094551324,0.000029717752,0.000011647744,0.00020484044,0.0006966504],"study_design_scores_gemma":[0.0000053574113,0.00006289466,0.99918884,0.000012092182,0.000018842144,0.0001462661,0.0002513834,0.00016490654,0.00000933966,0.0000073017854,0.00012893003,0.000003872671],"about_ca_topic_score_codex":0.009410135,"about_ca_topic_score_gemma":0.008109548,"teacher_disagreement_score":0.009410135,"about_ca_system_score_codex":0.00073370535,"about_ca_system_score_gemma":0.0002947241,"threshold_uncertainty_score":0.018710732},"labels":[],"label_agreement":null},{"id":"W4402407314","doi":"10.1080/13696998.2024.2399438","title":"Clinical and economic impact of first-line or drug-naïve catheter ablation and delayed second-line catheter ablation for atrial fibrillation using a patient-level simulation model","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Atrial fibrillation; Ablation; Catheter ablation; Catheter; Cardiology; Internal medicine; Drug; Surgery; Anesthesia; Pharmacology","score_opus":0.12685746263441255,"score_gpt":0.41165732898621876,"score_spread":0.2847998663518062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402407314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9625823,0.0005583345,0.016412282,0.001937015,0.000088487985,0.00028891664,0.0039647976,0.000115845214,0.014051965],"genre_scores_gemma":[0.99358976,0.00020929199,0.0030173694,0.00014676266,0.000014525542,0.00017909138,0.0009520438,0.000012502719,0.0018785063],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99875987,0.0007527754,0.00004188208,0.00013510873,0.00008027709,0.00023014308],"domain_scores_gemma":[0.9912999,0.0067315297,0.00069639407,0.00016132758,0.0005905084,0.0005203134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020781227,0.0013579315,0.0013073101,0.0010058628,0.0005538036,0.0020724356,0.0016717297,0.0028918392,0.0070177545],"category_scores_gemma":[0.0073047457,0.00072339113,0.0021484718,0.0010044426,0.00078395405,0.001023175,0.0009997846,0.00180053,0.000326725],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017120007,0.000076468714,0.0026321204,0.00001854267,0.0000489055,0.000054426702,0.000012248327,0.99551105,0.000057635807,0.0008167892,0.00021441172,0.00038617413],"study_design_scores_gemma":[0.00017179386,0.00018638482,0.001250066,0.000013825283,0.000060585415,0.00002410204,0.00004752942,0.9972905,0.000063291904,0.0006370006,0.00024029391,0.000014538127],"about_ca_topic_score_codex":0.059550118,"about_ca_topic_score_gemma":0.024492016,"teacher_disagreement_score":0.059550118,"about_ca_system_score_codex":0.0043527232,"about_ca_system_score_gemma":0.003251749,"threshold_uncertainty_score":0.11840695},"labels":[],"label_agreement":null},{"id":"W4402836199","doi":"10.1080/13696998.2024.2407631","title":"Epidemiology and burden of chronic insomnia disorder in Europe: an analysis of the 2020 National Health and Wellness Survey","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Sleep and related disorders","field":"Psychology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Epidemiology; Insomnia; Chronic insomnia; Psychiatry; Environmental health; Gerontology; Family medicine; Internal medicine; Sleep disorder","score_opus":0.026938506276656244,"score_gpt":0.3539406247598802,"score_spread":0.32700211848322397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402836199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9736574,0.003355365,0.0003477741,0.00026955985,0.000037310627,0.00003478555,0.021269226,0.000024358498,0.0010042195],"genre_scores_gemma":[0.9795958,0.0011123427,0.0003237236,0.00018529067,0.0000336094,0.000052830255,0.018475294,0.0000058114188,0.00021536116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99926263,0.0002152382,0.00014147202,0.00016145906,0.00012717147,0.00009195178],"domain_scores_gemma":[0.9987368,0.00012239882,0.00064551,0.00007424698,0.00025120066,0.00016982279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002045542,0.00031020714,0.0004098381,0.0015260398,0.0002050798,0.0006914736,0.0004150694,0.00039428874,0.000538059],"category_scores_gemma":[0.0018265567,0.00019184026,0.0011031239,0.0024235386,0.00017178255,0.00036721933,0.00072321296,0.0002584274,0.00015700092],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004071134,0.000008683607,0.9982755,0.000024828596,0.000118643475,0.000016827624,0.00002566961,0.00009046334,0.000026079195,0.000020307863,0.00048146796,0.0008707424],"study_design_scores_gemma":[0.0000036695003,0.000011241303,0.9994492,0.000011321586,0.000020012747,0.00002778529,0.000047230216,0.00012560059,0.000007289277,0.000009168805,0.00028594292,0.000001560207],"about_ca_topic_score_codex":0.043049753,"about_ca_topic_score_gemma":0.02192387,"teacher_disagreement_score":0.043049753,"about_ca_system_score_codex":0.0007248251,"about_ca_system_score_gemma":0.00066602504,"threshold_uncertainty_score":0.08559835},"labels":[],"label_agreement":null},{"id":"W4403231560","doi":"10.1080/13696998.2024.2413284","title":"Out of focus but still relevant? Influenza-related resource utilization and vaccination coverage gaps in adults below 60 years of age with underlying conditions: an analysis of 2016–2024 real-world data in Germany","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Global Affairs Canada","funders":"","keywords":"Medicine; Real world data; Vaccination; Focus (optics); Environmental health; Demography; Virology; Data science","score_opus":0.08751726145509976,"score_gpt":0.4022338561713753,"score_spread":0.31471659471627556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403231560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8250921,0.07489671,0.0011350409,0.0038174025,0.00012420211,0.0001510131,0.09347765,0.000037519578,0.001268289],"genre_scores_gemma":[0.9765841,0.005865077,0.0005995389,0.00075757207,0.000050722327,0.00013120146,0.015901169,0.000011951984,0.00009860613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949944,0.0016311525,0.0015770263,0.00070357503,0.00056446943,0.0005292931],"domain_scores_gemma":[0.9904055,0.003799245,0.0043076817,0.0005591488,0.0006431039,0.00028529944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00561451,0.000436119,0.0012806169,0.004072417,0.0002470922,0.0013026871,0.000780774,0.00066807395,0.0011687753],"category_scores_gemma":[0.017300867,0.00039144856,0.0033011967,0.007438861,0.00038534217,0.0013711485,0.0012444314,0.0005900917,0.0001831616],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048239378,0.000053553114,0.9596755,0.0068055037,0.0067707594,0.00039225313,0.0008092355,0.0012838561,0.00013483579,0.00090815924,0.0059015383,0.016782323],"study_design_scores_gemma":[0.000056517394,0.000073675255,0.98144597,0.0037352066,0.003072043,0.00035633214,0.0010615415,0.0014242117,0.00014579788,0.0003548676,0.008234772,0.000039021346],"about_ca_topic_score_codex":0.043426134,"about_ca_topic_score_gemma":0.039176363,"teacher_disagreement_score":0.043426134,"about_ca_system_score_codex":0.0014556964,"about_ca_system_score_gemma":0.0022253648,"threshold_uncertainty_score":0.086346745},"labels":[],"label_agreement":null},{"id":"W4403787695","doi":"10.1080/13696998.2024.2422227","title":"Matching-adjusted indirect comparison of acalabrutinib versus ibrutinib in relapsed/refractory mantle cell lymphoma","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Ibrutinib; Mantle cell lymphoma; Medicine; Oncology; Internal medicine; Refractory (planetary science); Lymphoma; Chronic lymphocytic leukemia; Leukemia; Metallurgy","score_opus":0.0384226166842584,"score_gpt":0.3214999179717034,"score_spread":0.283077301287445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403787695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97010404,0.010139616,0.010576701,0.00029045096,0.00042990313,0.0017513152,0.0028177996,0.00010753412,0.0037825957],"genre_scores_gemma":[0.9949281,0.00047265293,0.0022496483,0.0001567198,0.0000606023,0.00069013226,0.0008000416,0.000011459585,0.0006306145],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.98388773,0.01318392,0.0008083484,0.00088018697,0.0009345028,0.000305281],"domain_scores_gemma":[0.99137187,0.0060372874,0.0014126567,0.0006728558,0.00031662232,0.0001887455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012432243,0.0010615992,0.001922244,0.0010091643,0.00022328072,0.0009509664,0.0008071435,0.0007230934,0.0060028587],"category_scores_gemma":[0.02081735,0.00025916862,0.0044248668,0.000707344,0.00045604128,0.0006194321,0.001068089,0.001046636,0.00026615744],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6953174,0.0016009005,0.04397469,0.003950977,0.14142074,0.00016281105,0.00021561596,0.013811702,0.0033597704,0.0031117825,0.001899692,0.091173805],"study_design_scores_gemma":[0.26458743,0.22735809,0.2098488,0.0010805546,0.16428408,0.00092350773,0.0004825098,0.082183495,0.013309792,0.01629243,0.01933996,0.00030927925],"about_ca_topic_score_codex":0.0008374243,"about_ca_topic_score_gemma":0.0009196649,"teacher_disagreement_score":0.012432243,"about_ca_system_score_codex":0.0007786794,"about_ca_system_score_gemma":0.0006570845,"threshold_uncertainty_score":0.06574881},"labels":[],"label_agreement":null},{"id":"W4404297940","doi":"10.1080/13696998.2024.2419721","title":"Healthcare resource utilization and costs associated with first versus subsequent use of cariprazine for bipolar I disorder","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AbbVie Canada","keywords":"Medicine; Health care; Bipolar disorder; Resource (disambiguation); Bipolar I disorder; Resource use; Psychiatry; Mania; Environmental science; Environmental resource management; Mood; Economics","score_opus":0.057437312655586804,"score_gpt":0.31017611298156134,"score_spread":0.2527388003259745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404297940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983323,0.0005327424,0.00004806436,0.00009329372,0.0000051418087,0.000013668537,0.0006943373,0.0000021801145,0.00027824193],"genre_scores_gemma":[0.9987845,0.00021699879,0.000086869615,0.000041750594,0.000019181487,0.000013276405,0.0007724056,0.0000011368182,0.00006398544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986828,0.00036450964,0.00021411982,0.00023715464,0.00024060276,0.00026078976],"domain_scores_gemma":[0.99645305,0.0005022626,0.002467036,0.00007499195,0.0001375067,0.00036505607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000785776,0.00024507934,0.00038132697,0.00084558217,0.00029454433,0.0007617797,0.0003006387,0.00032079822,0.0010299109],"category_scores_gemma":[0.004955544,0.0001735501,0.0010893849,0.000938129,0.00019331674,0.00041407783,0.00067311066,0.00065200974,0.000064857486],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027116115,0.000067637615,0.9960537,0.000018673216,0.00017973149,0.000052640626,0.000028510127,0.00024661986,0.000058916423,0.000032123316,0.00010978334,0.0028804208],"study_design_scores_gemma":[0.000011903886,0.00012238057,0.998728,0.000012467124,0.00004781499,0.00013159179,0.00008414736,0.00073619763,0.000031340496,0.000023420846,0.000067186345,0.000003562872],"about_ca_topic_score_codex":0.011924468,"about_ca_topic_score_gemma":0.020916231,"teacher_disagreement_score":0.011924468,"about_ca_system_score_codex":0.001155374,"about_ca_system_score_gemma":0.0006265189,"threshold_uncertainty_score":0.023710132},"labels":[],"label_agreement":null},{"id":"W4404611184","doi":"10.1080/13696998.2024.2431413","title":"A US payer budget impact analysis of Flurpiridaz-PET-MPI compared to SPECT-MPI in the diagnosis of coronary artery disease","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cardiac Imaging and Diagnostics","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"GE Healthcare","keywords":"Medicine; Coronary artery disease; Cardiology; Internal medicine","score_opus":0.016928077055500534,"score_gpt":0.32028627512266167,"score_spread":0.30335819806716113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404611184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7716251,0.0052039707,0.110568896,0.014103569,0.00045812957,0.001395561,0.015225699,0.0003863609,0.08103282],"genre_scores_gemma":[0.97995454,0.00085988914,0.007784248,0.0005806926,0.000054514905,0.000517186,0.0014456037,0.00003316678,0.008770121],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9976665,0.0014791853,0.000057678415,0.0002462287,0.00015731654,0.0003931183],"domain_scores_gemma":[0.99450266,0.004223295,0.00044950267,0.00010059701,0.00038428922,0.00033960657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004888555,0.0012326544,0.0018124465,0.0020311137,0.0006346097,0.0031867975,0.0020019133,0.0028791788,0.0068898336],"category_scores_gemma":[0.012211566,0.0010210288,0.0022207575,0.001958119,0.0010936831,0.0017031075,0.0015691052,0.0021566092,0.00037885507],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028779396,0.000076523356,0.0028281545,0.00006167695,0.00011043023,0.00011531399,0.000022889913,0.9849325,0.000076924174,0.0077180704,0.0012746397,0.0024950951],"study_design_scores_gemma":[0.00021591217,0.00028492903,0.0022551848,0.000073851465,0.00020935107,0.00008598358,0.00011090362,0.98804873,0.0000940083,0.0065702926,0.002018208,0.000032654178],"about_ca_topic_score_codex":0.04643713,"about_ca_topic_score_gemma":0.018745996,"teacher_disagreement_score":0.04643713,"about_ca_system_score_codex":0.008874965,"about_ca_system_score_gemma":0.005252818,"threshold_uncertainty_score":0.092333674},"labels":[],"label_agreement":null},{"id":"W4405289127","doi":"10.1080/13696998.2024.2441072","title":"Cost-effectiveness analysis of radiofrequency renal denervation for uncontrolled hypertension in Canada","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; McGill University; Jewish General Hospital; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Medtronic (Canada); University of British Columbia; NOSM University; Western University; St. Michael's Hospital","funders":"","keywords":"Medicine; Denervation; Resistant hypertension; Internal medicine; Intensive care medicine; Blood pressure; Cardiology","score_opus":0.05458691882545098,"score_gpt":0.30531858271235324,"score_spread":0.25073166388690227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405289127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9067393,0.028556796,0.0066699986,0.006433123,0.00016819237,0.0019419782,0.025609558,0.00016396548,0.023717104],"genre_scores_gemma":[0.990218,0.0033539217,0.002376797,0.00022956777,0.000016762997,0.00014896746,0.002371552,0.000012466411,0.0012719256],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.997995,0.00072220224,0.000089774876,0.00015428527,0.00058548857,0.00045327205],"domain_scores_gemma":[0.99644756,0.0016287707,0.0003205043,0.00007628552,0.0011303526,0.00039647147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002990863,0.0008168747,0.0011887347,0.0015364351,0.00089320086,0.0016381914,0.0014899203,0.0007121467,0.0034079948],"category_scores_gemma":[0.010782015,0.00046693106,0.0026464413,0.0026170637,0.00059468334,0.0004792002,0.0007711392,0.0010717777,0.00008777762],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0123486435,0.0009085528,0.083278894,0.0052553727,0.007917084,0.0007702865,0.00035913353,0.76165634,0.0011374437,0.022056773,0.015763503,0.08854801],"study_design_scores_gemma":[0.006475553,0.0026817713,0.15187396,0.001924431,0.010824285,0.00048187643,0.0009107124,0.8007796,0.0014256913,0.006879124,0.015398011,0.00034490938],"about_ca_topic_score_codex":0.9784693,"about_ca_topic_score_gemma":0.96831435,"teacher_disagreement_score":0.10164471,"about_ca_system_score_codex":0.10164471,"about_ca_system_score_gemma":0.08712891,"threshold_uncertainty_score":0.73748744},"labels":[],"label_agreement":null},{"id":"W4405379562","doi":"10.1080/13696998.2024.2442240","title":"Real-world healthcare resource utilization of Alzheimer’s disease in the early and advanced stages: a retrospective cohort study","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novo Nordisk","keywords":"Medicine; Retrospective cohort study; Disease; Health care; Cohort; Emergency medicine; Internal medicine","score_opus":0.03722525300815707,"score_gpt":0.3788974881855275,"score_spread":0.34167223517737044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405379562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996642,0.0004166904,0.00025193128,0.000028439035,0.000007662093,0.000040722436,0.0023352746,0.00000429768,0.00027299483],"genre_scores_gemma":[0.9975446,0.00027305246,0.00018183731,0.000033092023,0.000012242484,0.00004343634,0.0018048421,0.0000034326793,0.00010340207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986124,0.00036021165,0.00023365299,0.00037883583,0.00022997045,0.00018488798],"domain_scores_gemma":[0.9975084,0.00034227417,0.0013067159,0.00039870467,0.00020918592,0.00023463734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001845099,0.00042868304,0.00053082086,0.0013124864,0.00047150123,0.0009105231,0.0005533018,0.0005207877,0.0010689043],"category_scores_gemma":[0.0030801685,0.0005943018,0.0010389967,0.0022364894,0.0003029422,0.0008038641,0.0007936285,0.0005763117,0.0002467619],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008595123,0.000024197829,0.9989831,0.000012474639,0.00015248005,0.000047749407,0.000050327675,0.000045584406,0.00004659052,0.000020747953,0.00008962967,0.00044117184],"study_design_scores_gemma":[0.000014998795,0.00008418045,0.99882823,0.000011467865,0.00006495396,0.00023043204,0.00016282583,0.00026805178,0.000027443553,0.000025440751,0.00027452726,0.000007420589],"about_ca_topic_score_codex":0.012066517,"about_ca_topic_score_gemma":0.012609564,"teacher_disagreement_score":0.012066517,"about_ca_system_score_codex":0.0004511629,"about_ca_system_score_gemma":0.00049544836,"threshold_uncertainty_score":0.023992538},"labels":[],"label_agreement":null},{"id":"W4405519798","doi":"10.1080/13696998.2024.2444157","title":"Systematic review of cost-effectiveness modelling studies for haemophilia","year":2024,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Medicine; Haemophilia; Cost effectiveness; Intensive care medicine; Systematic review; MEDLINE; Medical physics; Surgery; Risk analysis (engineering)","score_opus":0.2853292764518334,"score_gpt":0.5007652775846267,"score_spread":0.21543600113279332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405519798","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018247672,0.9921841,0.0015906038,0.00054921856,0.00019818514,0.00069052336,0.0022390033,0.000044965036,0.00067863887],"genre_scores_gemma":[0.0761352,0.91352105,0.0056099934,0.000729181,0.00017041931,0.002098901,0.0014806549,0.000042530173,0.00021211292],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9758809,0.015206315,0.004974683,0.0011658991,0.0023772435,0.0003948713],"domain_scores_gemma":[0.9172433,0.0705327,0.0074081183,0.0012926564,0.003228365,0.00029483106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022680724,0.0036379895,0.012569262,0.011744894,0.0005482341,0.0038480982,0.003330804,0.0026675467,0.008786374],"category_scores_gemma":[0.09408554,0.0017528371,0.02479119,0.010225773,0.00074447575,0.002336147,0.001812726,0.0024586222,0.0004530615],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005872997,0.000035034867,0.0007770531,0.8874189,0.07426765,0.000111612426,0.00007687781,0.0035392907,0.00008892283,0.0013423426,0.0018611094,0.029893955],"study_design_scores_gemma":[0.0011874657,0.00049401994,0.0034964008,0.6492969,0.31976795,0.00032552544,0.00016202532,0.0025462923,0.00023931426,0.0032715863,0.01911175,0.000100817495],"about_ca_topic_score_codex":0.014209851,"about_ca_topic_score_gemma":0.02068105,"teacher_disagreement_score":0.022680724,"about_ca_system_score_codex":0.008957587,"about_ca_system_score_gemma":0.011520159,"threshold_uncertainty_score":0.119948626},"labels":[],"label_agreement":null},{"id":"W4406230605","doi":"10.1080/13696998.2025.2451526","title":"Cost-effectiveness of finerenone therapy for patients with chronic kidney disease and type 2 diabetes in England &amp; Wales: results of the FINE-CKD model","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Chronic Kidney Disease and Diabetes","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Kidney disease; Type 2 diabetes; Diabetes mellitus; Internal medicine; Disease; Comorbidity; Intensive care medicine; Endocrinology","score_opus":0.01777631396868015,"score_gpt":0.28133102631907003,"score_spread":0.2635547123503899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406230605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724849,0.0046684677,0.0057594934,0.0023983817,0.00014369267,0.00060204265,0.0063099307,0.00006152423,0.0075716823],"genre_scores_gemma":[0.993624,0.0006859254,0.0016431836,0.00027226732,0.000025493704,0.00018326657,0.0021298379,0.000013915997,0.0014222704],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99793917,0.0014174595,0.00008401774,0.00018447317,0.00010116822,0.0002738224],"domain_scores_gemma":[0.99365234,0.0049021346,0.0005182562,0.0001944892,0.00033024434,0.00040255618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056497497,0.0010529076,0.0031384677,0.00071869104,0.0002937686,0.0015056388,0.0016632314,0.001103436,0.0050934614],"category_scores_gemma":[0.0119584035,0.0006715213,0.0048268302,0.0006808041,0.0005081345,0.0011376755,0.0017029494,0.0018261726,0.00029097695],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011797446,0.0006801987,0.045875512,0.0015783557,0.0037240428,0.0006402997,0.00019134558,0.9076863,0.0003665971,0.008367501,0.0054145525,0.013677886],"study_design_scores_gemma":[0.0067671277,0.0040809913,0.053711217,0.0007645024,0.004993221,0.0005586124,0.0005849952,0.91237265,0.0002839373,0.011358764,0.0043300013,0.00019400213],"about_ca_topic_score_codex":0.06405777,"about_ca_topic_score_gemma":0.036782082,"teacher_disagreement_score":0.06405777,"about_ca_system_score_codex":0.0037789803,"about_ca_system_score_gemma":0.003321703,"threshold_uncertainty_score":0.12736982},"labels":[],"label_agreement":null},{"id":"W4406690128","doi":"10.1080/13696998.2025.2457872","title":"Healthcare resource utilization and costs of using cariprazine as the first versus subsequent adjunctive therapy for major depressive disorder","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Treatment of Major Depression","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Health care; Major depressive disorder; Intensive care medicine; Psychiatry; Mood","score_opus":0.045006711778151035,"score_gpt":0.3490403308563574,"score_spread":0.30403361907820636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406690128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99576,0.0025346694,0.000071792914,0.00024814816,0.000015396214,0.000015586855,0.00096509035,0.000002839706,0.00038635658],"genre_scores_gemma":[0.99841666,0.00064057106,0.000090047026,0.000062351326,0.000017548366,0.0000139063595,0.0006950177,0.0000012267633,0.000062760104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831486,0.0006325237,0.00025651377,0.0002570888,0.0002685599,0.00027050212],"domain_scores_gemma":[0.9976432,0.00061719836,0.001334568,0.00005566361,0.00012372289,0.00022566544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011241442,0.00026356027,0.000519264,0.00079112244,0.00019322109,0.0008899566,0.00041355612,0.000388891,0.0010589482],"category_scores_gemma":[0.0065671857,0.00023476576,0.0019027268,0.0010603347,0.00020876901,0.0005274769,0.00070396875,0.00075968646,0.00007417513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018361137,0.00016267896,0.98319244,0.00015983002,0.0015772792,0.00009047309,0.00007220667,0.0012069765,0.000112049594,0.00022893088,0.00062906696,0.010731995],"study_design_scores_gemma":[0.000121859055,0.0005954444,0.9929074,0.00012835604,0.0007668295,0.0002650243,0.0003302669,0.004230082,0.00010418466,0.00019286576,0.00034179867,0.00001593694],"about_ca_topic_score_codex":0.01704705,"about_ca_topic_score_gemma":0.022209605,"teacher_disagreement_score":0.01704705,"about_ca_system_score_codex":0.0021582104,"about_ca_system_score_gemma":0.0008679376,"threshold_uncertainty_score":0.03389567},"labels":[],"label_agreement":null},{"id":"W4407741494","doi":"10.1080/13696998.2025.2470014","title":"The real-world impact of cariprazine on short- and long-term disability outcomes among commercially insured patients in the United States","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Term (time); Gerontology; Actuarial science; Demography; Economics","score_opus":0.025189035262283416,"score_gpt":0.36745650372665334,"score_spread":0.34226746846436995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407741494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99355245,0.0018748904,0.00007881998,0.00055909576,0.000012141158,0.000011269739,0.003310303,0.0000052985633,0.00059562665],"genre_scores_gemma":[0.9979545,0.00048538524,0.000073958814,0.000111021196,0.000020132822,0.000007632853,0.0012768479,0.0000013403479,0.00006917672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886763,0.0003720726,0.00015355594,0.00020773997,0.0002256261,0.00017327687],"domain_scores_gemma":[0.9945259,0.00095013494,0.0036312072,0.00013459114,0.00030612052,0.0004520888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012071179,0.00019948855,0.00024469616,0.00063939433,0.0002686252,0.0009328418,0.00032124046,0.00037705354,0.0010882113],"category_scores_gemma":[0.0058285,0.00013568603,0.0006293113,0.00084244163,0.0002917086,0.00058835273,0.000757241,0.00068698573,0.000115315626],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032724452,0.000064396605,0.9942093,0.00005871302,0.00023085784,0.00007441036,0.000047669655,0.00033139353,0.00006750967,0.00007720595,0.00048058727,0.00403075],"study_design_scores_gemma":[0.000020418234,0.00013274449,0.99802566,0.000041875566,0.0001041549,0.00016168112,0.00020606039,0.00081142725,0.000049889066,0.00005563479,0.00038442007,0.000006182168],"about_ca_topic_score_codex":0.021608977,"about_ca_topic_score_gemma":0.03243825,"teacher_disagreement_score":0.021608977,"about_ca_system_score_codex":0.0011884691,"about_ca_system_score_gemma":0.0006091447,"threshold_uncertainty_score":0.042966425},"labels":[],"label_agreement":null},{"id":"W4408054087","doi":"10.1080/13696998.2025.2473810","title":"Cost-effectiveness of wastewater and environmental monitoring of respiratory syncytial virus to guide universal infant immunoprophylaxis in Canada","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Respiratory viral infections research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Children's Hospital of Eastern Ontario; McMaster University; Hamilton Health Sciences; University of Ottawa","funders":"Natural Sciences and Engineering Research Council of Canada; Public Health Agency of Canada","keywords":"Medicine; Respiratory system; Cost effectiveness; Environmental health; Virology; Pediatrics; Intensive care medicine; Internal medicine; Risk analysis (engineering)","score_opus":0.02631463215619173,"score_gpt":0.3251406147955996,"score_spread":0.29882598263940785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408054087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9610038,0.0047435407,0.005004953,0.0037447044,0.00006939497,0.0005569665,0.0078012077,0.00014668208,0.016928721],"genre_scores_gemma":[0.9950759,0.00081858976,0.00143347,0.00011165691,0.0000049531222,0.00003950972,0.00085812964,0.000011378734,0.0016465046],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99772185,0.0006053101,0.00007007622,0.00021008484,0.0004104253,0.0009822707],"domain_scores_gemma":[0.9965305,0.001232334,0.00038287803,0.00006932153,0.0010481719,0.0007368898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022308836,0.0010439482,0.00091274595,0.0012590644,0.0012285355,0.0021865051,0.0018006157,0.0009449854,0.0031195292],"category_scores_gemma":[0.00688605,0.00061369146,0.0014830579,0.0015992557,0.001060552,0.0007469837,0.0011209117,0.0012064214,0.00011738261],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001450325,0.00020185787,0.0463347,0.00033122228,0.0003871973,0.00019901739,0.00008807826,0.9225825,0.0004273225,0.006478886,0.0032538527,0.01826518],"study_design_scores_gemma":[0.00063151587,0.0006824949,0.055078905,0.00021833369,0.0005110929,0.00010644845,0.00051687815,0.93453723,0.0008033921,0.002661884,0.004155711,0.0000961523],"about_ca_topic_score_codex":0.98880345,"about_ca_topic_score_gemma":0.98550814,"teacher_disagreement_score":0.13873672,"about_ca_system_score_codex":0.13873672,"about_ca_system_score_gemma":0.07805382,"threshold_uncertainty_score":0.9989433},"labels":[],"label_agreement":null},{"id":"W4408507154","doi":"10.1080/13696998.2025.2480479","title":"Bridging the gap in public healthcare services in developing countries: lessons from the family doctor contract services in China","year":2025,"lang":"en","type":"editorial","venue":"Journal of Medical Economics","topic":"Healthcare Systems and Reforms","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Bridging (networking); Medicine; China; Developing country; Health care; Family medicine; Nursing; Public relations; Economic growth; Political science; Law","score_opus":0.03394145539510101,"score_gpt":0.29999454107634044,"score_spread":0.2660530856812394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408507154","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018705221,0.0125579005,0.00009154233,0.19498558,0.790844,0.000013418042,0.00011331298,0.000014220189,0.0011929282],"genre_scores_gemma":[0.0029245045,0.012698812,0.00012333429,0.053638414,0.92581284,0.000025564395,0.00004589377,0.000026754566,0.004703797],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944455,0.0014594331,0.0008191818,0.00047992458,0.00229627,0.0004997777],"domain_scores_gemma":[0.9319936,0.049261387,0.0013789152,0.0007488017,0.01279968,0.003817665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018776681,0.0019337614,0.0029774779,0.003422522,0.004303595,0.010975379,0.003431322,0.022225827,0.0055318377],"category_scores_gemma":[0.0578517,0.0007885735,0.002241352,0.0037333376,0.0041912715,0.0064399084,0.0021537778,0.02482102,0.0013483012],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023214609,0.000013413768,0.000092105845,0.00027741818,0.00003449443,0.00014841382,0.000104092556,0.000036277772,0.000011819842,0.0015752623,0.9928114,0.0048721554],"study_design_scores_gemma":[0.00015923684,0.000042211952,0.002873023,0.0024270418,0.0002504741,0.00017799086,0.0009843295,0.00038276715,0.00009827893,0.005860539,0.98667175,0.00007239967],"about_ca_topic_score_codex":0.025535474,"about_ca_topic_score_gemma":0.06307723,"teacher_disagreement_score":0.025535474,"about_ca_system_score_codex":0.006164021,"about_ca_system_score_gemma":0.015253635,"threshold_uncertainty_score":0.099301815},"labels":[],"label_agreement":null},{"id":"W4408993723","doi":"10.1080/13696998.2025.2482372","title":"Characterizing the clinical and economic burden of COVID-19 among individuals with immunocompromising conditions in Ontario, Canada – a matched, population-based observational study","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Observational study; Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Vaccination; 2019-20 coronavirus outbreak; Population; Demography; Pediatrics; Gerontology; Family medicine; Internal medicine; Virology; Environmental health; Outbreak; Disease","score_opus":0.08074085739630515,"score_gpt":0.38380382450014033,"score_spread":0.3030629671038352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408993723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941261,0.0003397954,0.00007502452,0.00012186396,0.000006377638,0.000061304934,0.004406349,0.000003869517,0.00085922383],"genre_scores_gemma":[0.9970901,0.00024780422,0.000093421346,0.00008066098,0.000008008263,0.000028990804,0.0021618332,0.0000019556899,0.0002871801],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992188,0.00006944427,0.000081014936,0.00014007073,0.00021419511,0.0002764454],"domain_scores_gemma":[0.99824107,0.0000842481,0.00068681245,0.00009917069,0.00047132833,0.00041732297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000518668,0.00032921482,0.0004487607,0.00093281106,0.001753721,0.0010066939,0.00087594707,0.000394213,0.0013822588],"category_scores_gemma":[0.0017848689,0.00033924374,0.0007017931,0.0030240861,0.00052462035,0.00035545032,0.0008314509,0.00061059813,0.0001622205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034481538,0.000016983508,0.998659,0.00001742176,0.000039896076,0.00004440147,0.00019401073,0.000036595095,0.00005890126,0.000022695556,0.0003483078,0.00052712165],"study_design_scores_gemma":[0.000004934143,0.000016927577,0.99911183,0.000014196102,0.00001387266,0.000039995517,0.00035799394,0.00011172778,0.000010342639,0.000007752952,0.000306949,0.0000034626294],"about_ca_topic_score_codex":0.9713516,"about_ca_topic_score_gemma":0.9801112,"teacher_disagreement_score":0.028648376,"about_ca_system_score_codex":0.015909893,"about_ca_system_score_gemma":0.014349097,"threshold_uncertainty_score":0.115434885},"labels":[],"label_agreement":null},{"id":"W4409981668","doi":"10.1080/13696998.2025.2499333","title":"Cost-effectiveness analysis of implementing 20-valent pneumococcal conjugate vaccine into the Romanian pediatric national immunization program","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Pneumonia and Respiratory Infections","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Medicine; Pneumococcal conjugate vaccine; Immunization program; Immunization; Pediatrics; Conjugate; Vaccination; Romanian; Pneumococcal vaccination; Streptococcus pneumoniae; Virology; Immunology; Antibody; Antibiotics","score_opus":0.024306054771491812,"score_gpt":0.3696598415264782,"score_spread":0.34535378675498635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409981668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9686393,0.0051719565,0.012512161,0.0015912503,0.00013850023,0.00075390434,0.0018539187,0.000059536116,0.009279592],"genre_scores_gemma":[0.99595815,0.0007858636,0.0022910156,0.000088791414,0.000014068939,0.00017953986,0.00031364994,0.0000051592287,0.00036375358],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99616635,0.0030031265,0.00008999483,0.00021676335,0.00014662383,0.0003771619],"domain_scores_gemma":[0.99405366,0.004574844,0.00061895186,0.00013735572,0.00036418607,0.0002510454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056691985,0.00095341675,0.0014664284,0.0008767416,0.00028811902,0.0011180462,0.0013324978,0.0009429928,0.0049309637],"category_scores_gemma":[0.01392112,0.00051122747,0.0025677066,0.00071301014,0.0004921591,0.00087153964,0.0011470191,0.0012949014,0.00013891706],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036077017,0.00043574767,0.012805506,0.00068620563,0.0010097551,0.00022909006,0.00004427007,0.96325475,0.00031370137,0.0031162396,0.00071421766,0.0137827685],"study_design_scores_gemma":[0.0018917137,0.0053221122,0.020313654,0.0006483495,0.0028647543,0.0003244949,0.00029018463,0.96255004,0.000731202,0.0030617046,0.0019434061,0.000058398637],"about_ca_topic_score_codex":0.021785535,"about_ca_topic_score_gemma":0.008954777,"teacher_disagreement_score":0.021785535,"about_ca_system_score_codex":0.0058931354,"about_ca_system_score_gemma":0.0055690217,"threshold_uncertainty_score":0.043317437},"labels":[],"label_agreement":null},{"id":"W4410031891","doi":"10.1080/13696998.2025.2498853","title":"Axicabtagene ciloleucel compared to standard of care in Canadian patients with relapsed or refractory large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"EVERSANA (Canada); Spinal Cord Injury BC; University of British Columbia; Princess Margaret Cancer Centre","funders":"Gilead Sciences","keywords":"Medicine; Refractory (planetary science); Standard of care; Lymphoma; Oncology; Internal medicine; Pediatrics; Family medicine","score_opus":0.01783357241865267,"score_gpt":0.319916550429289,"score_spread":0.3020829780106363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410031891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93977696,0.031628143,0.0012999146,0.0042189816,0.00022239519,0.0014296857,0.011482383,0.0001405079,0.009801118],"genre_scores_gemma":[0.99089956,0.0035103306,0.0011652816,0.00047229,0.000036553443,0.00023513185,0.0029078457,0.000013789212,0.0007592368],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.998287,0.0011106143,0.000054390945,0.00012195345,0.0002290475,0.00019686879],"domain_scores_gemma":[0.99798644,0.000890844,0.00037348593,0.000071293616,0.000249026,0.00042893126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029726333,0.00133553,0.0016940767,0.0006947165,0.0005739125,0.0013010318,0.0017318503,0.0010394838,0.0039348598],"category_scores_gemma":[0.0069330684,0.00037506563,0.0037257685,0.0011104996,0.0006741378,0.0005489332,0.00068810914,0.0017561419,0.00015271489],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42116868,0.003505577,0.05409101,0.009666891,0.03160273,0.00042639236,0.00029014,0.28277564,0.0014303748,0.007510363,0.02327728,0.16425493],"study_design_scores_gemma":[0.2832828,0.033435114,0.114468,0.0033181652,0.041847706,0.0005418621,0.0006798781,0.49669874,0.001327808,0.006330459,0.01761445,0.00045503603],"about_ca_topic_score_codex":0.7504809,"about_ca_topic_score_gemma":0.78203195,"teacher_disagreement_score":0.24951911,"about_ca_system_score_codex":0.036038063,"about_ca_system_score_gemma":0.025681658,"threshold_uncertainty_score":0.5019771},"labels":[],"label_agreement":null},{"id":"W4410568479","doi":"10.1080/13696998.2025.2503660","title":"Cost-effectiveness of enzalutamide with androgen-deprivation therapy (ADT) versus ADT alone for the treatment of high-risk biochemically recurrent non-metastatic castration-sensitive prostate cancer in Canada","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"Sanofi; AstraZeneca; Pfizer; Astellas Pharma; Bristol-Myers Squibb","keywords":"Enzalutamide; Medicine; Androgen deprivation therapy; Prostate cancer; Oncology; Internal medicine; Castration; Androgen; Cancer; Androgen receptor; Hormone","score_opus":0.03357280887964614,"score_gpt":0.33903134205413193,"score_spread":0.3054585331744858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410568479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9396955,0.017438697,0.0051283664,0.0036815898,0.0001688172,0.0021647129,0.019958293,0.0001423784,0.011621685],"genre_scores_gemma":[0.9913669,0.002339918,0.0017395271,0.00021445156,0.000015462821,0.00020309135,0.00298399,0.000011190955,0.0011254213],"study_design_codex":"simulation_or_modeling","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985977,0.0005938068,0.0000648402,0.00014554583,0.00025691892,0.00034122128],"domain_scores_gemma":[0.9979225,0.0010169579,0.00034811615,0.00005073542,0.00026198066,0.00039987644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026678615,0.0009467329,0.0018043065,0.0009019643,0.000562774,0.0014823723,0.0014932404,0.0007325575,0.0038969468],"category_scores_gemma":[0.00693056,0.0005573998,0.0035957356,0.0010534689,0.0006551298,0.0005887025,0.0007879471,0.0013739575,0.00014676174],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056212645,0.0008390345,0.042727526,0.0032497663,0.00857064,0.0003646013,0.00013441245,0.8105147,0.0010092525,0.0076991683,0.008256852,0.060421433],"study_design_scores_gemma":[0.017188717,0.0066390126,0.07798642,0.0017036758,0.013324414,0.0004879263,0.00034723344,0.86597115,0.0014585749,0.006854813,0.0077845724,0.0002534959],"about_ca_topic_score_codex":0.8266618,"about_ca_topic_score_gemma":0.8173751,"teacher_disagreement_score":0.17333817,"about_ca_system_score_codex":0.04228611,"about_ca_system_score_gemma":0.03582688,"threshold_uncertainty_score":0.348718},"labels":[],"label_agreement":null},{"id":"W4410888471","doi":"10.1080/13696998.2025.2513766","title":"Real-world effectiveness of cariprazine in major depressive disorder and bipolar I disorder in the United States","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Treatment of Major Depression","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Bausch Health; AbbVie Canada; H. Lundbeck A/S; National Natural Science Foundation of China; Eisai; Purdue University; Biogen; Canadian Institutes of Health Research; Sunovion; Novo Nordisk; Sanofi; Pfizer","keywords":"Medicine; Bipolar disorder; Major depressive disorder; Psychiatry; Bipolar I disorder; Mania; Mood","score_opus":0.007955991016454639,"score_gpt":0.2904175366401365,"score_spread":0.28246154562368186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410888471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928571,0.0016657055,0.00028848092,0.00095476245,0.000023312074,0.00008371536,0.0031302364,0.00002393504,0.0009726403],"genre_scores_gemma":[0.9975853,0.00037654483,0.00043451082,0.00028469088,0.00002128158,0.000028811362,0.001220249,0.0000024010947,0.000046119796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99669755,0.00200479,0.0003241589,0.00043076198,0.00039784296,0.00014504405],"domain_scores_gemma":[0.98965186,0.0050150934,0.004059586,0.00038332233,0.00046005918,0.00043010406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004510221,0.00021837237,0.00044639854,0.00035082936,0.0002507661,0.0008842263,0.00041157808,0.00038980707,0.00077908393],"category_scores_gemma":[0.015476429,0.00018605698,0.00065147365,0.00062621565,0.00032643642,0.000494148,0.00050225726,0.0004962644,0.00008433859],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065914528,0.0011374538,0.93732196,0.00041363755,0.0013468522,0.00019394254,0.00012832848,0.012727727,0.00051129714,0.00034883415,0.0038543812,0.035424147],"study_design_scores_gemma":[0.0012176471,0.0032794508,0.9643841,0.00015348973,0.0008662883,0.00037542835,0.00040412246,0.02583321,0.0006182392,0.00037115108,0.0024571896,0.000039679293],"about_ca_topic_score_codex":0.018616958,"about_ca_topic_score_gemma":0.019725272,"teacher_disagreement_score":0.018616958,"about_ca_system_score_codex":0.001348393,"about_ca_system_score_gemma":0.0008255112,"threshold_uncertainty_score":0.037017167},"labels":[],"label_agreement":null},{"id":"W4412387662","doi":"10.1080/13696998.2025.2530862","title":"Cost-effectiveness analysis of pembrolizumab as an adjuvant treatment of early-stage non-small cell lung cancer following complete resection and platinum-based chemotherapy in Canada","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Merck Canada Inc. (Canada)","funders":"","keywords":"Medicine; Pembrolizumab; Stage (stratigraphy); Chemotherapy; Oncology; Lung cancer; Adjuvant chemotherapy; Adjuvant; Cancer; Internal medicine; Resection; Surgery; Immunotherapy","score_opus":0.024088500101018588,"score_gpt":0.3212812795561362,"score_spread":0.29719277945511763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412387662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9497473,0.02459807,0.0019842514,0.004664712,0.00014751835,0.0011708953,0.01149193,0.00008469836,0.0061106915],"genre_scores_gemma":[0.9932213,0.0028650714,0.0009354237,0.0003000132,0.000017735747,0.00012379415,0.0019917546,0.000009040324,0.0005357714],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.997875,0.0008687477,0.0001176394,0.00021141655,0.0004526957,0.0004745129],"domain_scores_gemma":[0.9967577,0.0010853582,0.0005958561,0.00009215142,0.0007461834,0.00072273763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029543205,0.00094231375,0.0015100404,0.001235003,0.00067393127,0.0015918245,0.0015148628,0.00092066533,0.0022860167],"category_scores_gemma":[0.010804883,0.0005495067,0.0039750705,0.001796274,0.00066623517,0.0005692971,0.0009892988,0.0014134094,0.00009605751],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08459325,0.0024064954,0.19429253,0.007912696,0.025638659,0.0009608734,0.00034474826,0.52431506,0.002430327,0.010549512,0.015236683,0.13131909],"study_design_scores_gemma":[0.024516085,0.0089930445,0.33621886,0.0028352584,0.03172605,0.0007934382,0.0009507384,0.57436424,0.0019456494,0.004537688,0.012679049,0.00043992753],"about_ca_topic_score_codex":0.9466938,"about_ca_topic_score_gemma":0.9456381,"teacher_disagreement_score":0.09298358,"about_ca_system_score_codex":0.09298358,"about_ca_system_score_gemma":0.065233275,"threshold_uncertainty_score":0.67464626},"labels":[],"label_agreement":null},{"id":"W4412511548","doi":"10.1080/13696998.2025.2536430","title":"Evaluating the impact of population-based and cohort-based models in cost-effectiveness analysis: a case study of pneumococcal conjugate vaccines in infants in Germany","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Pneumonia and Respiratory Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Medicine; Pneumococcal conjugate vaccine; Cohort; Population; Conjugate; Intensive care medicine; Pediatrics; Pneumococcal disease; Streptococcus pneumoniae; Internal medicine; Environmental health; Antibiotics","score_opus":0.0533297024258658,"score_gpt":0.4279798779205503,"score_spread":0.3746501754946845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412511548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98293555,0.0011893308,0.012852469,0.0006057861,0.000028035944,0.00023756715,0.00049413805,0.000027933222,0.0016292465],"genre_scores_gemma":[0.9952179,0.00035355616,0.0037902636,0.00004312107,0.000009725663,0.00010325519,0.00013077972,0.000005513131,0.00034595528],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9954745,0.0036397367,0.0001180429,0.00023002614,0.00018209273,0.00035564142],"domain_scores_gemma":[0.97247744,0.025162196,0.0010704108,0.00036153093,0.0005994794,0.00032897585],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011342101,0.0010955617,0.0012613666,0.0010950305,0.00038972107,0.0017341502,0.0012009152,0.001763391,0.0015716299],"category_scores_gemma":[0.024339372,0.0006542023,0.0024191998,0.000656123,0.00048154022,0.0010082821,0.0009190876,0.0012740192,0.00008381074],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011355622,0.00040094988,0.022877673,0.00019420333,0.0006513408,0.00043573967,0.00010080335,0.9642035,0.00022754502,0.0030710907,0.00023267223,0.0064688744],"study_design_scores_gemma":[0.0002801078,0.0007849378,0.01073843,0.00012762852,0.00054570497,0.00014109389,0.00020107873,0.9841887,0.0004015295,0.002091188,0.00045530725,0.000044386747],"about_ca_topic_score_codex":0.0569277,"about_ca_topic_score_gemma":0.028395267,"teacher_disagreement_score":0.9886579,"about_ca_system_score_codex":0.0064709564,"about_ca_system_score_gemma":0.0032381248,"threshold_uncertainty_score":0.11319274},"labels":[],"label_agreement":null},{"id":"W4412782195","doi":"10.1080/13696998.2025.2542026","title":"A systematic review of health state utility values for influenza and influenza-like illness","year":2025,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Medicine; Influenza-like illness; Intensive care medicine; Respiratory illness; Virology; Family medicine; Internal medicine; Virus; Respiratory system","score_opus":0.40617152015994623,"score_gpt":0.5262277801090721,"score_spread":0.12005625994912589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412782195","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011542292,0.995455,0.00038441425,0.00033760595,0.00012979428,0.0005009102,0.0015628863,0.000015910107,0.00045918504],"genre_scores_gemma":[0.023773892,0.9715417,0.0016790519,0.00057322346,0.00008654562,0.0013962208,0.00081272196,0.000012237352,0.00012443234],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9839392,0.0055227834,0.0066607473,0.0009827438,0.0025796897,0.00031493822],"domain_scores_gemma":[0.9499051,0.038249403,0.007436766,0.00060920726,0.0035125273,0.00028706674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013643899,0.0018134803,0.009474291,0.020750292,0.000648865,0.0030022243,0.0021823125,0.0016045131,0.0055412445],"category_scores_gemma":[0.085411675,0.0011061624,0.011343218,0.01893423,0.0011218901,0.0024844678,0.0020226787,0.0014900813,0.00031956413],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001477421,0.000008703854,0.00076202676,0.9542279,0.0084940335,0.00006156153,0.00014654946,0.00015055896,0.00006156429,0.000363211,0.0014642429,0.034111887],"study_design_scores_gemma":[0.00019433201,0.0001430836,0.0044647455,0.92370284,0.05580433,0.00030081224,0.00020163326,0.000121546684,0.00011607681,0.0005443927,0.014362102,0.00004410958],"about_ca_topic_score_codex":0.011859294,"about_ca_topic_score_gemma":0.025397588,"teacher_disagreement_score":0.020750292,"about_ca_system_score_codex":0.0062822644,"about_ca_system_score_gemma":0.0129537,"threshold_uncertainty_score":0.07215673},"labels":[],"label_agreement":null},{"id":"W4413329953","doi":"10.1080/13696998.2025.2549630","title":"The potential impact of the next-generation COVID-19 mRNA-1283 vaccine in Canada","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Moderna","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Virology; 2019-20 coronavirus outbreak; Internal medicine; Outbreak; Disease","score_opus":0.04340597853274404,"score_gpt":0.35164069687399546,"score_spread":0.30823471834125143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413329953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9363054,0.016123772,0.0042417976,0.010285008,0.000108677435,0.0003752865,0.015880663,0.000059020895,0.016620444],"genre_scores_gemma":[0.99166614,0.003183452,0.0016674672,0.0005924409,0.0000145826,0.00003721834,0.0015387951,0.00000974453,0.0012902083],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9984871,0.00046525823,0.000043819295,0.00012919803,0.00030419286,0.00057035347],"domain_scores_gemma":[0.9978325,0.00087785383,0.00023460256,0.000040109055,0.0007342893,0.0002807643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025350293,0.0005160312,0.0004904851,0.00058845064,0.0005698804,0.0015593005,0.00085103273,0.00044621585,0.002034173],"category_scores_gemma":[0.006424863,0.0002475258,0.0012959995,0.0010229163,0.00056240667,0.0005691064,0.0007786883,0.0010266762,0.0000849122],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006230873,0.00031563718,0.42893535,0.0020062241,0.0024349566,0.0007421865,0.0004455177,0.41573837,0.0017479442,0.028101988,0.017273862,0.096027106],"study_design_scores_gemma":[0.0017366332,0.0020257076,0.49621636,0.002155792,0.0051737996,0.00054877513,0.0026458825,0.43440905,0.00400665,0.012060804,0.038728092,0.0002924958],"about_ca_topic_score_codex":0.9851563,"about_ca_topic_score_gemma":0.9815731,"teacher_disagreement_score":0.9259556,"about_ca_system_score_codex":0.074044414,"about_ca_system_score_gemma":0.06929975,"threshold_uncertainty_score":0.53723234},"labels":[],"label_agreement":null},{"id":"W4413447400","doi":"10.1080/13696998.2025.2550860","title":"Projected hospitalization cost impact of the selective cytopheretic device in pediatric acute kidney injury","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Acute Kidney Injury Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seastar Chemicals (Canada)","funders":"","keywords":"Medicine; Acute kidney injury; Emergency medicine; Intensive care medicine; Internal medicine","score_opus":0.01172844044481387,"score_gpt":0.36020866980754135,"score_spread":0.3484802293627275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413447400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806652,0.0005609375,0.00513142,0.0011225326,0.000037632708,0.000051080326,0.009242958,0.000035414614,0.0031529365],"genre_scores_gemma":[0.99556124,0.00024621133,0.0008318692,0.00005991975,0.0000079421925,0.000037828195,0.0025790022,0.0000052993155,0.00067068066],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9996618,0.00013715505,0.00002028961,0.000047517555,0.000049636623,0.000083551626],"domain_scores_gemma":[0.999218,0.00040830782,0.00015044677,0.00001865232,0.0001152718,0.00008924972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008418988,0.00045577227,0.0003193698,0.00048183842,0.00023690707,0.0009955928,0.000671035,0.00057358353,0.0032502364],"category_scores_gemma":[0.0031102262,0.00031648128,0.0009967953,0.0007391375,0.00021553267,0.000743846,0.00047872216,0.0008366793,0.00027126452],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000536002,0.00015407368,0.15289733,0.00011343629,0.00031271367,0.0005261499,0.000046098226,0.8290208,0.00035112668,0.005099043,0.0027179364,0.008225143],"study_design_scores_gemma":[0.00014303457,0.0004483704,0.09619036,0.00011292027,0.00042959367,0.00066129566,0.00029373096,0.8959281,0.0006895977,0.0029003245,0.0021617576,0.000040909497],"about_ca_topic_score_codex":0.0368862,"about_ca_topic_score_gemma":0.024987046,"teacher_disagreement_score":0.0368862,"about_ca_system_score_codex":0.0032683625,"about_ca_system_score_gemma":0.0016189367,"threshold_uncertainty_score":0.07334304},"labels":[],"label_agreement":null},{"id":"W4413582459","doi":"10.1080/13696998.2025.2551449","title":"Cost-effectiveness of insulin icodec for the treatment of type 2 diabetes in Canada","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); EVERSANA (Canada)","funders":"Novo Nordisk Canada; Centre de Regulació Genòmica","keywords":"Medicine; Type 2 diabetes; Insulin; Diabetes mellitus; Internal medicine; Intensive care medicine; Endocrinology","score_opus":0.03849923940399257,"score_gpt":0.3348081547398108,"score_spread":0.2963089153358182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413582459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7911721,0.14909258,0.0027944858,0.009529019,0.0005027055,0.0013267447,0.016759345,0.0001245776,0.028698424],"genre_scores_gemma":[0.97888273,0.014417804,0.0018822635,0.000889025,0.00004942969,0.00010952337,0.0025919038,0.000012993123,0.0011642813],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99833703,0.00052801793,0.00011025759,0.00014485515,0.00061687024,0.00026308894],"domain_scores_gemma":[0.9979254,0.00058022764,0.00033910965,0.000046217294,0.0007010529,0.00040795645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016233973,0.00054574356,0.00081355695,0.001408002,0.00063710473,0.0016950544,0.00088643894,0.00061226217,0.0030466197],"category_scores_gemma":[0.008030943,0.00023268949,0.0020844461,0.002281471,0.00046392795,0.00045952862,0.0007771538,0.0009671984,0.00008168523],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0400861,0.0012569407,0.30295783,0.012296723,0.0143365795,0.0007306612,0.00036875127,0.08411435,0.0014922698,0.009173539,0.026020398,0.5071659],"study_design_scores_gemma":[0.016691327,0.008053632,0.714753,0.011119939,0.03455904,0.0019476555,0.001808316,0.1522179,0.0025818856,0.0072061396,0.048700802,0.00036030856],"about_ca_topic_score_codex":0.9075227,"about_ca_topic_score_gemma":0.91815674,"teacher_disagreement_score":0.09247732,"about_ca_system_score_codex":0.042217277,"about_ca_system_score_gemma":0.047170073,"threshold_uncertainty_score":0.30630922},"labels":[],"label_agreement":null},{"id":"W4413992600","doi":"10.1080/13696998.2025.2555144","title":"Real world evidence on health care resource utilization and economic burden of arrhythmias in patients with COPD","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"iRhythm Technologies","keywords":"Medicine; COPD; Real world evidence; Health care; Intensive care medicine; Resource (disambiguation); Internal medicine; Economic growth","score_opus":0.023086528648673867,"score_gpt":0.32753139108201673,"score_spread":0.30444486243334284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413992600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9392233,0.038327258,0.0010011895,0.008943138,0.00014341588,0.00003361164,0.007104047,0.00001289151,0.0052111577],"genre_scores_gemma":[0.9933217,0.0039910744,0.00024095176,0.00047363236,0.00013851325,0.000013951037,0.001746428,0.0000034309076,0.00007029296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99470747,0.0029356198,0.00071178476,0.00047732517,0.00088250614,0.0002852444],"domain_scores_gemma":[0.9610657,0.019888422,0.014403615,0.0014764951,0.0023949132,0.0007708663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067674876,0.00034687592,0.0005064568,0.002216742,0.00036665803,0.0020479495,0.00074918865,0.00079572044,0.0025336635],"category_scores_gemma":[0.03418101,0.00028621047,0.0016321415,0.0029035388,0.00082453986,0.0013525963,0.0013776887,0.0009837863,0.0002283821],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000584713,0.00006922708,0.9784106,0.0006031699,0.0017820031,0.00010445951,0.00009599714,0.0019031041,0.00006387467,0.0009938097,0.0011544499,0.014234573],"study_design_scores_gemma":[0.000055893477,0.00015406964,0.99176097,0.00077249715,0.000729335,0.0002513148,0.00035902378,0.002560949,0.000065447006,0.001073748,0.002194591,0.000022073402],"about_ca_topic_score_codex":0.008259485,"about_ca_topic_score_gemma":0.0075583532,"teacher_disagreement_score":0.008259485,"about_ca_system_score_codex":0.0011871759,"about_ca_system_score_gemma":0.00090027595,"threshold_uncertainty_score":0.035790265},"labels":[],"label_agreement":null},{"id":"W4414882805","doi":"10.1080/13696998.2025.2560759","title":"Foslevodopa/foscarbidopa (LDp/CDp) in advanced Parkinson’s disease (aPD): demonstration of savings from a societal perspective in the UK","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"AbbVie","keywords":"Perspective (graphical); Health care; Disease; Healthcare system; MEDLINE; Health economics; Public health","score_opus":0.011813621235428545,"score_gpt":0.2903740562733734,"score_spread":0.27856043503794486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414882805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9567753,0.0062494804,0.01099576,0.002340436,0.00010866981,0.00023425538,0.0034740844,0.0000967649,0.019725144],"genre_scores_gemma":[0.9965205,0.0008374138,0.0013518668,0.000051326126,0.0000051207144,0.00003779249,0.00035778774,0.0000059886456,0.0008321127],"study_design_codex":"simulation_or_modeling","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992786,0.00043032752,0.000046628356,0.00007144326,0.000107517466,0.00006543998],"domain_scores_gemma":[0.99905723,0.00060581835,0.00009875571,0.000025666472,0.00015465879,0.000057893045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001013842,0.00047137224,0.00054441456,0.0003781574,0.00018571367,0.00094692316,0.00051570695,0.0008519815,0.0022834637],"category_scores_gemma":[0.0035076744,0.00026462434,0.0009398628,0.0005276788,0.00032660575,0.00065615145,0.0006834877,0.00061560737,0.00018705452],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026738937,0.00020438447,0.019194044,0.0013679228,0.00037306058,0.00089103275,0.00022016307,0.91517186,0.0013946845,0.004998629,0.0036168967,0.049893517],"study_design_scores_gemma":[0.0017064868,0.0032955976,0.036794934,0.0007648889,0.0008791973,0.0007229791,0.00041301418,0.9362807,0.002249962,0.005937229,0.010847179,0.00010783842],"about_ca_topic_score_codex":0.10635142,"about_ca_topic_score_gemma":0.07861639,"teacher_disagreement_score":0.10635142,"about_ca_system_score_codex":0.0057196775,"about_ca_system_score_gemma":0.0016138485,"threshold_uncertainty_score":0.21146482},"labels":[],"label_agreement":null},{"id":"W4416697794","doi":"10.1080/13696998.2025.2587415","title":"Quantifying treatment value under IRA: a case study of rifaximin for the treatment of overt hepatic encephalopathy using QALY and non-QALY measures","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Liver Disease and Transplantation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bausch Health (Canada)","funders":"Bausch Health","keywords":"Rifaximin; Hepatic encephalopathy; Value (mathematics); Symptomatic treatment; Encephalopathy","score_opus":0.08623451281034923,"score_gpt":0.36309682990879755,"score_spread":0.27686231709844833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416697794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.894639,0.010810544,0.047784336,0.015242781,0.00014118187,0.0016951053,0.0020164642,0.00009780268,0.027572664],"genre_scores_gemma":[0.9852861,0.0008374547,0.012625228,0.00023879478,0.000046649544,0.0002468133,0.00012439665,0.000018709276,0.0005757759],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.98455817,0.0133756045,0.0002711515,0.00045039802,0.0007310828,0.0006135896],"domain_scores_gemma":[0.93275553,0.061111372,0.0026490786,0.0010837547,0.0016136168,0.000786609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021994056,0.00091176026,0.0013121357,0.0018407484,0.0011622937,0.0026012461,0.0014199879,0.0026047297,0.004377211],"category_scores_gemma":[0.049404215,0.0004732348,0.0032626574,0.0023727324,0.0012214483,0.0018119764,0.0015629379,0.0028505696,0.00021069674],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009448276,0.0052296873,0.14028497,0.0024125902,0.0023536433,0.0109745255,0.0019897746,0.5418703,0.0018723498,0.113869816,0.011019893,0.15867428],"study_design_scores_gemma":[0.0028122405,0.0076419804,0.056617655,0.001243001,0.0014886679,0.0059329895,0.0039042528,0.8516921,0.0030525606,0.048960015,0.01633923,0.0003152867],"about_ca_topic_score_codex":0.016903974,"about_ca_topic_score_gemma":0.011999466,"teacher_disagreement_score":0.021994056,"about_ca_system_score_codex":0.008525148,"about_ca_system_score_gemma":0.0030459403,"threshold_uncertainty_score":0.11631709},"labels":[],"label_agreement":null},{"id":"W4416836832","doi":"10.1080/13696998.2025.2587412","title":"Economic impact of using cariprazine as the first versus subsequent adjunctive therapy for Medicaid beneficiaries with major depressive disorder","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Mental Health Treatment and Access","field":"Psychology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicaid; Major depressive disorder; Economic impact analysis; Depression (economics); Economic analysis; Cohort study","score_opus":0.030970692370175607,"score_gpt":0.38633706116779126,"score_spread":0.35536636879761563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416836832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99431074,0.0025389025,0.00006690163,0.001034489,0.000021887685,0.00002996629,0.00083328027,0.0000037135167,0.0011601294],"genre_scores_gemma":[0.9984084,0.0007426527,0.00008761301,0.00014725166,0.000023186725,0.000012936877,0.00048665373,0.0000010618861,0.000090240304],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987465,0.0005504254,0.00011040617,0.00010122186,0.00023680861,0.00025458075],"domain_scores_gemma":[0.9969626,0.00090793334,0.0015614372,0.000048887676,0.00012978434,0.00038935806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013523051,0.00018852564,0.0003238966,0.00064031396,0.00027440183,0.0008468324,0.00027838824,0.0003862066,0.0013009903],"category_scores_gemma":[0.009415774,0.00014736627,0.0013838738,0.00062788423,0.0002582237,0.000443726,0.0008761516,0.00063744874,0.000055298708],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041560624,0.00037523746,0.9576513,0.00020897464,0.0012407721,0.00027977524,0.000079618774,0.0021124117,0.0002567078,0.0006989898,0.0014649393,0.0314752],"study_design_scores_gemma":[0.00028047,0.0011655594,0.9890315,0.00020704106,0.0011503871,0.00053566304,0.00038693458,0.0057155215,0.0001858988,0.00041716965,0.0009068892,0.000016916183],"about_ca_topic_score_codex":0.023244405,"about_ca_topic_score_gemma":0.036096517,"teacher_disagreement_score":0.023244405,"about_ca_system_score_codex":0.002631501,"about_ca_system_score_gemma":0.0013470678,"threshold_uncertainty_score":0.046218216},"labels":[],"label_agreement":null},{"id":"W4417299894","doi":"10.1080/13696998.2025.2599670","title":"Impact of pembrolizumab on health outcomes and productivity in earlier-stage cancers within the US Medicare population","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Merck Canada; Merck","keywords":"Pembrolizumab; Productivity; Population; Investment (military); Work productivity; Exploratory analysis","score_opus":0.016483279543900966,"score_gpt":0.34714052042635307,"score_spread":0.33065724088245213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417299894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939173,0.000428053,0.002084377,0.00064811966,0.000012541825,0.00007113699,0.0011682337,0.000013950006,0.0016563262],"genre_scores_gemma":[0.998133,0.00013394415,0.0006472501,0.00008791237,0.0000047748445,0.000029909876,0.00038061664,0.0000018335811,0.00058088324],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99911124,0.00044011604,0.00003391581,0.00013323735,0.00008341304,0.00019809791],"domain_scores_gemma":[0.99792236,0.0012036676,0.000486159,0.00006235565,0.00013297047,0.00019250043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002847443,0.000500395,0.0004886853,0.0004906997,0.00029302062,0.001172389,0.0004443162,0.000679149,0.002401708],"category_scores_gemma":[0.005382298,0.00026275113,0.0011887606,0.00044591815,0.00035430427,0.00073694595,0.0007770372,0.00076064636,0.00015965794],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015010912,0.0004774946,0.32871434,0.0001303642,0.0007580434,0.00039175988,0.00008978962,0.64812034,0.0009228559,0.0017138447,0.00097346434,0.01620662],"study_design_scores_gemma":[0.0004586178,0.00287494,0.24157904,0.00015374053,0.0009402856,0.000409441,0.0003842828,0.7458176,0.0013206195,0.0031658057,0.0028409727,0.000054654956],"about_ca_topic_score_codex":0.027205542,"about_ca_topic_score_gemma":0.01706284,"teacher_disagreement_score":0.027205542,"about_ca_system_score_codex":0.0034124418,"about_ca_system_score_gemma":0.0016536737,"threshold_uncertainty_score":0.054094374},"labels":[],"label_agreement":null},{"id":"W4417432359","doi":"10.1080/13696998.2025.2600217","title":"Cost-effectiveness of chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Chimeric antigen receptor; Refractory (planetary science); Antibody therapy; Immunotherapy; Salvage therapy; Cell therapy; Safety profile","score_opus":0.12464273081717334,"score_gpt":0.41862964772985595,"score_spread":0.29398691691268264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417432359","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003202148,0.99485284,0.0004505523,0.00021826239,0.00013040254,0.0003513794,0.0005017326,0.00001916074,0.00027351864],"genre_scores_gemma":[0.11985044,0.8747464,0.0020936655,0.0007549329,0.00021421976,0.0013446305,0.0006645361,0.000026676471,0.00030444228],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99052763,0.004815302,0.0025486446,0.00074969465,0.0010738359,0.00028494955],"domain_scores_gemma":[0.9818841,0.013887145,0.0025035688,0.00033968344,0.0011778766,0.00020761638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013481334,0.0028249773,0.021605179,0.0080015715,0.0005442714,0.0037157745,0.0021922125,0.0022816556,0.004326828],"category_scores_gemma":[0.032564227,0.0016337904,0.037786536,0.008197008,0.0007316411,0.0018964245,0.0013980643,0.0020400991,0.0002979792],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015180364,0.000028442451,0.0013808697,0.5214433,0.4605494,0.000110143345,0.00004604688,0.0009035596,0.0001394047,0.00019366741,0.00058784644,0.013099234],"study_design_scores_gemma":[0.0007562035,0.00020693208,0.0018509928,0.042714175,0.9520543,0.00010309309,0.000038047332,0.0003381279,0.000105347615,0.00026184373,0.0015468905,0.00002407202],"about_ca_topic_score_codex":0.008408166,"about_ca_topic_score_gemma":0.014774326,"teacher_disagreement_score":0.021605179,"about_ca_system_score_codex":0.004318953,"about_ca_system_score_gemma":0.004406654,"threshold_uncertainty_score":0.07129693},"labels":[],"label_agreement":null},{"id":"W7117357242","doi":"10.1080/13696998.2025.2604971","title":"A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"AstraZeneca United States","keywords":"Ibrutinib; Tolerability; Drug; Health care; Lymphoma; Resource use","score_opus":0.02686499075694019,"score_gpt":0.3300574816797413,"score_spread":0.3031924909228011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117357242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99935657,0.00019683628,0.000026608755,0.000031065116,0.0000035131109,0.000017059803,0.00021320619,9.74914e-7,0.00015422753],"genre_scores_gemma":[0.9995357,0.00006131559,0.00002998126,0.000039316114,0.00001051081,0.000018755658,0.00027341096,6.6955346e-7,0.000030367928],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820995,0.00080897915,0.00020014455,0.00033685516,0.0002407649,0.00020335261],"domain_scores_gemma":[0.99532014,0.00091528444,0.0026635244,0.00014977674,0.00033745388,0.0006138586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015430856,0.00021517006,0.0003457125,0.0006196875,0.0003744958,0.00090498675,0.00038293257,0.00047976506,0.0016808378],"category_scores_gemma":[0.0047013992,0.00021538476,0.0006494376,0.0011519849,0.0003775542,0.0006569523,0.00053971726,0.0005628196,0.00017864413],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015095224,0.00029864523,0.9957307,0.00003586541,0.00028601286,0.000062799874,0.000105805295,0.0000831653,0.00009145697,0.000021247892,0.00015483053,0.0016200596],"study_design_scores_gemma":[0.00036396037,0.0027145226,0.99454474,0.00002365368,0.00020188285,0.00027900035,0.00066484284,0.00075039343,0.00007835425,0.000033068518,0.00033388846,0.000011655242],"about_ca_topic_score_codex":0.004547221,"about_ca_topic_score_gemma":0.005566825,"teacher_disagreement_score":0.004547221,"about_ca_system_score_codex":0.0011518218,"about_ca_system_score_gemma":0.00054945954,"threshold_uncertainty_score":0.009041488},"labels":[],"label_agreement":null}]}